var images_info;if (!images_info) images_info =[]; images_info["58"]={"58001":{"type":"graphic_figure","displayName":"CRP troponin non ST ACS","title":"CRP and troponins predict outcome in non-ST elevation ACS","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CRP and troponins predict outcome in non-ST elevation ACS</div><div class=\"cntnt\"><img style=\"width:449px; height:404px;\" src=\"images/CARD/58001_CRP_troponin_non_ST_ACS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the FRISC trial of 917 patients with a non-ST elevation acute coronary syndrome (unstable angina or non-ST elevation myocardial infarction), elevated levels of C-reactive protein, obtained within 24 hours, were associated with an increased incidence of death from cardiac causes at a mean follow-up of 37 months; its effects were additive to maximal serum troponin T levels.</div><div class=\"graphic_reference\">Data from: Lindahl B, Toss H, Siegbahn A, et al. N Engl J Med 2000; 343:1139.</div><div id=\"graphicVersion\">Graphic 58001 Version 2.0</div></div></div>"},"58002":{"type":"graphic_diagnosticimage","displayName":"Abdominal pregnancy","title":"Abdominal pregnancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Abdominal pregnancy</div><div class=\"cntnt\"><img style=\"width:396px; height:274px;\" src=\"images/OBGYN/58002_Abdominal_pregnancy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transabdominal ultrasonography of an abdominal pregnancy at 15 weeks of gestation. Note the lack of myometrium around the gestational sac.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 58002 Version 2.0</div></div></div>"},"58003":{"type":"graphic_picture","displayName":"Amyloid high power HandE","title":"Amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amyloidosis</div><div class=\"cntnt\"><img style=\"width:371px; height:262px;\" src=\"images/GAST/58003_Amyloid_high_power_HandE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power magnification of blood vessels (a) and lamina propria (b) using hematoxylin and eosin stain from a patient with gastrointestinal amyloidosis. There is prominent infiltration by eosinophilic amyloid deposits (arrows).</div><div class=\"graphic_reference\">Courtesy of Michael Camilleri, MD.</div><div id=\"graphicVersion\">Graphic 58003 Version 1.0</div></div></div>"},"58004":{"type":"graphic_picture","displayName":"Fecal cylinder DAPI stain","title":"Fecal cylinder with DAPI stain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fecal cylinder with DAPI stain</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/GAST/58004_Fecal_cylinder_DAPI_stain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A fecal cylinder with DAPI stain. Multiple single microscopic fields taken at magnification of x100 have been used to create a composite overview. The center of the cylinder contains no leukocytes and the bacteria are homogeneously distributed. The cylinder has no mucus cover but instead the &quot;germinal&quot; zone is infiltrated by many leukocytes (arrows). The findings are typical for ulcerative colitis.</div><div class=\"graphic_reference\">Courtesy of Alexander Swidsinski, MD, and Vera Loening-Baucke, MD.</div><div id=\"graphicVersion\">Graphic 58004 Version 2.0</div></div></div>"},"58007":{"type":"graphic_table","displayName":"Mammalian tissues expressing gastrin","title":"Mammalian tissues expressing gastrin and its metabolite intermediates (progastrin, glycine extended derivatives and gastrin)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mammalian tissues expressing gastrin and its metabolite intermediates (progastrin, glycine extended derivatives and gastrin)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Gastrointestinal tract</td>\n\n</tr>\n<tr>\n<td>Gastric antrum</td>\n\n</tr>\n<tr>\n<td>Jejunum</td>\n\n</tr>\n<tr>\n<td>Ileum</td>\n\n</tr>\n<tr>\n<td>Colon</td>\n\n</tr>\n<tr>\n<td>Pancreas</td>\n\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Genital tract</td>\n\n</tr>\n<tr>\n<td>Ovaries</td>\n\n</tr>\n<tr>\n<td>Testicles</td>\n\n</tr>\n<tr>\n<td>Spermatoza</td>\n\n</tr><tr><td class=\"subtitle1_single\">Neurodendocrine tissue</td></tr><tr><td>Cerebellum</td></tr><tr><td>Vagus nerve</td></tr><tr><td>Hypothalamus</td></tr><tr><td>Pituitary</td></tr><tr><td>Adrenal medulla</td></tr><tr><td class=\"subtitle1_single\">Respiratory tract</td></tr><tr><td>Bronchial mucosa</td></tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: Rehfeld JF, Physiologic Reviews, 1998; 74:1087.</div><div id=\"graphicVersion\">Graphic 58007 Version 4.0</div></div></div>"},"58009":{"type":"graphic_diagnosticimage","displayName":"Proximal PA interrupt I","title":"Proximal interruption of the right pulmonary artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proximal interruption of the right pulmonary artery</div><div class=\"cntnt\"><img style=\"width:360px; height:442px;\" src=\"images/PULM/58009_Proximal_PA_interrupt_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest radiograph shows a small right lung with a diminutive right descending pulmonary artery.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 58009 Version 2.0</div></div></div>"},"58010":{"type":"graphic_picture","displayName":"Tinel test carpal tunnel","title":"The Tinel test for median nerve injury at the carpal tunnel","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The Tinel test for median nerve injury at the carpal tunnel</div><div class=\"cntnt\"><img style=\"width:426px; height:284px;\" src=\"images/RHEUM/58010_Tinel_test_carpal_tunnel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a patient with the carpal tunnel syndrome, tapping over a compressed nerve at the wrist reproduces pain and paresthesia, proximal or distal to the site of compression.</div><div class=\"graphic_reference\">Reproduced with permission from Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.</div><div id=\"graphicVersion\">Graphic 58010 Version 2.0</div></div></div>"},"58011":{"type":"graphic_figure","displayName":"Muscles of the face","title":"Muscles of the face","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Muscles of the face</div><div class=\"cntnt\"><img style=\"width:542px; height:402px;\" src=\"images/DERM/58011_Muscles-of-the-face.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 58011 Version 3.0</div></div></div>"},"58012":{"type":"graphic_figure","displayName":"Volume regulation of ADH","title":"Hypovolemic stimulus to ADH release","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypovolemic stimulus to ADH release</div><div class=\"cntnt\"><img style=\"width:415px; height:247px;\" src=\"images/NEPH/58012_Volume_regulation_of_ADH.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relationship of plasma antidiuretic hormone (ADH) concentrations to isosmotic changes in blood volume in the rat. Much higher ADH levels can occur with hypovolemia than with hyperosmolality, although a relatively large fall in blood volume is required before this response is initiated.</div><div class=\"graphic_reference\">Data from Dunn FL, Brennan TJ, Nelson AE,&nbsp;et al.&nbsp;J Clin Invest 1973; 52:3212.</div><div id=\"graphicVersion\">Graphic 58012 Version 2.0</div></div></div>"},"58013":{"type":"graphic_diagnosticimage","displayName":"AP view comminuted midshaft femur fracture","title":"AP view of a comminuted midshaft femur fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">AP view of a comminuted midshaft femur fracture</div><div class=\"cntnt\"><img style=\"width:236px; height:396px;\" src=\"images/EM/58013_Femur_fx_mid_AP_XR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anteroposterior (AP) radiograph shows a comminuted, angulated midshaft femur fracture prior to operative repair.</div><div class=\"graphic_reference\">Courtesy of Thomas J Mezzanotte, MD.</div><div id=\"graphicVersion\">Graphic 58013 Version 3.0</div></div></div>"},"58014":{"type":"graphic_figure","displayName":"Cardiovascular risk in T2DM","title":"Increased cardiovascular risk in type 2 diabetes","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Increased cardiovascular risk in type 2 diabetes</div><div class=\"cntnt\"><img style=\"width:526px; height:236px;\" src=\"images/ENDO/58014_CardiovascularriskinNIDD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Calculated effects of different interventions on coronary and total deaths in 1000 normal and 1000 men with type 2 diabetes aged 35 to 57 years without a history of myocardial infarction. Although risk was reduced by the therapeutic interventions (particularly cessation of smoking), there was a residual three- to fourfold increase in mortality in the diabetic men, due presumably to the effects of hyperglycemia or hyperinsulinemia.</div><div class=\"graphic_footnotes\">BP: blood pressure.</div><div class=\"graphic_reference\">Data from: Yudkin JS. How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects.&nbsp;BMJ 1993; 306:1313.</div><div id=\"graphicVersion\">Graphic 58014 Version 2.0</div></div></div>"},"58018":{"type":"graphic_diagnosticimage","displayName":"Hilar adenopathy PA","title":"Sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sarcoidosis</div><div class=\"cntnt\"><img style=\"width:443px; height:232px;\" src=\"images/PULM/58018_Hilar_adenopathy_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Young woman with acute onset of erythema nodosum and no respiratory complaints. Left: The chest radiograph shows bilateral hilar adenopathy (Stage I). Right: A follow-up chest radiograph on no therapy is normal.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King Jr, MD.</div><div id=\"graphicVersion\">Graphic 58018 Version 6.0</div></div></div>"},"58019":{"type":"graphic_table","displayName":"Narrow QRS complex tachycardia classification by anatomy","title":"Classification of narrow QRS complex tachycardias by structures required for initiation and maintenance","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of narrow QRS complex tachycardias by structures required for initiation and maintenance</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Atrial tissue only</td> </tr> <tr> <td>Sinus tachycardia</td> </tr> <tr> <td>Inappropriate sinus tachycardia</td> </tr> <tr> <td>Sinoatrial nodal reentrant tachycardia (SANRT)</td> </tr> <tr> <td>Intraatrial reentrant tachycardia (IART)</td> </tr> <tr> <td>Atrial tachycardia</td> </tr> <tr> <td>Multifocal atrial tachycardia</td> </tr> <tr> <td>Atrial fibrillation</td> </tr> <tr> <td>Atrial flutter</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">AV junction</td> </tr> <tr> <td>AV nodal reentrant tachycardia (AVNRT)</td> </tr> <tr> <td>Atrioventricular reentrant tachycardia (AVRT)</td> </tr> <tr> <td class=\"sublist1_start\">Junctional tachycardia</td> </tr> <tr> <td class=\"sublist1\">Junctional ectopic tachycardia in children</td> </tr> <tr> <td class=\"sublist1\">Nonparoxysmal junctional tachycardia in adults</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58019 Version 2.0</div></div></div>"},"58023":{"type":"graphic_table","displayName":"Common pain behav elderly","title":"Common pain behaviors in cognitively impaired elderly persons","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common pain behaviors in cognitively impaired elderly persons</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Facial expressions</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Slight frown; sad, frightened face</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Grimacing, wrinkled forehead, closed or tightened eyes</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Any distorted expression</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Rapid blinking</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Verbalizations, vocalizations</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Sighing, moaning, groaning</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Grunting, chanting, calling out</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Noisy breathing</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Asking for help</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Verbally abusive</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Body movements</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Rigid, tense body posture, guarding</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Fidgeting</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Increased pacing, rocking</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Restricted movement</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Gait or mobility changes</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Changes in interpersonal interactions</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Aggressive, combative, resisting care</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Decreased social interactions</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Socially inappropriate, disruptive</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Withdrawn</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Changes in activity patterns or routines</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Refusing food, appetite change</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Increase in rest periods</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Sleep, rest pattern changes</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Sudden cessation of common routines</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Increased wandering</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Mental status changes</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Crying or tears</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Increased confusion</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Irritability or distress</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_lgnd\">Some patients demonstrate little or no specific behavior associated with severe pain.</div><div class=\"graphic_reference\">AGS Panel on Persistent Pain in Older Persons</div><div id=\"graphicVersion\">Graphic 58023 Version 1.0</div></div></div>"},"58024":{"type":"graphic_figure","displayName":"Arteries of the neck","title":"Arteries of the neck","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Arteries of the neck</div><div class=\"cntnt\"><img style=\"width:459px; height:395px;\" src=\"images/PEDS/58024_Arteries_of_the_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The vertebral arteries arise from the subclavian arteries. They angle backwards to the transverse processes of C6 and run superiorly through the transverse foramina of C6-C1 to the inferior surface of the skull. The vertebral arteries join together at the base of the brain to form the basilar artery.</div><div id=\"graphicVersion\">Graphic 58024 Version 1.0</div></div></div>"},"58026":{"type":"graphic_table","displayName":"Wheelchair transportation","title":"Guidelines for safe transportation of children in wheelchairs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for safe transportation of children in wheelchairs</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td>The wheelchair should be secured in a forward-facing position</td>\n   </tr>\n   <tr>\n   <td>The wheelchair should be secured with four-point tie-down devices</td>\n   </tr>\n   <tr>\n   <td>Lap boards or metal or plastic trays should be removed and secured separately</td>\n   </tr>\n   <tr>\n   <td>An occupant restraint that has been tested at 30 mph and 20G force conditions and that includes upper and lower torso restraint (ie, shoulder harness and lap belt) should be provided</td>\n   </tr>\n   <tr>\n   <td>Head bands should not be used to restrain the child's head separately from the torso</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=57016&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Wheelchair_transportation.htm</title></head></div><div class=\"graphic_reference\">Data from: Bull, M, Agran, P, Laraque, D, et al. American Academy of Pediatrics. Committee on Injury and Poison Prevention. Transporting children with special health care needs. Pediatrics 1999; 104:988. (Reaffirmed March 2013).</div><div id=\"graphicVersion\">Graphic 58026 Version 2.0</div></div></div>"},"58028":{"type":"graphic_figure","displayName":"VF bilat quadrantanopia","title":"Bilateral quadrantanopia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bilateral quadrantanopia</div><div class=\"cntnt\"><img style=\"width:504px; height:214px;\" src=\"images/NEURO/58028_VF_bilat_quadrantanopia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Goldmann visual field showing a &quot;checker board&quot; bilateral homonymous quadrantanopia. There is a left homonymous inferior quadrantanopia and a right superior homonymous quadrantanopia. This patient sustained a head injury with bilateral occipital lobe contusion.</div><div id=\"graphicVersion\">Graphic 58028 Version 1.0</div></div></div>"},"58030":{"type":"graphic_picture","displayName":"Immersion burn","title":"Immersion burn","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Immersion burn</div><div class=\"cntnt\"><img style=\"width:540px; height:347px;\" src=\"images/EM/58030_Immersionburnedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the sharp demarcation between the burn and normal skin and the absence of drip or splash marks, as well as the characteristic distribution on the buttocks and lower legs. Sparing of the thicker skin of palms or soles, and of skin folds where knees and hips are flexed, is also a common finding.</div><div class=\"graphic_reference\">Reproduced with permission from: Reece RM, Ludwig S. Child Abuse: Medical Diagnosis and management, 2nd ed, Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright © 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58030 Version 5.0</div></div></div>"},"58031":{"type":"graphic_table","displayName":"Differential diagnosis of night sweats or flushing","title":"Differential diagnosis of night sweats or flushing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of night sweats or flushing</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Malignancy </td> </tr> <tr> <td class=\"sublist1_start\">Lymphoma </td> </tr> <tr> <td class=\"sublist1\">Non-Hodgkin lymphoma </td> </tr> <tr> <td class=\"sublist1\">Hodgkin lymphoma</td> </tr> <tr> <td class=\"sublist1_start\">Solid tumors </td> </tr> <tr> <td class=\"sublist1\">Germ cell tumors </td> </tr> <tr> <td class=\"sublist1\">Medullary carcinoma of the thyroid </td> </tr> <tr> <td class=\"sublist1\">Prostate cancer </td> </tr> <tr> <td class=\"sublist1\">Renal cell carcinoma </td> </tr> <tr> <td class=\"sublist1\">Miscellaneous cancers </td> </tr> <tr> <td class=\"subtitle1_single\">Infections </td> </tr> <tr> <td class=\"sublist1_start\">Mycobacterial </td> </tr> <tr> <td class=\"sublist1\">Tuberculosis </td> </tr> <tr> <td class=\"sublist1\">Atypical mycobacteria </td> </tr> <tr> <td class=\"sublist1_start\">Bacterial </td> </tr> <tr> <td class=\"sublist1\">Abscess </td> </tr> <tr> <td class=\"sublist1\">Brucellosis </td> </tr> <tr> <td class=\"sublist1\">Endocarditis </td> </tr> <tr> <td class=\"sublist1\">Osteomyelitis </td> </tr> <tr> <td class=\"sublist1_start\">Fungal infections </td> </tr> <tr> <td class=\"sublist1_start\">Viral </td> </tr> <tr> <td class=\"sublist1\"> <p>HIV infection</p> <p>Chronic hepatitis C</p> </td> </tr> <tr> <td class=\"subtitle1_single\">Medications</td> </tr> <tr> <td class=\"subtitle1_single\">Substance withdrawal </td> </tr> <tr> <td>Alcohol</td> </tr> <tr> <td>Cocaine</td> </tr> <tr> <td>Opioids</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Endocrine disorders </td> </tr> <tr> <td>Carcinoid syndrome</td> </tr> <tr> <td>Diabetes insipidus</td> </tr> <tr> <td>Hyperthyroidism</td> </tr> <tr> <td>Hypoglycemia</td> </tr> <tr> <td>Pheochromocytoma</td> </tr> <tr> <td>Postorchiectomy</td> </tr> <tr> <td class=\"subtitle1_single\">Menopause </td> </tr> <tr> <td class=\"subtitle1_single\">Neurologic disorders </td> </tr> <tr> <td>Autonomic dysreflexia</td> </tr> <tr> <td>Autonomic neuropathy</td> </tr> <tr> <td>Post-traumatic syringomyelia</td> </tr> <tr> <td>Stroke</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous </td> </tr> <tr> <td>Chronic fatigue syndrome</td> </tr> <tr> <td>Common blushing</td> </tr> <tr> <td>Food additives</td> </tr> <tr> <td>Gastroesophageal reflux</td> </tr> <tr> <td>Mastocytosis</td> </tr> <tr> <td>Panic disorder</td> </tr> <tr> <td>Rosacea</td> </tr> <tr> <td>Sleep apnea</td> </tr> <tr> <td>Temporal arteritis</td> </tr> <tr> <td>Idiopathic hyperhidrosis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.</div><div id=\"graphicVersion\">Graphic 58031 Version 3.0</div></div></div>"},"58032":{"type":"graphic_figure","displayName":"Weber and Rinne tests","title":"Evaluation of hearing loss, Weber and Rinne tests","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Evaluation of hearing loss, Weber and Rinne tests</div><div class=\"cntnt\"><img style=\"width:511px; height:565px;\" src=\"images/PC/58032_Evaluation_of_hearing_loss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><STRONG>Weber test:&nbsp;</STRONG>Place the base of a struck tuning fork on the bridge of the forehead, nose, or teeth. In a normal test, there is no lateralization of sound. With unilateral conductive loss, sound lateralizes towards affected ear. With unilateral sensorineural loss, sound lateralizes to the normal or better-hearing side.<br /><STRONG>Rinne test:</STRONG> Place the base of a struck tuning fork on the mastoid bone behind the ear. Have the patient indicate when sound is no longer heard. Move fork (held at base) beside ear and ask if now audible. In a normal test, AC &gt; BC; patient can hear fork at ear. With conductive loss, BC &gt; AC; patient will not hear fork at ear.</div><div id=\"graphicVersion\">Graphic 58032 Version 10.0</div></div></div>"},"58035":{"type":"graphic_table","displayName":"Constrictive bronchiolitis","title":"Conditions associated with the histologic finding of constrictive bronchiolitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with the histologic finding of constrictive bronchiolitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Inhalation of dusts or toxins</td> </tr> <tr> <td class=\"sublist1\">Mineral dusts - asbestos, silica, iron oxide, aluminum oxide, talc, mica, and coal</td> </tr> <tr> <td class=\"sublist1\">Toxins - NO<sub>2</sub>, sulfur dioxide, ammonia, chlorine, and phosgene</td> </tr> <tr> <td>Drug reaction</td> </tr> <tr> <td>Infection - viral, mycoplasma</td> </tr> <tr> <td>Connective tissue disease, especially rheumatoid arthritis</td> </tr> <tr> <td>Chronic rejection in heart-lung, lung, and bone marrow transplant recipients</td> </tr> <tr> <td>Hypersensitivity reactions</td> </tr> <tr> <td>Ulcerative colitis</td> </tr> <tr> <td>Idiopathic</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NO<SUB>2</SUB>: nitrogen dioxide.</div><div class=\"graphic_reference\">Adapted from Myers JL, Colby TV, Clin Chest Med 1993; 14:611.</div><div id=\"graphicVersion\">Graphic 58035 Version 2.0</div></div></div>"},"58037":{"type":"graphic_figure","displayName":"Superficial anatomy of the axilla","title":"Superficial anatomy of the axilla","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">Superficial anatomy of the axilla</div><div class=\"cntnt\"><img style=\"width:602px; height:355px;\" src=\"images/SURG/58037_Superficial_anat_axilla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Superficial dissection of the pectoral region of the female. On the left side, observe the breast (skin removed) extending from the 2nd through the 6th ribs. Observe also the axillary tail extending into the axilla. The nonlactating breast consists primarily of fat. On the right side, observe the deep pectoral fascia covering the pectoralis major. Observe that the mammary gland lies in the subcutaneous connective tissue, or superficial fascia, between the skin and deep fascia.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF. Clinical Oriented Anatomy, Fourth Ed. Baltimore, Lippincott Williams &amp; Wilkins 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58037 Version 2.0</div></div></div>"},"58039":{"type":"graphic_picture","displayName":"B anthracis Gram stain","title":"<em>Bacillus anthracis</em> Gram stain","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\"><em>Bacillus anthracis</em> Gram stain</div><div class=\"cntnt\"><img style=\"width:754px; height:517px;\" src=\"images/ID/58039_BanthracisGramstain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This Gram-stained culture specimen shows chains of gram-positive, rod-shaped <em>Bacillus anthracis</em> bacteria.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Public Health Image Library (PHIL). Available at: <a href=\"https://phil.cdc.gov/Details.aspx?pid=2105\" target=\"_blank\">https://phil.cdc.gov/Details.aspx?pid=2105</a> (Accessed on March 18, 2018.)</div><div id=\"graphicVersion\">Graphic 58039 Version 4.0</div></div></div>"},"58045":{"type":"graphic_table","displayName":"Succimer pediatric lead treatment protocol","title":"Pediatric lead treatment protocol with succimer (meso-2,3-dimercaptosuccinic acid [DMSA])","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric lead treatment protocol with succimer (meso-2,3-dimercaptosuccinic acid [DMSA])</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Week/day</td> <td class=\"subtitle1\">Treatment</td> <td class=\"subtitle1\">Observation</td> </tr> <tr> <td rowspan=\"2\">0/0</td> <td>DMSA 3 times per day for 5 days*</td> <td rowspan=\"2\">1, 2, 3, 4, 5</td> </tr> <tr> <td>Vitamins and milk<sup>&#182;</sup></td> </tr> <tr> <td rowspan=\"2\">0/5</td> <td>DMSA twice a day for 14 days*</td> <td rowspan=\"2\">2, 3, 4</td> </tr> <tr> <td>Calcium and iron supplementation if necessary</td> </tr> <tr> <td>1/7</td> <td>&nbsp;</td> <td>2, 3, 4</td> </tr> <tr> <td>3/21</td> <td>&nbsp;</td> <td>1, 2, 3, 4</td> </tr> <tr> <td>5/35</td> <td>&nbsp;</td> <td>3 and other tests to check previous abnormalities or as clinically necessary</td> </tr> <tr> <td>7/49</td> <td>&nbsp;</td> <td>1, 3</td> </tr> <tr> <td>9/63</td> <td>&nbsp;</td> <td>3</td> </tr> <tr> <td>11/77</td> <td>&nbsp;</td> <td>1, 3</td> </tr> <tr> <td colspan=\"3\">Lead levels are then obtained at 15 weeks and then every 1-2 months until &#60;45 mcg/dL (2.17 micromol/L)&nbsp;with&nbsp;history and physical examination&nbsp;every other visit. The frequency of visits is individualized by patent's needs.</td> </tr> <tr> <td colspan=\"3\">Retreat&nbsp;if level rebounds to &#62;80 percent&nbsp;of original blood level and is &#8805;45 mcg/dL (2.17 micromol/L).</td> </tr> <tr> <td colspan=\"3\">1. History and physical exam</td> </tr> <tr> <td colspan=\"3\">2. Complete blood count, urinalysis</td> </tr> <tr> <td colspan=\"3\">3. Venous lead level and free erythrocyte protoporphyrin</td> </tr> <tr> <td colspan=\"3\">4. Serum electrolytes, glucose, blood urea nitrogen, creatinine, aspartate aminotransferase, alanine aminotransferase, calcium, magnesium</td> </tr> <tr> <td colspan=\"3\">5. Iron panel (serum iron, total iron binding capacity [transferrin], and ferritin)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* DMSA:10 mg/kg/dose or 350 mg/M2 /dose rounded to nearest 100 mg, 3 times a day for 5 days; followed by twice a day for 14 days. Capsules only may be opened and sprinkled on small amounts of food.<br />¶ Supplement with: multivitamin with iron and 2-3 8 oz glasses of milk per day for calcium supplementation.</div><div id=\"graphicVersion\">Graphic 58045 Version 7.0</div></div></div>"},"58046":{"type":"graphic_picture","displayName":"Hypospadias variants","title":"Hypospadias variants","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypospadias variants</div><div class=\"cntnt\"><img style=\"width:341px; height:570px;\" src=\"images/PEDS/58046_Hypospadiascomposite.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Composite of cases demonstrating increasing severity of hypospadias. A through D show standard hypospadias, and E through F show&nbsp;severe hypospadias. Note the progressive severity of the location of the ectopic urethral meatus from coronal margin (A), distal penile shaft (B, C), mid-penile shaft (D), scrotum (E),&nbsp;and perineum (F).</div><div class=\"graphic_reference\">Courtesy of Laurence S Baskin, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 58046 Version 7.0</div></div></div>"},"58047":{"type":"graphic_diagnosticimage","displayName":"MRI in normal versus SpA","title":"Comparison of magnetic resonance imaging findings in a normal subject and in a spondyloarthritis patient","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Comparison of magnetic resonance imaging findings in a normal subject and in a spondyloarthritis patient</div><div class=\"cntnt\"><img style=\"width:596px; height:260px;\" src=\"images/RHEUM/58047_MRI_normal_versus_SpA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a STIR sequence. Bone edema is seen in the SpA but not in the normal subject. Bone edema indicated by arrow.</div><div class=\"graphic_footnotes\">STIR: short tau inversion recovery; SpA: spondyloarthritis.</div><div class=\"graphic_reference\">Courtesy of Xenofon Baraliakos, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität, Herne, Germany.</div><div id=\"graphicVersion\">Graphic 58047 Version 7.0</div></div></div>"},"58048":{"type":"graphic_table","displayName":"Stress fracture imaging findings and severity classification","title":"Stress fracture imaging findings and severity classification","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stress fracture imaging findings and severity classification</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Grade\n   </td>\n   <td  class=\"subtitle1\">\n   Plain radiographs\n   </td>\n   <td  class=\"subtitle1\">\n   Bone scan<sup>[1]</sup>\n   </td>\n   <td  class=\"subtitle1\">\n   MRI<sup>[2]</sup>\n   </td>\n   </tr>\n   <tr>\n   <td>1</td>\n   <td>Normal</td>\n   <td>Small ill-defined cortical area of mildly increased activity</td>\n   <td>Positive STIR image</td>\n   </tr>\n   <tr>\n   <td>2</td>\n   <td>Normal</td>\n   <td>Larger well-defined elongated cortical area of moderately increased activity</td>\n   <td>Positive STIR and T2-weighted images</td>\n   </tr>\n   <tr>\n   <td>3</td>\n   <td>&#177; Periosteal reaction</td>\n   <td>Wide, fusiform cortico-medullary area of highly increased activity</td>\n   <td>Positive T1- and T2-weighted images, no cortical fracture line</td>\n   </tr>\n   <tr>\n   <td>4</td>\n   <td>Periosteal reaction, &#177; fracture line</td>\n   <td>Extensive trans-cortical area of intensely increased activity</td>\n   <td>Cortical fracture line; positive T1- and T2-weighted images</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">3.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=13289&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Stress_fx_XR_classificatn.htm</title></head></div><div class=\"graphic_footnotes\">STIR: short-tau inversion sequence.</div><div class=\"graphic_reference\">1. Zwas, TS, Elkanovitch, R, Frank, G. Interpretation and classification of bone scintigraphic findings in stress fractures. J Nucl Med 1987;28(4):452.<br>2. Fredericson, M, Bergman, AG, Hoffman, KL, Dillingman, MS. Tibial stress reaction in runners: Correlation of clinical symptoms and scintigraphy with a new magnetic resonance imaging grading system. Am J Sports Med 1995;23:472.</div><div id=\"graphicVersion\">Graphic 58048 Version 2.0</div></div></div>"},"58049":{"type":"graphic_figure","displayName":"Open oophorectomy c","title":"Open oophorectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Open oophorectomy</div><div class=\"cntnt\"><img style=\"width:434px; height:380px;\" src=\"images/OBGYN/58049_Open_oophorectomy_c.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The infundibulopelvic ligament (ovarian vessels) is then doubly ligated.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 58049 Version 2.0</div></div></div>"},"58051":{"type":"graphic_figure","displayName":"EPA DPA DHA chemicals","title":"Structure of long-chain n-3 PUFA found in fish oil","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Structure of long-chain n-3 PUFA found in fish oil</div><div class=\"cntnt\"><img style=\"width:528px; height:469px;\" src=\"images/PC/58051_EPA_DPA_DHA_chemicals.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long-chain n-3 PUFA are almost exclusively derived from seafood sources and include eicosapentaenoic acid (EPA,20:5n-3), docosapentaenoic acid (DPA,22:5n-3), and docosahexaenoic acid (DHA,22:6n-3). Given the long carbon chains and multiple double bonds, these fatty acids have complex 3-dimensional configurations, very different from the relatively straight chains of most other fatty acids.</div><div id=\"graphicVersion\">Graphic 58051 Version 2.0</div></div></div>"},"58052":{"type":"graphic_figure","displayName":"Role of nicotinic muscarinic","title":"Parasympathetic innervation of airways","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parasympathetic innervation of airways</div><div class=\"cntnt\"><img style=\"width:344px; height:396px;\" src=\"images/PULM/58052_Role_of_nicotinic_muscarini.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ganglionic transmission is mediated via nicotinic receptors (N), while the M<sub>1</sub> receptors may play a facilitatory role. M<sub>2</sub> receptors at the postganglionic terminal may inhibit release of acetylcholine (Ach), which acts on M<sub>3</sub> receptors on airway smooth muscle to cause bronchoconstriction.</div><div class=\"graphic_reference\">Redrawn from Barnes, PJ, Life Sciences, 1993; 52:521.</div><div id=\"graphicVersion\">Graphic 58052 Version 1.0</div></div></div>"},"58053":{"type":"graphic_waveform","displayName":"Poor R wave progress tutorial","title":"Poor R wave progression","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Poor R wave progression</div><div class=\"cntnt\"><img style=\"width:525px; height:144px;\" src=\"images/CARD/58053_Poor_R_wave_progress_tutori.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The R wave height does not become progressively taller from leads V1 to V3 or V4; in this example it remains of low amplitude until V6.</div><div id=\"graphicVersion\">Graphic 58053 Version 2.0</div></div></div>"},"58054":{"type":"graphic_algorithm","displayName":"Pelvic pain in the pregnant adolescent female with vaginal bleed","title":"Pelvic pain in the pregnant adolescent female with vaginal bleeding","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Pelvic pain in the pregnant adolescent female with vaginal bleeding</div><div class=\"cntnt\"><img style=\"width:474px; height:468px;\" src=\"images/EM/58054_Pelvic_pain_preg_adol_edt3.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">US: ultrasound.</div><div id=\"graphicVersion\">Graphic 58054 Version 5.0</div></div></div>"},"58055":{"type":"graphic_diagnosticimage","displayName":"Breast MRI of occult primary breast cancer","title":"Breast MRI of occult primary breast cancer","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Breast MRI of occult primary breast cancer</div><div class=\"cntnt\"><img style=\"width:504px; height:261px;\" src=\"images/SURG/58055_Breast_MRI_occ_prim_br_cx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Breast MRI can be useful for identifying an occult primary breast cancer when a patient presents with an unknown primary cancer. This MRI depicts a patient who presented with an axillary lymph node metastasis with an unremarkable clinical breast examination and a negative mammogram. The MRI detected a 6 mm suspiciously enhancing irregular mass in the outer inferior right breast (arrow). Biopsy revealed an invasive lobular carcinoma.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 58055 Version 4.0</div></div></div>"},"58056":{"type":"graphic_table","displayName":"Causes bone excrescences","title":"Causes of spinal bony excrescences","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of spinal bony excrescences</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Diffuse idiopathic skeletal hyperostosis</td>\n</tr>\n<tr>\n<td>Spondylitis deformans</td>\n</tr>\n<tr>\n<td>Ankylosing spondylitis</td>\n</tr>\n<tr>\n<td>Acromegaly</td>\n</tr>\n<tr>\n<td>Hypoparathyroidism</td>\n</tr>\n<tr>\n<td>Fluorosis</td>\n</tr>\n<tr>\n<td>Ochronosis</td>\n</tr>\n<tr>\n<td>Retinoids</td>\n</tr>\n<tr>\n<td>Trauma</td>\n</tr>\n<tr>\n<td>X-linked hypophosphatemic osteomalacia</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from Utsinger, PD. Diffuse idiopathic skeletal hyperostosis. Clin Rheum Dis 1985; 11:325. Copyright &#169; 1985 W.B. Saunders Company.</div><div id=\"graphicVersion\">Graphic 58056 Version 1.0</div></div></div>"},"58057":{"type":"graphic_picture","displayName":"AC shear test","title":"Acromioclavicular shear test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acromioclavicular shear test</div><div class=\"cntnt\"><img style=\"width:432px; height:316px;\" src=\"images/EM/58057_AC_shear_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Exerting a shear force across the acromioclavicular (AC) joint often elicits pain in patients with AC disorders.</div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 58057 Version 1.0</div></div></div>"},"58058":{"type":"graphic_picture","displayName":"Enteroatmospheric fistula","title":"Enteroatmospheric fistula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Enteroatmospheric fistula</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/SURG/58058_Enteroatmospheric_fist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Enteroatmospheric or exposed fistulas occur in the midst of an open abdomen with no overlying soft tissue. These fistulas occur when the abdomen is left open after trauma or emergency surgery. This photograph shows the appearance of superficial exposed fistulas draining atop the granulating wound of a frozen abdomen with an obliterated peritoneal cavity.</div><div id=\"graphicVersion\">Graphic 58058 Version 2.0</div></div></div>"},"58059":{"type":"graphic_picture","displayName":"Stye - lower lid","title":"Stye","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Stye</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/58059_Hordeolum1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An abscess is present below the lash line.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc</div><div id=\"graphicVersion\">Graphic 58059 Version 4.0</div></div></div>"},"58060":{"type":"graphic_table","displayName":"Organisms that cause eumycetoma","title":"Eumycetoma etiological agents according to their frequency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Eumycetoma etiological agents according to their frequency</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Black grains eumycetomas</td> </tr> <tr> <td class=\"subtitle2_single\">Most frequent </td> </tr> <tr> <td class=\"indent1\"><em>Madurella mycetomatis</em> </td> </tr> <tr> <td class=\"indent1\"><em>Trematosphaeria grisea </em>(formerly <em>Madurella grisea</em>)</td> </tr> <tr> <td class=\"indent1\"><em>Falciformispora senegalensis </em>(formerly <em>Leptosphaeria senegalensis</em>)&nbsp;</td> </tr> <tr> <td class=\"subtitle2_single\">Less frequent </td> </tr> <tr> <td class=\"indent1\"><em>Medicopsis romeroi </em>(formerly <em>Pyrenochaeta romeroi</em>)</td> </tr> <tr> <td class=\"subtitle2_single\">Rare </td> </tr> <tr> <td class=\"indent1\"><em>Biatriospora mackinnonii </em>(formerly <em>Pyrenochaeta mackinnonii </em>and <em>Nigrograma mackinnonii</em>)</td> </tr> <tr> <td class=\"indent1\"><em>Cladophialophora bantiana</em> </td> </tr> <tr> <td class=\"indent1\"><em>Corynespora cassicola</em> </td> </tr> <tr> <td class=\"indent1\"><em>Curvularia lunata</em> </td> </tr> <tr> <td class=\"indent1\"><em>Emarellia grisea</em></td> </tr> <tr> <td class=\"indent1\"><em>Emarellia paragrisea</em></td> </tr> <tr> <td class=\"indent1\"><em>Exophiala jeanselmei</em> </td> </tr> <tr> <td class=\"indent1\"><em>Falciformispora tompkinsii </em>(formerly <em>Leptosphaeria tompkinsii</em>)</td> </tr> <tr> <td class=\"indent1\"><em>Madurella fahalii&nbsp;</em> </td> </tr> <tr> <td class=\"indent1\"><em>Madurella pseudomycetomatis</em></td> </tr> <tr> <td class=\"indent1\"><em>Madurella tropicana </em></td> </tr> <tr> <td class=\"indent1\"><em>Phialophora verrucosa</em> </td> </tr> <tr> <td class=\"indent1\"><em>Pseudochaetosphaeronema larense</em></td> </tr> <tr> <td class=\"indent1\"><em>Rhytidhysteron rufulum</em></td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">White to yellow grains eumycetomas</td> </tr> <tr> <td class=\"subtitle2_single\">Most frequent </td> </tr> <tr> <td class=\"indent1\"><em>Scedosporium apiospermum </em>species complex (formerly <em>Pseudoallescheria boydii</em>/<em>Scedosporium apiospermum</em>)</td> </tr> <tr> <td class=\"subtitle2_single\">Less frequent </td> </tr> <tr> <td class=\"indent1\"><em>Acremonium falciforme</em> </td> </tr> <tr> <td class=\"indent1\"><em>Fusarium solani</em> </td> </tr> <tr> <td class=\"subtitle2_single\">Rare </td> </tr> <tr> <td class=\"indent1\"><em>Acremonium kiliense</em> </td> </tr> <tr> <td class=\"indent1\"><em>Acremonium recifei</em> </td> </tr> <tr> <td class=\"indent1\"><em>Arthrographis kalrae</em> </td> </tr> <tr> <td class=\"indent1\"><em>Aspergillus flavus</em> </td> </tr> <tr> <td class=\"indent1\"><em>Aspergillus fumigatus</em> </td> </tr> <tr> <td class=\"indent1\"><em>Aspergillus nidulans</em> </td> </tr> <tr> <td class=\"indent1\"><em>Cylindrocarpon cyanescens</em> </td> </tr> <tr> <td class=\"indent1\"><em>Cylindrocarpon destructans</em> </td> </tr> <tr> <td class=\"indent1\"><em>Cylindrocarpon lichenicola</em> </td> </tr> <tr> <td class=\"indent1\"><em>Fusarium keratoplasticum </em></td> </tr> <tr> <td class=\"indent1\"><em>Fusarium pseudensiforme</em></td> </tr> <tr> <td class=\"indent1\"><em>Neotestudina rosatii</em> </td> </tr> <tr> <td class=\"indent1\"><em>Paecilomyces&nbsp;lilacinus</em> </td> </tr> <tr> <td class=\"indent1\"><em>Phaeoacremonium krajdenii</em></td> </tr> <tr> <td class=\"indent1\"><em><em>Phaeoacremonium&nbsp;parasiticum</em></em>&nbsp;&nbsp;</td> </tr> <tr> <td class=\"indent1\"><em>​Phaeoacremonium sphinctrophorum</em></td> </tr> <tr> <td class=\"indent1\"><em>Pleurostomophora ochracea</em></td> </tr> <tr> <td class=\"indent1\"><em>Polycytella hominis</em> </td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58060 Version 5.0</div></div></div>"},"58061":{"type":"graphic_picture","displayName":"RMSF rash","title":"Rocky Mountain spotted fever rash","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rocky Mountain spotted fever rash</div><div class=\"cntnt\"><img style=\"width:322px; height:178px;\" src=\"images/ID/58061_RMSF_rash.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Child with Rocky Mountain spotted fever has the rash that is characteristic but typically does not appear until several days after fever onset.</div><div class=\"graphic_reference\">From: Fatal Cases of Rocky Mountain Spotted Fever in Family Clusters --- Three States, 2003. MMWR Morb Mortal Wkly Rep 2004; 53(19):407. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5319a1.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5319a1.htm</a>.</div><div id=\"graphicVersion\">Graphic 58061 Version 5.0</div></div></div>"},"58062":{"type":"graphic_diagnosticimage","displayName":"Arachnoid cyst","title":"Arachnoid cyst at 26 postmenstrual weeks","html":"<div class=\"graphic\"><div style=\"width: 635px\" class=\"figure\"><div class=\"ttl\">Arachnoid cyst at 26 postmenstrual weeks</div><div class=\"cntnt\"><img style=\"width:615px; height:185px;\" src=\"images/OBGYN/58062_Arachnoid_cyst_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A, axial section showing the sonolucent defect (arrow), which does not communicate with the ventricles. Panels B and C are transvaginal scans. Panel B is a coronal section showing the cyst (arrow), which pushes the brain parenchyma to one side. However, there is no hydrocephaly. Panel C, more precisely shows the location of the cyst, which is in the quadrigeminal cistern, just inferior and posterior to the corpus callosum. No hydrocephaly is evident.</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 58062 Version 4.0</div></div></div>"},"58063":{"type":"graphic_diagnosticimage","displayName":"Spina bifida 3D","title":"Spina bifida","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spina bifida</div><div class=\"cntnt\"><img style=\"width:221px; height:343px;\" src=\"images/OBGYN/58063_Spina_bifida_3D.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three-dimensional surface rendering of the spinal defect.</div><div id=\"graphicVersion\">Graphic 58063 Version 3.0</div></div></div>"},"58064":{"type":"graphic_table","displayName":"History reading difficulty","title":"Important aspects of the history in a child with reading difficulty","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important aspects of the history in a child with reading difficulty</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Feature</td> <td class=\"subtitle1\">Clinical implications</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Perinatal history</td> </tr> <tr> <td class=\"indent1\">Maternal drug or alcohol intake</td> <td>May cause neurologic problems<span style=\"color: black;\"> (eg, fetal alcohol spectrum disorder)</span></td> </tr> <tr> <td class=\"indent1\">Congenital infections</td> <td>May cause neurologic or hearing problems</td> </tr> <tr> <td class=\"indent1\">Gestational age, birth weight</td> <td>Premature birth is a risk for learning disability</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Medical history</td> </tr> <tr> <td class=\"indent1\">Recurrent or persistent ear infections</td> <td>May be associated with hearing impairment</td> </tr> <tr> <td class=\"indent1\">Iron deficiency</td> <td>Associated with neurologic deficits</td> </tr> <tr> <td class=\"indent1\">Lead poisoning</td> <td>Associated with neurologic deficits and hearing impairment</td> </tr> <tr> <td class=\"indent1\">Seizures</td> <td>May be associated with neurologic problems</td> </tr> <tr> <td class=\"indent1\">Frequent injuries</td> <td>May indicate coordination difficulties, history of closed head injury, poor supervision, and/or environmental deprivation</td> </tr> <tr> <td class=\"indent1\">Chronic illness or medication usage</td> <td>May be associated with side effects or school absences with secondary effects on learning</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Developmental history</td> </tr> <tr> <td class=\"indent1\">Delayed or disordered acquisition of language milestones and communication skills</td> <td>Language delay is a risk for reading difficulty</td> </tr> <tr> <td class=\"indent1\">Uneven pattern of skills and interests</td> <td>May indicate learning disability</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Behavioral history</td> </tr> <tr> <td class=\"indent1\">Problems with attention, impulsivity, overactivity, acting out</td> <td>Behavioral problems may affect learning</td> </tr> <tr> <td class=\"indent1\">Sadness</td> <td>Emotional problems may affect learning</td> </tr> <tr> <td class=\"indent1\">Poor self-esteem</td> <td>May be a consequence of reading difficulty</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Social history</td> </tr> <tr> <td class=\"indent1\">Child abuse or neglect, or other social stressors (eg, homelessness, poverty, illness in family member)</td> <td>These stressors may affect learning</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Family history</td> </tr> <tr> <td class=\"indent1\">Learning problems, reading or spelling problems, avoidance of reading, school failure among first-degree relatives</td> <td>Increases risk of reading disability</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">School history</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Academic achievement</td> </tr> <tr> <td class=\"indent2\">Best and worst subjects</td> <td>Children with reading disability may excel in other areas or areas of interest (eg, math, science)</td> </tr> <tr> <td class=\"indent2\">History of grade retention</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Classroom behavior</td> </tr> <tr> <td class=\"indent2\">Long-standing problems with attention, impulsivity, overactivity</td> <td>Reading disability is associated with attention deficit hyperactivity disorder, which can further interfere with school function</td> </tr> <tr> <td class=\"indent2\">Depression, moodiness</td> <td>Emotional problems may affect learning</td> </tr> <tr> <td class=\"indent2\">Behavior differs in reading versus other subjects</td> <td>Children with reading difficulty may \"act out\" during activities that require reading</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Attendance</td> </tr> <tr> <td class=\"indent2\">Excessive absenteeism</td> <td>Frequent absences may affect learning</td> </tr> <tr> <td class=\"indent2\">School avoidance</td> <td>Children with reading difficulty may try to avoid school</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Past psychoeducational testing</td> </tr> <tr> <td class=\"indent2\">Discrepancy between cognitive abilities and academic achievement</td> <td>Suggestive of a learning disability</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Special educational services</td> </tr> <tr> <td class=\"indent2\">Response to educational interventions</td> <td>Lack of response suggests a learning disability rather than lack of exposure to reading and or inadequate instruction before formal schooling</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58064 Version 4.0</div></div></div>"},"58066":{"type":"graphic_movie","displayName":"Inlet VSD 4 chamber 2D and color","title":"Inlet VSD 4 chamber 2D and color","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Inlet VSD 4 chamber 2D and color</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/58066_InletVSD4chamb2Dmovie.mp4\" style=\"width:496px;height:400px\"></div><img style=\"width:560px; height:440px;\" src=\"images/CARD/58066_InletVSD4chamb2Dposter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In these paired apical images (inverted), the atrioventricular valves can be seen to move in the same plane. In both panels, there are abnormal mitral valve attachments to the trabecular portion of the intraventricular septum in addition to the more normal septal attachments of the tricuspid valve. In the right hand panel, color flow mapping demonstrates the left-to-right flow across the large septal defect.</div><div class=\"graphic_footnotes\">RA: right atrium; LA: left atrium; TV: tricuspid valve; MV: mitral valve; RV: right ventricle; LV: left ventricle; IVS: intraventricular septum; arrow: VSD.</div><div id=\"graphicVersion\">Graphic 58066 Version 4.0</div></div></div>"},"58067":{"type":"graphic_picture","displayName":"Nummular eczema legs","title":"Nummular eczema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nummular eczema</div><div class=\"cntnt\"><img style=\"width:350px; height:272px;\" src=\"images/DERM/58067_Nummulareczemalegs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These coin-shaped, scaly lesions on the thigh show evidence of postinflammatory hyperpigmentation.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58067 Version 6.0</div></div></div>"},"58068":{"type":"graphic_picture","displayName":"Gastric leiomyoma Endosc","title":"Gastric leiomyoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric leiomyoma</div><div class=\"cntnt\"><img style=\"width:324px; height:315px;\" src=\"images/GAST/58068_Gastric_leiomyoma_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy shows a protuberance in the antrum with overlying normal appearing mucosa (arrow). The diagnosis of a gastric leiomyoma was made during a subsequent endoscopic ultrasound.</div><div class=\"graphic_reference\">Courtesy of Laurence Bailen, MD.</div><div id=\"graphicVersion\">Graphic 58068 Version 1.0</div></div></div>"},"58070":{"type":"graphic_table","displayName":"US findings celiac disease","title":"Demographic profile and ultrasound findings of patients with celiac disease and healthy controls","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Demographic profile and ultrasound findings of patients with celiac disease and healthy controls</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Celiac disease</td> <td class=\"subtitle1\">Healthy controls</td> </tr> <tr> <td><strong>Number (female/male)</strong></td> <td>50 (39/11)</td> <td>38 (20/18)</td> </tr> <tr> <td><strong>Age [years]</strong></td> <td>45 &#177; 16 [18-77]</td> <td>40 &#177; 9 [32-66]</td> </tr> <tr> <td><strong>Body weight [kg]</strong></td> <td>57 &#177; 11 [35-87]</td> <td>78 &#177; 14 [55-120]</td> </tr> <tr> <td><strong>Body length [cm]</strong></td> <td>165 &#177; 8 [145-183]</td> <td>176 &#177; 10 [156-196]</td> </tr> <tr> <td><strong>\"Laundry phenomenon\"*</strong></td> <td>16/50 (32 percent)<sup>&#182;<sup></sup></sup></td> <td>0</td> </tr> <tr> <td><strong>Bowel wall thickening</strong></td> <td>4/50 (8 percent)<sup>&#916;</sup></td> <td>0</td> </tr> <tr> <td><strong>Lymph node detection rate</strong></td> <td>24/50 (48 percent)</td> <td>14/38 (37 percent)</td> </tr> <tr> <td><strong>Spleen volume [mL]</strong></td> <td>109 &#177; 34 [33-192]</td> <td>149 &#177; 40 [66-210]</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Hyperechoic images, like laundry in the drum of a washing machine.<br />&para; All 16 patients with active celiac disease.<br />&Delta; All four patients with malignant disease.</div><div id=\"graphicVersion\">Graphic 58070 Version 4.0</div></div></div>"},"58071":{"type":"graphic_diagnosticimage","displayName":"Cystic hygroma MRI I","title":"Cystic hygroma in left axillary region","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cystic hygroma in left axillary region</div><div class=\"cntnt\"><img style=\"width:396px; height:240px;\" src=\"images/PULM/58071_Cystic_hygroma_MRI_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spin-echo, T2-weighted MR sequence shows high signal mass in the left axilla, which corresponds to the cyst seen on the CT scan.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 58071 Version 3.0</div></div></div>"},"58072":{"type":"graphic_picture","displayName":"Nasal mask for ventilation","title":"Nasal mask for intermittent positive pressure ventilation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nasal mask for intermittent positive pressure ventilation</div><div class=\"cntnt\"><img style=\"width:308px; height:158px;\" src=\"images/PULM/58072_Nasal_mask_for_ventilation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The nasal mask, developed in the 1980s for administration of continuous positive airway pressure (CPAP) in patients with obstructive sleep apnea, is used to provide nocturnal assisted ventilation for a variety of disorders.</div><div class=\"graphic_reference\">Courtesy of Peter C Gay, MD.</div><div id=\"graphicVersion\">Graphic 58072 Version 2.0</div></div></div>"},"58075":{"type":"graphic_waveform","displayName":"Mitral stenosis gradients","title":"Mitral stenosis gradients","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Mitral stenosis gradients</div><div class=\"cntnt\"><img style=\"width:491px; height:337px;\" src=\"images/CARD/58075_Mitralstenosisgradients.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mitral Stenosis. The LV and PCW (left side) is compared with LV and LA pressures (transseptal) to demonstrate differences in mitral gradients.</div><div class=\"graphic_footnotes\">LV: left ventricle; PCW: pulmonary capillary wedge; LA: left atrial</div><div id=\"graphicVersion\">Graphic 58075 Version 3.0</div></div></div>"},"58076":{"type":"graphic_table","displayName":"Examples of agoraphobic behaviors","title":"Examples of agoraphobic safety behaviors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of agoraphobic safety behaviors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Travelling with a familiar person</td> </tr> <tr> <td>Carrying a cell phone</td> </tr> <tr> <td>Carrying medication</td> </tr> <tr> <td>Carrying a water bottle</td> </tr> <tr> <td>Sitting close to an exit or a door</td> </tr> <tr> <td>Taking a medication prophylactically (eg, anti-diarrheal or anti-nauseant)</td> </tr> <tr> <td>Carrying a paper bag (in case of hyperventilation)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58076 Version 1.0</div></div></div>"},"58078":{"type":"graphic_table","displayName":"Molecular tests for meningitis","title":"Molecular tests for meningitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Molecular tests for meningitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Etiology</td> <td class=\"subtitle1\">Availability<sup>*</sup></td> <td class=\"subtitle1\">When inclusion of NAT is indicated</td> <td class=\"subtitle1\">Preferred testing method(s)<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Bacteria</td> </tr> <tr> <td class=\"indent1\">Common pathogens (eg, <em>Streptococcus pneumoniae</em>, <em>Haemophilus influenzae</em>)</td> <td>Yes<sup>&#916;</sup></td> <td>Gram stain positive, culture negative; prior antibacterial therapy</td> <td>Gram stain and&nbsp;culture</td> </tr> <tr> <td class=\"indent1\">Fastidious organisms (<em>Mycoplasma</em> spp, <em>Tropheryma</em> spp, <em>Brucella </em>spp)</td> <td>Yes</td> <td>When clinically suspected</td> <td>Serology, NAT +/&ndash; culture</td> </tr> <tr> <td class=\"indent1\">Mycobacterium tuberculosis<sup>&#9674;</sup></td> <td>Yes</td> <td>When clinically suspected</td> <td>AFB stain, culture, and NAT</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Prior antibiotic therapy<sup>&#167;</sup></td> <td>Yes<sup>&#916;</sup></td> <td>Rarely</td> <td>Culture prior to antibacterial therapy</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Viruses</td> </tr> <tr> <td class=\"indent1\">Adenoviruses</td> <td>Yes</td> <td>Rarely</td> <td>Testing of alternative sites (eg, respiratory) +/&ndash; CSF</td> </tr> <tr> <td class=\"indent1\">Arboviruses</td> <td>Limited</td> <td>When clinically suspected</td> <td>Serology and NAT</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus (CMV)</td> <td>Yes<sup>&#916;</sup></td> <td>When clinically suspected</td> <td>NAT, preferably quantitative</td> </tr> <tr> <td class=\"indent1\">Epstein Barr Virus (EBV)</td> <td>Yes</td> <td>When clinically suspected</td> <td>Serology and NAT, preferably quantitative</td> </tr> <tr> <td class=\"indent1\">Enteroviruses</td> <td>Widespread<sup>&#916;</sup></td> <td>When clinically suspected</td> <td>NAT</td> </tr> <tr> <td class=\"indent1\">Human herpesvirus 6 (HHV-6)</td> <td>Yes<sup>&#916;</sup></td> <td>When clinically suspected</td> <td>NAT, preferably quantitative</td> </tr> <tr> <td class=\"indent1\">Herpes simplex virus (HSV)</td> <td>Widespread<sup>&#916;</sup></td> <td>When clinically suspected</td> <td>NAT</td> </tr> <tr> <td class=\"indent1\">Influenza</td> <td>Yes</td> <td>Rarely</td> <td>Testing of alternative sites (eg, respiratory) +/&ndash; CSF</td> </tr> <tr> <td class=\"indent1\">Lymphocytic choriomeningitis virus</td> <td>Limited</td> <td>Rarely</td> <td>Serology</td> </tr> <tr> <td class=\"indent1\">Mumps</td> <td>Limited</td> <td>Rarely</td> <td>Viral culture, serology, and NAT</td> </tr> <tr> <td class=\"indent1\">Parechoviruses<sup>&#165;</sup></td> <td>Yes<sup>&#916;</sup></td> <td>Primarily in young children (&#60;5 years old)</td> <td>NAT</td> </tr> <tr> <td class=\"indent1\">Varicella-zoster virus</td> <td>Yes<sup>&#916;</sup></td> <td>When clinically suspected</td> <td>NAT</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">West Nile virus<sup>&#135;</sup></td> <td>Yes</td> <td>Rarely (unless immunodeficient)</td> <td>Serology</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Rickettsia<sup>&#134;</sup></td> <td>Limited</td> <td>Occasionally</td> <td>Serology</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Spirochetes</td> </tr> <tr> <td class=\"indent1\"><em>Leptospira</em></td> <td>Limited</td> <td>Rarely</td> <td>Serology</td> </tr> <tr> <td class=\"indent1\"><em>Borrelia burgdorferi</em> (the agent of Lyme disease)</td> <td>Yes</td> <td>Yes</td> <td>Serology, NAT</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>Treponema pallidum</em> (syphilis)</td> <td>Limited</td> <td>No</td> <td>Serology, CSF VDRL</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Fungal</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>Cryptococcus</em> spp</td> <td>Yes<sup>&#916;</sup></td> <td>No</td> <td>Antigen detection, culture</td> </tr> <tr> <td class=\"subtitle2_left\">Other fungi (eg, <em>Coccidioides</em> spp)</td> <td>Limited</td> <td>Rarely</td> <td>Culture, serology</td> </tr> <tr> <td class=\"subtitle2_left\">Parasites</td> <td>Limited</td> <td>Rarely</td> <td>Serology, histologic exam, NAT for select pathogens</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PPV: positive predictive value; PCR: polymerase chain reaction; CDC: Centers for Disease Control and Prevention; NAT: nucleic acid amplification testing; CSF: cerebrospinal fluid; AFB: acid-fast bacilli; VDRL: Venereal Disease Research Laboratories; FDA: US Food and Drug Administration.<br />* Widespread: readily available; Yes: consistently available, but not yet common; Limited: one or two specialized laboratories (eg, CDC or research groups).<br />¶&nbsp;Test on CSF except where noted.<br />Δ&nbsp;Also available as part of FDA-cleared multiplex NAT at some centers and referral laboratories.<br />◊&nbsp;Poor sensitivity, high PPV, rapid.<br />§&nbsp;16s rDNA \"universal\" PCR.<br />¥&nbsp;Not detected by most enterovirus assays.<br />‡&nbsp;Virus is usually cleared from blood and CSF prior to symptom onset.<br />†&nbsp;Limited experience from CSF.</div><div id=\"graphicVersion\">Graphic 58078 Version 8.0</div></div></div>"},"58079":{"type":"graphic_figure","displayName":"Number BPmeds HTNcontrol","title":"Average number of antihypertensive agents needed per patient to achieve target systolic BP goals","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Average number of antihypertensive agents needed per patient to achieve target systolic BP goals</div><div class=\"cntnt\"><img style=\"width:463px; height:264px;\" src=\"images/NEPH/58079_Number_BPmeds_HTNcontrol.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Updated from: Bakris GL. Preserving renal function in adults with hypertension and diabetes: A consensus approach. Am J Kidney Dis 2000; 36:646.</div><div id=\"graphicVersion\">Graphic 58079 Version 2.0</div></div></div>"},"58081":{"type":"graphic_figure","displayName":"McRoberts position","title":"Effect of McRoberts positioning relative to lithotomy position","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Effect of McRoberts positioning relative to lithotomy position</div><div class=\"cntnt\"><img style=\"width:232px; height:451px;\" src=\"images/OBGYN/58081_McRoberts_position.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The patient's legs have been hyperflexed by assistants. The 16 degree rotation for a 10.5-cm obstetric conjugate (ideally) moves the symphisis pubis 9 mm anteriorly and 28 mm in a cephalad direction.<br />(B) Lithotomy position.</div><div class=\"graphic_reference\">Reproduced with permission from: Poggi SH, Spong CY, Allen AH. Prioritizing posterior arm delivery during severe shoulder dystocia. Obstet Gynecol 2003; 101:1068. Copyright © 2003 American College of Obstetricians and Gynecologists.</div><div id=\"graphicVersion\">Graphic 58081 Version 3.0</div></div></div>"},"58083":{"type":"graphic_diagnosticimage","displayName":"Brain atrophy MS","title":"Brain atrophy in multiple sclerosis on MRI","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\">Brain atrophy in multiple sclerosis on MRI</div><div class=\"cntnt\"><img style=\"width:581px; height:226px;\" src=\"images/NEURO/58083_Brain_atrophy_MS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These brain MRI images were acquired over the course of seven years from a single untreated patient with multiple sclerosis, and show progression of generalized brain atrophy from the first scan (left panel) to the most recent (right panel).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Biogen Idec, Inc. Copyright &copy; 2012.</div><div id=\"graphicVersion\">Graphic 58083 Version 4.0</div></div></div>"},"58084":{"type":"graphic_table","displayName":"Clinical presentations of gonadotroph adenomas","title":"Clinical presentations of gonadotroph adenomas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical presentations of gonadotroph adenomas</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Neurologic symptoms (most common)</td> </tr> <tr> <td>Visual impairment</td> </tr> <tr> <td>Headache</td> </tr> <tr> <td>Other (including diplopia, seizures, and CSF rhinorrhea)</td> </tr> <tr> <td class=\"subtitle1_single\">Incidental finding</td> </tr> <tr> <td>When an imaging procedure is performed because of an unrelated symptom</td> </tr> <tr> <td class=\"subtitle1_single\">Hypopituitarism</td> </tr> <tr> <td>Biochemical evidence (most common)</td> </tr> <tr> <td>Clinical symptoms (less common, but include oligomenorrhea or amenorrhea in women, decreased libido and/or erectile dysfunction in men)</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical syndromes due to hormonal hypersecretion (rare)</td> </tr> <tr> <td>Ovarian hyperstimulation when FSH is secreted excessively in a premenopausal woman</td> </tr> <tr> <td>Premature puberty when intact LH is secreted in a prepubertal boy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CSF: cerebrospinal fluid; FSH: follicle-stimulating hormone; LH: luteinizing hormone.</div><div id=\"graphicVersion\">Graphic 58084 Version 3.0</div></div></div>"},"58085":{"type":"graphic_diagnosticimage","displayName":"Plain film billie club","title":"Colonic foreign body","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Colonic foreign body</div><div class=\"cntnt\"><img style=\"width:348px; height:432px;\" src=\"images/GAST/58085_Plain_film_billie_club.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain film demonstrating a Billie club extending towards the right upper quadrant (arrow).</div><div class=\"graphic_reference\">Courtesy of Scott Steele, MD.</div><div id=\"graphicVersion\">Graphic 58085 Version 2.0</div></div></div>"},"58086":{"type":"graphic_figure","displayName":"Thyroid anatomy","title":"Thyroid anatomy","html":"<div class=\"graphic\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Thyroid anatomy</div><div class=\"cntnt\"><img style=\"width:608px; height:436px;\" src=\"images/SURG/58086_Detailed_thyroid_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dissection of the anterior neck. Anterior view. The fascia has been removed, and the muscles on the left side have been reflected to show the hyoid bone, thyroid gland, and structures related to the carotid sheath (carotid artery, internal jugular vein [IJV], vagus nerve [CN X], and deep cervical lymph nodes).</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF. Clinical Oriented Anatomy, Fourth Edition. Baltimore: Lippincott Williams &amp; Wilkins, 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58086 Version 5.0</div></div></div>"},"58087":{"type":"graphic_figure","displayName":"Monosymptomatic enuresis epidemiology","title":"Epidemiology and prognosis of monosymptomatic enuresis","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Epidemiology and prognosis of monosymptomatic enuresis</div><div class=\"cntnt\"><img style=\"width:488px; height:353px;\" src=\"images/PEDS/58087_Monosymptomatic_enuresis_epidemiology.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Nev&#233;us T, Eggert P, Evans J, et al. Evaluation and treatment of monosymptomatic enuresis - a standardisation document from the International Children's Continence Society (ICCS). Copyright &#169; 2009 ICCS.</div><div id=\"graphicVersion\">Graphic 58087 Version 3.0</div></div></div>"},"58088":{"type":"graphic_figure","displayName":"Basic vertebral anatomy","title":"Basic vertebral anatomy","html":"<div class=\"graphic\"><div style=\"width: 626px\" class=\"figure\"><div class=\"ttl\">Basic vertebral anatomy</div><div class=\"cntnt\"><img style=\"width:606px; height:456px;\" src=\"images/EM/58088_Basicvertebralanatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A &quot;typical&quot; vertebra, represented by L2.<br> (A) Functional components include the vertebral body (bone color), a vertebral arch (red), and seven processes: three for muscle attachment and leverage (blue) and four that participate in synovial joints with adjacent vertebrae (yellow).<br> (B, C) Bony formations of the vertebrae are demonstrated. The vertebral foramen is bounded by the vertebral arch and body. A small superior vertebral notch and a larger inferior vertebral notch flank the pedicle.<br> (D) The superior and inferior notches of adjacent vertebrae plus the IV disc that unites them form the IV foramen for the passage of a spinal nerve and its accompanying vessels. Note that each articular process has an articular facet where contact occurs with the articular facets of adjacent vertebrae (B-D).</div><div class=\"graphic_footnotes\">IV: intervertebral.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 58088 Version 11.0</div></div></div>"},"58089":{"type":"graphic_figure","displayName":"Relative risks of the main complications of CKD","title":"Relative risks of major complications of chronic kidney disease based upon a continuous meta-analysis","html":"<div class=\"graphic\"><div style=\"width: 648px\" class=\"figure\"><div class=\"ttl\">Relative risks of major complications of chronic kidney disease based upon a continuous meta-analysis</div><div class=\"cntnt\"><img style=\"width:628px; height:398px;\" src=\"images/NEPH/58089_Summary_risks_meta-analysis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Summary of continuous meta-analysis (adjusted RR) for general population cohorts with ACR. Mortality is reported for general population cohorts assessing albuminuria as urine ACR. Kidney outcomes are reported for general population cohorts assessing albuminuria as either urine ACR or dipstick. eGFR is expressed as a continuous variable. The three lines represent urine ACR of &lt;30 mg/g or dipstick negative and trace (blue), urine ACR 30-299 mg/g or dipstick 1+ positive (green), and urine ACR &gt;300 mg/g or dipstick &gt;2+ positive (red). All results are adjusted for covariates and compared with reference point of eGFR of 95 mL/min per 1.73 m<sup>2</sup> and ACR of &lt;30 mg/g or dipstick negative (diamond). Each point represents the pooled RR from a meta-analysis. Solid circles indicate statistical significance compared with the reference point (p&lt;0.05); triangles indicate non-significance. Red arrows indicate eGFR of 60 mL/min per 1.73 m<sup>2</sup>, threshold value of eGFR for the current definition of CKD.</div><div class=\"graphic_footnotes\">CKD: chronic kidney disease; ACR: albumin creatinine ratio; HR: hazard ratio; eGFR: estimated glomerular filtration rate; RR: relative risk.</div><div class=\"graphic_reference\">Reprinted by Permission from Macmillan Publishers Ltd: Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2010; 80:17. Copyright &copy; 2010.</div><div id=\"graphicVersion\">Graphic 58089 Version 6.0</div></div></div>"},"58090":{"type":"graphic_picture","displayName":"TA stapling device","title":"TA stapling device","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">TA stapling device</div><div class=\"cntnt\"><img style=\"width:576px; height:335px;\" src=\"images/SURG/58090_TA_stapling_device_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Picture of a DST Series&#8482; TA&#8482; Single Use Reloadable Stapler.</div><div class=\"graphic_reference\">Copyright &#169; 2011 Covidien. All rights reserved. Used with the permission of Covidien.</div><div id=\"graphicVersion\">Graphic 58090 Version 1.0</div></div></div>"},"58091":{"type":"graphic_diagnosticimage","displayName":"Tissue Doppler echocardiogram LV","title":"Example of tissue Doppler echocardiographic imaging of left ventricle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Example of tissue Doppler echocardiographic imaging of left ventricle</div><div class=\"cntnt\"><img style=\"width:387px; height:263px;\" src=\"images/CARD/58091_TissueDopplerechoLV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown is an example of low velocity Doppler imaging of myocardial motion, known as tissue Doppler. In this example, velocities of up to 8 cm/sec are color coded according to direction and velocity. As shown in the upper left velocity display, myocardial motion towards the transducer is coded in shades of red and orange (hot colors) and away motion in blue and green (cool colors). The normal short axis precordial image at the top of the screen is shown in mid systole with the anteroseptal walls moving away from the transducer and the posteroinferior walls toward. An M-mode tracing details the midseptum and the posterior wall. Note that at peak systole both opposing walls accelerate to at least 8 m/sec and also that there is a gradient of velocity within the myocardium (endocardial layers fastest).</div><div id=\"graphicVersion\">Graphic 58091 Version 4.0</div></div></div>"},"58092":{"type":"graphic_figure","displayName":"Obstructive flow volume curve","title":"Obstructive defect","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Obstructive defect</div><div class=\"cntnt\"><img style=\"width:460px; height:333px;\" src=\"images/PEDS/58092_Obstructive_flow_volume_cur.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The flow-volume curve in a&nbsp;patient with an obstructive defect (red, solid line) demonstrates scooping of the expiratory portion of the&nbsp;flow-volume&nbsp;curve&nbsp;compared&nbsp;with the predicted curve (blue, dashed line). The&nbsp;expiratory flow rate is reduced over most of the&nbsp;vital capacity.</div><div id=\"graphicVersion\">Graphic 58092 Version 4.0</div></div></div>"},"58093":{"type":"graphic_picture","displayName":"Fourniers gangrene","title":"Fournier's gangrene in a patient with diabetes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fournier's gangrene in a patient with diabetes</div><div class=\"cntnt\"><img style=\"width:291px; height:432px;\" src=\"images/PC/58093_Fourniers_gangrene.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Necrotizing fasciitis of the perineum (Fournier's gangrene) can involve the scrotum. The infection can begin abruptly with severe pain and may spread rapidly.</div><div class=\"graphic_reference\">Reproduced with permission from Lawrence B Stack, MD.</div><div id=\"graphicVersion\">Graphic 58093 Version 1.0</div></div></div>"},"58095":{"type":"graphic_diagnosticimage","displayName":"Benign granuloma CT","title":"Benign granuloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Benign granuloma</div><div class=\"cntnt\"><img style=\"width:361px; height:243px;\" src=\"images/PULM/58095_Benign_granuloma_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan confirms the location of the nodule in the lateral segment of the right middle lobe, abutting the major fissure and the parietal pleura. A small central lucency indicates incipient cavitation.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 58095 Version 3.0</div></div></div>"},"58102":{"type":"graphic_picture","displayName":"IgA nephropathy EM","title":"Electron micrograph showing mesangial immunoglobulin A (IgA) deposits","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electron micrograph showing mesangial immunoglobulin A (IgA) deposits</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/58102_IgA_nephropathy_EM_Edit1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power electron micrograph in IgA nephropathy. The primary finding is electron-dense deposits that are limited to the mesangial regions (D). The glomerular basement membrane (GBM) is normal, and there are no glomerular capillary wall deposits.</div><div class=\"graphic_footnotes\">Endo: endothelial cell nucleus.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 58102 Version 7.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Electron micrograph of a normal glomerulus</div><div class=\"cntnt\"><img style=\"width:377px; height:266px;\" src=\"images/NEPH/50018_Normal_glomerulus_EM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron-dense deposits are present. Two normal platelets are seen in the capillary lumen.</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 50018 Version 7.0</div></div></div>"},"58103":{"type":"graphic_figure","displayName":"Brown Sequard syndrome","title":"Location of lesion in Brown-Sequard syndrome","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Location of lesion in Brown-Sequard syndrome</div><div class=\"cntnt\"><img style=\"width:542px; height:353px;\" src=\"images/NEURO/58103_Brown_Sequard_syndrome.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 58103 Version 2.0</div></div></div>"},"58104":{"type":"graphic_table","displayName":"Major causes of DIC","title":"Major causes of disseminated intravascular coagulation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of disseminated intravascular coagulation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Events that initiate DIC</td> </tr> <tr> <td class=\"indent1\">Septicemia - Gram negative and Gram positive</td> </tr> <tr> <td class=\"indent1\">Crush injury or complicated surgery</td> </tr> <tr> <td class=\"indent1\">Severe head injury</td> </tr> <tr> <td class=\"indent1\">Cancer procoagulant (Trousseau's syndrome)</td> </tr> <tr> <td class=\"indent1\">Acute leukemia, especially promyelocytic</td> </tr> <tr> <td class=\"sublist2_start\">Complications of pregnancy</td> </tr> <tr> <td class=\"sublist2\">Amniotic fluid embolism</td> </tr> <tr> <td class=\"sublist2\">Abruptio placentae</td> </tr> <tr> <td class=\"sublist2\">HELLP syndrome</td> </tr> <tr> <td class=\"sublist2\">Eclampsia and severe preeclampsia</td> </tr> <tr> <td class=\"sublist2\">Septic abortion</td> </tr> <tr> <td class=\"indent1\">Amphetamine overdose</td> </tr> <tr> <td class=\"indent1\">Giant hemangioma (Kasabach-Merritt syndrome)</td> </tr> <tr> <td class=\"indent1\">Abdominal aortic aneurysm</td> </tr> <tr> <td class=\"indent1\">Peritoneovenous shunt</td> </tr> <tr> <td class=\"indent1\">Acute hemolytic transfusion reaction (ABO incompatibility)</td> </tr> <tr> <td class=\"indent1\">Paroxysmal nocturnal hemoglobinuria</td> </tr> <tr> <td class=\"indent1\">Snake and viper venoms</td> </tr> <tr> <td class=\"sublist2_start\">Liver disease</td> </tr> <tr> <td class=\"sublist2\">Fulminant hepatic failure</td> </tr> <tr> <td class=\"sublist2\">Reperfusion after liver transplantation</td> </tr> <tr> <td class=\"indent1\">Heat stroke</td> </tr> <tr> <td class=\"indent1\">Burns</td> </tr> <tr> <td class=\"indent1\">Purpura fulminans</td> </tr> <tr> <td class=\"subtitle1_single\">Events that complicate and propagate DIC</td> </tr> <tr> <td class=\"indent1\">Shock</td> </tr> <tr> <td class=\"indent1\">Complement pathway activation</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58104 Version 3.0</div></div></div>"},"58106":{"type":"graphic_diagnosticimage","displayName":"Greenstick and complete fracture","title":"Midshaft forearm fracture","html":"<div class=\"graphic\"><div style=\"width: 509px\" class=\"figure\"><div class=\"ttl\">Midshaft forearm fracture</div><div class=\"cntnt\"><img style=\"width:489px; height:371px;\" src=\"images/EM/58106_Greenstick_and_complete_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">6-year-old with unstable midshaft radius and ulna fracture with significant dorsal displacement and volar angulation. The radius fracture is a greenstick with 30 degrees of angulation. The ulna fracture is complete with angulation and displacement.</div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD.</div><div id=\"graphicVersion\">Graphic 58106 Version 3.0</div></div></div>"},"58108":{"type":"graphic_table","displayName":"Disorders Ca sensing CaSR","title":"Disorders of extracellular calcium-sensing by the CaSR","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders of extracellular calcium-sensing by the CaSR</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Disorders with generalized decrease in sensitivity to Ca<sup>2+</sup> (affecting all CaSR-expressing tissue)</td> </tr> <tr> <td>FHH</td> </tr> <tr> <td>NHPT and NSHPT</td> </tr> <tr> <td>Familial isolated hyperparathyroidism caused by CaSR mutations</td> </tr> <tr> <td>Autoimmune hypocalciuric hypercalcemia</td> </tr> <tr> <td class=\"subtitle1_single\">Disorders with parathyroid-specific decrease in sensitivity to Ca<sup>2+</sup></td> </tr> <tr> <td>Primary hyperparathyroidism</td> </tr> <tr> <td>Severe uremic secondary and tertiary hyperparathyroidism</td> </tr> <tr> <td class=\"subtitle1_single\">Disorders with generalized increase in sensitivity to Ca<sup>2+</sup></td> </tr> <tr> <td>ADH due to activating CaSR mutations</td> </tr> <tr> <td>ADH with features of Bartter syndrome</td> </tr> <tr> <td>Hypoparathyroidism due to activating antibodies to the CaSR</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CaSR: calcium-sensing receptor; Ca: calcium; FHH: familial hypocalciuric hypercalcemia; NHPT: neonatal hyperparathyroidism; NSHPT: neonatal severe hyperparathyroidism; ADH: autosomal dominant hypoparathyroidism.</div><div id=\"graphicVersion\">Graphic 58108 Version 4.0</div></div></div>"},"58111":{"type":"graphic_waveform","displayName":"Advanced case 9 with answer","title":"Mobitz type I AV block and acute inferior MI","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Mobitz type I AV block and acute inferior MI</div><div class=\"cntnt\"><img style=\"width:540px; height:87px;\" src=\"images/CARD/58111_Advancedcase9withanswer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This rhythm strip shows sinus rhythm with Mobitz type I (Wenckebach) atrioventricular block with 4:3 and 3:2 conduction and progressive prolongation of the PR intervals of conducted beats. The marked ST segment elevation suggests acute inferior wall ischemia or infarction that is likely the substrate for the arrhythmia.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 58111 Version 3.0</div></div></div>"},"58113":{"type":"graphic_table","displayName":"Characteristics of good candidates for psychodynamic therapy","title":"Psychological characteristics that indicate a patient is a good candidate for psychodynamic psychotherapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Psychological characteristics that indicate a patient is a good candidate for psychodynamic psychotherapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Significant symptoms and suffering due to intrapsychic conflict centered upon competing wishes and urges</td> </tr> <tr> <td>Motivation to understand the unconscious patterns in one's life that lead to self-defeating behavior and hurting others that one doesn't wish to hurt</td> </tr> <tr> <td>Ability to anticipate the consequences of one's actions (judgment)</td> </tr> <tr> <td>Intact reality testing (ability to assess reality) that is not impaired by faulty judgment or grossly disturbed by psychosis</td> </tr> <tr> <td>Good impulse control</td> </tr> <tr> <td>Meaningful object relations, which is the ability to relate to significant others in a meaningful and consistent way, form intimate relationships, tolerate separation and loss, and maintain autonomy and independence</td> </tr> <tr> <td>Ability to sustain activity such as work or school despite setbacks</td> </tr> <tr> <td>Ability to regress in the service of the ego, which involves using the irrational processes of the unconscious to develop alternative ways of thinking and feeling, and also involves activities that help one to recover from the stress of life, in order to continue to function well</td> </tr> <tr> <td>Ability to tolerate frustration and intense affects associated with exploring unpleasant aspects of the self</td> </tr> <tr> <td>Mentalizing capacity, which is the ability to see that internal, mental states explain behavior; and the ability to sense the mental state of another person and respond accordingly</td> </tr> <tr> <td>Capacity for insight (psychological mindedness)</td> </tr> <tr> <td>Capacity to understand analogies and metaphors</td> </tr> <tr> <td>Reflective responses to the clinician's initial interpretations of transference and resistance</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58113 Version 2.0</div></div></div>"},"58114":{"type":"graphic_picture","displayName":"Pityriasis tinea amiantacea","title":"Pityriasis (tinea) amiantacea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pityriasis (tinea) amiantacea</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/58114_Pityr_tinea_amiantacea_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thick accumulation of scales that cement the proximal part of the hair in a healthy 10-year-old girl with pityriasis amiantacea.</div><div class=\"graphic_reference\">Copyright © Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 58114 Version 5.0</div></div></div>"},"58115":{"type":"graphic_table","displayName":"Diet and stoma PI","title":"Foods that can affect bowel movements and gas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Foods that can affect bowel movements and gas</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Foods that make odor worse</td> </tr> <tr> <td>Beans</td> </tr> <tr> <td>Asparagus</td> </tr> <tr> <td>Broccoli</td> </tr> <tr> <td>Brussel sprouts</td> </tr> <tr> <td>Cauliflower</td> </tr> <tr> <td>Cabbage</td> </tr> <tr> <td>Eggs</td> </tr> <tr> <td>Fish</td> </tr> <tr> <td>Onions</td> </tr> <tr> <td>Some spices</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Foods that increase gas</td> </tr> <tr> <td>Beans</td> </tr> <tr> <td>Beer and carbonated soda</td> </tr> <tr> <td>Broccoli</td> </tr> <tr> <td>Brussel sprouts</td> </tr> <tr> <td>Cauliflower</td> </tr> <tr> <td>Cabbage</td> </tr> <tr> <td>Corn</td> </tr> <tr> <td>Cucumbers</td> </tr> <tr> <td>Mushrooms</td> </tr> <tr> <td>Peas</td> </tr> <tr> <td>Radishes</td> </tr> <tr> <td>Spinach</td> </tr> <tr> <td>Dairy products</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Foods that make bowel movements thicker</td> </tr> <tr> <td>Apple sauce</td> </tr> <tr> <td>Bananas</td> </tr> <tr> <td>Cheese</td> </tr> <tr> <td>Boiled milk</td> </tr> <tr> <td>Marshmallows</td> </tr> <tr> <td>Pasta</td> </tr> <tr> <td>Creamy peanut butter</td> </tr> <tr> <td>Pretzels</td> </tr> <tr> <td>Rice</td> </tr> <tr> <td>Bread</td> </tr> <tr> <td>Tapioca</td> </tr> <tr> <td>Toast</td> </tr> <tr> <td>Yogurt</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Foods that make bowel movements looser</td> </tr> <tr> <td>Green beans</td> </tr> <tr> <td>Beer</td> </tr> <tr> <td>Broccoli</td> </tr> <tr> <td>Fresh fruits</td> </tr> <tr> <td>Grape juice</td> </tr> <tr> <td>Raw vegetables</td> </tr> <tr> <td>Prunes</td> </tr> <tr> <td>Spicy foods</td> </tr> <tr> <td>Fried foods</td> </tr> <tr> <td>Chocolate</td> </tr> <tr> <td>Leafy green vegetables</td> </tr> <tr> <td>Spinach</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58115 Version 1.0</div></div></div>"},"58116":{"type":"graphic_picture","displayName":"Gonorrhea penile ulcer","title":"Gonorrhea with a genital ulcer","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Gonorrhea with a genital ulcer</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/58116_Gonorrhea_penile_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A penile ulcer is present in this patient with gonorrhea. Purulent discharge from the urethra is also evident.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 58116 Version 3.0</div></div></div>"},"58118":{"type":"graphic_picture","displayName":"Fistulotomy","title":"Fistulotomy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Fistulotomy</div><div class=\"cntnt\"><img style=\"width:504px; height:219px;\" src=\"images/PC/58118_Mammary_duct_fistula_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The treatment for a mammary duct fistula is surgical, by means of excising or opening up the fistula. This results in a scar across the nipple and areola and is not the preferred treatment.</div><div class=\"graphic_reference\">Courtesy of Michael J Dixon, MD.</div><div id=\"graphicVersion\">Graphic 58118 Version 5.0</div></div></div>"},"58120":{"type":"graphic_waveform","displayName":"EPS tracing during atrial tachycardia mapping","title":"Electrophysiology study (EPS) tracing during mapping of atrial tachycardia","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Electrophysiology study (EPS) tracing during mapping of atrial tachycardia</div><div class=\"cntnt\"><img style=\"width:564px; height:407px;\" src=\"images/CARD/58120_Mappingatrialtachycardia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown are three surface electrocardiogram (ECG) leads (I, aVF, V1) and intracardiac recordings from the high posterior right atrium (HRA); posterior left atrium (USER1 and USER 3); proximal, mid, and distal coronary sinuses (CS9-10, CS5-6, CS1-2); and right ventricular apex (RVA). The patient had an incessant atrial tachycardia and dilated cardiomyopathy (left ventricular ejection fraction 9 percent) referred for cardiac transplant evaluation. The P wave (*) falls at the end of the T wave in the surface ECG; its onset is difficult to discern. However, the intracardiac electrograms demonstrate obvious atrial (A) and ventricular (V) activity. Activation mapping involves positioning the mapping catheters in the right (HRA) and left atria (USER) to record earliest electrical activity during the tachycardia. The left atrial catheter records earlier electrical activity (arrow) than the right atrial catheter, but the timing with respect to the surface P wave is obscured because of the T wave of the preceding QRS complex.</div><div id=\"graphicVersion\">Graphic 58120 Version 7.0</div></div></div>"},"58121":{"type":"graphic_diagnosticimage","displayName":"Amiodarone pneumonitis CT","title":"Amiodarone pulmonary toxicity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amiodarone pulmonary toxicity</div><div class=\"cntnt\"><img style=\"width:343px; height:504px;\" src=\"images/PULM/58121_Amiodarone_pneumonitis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic scan obtained without intravenous contrast material reveals a high-attenuation right upper lobe consolidation (upper panel). Images from the upper abdomen (lower panel) demonstrate increased attenuation of the liver parenchyma. The attenuation of this lesion is the result of iodine deposition from chronic amiodarone therapy.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 58121 Version 3.0</div></div></div>"},"58124":{"type":"graphic_picture","displayName":"Erythema gyratum repens","title":"Erythema gyratum repens","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema gyratum repens</div><div class=\"cntnt\"><img style=\"width:261px; height:391px;\" src=\"images/ONC/58124_Erythema_gyratum_repens.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Callen, Jeffrey. Color Atlas of Dermatology. WB Saunders 2000. p.70. Copyright &#169; 2000 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 58124 Version 1.0</div></div></div>"},"58125":{"type":"graphic_picture","displayName":"Urothelial CIS C","title":"Urothelial carcinoma in situ (CIS)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urothelial carcinoma in situ (CIS)</div><div class=\"cntnt\"><img style=\"width:432px; height:309px;\" src=\"images/ONC/58125_Urothelial_CIS_C.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 58125 Version 1.0</div></div></div>"},"58126":{"type":"graphic_table","displayName":"Tips for avoiding animal allergens (urine, saliva, or dander) PI","title":"Tips for avoiding animal allergens (urine, saliva, or dander) in your home","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tips for avoiding animal allergens (urine, saliva, or dander) in your home</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">If possible, remove animals from your home</td> </tr> <tr> <td class=\"indent1\">Keep any animals outside, in the garage, or in a kennel. Keeping them out of certain rooms in the house will <strong>not</strong> remove animal allergens from your home.</td> </tr> <tr> <td class=\"indent1\">After you remove the animal, clean your home thoroughly.</td> </tr> <tr> <td class=\"subtitle1_single\">If you cannot remove the animals from your home, try these steps</td> </tr> <tr> <td class=\"indent1\">Use an air filter with a \"HEPA\" filter, but keep in mind that air filters help only a little. Most of the animal allergens in your home are not floating in the air. Air filters only remove allergens that are floating in the air.</td> </tr> <tr> <td class=\"indent1\">Reduce the number of things in your home where allergens can build up. Examples include carpets, fabric-covered furniture, and drapes. Replace these with bare floors, furniture that is not covered with fabric, and window blinds.</td> </tr> <tr> <td class=\"indent1\">Every week, vacuum with a vacuum cleaner that has a \"HEPA\" filter.</td> </tr> <tr> <td class=\"indent1\">If you are allergic to your dog, bathing your dog two times per week might help reduce your symptoms. If you are allergic to your cat, bathing your cat will probably not reduce your symptoms.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HEPA: high-efficiency particulate air filter.</div><div id=\"graphicVersion\">Graphic 58126 Version 9.0</div></div></div>"},"58127":{"type":"graphic_table","displayName":"Differential diagnosis acute knee pain athlete - Part B","title":"Differential diagnosis of acute knee pain in the young athlete: Part B","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of acute knee pain in the young athlete: Part B</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Condition</td>\n\n      <td class=\"subtitle1\">Mechanism of injury</td>\n\n      <td class=\"subtitle1\">Clinical Features</td>\n\n      <td class=\"subtitle1\">Comments</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"4\" rowspan=\"1\" class=\"subtitle2_left\">Lateral\npain</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"5\" class=\"indent1\">LCL injury</td>\n\n      <td colspan=\"1\" rowspan=\"5\">Varus force</td>\n\n      <td>Localized swelling and stiffness</td>\n\n      <td colspan=\"1\" rowspan=\"5\">Associated with superficial peroneal nerve injuries,\nchondral injuries, and medial meniscal injuries</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Able to ambulate</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Localized pain, swelling, ecchymosis</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Pain along course of ligament (examine in figure of 4\nposition)</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Laxity with varus stress and 30 degrees of knee flexion</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"8\" class=\"indent1\">Lateral\nmeniscal tear</td>\n\n      <td colspan=\"1\" rowspan=\"8\">Twisting injury</td>\n\n      <td>Usually able to ambulate, but weight bearing is limited\nby pain </td>\n\n      <td colspan=\"1\" rowspan=\"8\">&nbsp;</td>\n\n    </tr>\n<tr><td>Knee swelling and stiffness develop over two to three days</td></tr>\n    <tr>\n\n      \n\n      \n\n      <td>Mechanical symptoms</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      \n\n      \n\n      <td>Lateral pain with twisting or squatting</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      \n\n      \n\n      <td>Lateral joint line\ntenderness&nbsp;&nbsp;&nbsp;</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      \n\n      \n\n      <td>Positive McMurray test</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      \n\n      \n\n      <td>Positive bounce home test</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      \n\n      \n\n      <td>Decreased range of motion</td>\n\n      \n\n    </tr>\n\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=51390&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>DDx_Acute_knee_pain_athle1.htm</title></head></div><div class=\"graphic_footnotes\">LCL: lateral collateral ligament.</div><div id=\"graphicVersion\">Graphic 58127 Version 4.0</div></div></div>"},"58128":{"type":"graphic_figure","displayName":"Hormone levels in HF","title":"Hormone levels in HF","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Hormone levels in HF</div><div class=\"cntnt\"><img style=\"width:477px; height:223px;\" src=\"images/CARD/58128_HormonelevelsinHF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plasma levels of norepinephrine, renin activity, and antidiuretic hormone are increased two- to eightfold (when compared&nbsp;with normal subjects) in patients with stable heart failure treated with digitalis, but not diuretics or vasodilators.</div><div class=\"graphic_footnotes\">HF: heart failure.</div><div class=\"graphic_reference\">Data from: Francis GS, Goldsmith SR, Levine TB, et al. Ann Intern Med 1984; 101:370.</div><div id=\"graphicVersion\">Graphic 58128 Version 4.0</div></div></div>"},"58129":{"type":"graphic_picture","displayName":"Acne keloidalis","title":"Acne keloidalis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acne keloidalis</div><div class=\"cntnt\"><img style=\"width:396px; height:296px;\" src=\"images/PC/58129_Acne_keloidalis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypertrophic scarring and flesh-colored papules are seen in this patient.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP, MD. Goodheart's Photoguide of Common Skin Disorders, 2nd ed. Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright ©2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58129 Version 2.0</div></div></div>"},"58130":{"type":"graphic_picture","displayName":"Ascaris lumbricoides Endosc","title":"Biliary ascariasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Biliary ascariasis</div><div class=\"cntnt\"><img style=\"width:288px; height:328px;\" src=\"images/GAST/58130_Ascaris_lumbricoides_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An adult Ascaris lumbricoides worm protruding from the major papilla is grasped with a forceps during endoscopic retrograde cholangiopancreatography.</div><div class=\"graphic_reference\">Courtesy of D Nageshwar Reddy, MD.</div><div id=\"graphicVersion\">Graphic 58130 Version 1.0</div></div></div>"},"58131":{"type":"graphic_figure","displayName":"Smoking acutely raises BP","title":"First cigarette raises blood pressure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">First cigarette raises blood pressure</div><div class=\"cntnt\"><img style=\"width:371px; height:255px;\" src=\"images/NEPH/58131_Smoking_acutely_raises_BP.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Change in systolic blood pressure over 15 minutes after smoking the first cigarette of the day (blue squares) or during sham smoking (red circles) in 10 normotensive smokers. Smoking was associated with a 15 to 20 mmHg rise in systolic pressure that began to dissipate at 15 minutes.</div><div class=\"graphic_reference\">Data from Gropelli, A, Giorgi, DM, Omboni, S, et al, J Hypertens 1992; 10:495.</div><div id=\"graphicVersion\">Graphic 58131 Version 1.0</div></div></div>"},"58132":{"type":"graphic_diagnosticimage","displayName":"Interstitial pneumonitis CT","title":"Interstitial pneumonitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Interstitial pneumonitis</div><div class=\"cntnt\"><img style=\"width:344px; height:322px;\" src=\"images/ID/58132_Interstitial_pneumonitis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest computed tomography scan in a patient six months after liver transplantation reveals both interstitial and consolidative infiltrates. This pattern suggests a dual infection with cytomegalovirus and<em> Pneumocystis jirovecii</em>, both of which were documented by transbronchial biopsy.</div><div class=\"graphic_reference\">Courtesy of Jay Fishman, MD.</div><div id=\"graphicVersion\">Graphic 58132 Version 7.0</div></div></div>"},"58136":{"type":"graphic_picture","displayName":"Malignant gastric ulcer Endosc","title":"Malignant and benign gastric ulcer: Endoscopic appearance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malignant and benign gastric ulcer: Endoscopic appearance</div><div class=\"cntnt\"><img style=\"width:353px; height:486px;\" src=\"images/GAST/58136_Malignant_gastric_ulcer_End.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy showing the differences between the endoscopic appearance of malignant and benign gastric ulcers.<br />(A) Retroflexed views were required on endoscopy to detect this malignant gastric ulcer of the cardia. Note the absence of folds radiating to the base and the exophytic appearance. Biopsies confirmed the presence of adenocarcinoma.<br />(B) Benign gastric ulcer in the prepyloric region. The ulcer is well-circumscribed with folds radiating to the ulcer base.</div><div class=\"graphic_reference\">Courtesy of Paul C Schroy III, MD.</div><div id=\"graphicVersion\">Graphic 58136 Version 3.0</div></div></div>"},"58137":{"type":"graphic_picture","displayName":"Mucinous neoplasm panc Gross I","title":"Pancreatic mucinous cystic neoplasm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreatic mucinous cystic neoplasm</div><div class=\"cntnt\"><img style=\"width:429px; height:288px;\" src=\"images/GAST/58137_Mucinous_neoplasm_panc_Gros.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical specimen of a mucinous cystic neoplasm consisting of multiple cystic spaces.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 58137 Version 2.0</div></div></div>"},"58138":{"type":"graphic_figure","displayName":"Silicone band sterilization C","title":"Silicone band sterilization by laparoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Silicone band sterilization by laparoscopy</div><div class=\"cntnt\"><img style=\"width:301px; height:306px;\" src=\"images/OBGYN/58138_Tubal_ring_sterilization_C.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 58138 Version 2.0</div></div></div>"},"58139":{"type":"graphic_figure","displayName":"Seldinger cricothyrotomy step 6","title":"Seldinger cricothyrotomy technique: Step 6","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Seldinger cricothyrotomy technique: Step 6</div><div class=\"cntnt\"><img style=\"width:473px; height:446px;\" src=\"images/EM/58139_Cric_Seldinger_step_six.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Remove the tissue dilator and guidewire as a unit, leaving the airway catheter in the trachea.</div><div id=\"graphicVersion\">Graphic 58139 Version 3.0</div></div></div>"},"58142":{"type":"graphic_table","displayName":"Ovarian failure anticancer Rx","title":"Chemotherapy-associated ovarian toxicity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chemotherapy-associated ovarian toxicity</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Class (action)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Definitely associated with ovarian damage</td> </tr> <tr> <td class=\"indent1\">Nitrogen mustard</td> <td>Mechlorethamine (alkylating agent)</td> </tr> <tr> <td class=\"indent1\">L-phenylalanine mustard</td> <td>Mechlorethamine (alkylating agent)</td> </tr> <tr> <td class=\"indent1\">Chlorambucil</td> <td>Chloroethylamine (alkylating agent)</td> </tr> <tr> <td class=\"indent1\">Cyclophosphamide</td> <td>Chloroethylamine (alkylating agent)</td> </tr> <tr> <td class=\"indent1\">Melphalan</td> <td>Mechlorethamine (alkylating agent)</td> </tr> <tr> <td class=\"indent1\">Busulfan</td> <td>Alkylalkane sulfonate (alkylating agent)</td> </tr> <tr> <td class=\"indent1\">Procarbazine</td> <td>Substituted hydrazine</td> </tr> <tr> <td class=\"indent1\">Dacarbazine</td> <td>Alkylating agent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Probably associated with ovarian damage</td> </tr> <tr> <td class=\"indent1\">Vinblastine</td> <td>Vinca alkaloid</td> </tr> <tr> <td class=\"indent1\">Cytosine arabinoside (Ara-C)</td> <td>Antimetabolite</td> </tr> <tr> <td class=\"indent1\">Cis-platinum</td> <td>Heavy metal</td> </tr> <tr> <td class=\"indent1\">Carmustine</td> <td>Nitrosourea (alkylating agent)</td> </tr> <tr> <td class=\"indent1\">Lomustine</td> <td>Nitrosourea (alkylating agent)</td> </tr> <tr> <td class=\"indent1\">VP-16 (etoposide)</td> <td>Podophyllotoxin</td> </tr> <tr> <td class=\"indent1\">Imatinib</td> <td>Tyrosine kinase inhibitor</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Low probability of ovarian damage</td> </tr> <tr> <td class=\"indent1\">Methotrexate</td> <td>Antimetabolite</td> </tr> <tr> <td class=\"indent1\">Fluorouracil (5-FU)</td> <td>Antimetabolite</td> </tr> <tr> <td class=\"indent1\">6-mercaptopurine</td> <td>Antimetabolite</td> </tr> <tr> <td class=\"indent1\">Vincristine</td> <td>Vinca alkaloid</td> </tr> <tr> <td class=\"indent1\">Mitomycin</td> <td>Antibiotic (alkylating agent)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Unknown</td> </tr> <tr> <td class=\"indent1\">VM-26</td> <td>Podophyllotoxin</td> </tr> <tr> <td class=\"indent1\">Daunorubicin</td> <td>Anthracycline</td> </tr> <tr> <td class=\"indent1\">Bleomycin</td> <td>Peptide</td> </tr> <tr> <td class=\"indent1\">Vindesine</td> <td>Vinca alkaloid</td> </tr> <tr> <td class=\"indent1\">Doxorubicin</td> <td>Anthracyclin</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58142 Version 12.0</div></div></div>"},"58143":{"type":"graphic_picture","displayName":"Barretts esophagus diamine","title":"Barrett's esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Barrett's esophagus</div><div class=\"cntnt\"><img style=\"width:328px; height:378px;\" src=\"images/GAST/58143_Barretts_esophagus_diamine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of a biopsy specimen from a patient with Barrett's esophagus has been stained with diamine. This stain demonstrates goblet cells containing sulfated mucins (brown) and nonsulfated mucins (blue).</div><div class=\"graphic_reference\">From: Lewin KJ, Appelman HD. Tumors of the esophagus and stomach. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 18, 1996, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 58143 Version 3.0</div></div></div>"},"58144":{"type":"graphic_picture","displayName":"Endosc fundic gland polyp B","title":"Fundic gland polyp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fundic gland polyp</div><div class=\"cntnt\"><img style=\"width:354px; height:373px;\" src=\"images/GAST/58144_Endosc_fundic_gland_polyp_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper endoscopy showing a small polyp in the gastric fundus proven to be a fundic gland polyp after it was removed.</div><div class=\"graphic_reference\">Courtesy of David Y Graham, MD.</div><div id=\"graphicVersion\">Graphic 58144 Version 1.0</div></div></div>"},"58146":{"type":"graphic_figure","displayName":"Timing of nocturnal asthma","title":"Timing of dyspneic episodes in asthma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Timing of dyspneic episodes in asthma</div><div class=\"cntnt\"><img style=\"width:361px; height:251px;\" src=\"images/PULM/58146_Timing_of_nocturnal_asthma.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Time course of dyspneic episodes in 3129 mainly asthmatic patients. Most of the episodes occurred at night.</div><div class=\"graphic_reference\">Adapted from Dethlefsen, U, Repgas, R, Clin Med 1985; 80:44.</div><div id=\"graphicVersion\">Graphic 58146 Version 2.0</div></div></div>"},"58149":{"type":"graphic_waveform","displayName":"ECG of sinus rhythm","title":"Normal ECG","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:466px; height:324px;\" src=\"images/CARD/58149_Sinusrhythm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal sinus rhythm at a rate of 71 beats/minute, a P wave axis of 45°, and a PR interval of 0.15 seconds.</div><div class=\"graphic_footnotes\">ECG: electrocardiogram.</div><div class=\"graphic_reference\">Courtesy of Morton Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 58149 Version 4.0</div></div></div>"},"58150":{"type":"graphic_figure","displayName":"Human Th subsets","title":"Human T helper (Th) cell subsets","html":"<div class=\"graphic\"><div style=\"width: 806px\" class=\"figure\"><div class=\"ttl\">Human T helper (Th) cell subsets</div><div class=\"cntnt\"><img style=\"width:786px; height:554px;\" src=\"images/ALLRG/58150_Human_Th_subsets.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">​CD4+: cluster of differentiation 4 positive; IL: interleukin; TGF-beta: transforming growth factor-beta; STAT: signal transducer and activator of transcription; T-bet: a transcription factor also called TBX21, for T-box 21; GATA-3: a transcription factor that binds to the deoxyribonucleic acid (DNA) sequence \"GATA\"; ROR-gamma T: RAR-related orphan receptor-gamma T; Foxp3: forkhead box P3; IFN-gamma: interferon-gamma; TNF-beta: tumor necrosis factor-beta.</div><div id=\"graphicVersion\">Graphic 58150 Version 3.0</div></div></div>"},"58154":{"type":"graphic_diagnosticimage","displayName":"Normal saline implants","title":"Normal saline implants","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal saline implants</div><div class=\"cntnt\"><img style=\"width:318px; height:582px;\" src=\"images/PC/58154_Mammog_norm_saline_implants.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral CC (panels A and B) and MLO (panels C and D) mammographic views obtained with a saline implant in place. The implant capsule is intact. Normal folds (thin arrow) and implant valve (thick arrow) can be seen.</div><div class=\"graphic_footnotes\">CC: cradiocaudal; MLO: mediolateral oblique.</div><div id=\"graphicVersion\">Graphic 58154 Version 7.0</div></div></div>"},"58155":{"type":"graphic_diagnosticimage","displayName":"Agenesis left lung","title":"Agenesis of left lung in newborn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Agenesis of left lung in newborn</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/PULM/58155_Agenesis_left_lung.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cardiomediastinal silhouette is shifted to the left and the right lung is hyperexpanded. Vertebral anomalies and scoliosis are present.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 58155 Version 2.0</div></div></div>"},"58156":{"type":"graphic_figure","displayName":"Morphologic variants HCM","title":"Morphologic variants of hypertrophic cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Morphologic variants of hypertrophic cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:319px; height:443px;\" src=\"images/CARD/58156_Morphologic_variants_HCM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HCM typically presents with asymmetric or localized areas of LV hypertrophy, which are diagrammed in B to E.<br />(A) Normal LV wall thickness.<br />(B) ASH.<br />(C) Sigmoid septum, which is more common in older adults.<br />(D) Midcavity hypertrophy associated with midcavity obstruction.<br />(E) Predominantly free wall hypertrophy, an unusual pattern in HCM.<br />(F) LV wall thinning (associated with low LV ejection fraction) and biatrial enlargement.<br />(G) Predominantly apical LV hypertrophy.<br />(H) Severe concentric hypertrophy with cavity obliteration.<br />(I) Biventricular hypertrophy.<br />(J) Mild to moderate symmetric hypertrophy.</div><div class=\"graphic_footnotes\">ASH: asymmetrical septal hypertrophy; HCM: hypertrophic cardiomyopathy; LV: left ventricular.</div><div id=\"graphicVersion\">Graphic 58156 Version 4.0</div></div></div>"},"58157":{"type":"graphic_table","displayName":"Major causes of hyperkalemia","title":"Major causes of hyperkalemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of hyperkalemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Increased potassium release from cells</td> </tr> <tr> <td>Pseudohyperkalemia</td> </tr> <tr> <td>Metabolic acidosis</td> </tr> <tr> <td>Insulin deficiency, hyperglycemia, and hyperosmolality</td> </tr> <tr> <td>Increased tissue catabolism</td> </tr> <tr> <td>Beta blockers</td> </tr> <tr> <td>Exercise</td> </tr> <tr> <td>Hyperkalemic periodic paralysis</td> </tr> <tr> <td class=\"sublist1_start\">Other</td> </tr> <tr> <td class=\"sublist1\">Overdose of digitalis or related digitalis glycosides</td> </tr> <tr> <td class=\"sublist1\">Red cell transfusion</td> </tr> <tr> <td class=\"sublist1\">Succinylcholine</td> </tr> <tr> <td class=\"sublist1\">Arginine hydrochloride</td> </tr> <tr> <td class=\"sublist1\">Activators of ATP-dependent potassium channels (eg, calcineurin inhibitors, diazoxide, minoxidil, and some volatile anesthetics)</td> </tr> <tr> <td class=\"subtitle1_single\">Reduced urinary potassium excretion</td> </tr> <tr> <td>Reduced aldosterone secretion</td> </tr> <tr> <td>Reduced response to aldosterone</td> </tr> <tr> <td class=\"sublist1_start\">Reduced distal sodium and water delivery</td> </tr> <tr> <td class=\"sublist1\">Effective arterial blood volume depletion</td> </tr> <tr> <td>Acute and chronic kidney disease</td> </tr> <tr> <td class=\"sublist1_start\">Other</td> </tr> <tr> <td class=\"sublist1\">Selective impairment in potassium secretion</td> </tr> <tr> <td class=\"sublist1\">Gordon's syndrome</td> </tr> <tr> <td class=\"sublist1\">Ureterojejunostomy</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58157 Version 6.0</div></div></div>"},"58158":{"type":"graphic_picture","displayName":"Acute NAION fundus","title":"Acute nonarteritic anterior ischemic optic neuropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute nonarteritic anterior ischemic optic neuropathy</div><div class=\"cntnt\"><img style=\"width:370px; height:361px;\" src=\"images/NEURO/58158_Acute_NAION_fundus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fundus of a patient with acute nonarteritic anterior ischemic optic neuropathy.</div><div class=\"graphic_reference\">Courtesy of Madhura Tamhankar, MD and Nicholas J Volpe, MD.</div><div id=\"graphicVersion\">Graphic 58158 Version 1.0</div></div></div>"},"58159":{"type":"graphic_figure","displayName":"Flexion deflexion vertex","title":"Presentation, breech, cranial diameters","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Presentation, breech, cranial diameters</div><div class=\"cntnt\"><img style=\"width:526px; height:228px;\" src=\"images/OBGYN/58159_Flexion_deflexion_vertex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Importance of cranial flexion is emphasized by noting the increased diameters presented to the birth canal with progressive deflection. A) Flexed head. B) Military position. C, D) Progressive deflection.</div><div class=\"graphic_reference\">Reproduced with permission from: LifeART, Obstetrics &amp; Gynecology. Copyright &#169;2009 Lippincott Williams &amp; Wilkins. All rights reserved.</div><div id=\"graphicVersion\">Graphic 58159 Version 1.0</div></div></div>"},"58160":{"type":"graphic_diagnosticimage","displayName":"Spine MRI findings in leptomeningeal metastases","title":"Spine MRI findings in patients with leptomeningeal metastases","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spine MRI findings in patients with leptomeningeal metastases</div><div class=\"cntnt\"><img style=\"width:313px; height:386px;\" src=\"images/RADIOL/58160_MRI_lumbar_spine_patient_w.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Post-contrast MR imaging through the cervical (A, B) spine showing abnormal thick and nodular leptomeningeal enhancement (arrows) coating the spinal cord, consistent with widespread leptomeningeal metastases. Images C and D demonstrate characteristic nodular enhancement within the cauda equina.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging. </div><div class=\"graphic_reference\">Images A and B courtesy of Joseph Farnam, MD; Images C and D courtesy of Alexis Demopoulos, MD, and Jerome Posner, MD.</div><div id=\"graphicVersion\">Graphic 58160 Version 3.0</div></div></div>"},"58162":{"type":"graphic_table","displayName":"Coronary artery abnormalities","title":"Coronary artery abnormalities causing pediatric chest pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Coronary artery abnormalities causing pediatric chest pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Anomalous origin of the left coronary artery from the main pulmonary artery (coronary artery fistula)</td> </tr> <tr> <td>2. Anomalous origin of the left coronary artery from the right sinus of Valsalva</td> </tr> <tr> <td>3. Anomalous origin of the right coronary artery from the left sinus of Valsalva</td> </tr> <tr> <td>4. Coronary ostial stenosis or atresia</td> </tr> <tr> <td>5. Premature atherosclerosis (eg, progeria, familial hyperlipidemia)</td> </tr> <tr> <td>6. Kawasaki disease complicated by coronary artery aneurysm or stenosis</td> </tr> <tr> <td>7. Coronary artery spasm</td> </tr> <tr> <td>8. Coronary thrombosis associated with paradoxical embolus or hypercoagulable state</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Robert L Geggel, MD.</div><div id=\"graphicVersion\">Graphic 58162 Version 3.0</div></div></div>"},"58163":{"type":"graphic_figure","displayName":"Evolution of hepatic encephal","title":"Evolution of hepatic encephalopathy","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Evolution of hepatic encephalopathy</div><div class=\"cntnt\"><img style=\"width:502px; height:315px;\" src=\"images/GAST/58163_Evolution_of_hepatic_enceph.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 58163 Version 1.0</div></div></div>"},"58166":{"type":"graphic_figure","displayName":"Digoxin and HF mortality","title":"Digoxin reduces death and hospitalization due to worsening HF","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Digoxin reduces death and hospitalization due to worsening HF</div><div class=\"cntnt\"><img style=\"width:410px; height:284px;\" src=\"images/CARD/58166_Digoxin_and_HF_mortality.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 6800 patients with heart failure randomized to therapy with digoxin or placebo, patients treated with digoxin had a significant decrease in the combined endpoints of death from heart failure and hospitalization for worsening HF (p&lt;0.001).</div><div class=\"graphic_reference\">Data from: The Digitalis Investigation Group, N Engl J Med 1997; 336:525.</div><div id=\"graphicVersion\">Graphic 58166 Version 3.0</div></div></div>"},"58167":{"type":"graphic_picture","displayName":"Tucker-McLane forceps","title":"Tucker-McLane forceps","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Tucker-McLane forceps</div><div class=\"cntnt\"><img style=\"width:468px; height:275px;\" src=\"images/OBGYN/58167_Tucker-McLane_forceps.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Tucker-McLane forceps are Elliott type with blades that are smooth and solid.</div><div class=\"graphic_reference\">Reproduced with permission from: Aron Schuftan, MD. Copyright &#169; Aron Schuftan, MD.</div><div id=\"graphicVersion\">Graphic 58167 Version 4.0</div></div></div>"},"58168":{"type":"graphic_picture","displayName":"Beard distribution hemangioma","title":"Hemangioma in the beard distribution","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemangioma in the beard distribution</div><div class=\"cntnt\"><img style=\"width:390px; height:263px;\" src=\"images/PEDS/58168_Beard_distribution_hemangio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The \"beard\" (Segment 3) distribution includes the preauricular skin, chin, anterior neck, and/or lower lip. Patients with segmental hemangiomas in this location are at increased risk of concomitant airway hemangioma and should also be evaluated for PHACE syndrome.</div><div class=\"graphic_reference\">Courtesy of Denise W Metry, MD</div><div id=\"graphicVersion\">Graphic 58168 Version 3.0</div></div></div>"},"58169":{"type":"graphic_picture","displayName":"Viral exanthem","title":"Viral exanthem","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Viral exanthem</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/DERM/58169_ViralexanthemPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous macules are present on the skin of this patient with a viral exanthem.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 58169 Version 6.0</div></div></div>"},"58171":{"type":"graphic_figure","displayName":"Auvard weighted speculum","title":"Auvard weighted speculum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Auvard weighted speculum</div><div class=\"cntnt\"><img style=\"width:332px; height:478px;\" src=\"images/OBGYN/58171_Auvard_weighted_speculum.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 58171 Version 1.0</div></div></div>"},"58172":{"type":"graphic_figure","displayName":"SCFE Blanch sign of Steel","title":"Blanch sign of Steel","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Blanch sign of Steel</div><div class=\"cntnt\"><img style=\"width:464px; height:221px;\" src=\"images/PEDS/58172_SCFE_Blanch_sign_of_Steel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With posterior slippage of the femoral epiphysis, the portion that is located behind the metaphysis may be projected as a semicircular area of increased density on the neck of the femur. This radiographic sign is known as the &quot;Blanch sign of Steel.&quot;</div><div class=\"graphic_reference\">Reproduced with permission from: Steel, HH. J Bone Joint Surg 1986; 68A:920. Copyright &#169; 1986 The Journal of Bone and Joint Surgery, Inc.</div><div id=\"graphicVersion\">Graphic 58172 Version 1.0</div></div></div>"},"58173":{"type":"graphic_picture","displayName":"Striate palmar xanthomata","title":"Palmar xanthomata","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palmar xanthomata</div><div class=\"cntnt\"><img style=\"width:387px; height:265px;\" src=\"images/PC/58173_Striate_palmar_xanthomata.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Striate xanthomata of the palmar creases in a patient with type III hyperlipoproteinemia.</div><div class=\"graphic_reference\">Reproduced with permission from: Durrington, P. Dyslipidaemia. Lancet 2003; 362:717. Copyright &#169; 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 58173 Version 1.0</div></div></div>"},"58174":{"type":"graphic_diagnosticimage","displayName":"NSCLC liver met CT","title":"Liver metastasis-CT","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Liver metastasis-CT</div><div class=\"cntnt\"><img style=\"width:396px; height:354px;\" src=\"images/PULM/58174_NSCLC_liver_met_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT of the liver showing multiple low-density masses in a 74-year-old man with a right hilar mass. Ultrasound guided needle aspirate confirmed metastatic non-small cell lung cancer.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 58174 Version 3.0</div></div></div>"},"58175":{"type":"graphic_figure","displayName":"Wall climb exercises","title":"Wall climb exercises","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Wall climb exercises</div><div class=\"cntnt\"><img style=\"width:444px; height:406px;\" src=\"images/RHEUM/58175_Wall_climb_exercises.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Wall climbs should be performed in shoulder flexion (right) and abduction (left).</div><div id=\"graphicVersion\">Graphic 58175 Version 2.0</div></div></div>"},"58176":{"type":"graphic_table","displayName":"Cisplatin 60 plus etoposide for small cell lung cancer","title":"Cisplatin (60 mg/m<SUP>2</SUP>) plus etoposide for extensive stage small cell lung cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cisplatin (60 mg/m<SUP>2</SUP>) plus etoposide for extensive stage small cell lung cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16.66%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"6\"><strong>Cycle length:</strong> Every 21 days for four cycles. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\" colspan=\"3\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Cisplatin</td> <td>60 mg/m<sup>2</sup> IV</td> <td colspan=\"3\">Dilute in 250 mL normal saline (NS) and administer over 60 minutes. Do not administer with aluminum needles or sets.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Etoposide</td> <td>120 mg/m<sup>2</sup> IV daily</td> <td colspan=\"3\">Dilute in 500 mL NS* or 5% dextrose in water (D5W) to final concentration &#60;0.4 mg/mL. Infuse over 30 to 60 minutes; if infused more rapidly, severe hypotension may occur.</td> <td>Days 1, 2, and 3</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"6\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"5\"> <ul> <li>IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. </li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity\", section on prevention. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"5\"> <ul> <li>HIGH. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"5\"> <ul> <li>Routine prophylaxis not indicated. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"5\"> <ul> <li>Cisplatin is an irritant but can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"5\"> <ul> <li>Primary prophylaxis with hematopoietic growth factors is not recommended. </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"5\"> <ul> <li>The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Such patients were excluded from the original trial.<sup>[1]</sup> A lower starting dose of etoposide may be needed for patients with renal or liver impairment.<sup>[2]</sup> </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"6\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"6\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"6\"> <ul class=\"decimal_heading\"> <li>Basic metabolic panel (creatinine and electrolytes) and liver function tests prior to each cycle. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"6\"> <ul class=\"decimal_heading\"> <li>Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"6\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"5\"><strong>Myelotoxicity</strong></td> <td colspan=\"5\"> <ul> <li>Day 1 ANC should be &#62;1500 cells/microL and platelets should be &#62;75,000/microL for treatment during each cycle. Etoposide dose reductions should be based on the following table, taking into account the nadir ANC and platelet count along with day 1 ANC and platelet count for each cycle.<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td class=\"subtitle3\">Etoposide dose</td> <td class=\"subtitle3\">Nadir ANC (cells/mm)</td> <td class=\"subtitle3\">Nadir platelet count per microL</td> <td class=\"subtitle3\">Day 1 ANC</td> <td class=\"subtitle3\">Day 1 platelet</td> </tr> <tr> <td>25% reduction</td> <td>750 to 999</td> <td>50,000 to 99,999</td> <td>&#62;2000</td> <td>&#62;100,000</td> </tr> <tr> <td>50% reduction</td> <td>&#60;750</td> <td>&#60;50,000</td> <td>&#62;2000</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Hold</td> <td>&#60;750</td> <td>&#60;50,000</td> <td>1500 to 2000</td> <td>75,000 to 100,000</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Neurotoxicity</strong></td> <td colspan=\"5\"> <ul> <li>Neuropathy usually is seen with cumulative doses of cisplatin &#62;400 mg/m<sup>2</sup>, although there is marked interindividual variation. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Nephrotoxicity</strong></td> <td colspan=\"5\"> <ul> <li>Hold cisplatin until serum creatinine &#60;1.5 mg/dL and/or blood urea nitrogen &#60;25 mg/dL. For grade &#8805;2 nephrotoxicity during treatment (creatinine &#62;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, and cisplatin dose reduced if &#60;60 mL/min. </li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other severe non-hematologic toxicity</strong></td> <td colspan=\"5\"> <ul> <li>Etoposide and cisplatin should be withheld or doses decreased depending on clinical judgement. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"6\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count; ANC: absolute neutrophil count.<br />* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Schiller JH, et al. J Clin Oncol 2001; 19:2114.</LI>&#xD;&#xA;<LI>Etoposide injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed December 8, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 58176 Version 22.0</div></div></div>"},"58177":{"type":"graphic_picture","displayName":"Capillaria philippinensis eggs","title":"<EM>Capillaria philippinensis</EM> eggs","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\"><EM>Capillaria philippinensis</EM> eggs</div><div class=\"cntnt\"><img style=\"width:548px; height:275px;\" src=\"images/ID/58177_Capillaria_philippinensis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) <EM>Capillaria philippinensis</EM> eggs. These unembryonated eggs measure 35 to 45 mcm in length by 20 to 25 mcm in width. They have two inconspicuous polar prominences and a striated shell.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Intestinal capillariasis. Available at: <A href=\"http://www.cdc.gov/dpdx/intestinalCapillariasis/index.html\">http://www.cdc.gov/dpdx/intestinalCapillariasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 58177 Version 5.0</div></div></div>"},"58178":{"type":"graphic_picture","displayName":"Parinaud syndrome 2","title":"Parinaud syndrome (dorsal midbrain syndrome)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parinaud syndrome (dorsal midbrain syndrome)</div><div class=\"cntnt\"><img style=\"width:370px; height:514px;\" src=\"images/PEDS/58178_Parinaud_syndrome_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient has (A) bilateral lid retraction, pupillary dilatation; (B) the inability to look upward. The pupils do not react to light but do constrict to near effort.</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology,&#160;2nd ed,&#160;Lippincott Williams &amp; Wilkins, 2001. Copyright &#169; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58178 Version 2.0</div></div></div>"},"58179":{"type":"graphic_figure","displayName":"Steroidogenesis by zone","title":"Steroidogenesis by zone","html":"<div class=\"graphic\"><div style=\"width: 750px\" class=\"figure\"><div class=\"ttl\">Steroidogenesis by zone</div><div class=\"cntnt\"><img style=\"width:730px; height:506px;\" src=\"images/PEDS/58179_Steroidogen_zone_PR_edit3.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Outline of the organization of the major steroid biosynthetic pathways in the adrenal cortex. The top (blue) row shows the zona glomerulosa pathway to aldosterone that is angiotensin responsive. The middle (orange) row shows the pathway to cortisol that occurs in the zona fasciculata, and the lower (green) row shows the pathways to dehydroepiandrosterone sulfate (DHEAS) and other 17-ketosteroids that occur in the zona reticularis; these zones are ACTH-responsive. The dashed box surrounds pathways that are common to all adrenocortical zones and the gonads. The dashed arrow pathways are relatively minor. Compound S (Cmpd S) = 11-deoxycortisol. Corticosterone and 18-hydroxycorticosterone, the successive 11β- and 18-hydroxyl intermediates between deoxycorticosterone (DOC) and aldosterone, are not shown. The steroidogenic enzymes are italicized. Cytochrome P450 enzyme activities are: Side chain cleavage; 17α-hydroxylase/17,20-lyase; 21 hydroxylase (<EM>21H</EM>); aldosterone synthase (aldo synth; 11β-hydroxylase/18-hydroxylase/18-dehydrogenase); type 1 (zona fasciculata) 11β-hydroxylase (<EM>11βH</EM>); and aromatase. Non-P450 enzyme activities are carried out by steroidogenic acute regulatory protein (<EM>StAR</EM>); type 2 Δ<SUP>5</SUP>-isomerase-3β-hydroxysteroid dehydrogenase (<EM>3βHSD</EM>); type 5 17β-hydroxysteroid dehydrogenase (<EM>17βHSD</EM>); and type 2A1 sulfotransferase (<EM>SULT</EM>). Clinically relevant cofactors are P450 oxidoreductase (<EM>POR</EM>), cytochrome b5 (<EM>CYb5</EM>), and type 2 3'phosphoadenosine-5'phosphosulfate synthase (<EM>PAPSS</EM>).</div><div class=\"graphic_reference\">Modified with permission from: Rosenfield RL. Clinical review: Identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92:787. http://jcem.endojournals.org/. Copyright © 2007 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 58179 Version 9.0</div></div></div>"},"58181":{"type":"graphic_table","displayName":"Urine test drugs of abuse","title":"Urine testing for drugs of abuse (addictive drugs)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Urine testing for drugs of abuse (addictive drugs)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"45%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Duration of detectability in urine</td> <td class=\"subtitle1\">Drugs causing false positive preliminary urine screens</td> </tr> <tr> <td>Amphetamines</td> <td>2 to 3 days</td> <td>Ephedrine, pseudoephedrine, phenylephrine, selegiline, chlorpromazine, trazodone, bupropion, desipramine, amantadine, ranitidine</td> </tr> <tr> <td>Cocaine</td> <td>2 to 3 days</td> <td>Topical anesthetics containing cocaine</td> </tr> <tr> <td>Marijuana</td> <td>1 to 7 days (light use); 1 month with chronic moderate to heavy use</td> <td>Ibuprofen, naproxyn, dronabinol, efavirenz, hemp seed oil</td> </tr> <tr> <td>Opiates</td> <td>1 to 3 days</td> <td>Rifampin, fluoroquinolones, poppy seeds, quinine in tonic water</td> </tr> <tr> <td>Phencyclidine</td> <td>7 to 14 days</td> <td>Ketamine, dextromethorphan</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: The Medical Letter 2002; 44:71.</div><div id=\"graphicVersion\">Graphic 58181 Version 5.0</div></div></div>"},"58182":{"type":"graphic_diagnosticimage","displayName":"Langerhans histiocytosis CT I","title":"Cystic changes in Langerhans cell histiocytosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cystic changes in Langerhans cell histiocytosis</div><div class=\"cntnt\"><img style=\"width:377px; height:204px;\" src=\"images/PULM/58182_Langerhans_histiocytosis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Langerhans cell histiocytosis (eosinophilic granuloma) in an adolescent boy characterized by multiple cysts in the upper and lower lobes. The cysts are interspersed throughout the parenchyma and have a slightly thick wall. A posterior right upper lobe nodule&nbsp;is part of the disease process.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 58182 Version 3.0</div></div></div>"},"58183":{"type":"graphic_picture","displayName":"PEL staining","title":"Immunocytochemistry staining on a cell block from a patient with primary effusion lymphoma","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Immunocytochemistry staining on a cell block from a patient with primary effusion lymphoma</div><div class=\"cntnt\"><img style=\"width:535px; height:415px;\" src=\"images/PULM/58183_PEL_staining.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panels A-D, magnification x600. A) Membrane and cytoplasm negative for Pankeratin. B) Cells negative for CD3 and CD45. C) Cytoplasmic membrane positive for CD138 indicating plasma cell differentiation. D) Nucleus positive for HHV8 (LANA-1).</div><div class=\"graphic_reference\">Courtesy of Jose Joseph, MD.</div><div id=\"graphicVersion\">Graphic 58183 Version 1.0</div></div></div>"},"58184":{"type":"graphic_diagnosticimage","displayName":"Mutilans in psoriasis x ray","title":"Arthritis mutilans in psoriatic arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Arthritis mutilans in psoriatic arthritis</div><div class=\"cntnt\"><img style=\"width:360px; height:251px;\" src=\"images/RHEUM/58184_Mutilans_in_psoriasis_x_ray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiograph demonstrating marked deformity and destruction of the hand digits in a patient with classic psoriatic arthritis and arthritis mutilans.</div><div class=\"graphic_reference\">Courtesy of Peter H Schur, MD.</div><div id=\"graphicVersion\">Graphic 58184 Version 2.0</div></div></div>"},"58185":{"type":"graphic_figure","displayName":"Pathophysiology of acute malignant hyperthermia","title":"Pathophysiology of acute malignant hyperthermia","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Pathophysiology of acute malignant hyperthermia</div><div class=\"cntnt\"><img style=\"width:483px; height:742px;\" src=\"images/SURG/58185_MHmechanisms.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Exposure of an individual who has a genetic susceptibility (ryanodine receptor [<em>RYR1</em>] or dihydropyridine receptor [<em>DHP</em>] mutation) to an anesthetic triggering agent (ie, volatile inhalational anesthetic agent, succinylcholine, or both) may result in malignant hyperthermia. This reaction is caused by an altered calcium balance between the lumen of the sarcoplasmic reticulum (SR) and the sarcoplasm. Normally, muscle cell depolarization is sensed by the DHP receptor, which is thought to signal RYR1 opening by a direct physical connection. In malignant hyperthermia, accumulation of abnormally high levels of calcium in the sarcoplasm causes uncontrolled anaerobic and aerobic metabolism and sustained muscle cell contraction. This results in the clinical manifestations of respiratory acidosis, metabolic acidosis, muscle rigidity, and hyperthermia. If the process continues unabated, adenosine triphosphate (ATP) depletion eventually causes widespread muscle fiber hypoxia (cell death, rhabdomyolysis), which manifests clinically as hyperkalemia and myoglobinuria and an increase in creatine kinase. Dantrolene sodium binds to RYR1, causing it to favor the closed state, thereby reversing the uninhibited flow of calcium into the sarcoplasm.</div><div class=\"graphic_reference\">Reproduced with permission from: Litman RS, Rosenberg H. Malignancy Hyperthermia: Update on Susceptibility Testing. JAMA 2005; 293:2918. Copyright © 2005 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 58185 Version 16.0</div></div></div>"},"58187":{"type":"graphic_picture","displayName":"PCLBCL-LT histology","title":"Skin biopsy from a patient with a primary cutaneous diffuse large B-cell lymphoma, leg type","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin biopsy from a patient with a primary cutaneous diffuse large B-cell lymphoma, leg type</div><div class=\"cntnt\"><img style=\"width:424px; height:576px;\" src=\"images/HEME/58187_PCLBCL-LT_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This skin biopsy shows a monotonous proliferation of large cells with round to oval nuclei and prominent nucleoli.</div><div id=\"graphicVersion\">Graphic 58187 Version 1.0</div></div></div>"},"58189":{"type":"graphic_picture","displayName":"Water manometer for pleural pressure measurement 22G needle","title":"Water manometer for pleural pressure measurement: 22G needle interposed","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Water manometer for pleural pressure measurement: 22G needle interposed</div><div class=\"cntnt\"><img style=\"width:540px; height:263px;\" src=\"images/PULM/58189_Water_manometer_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An illustration of the interposed 22-gauge (G) needle for the water manometer. Both IV tubes must be carefully purged of air prior to acquiring pleural pressures.</div><div class=\"graphic_reference\">Reproduced with permission from the American College of Chest Physicians. Doelken P, Huggins JT, Pastis NJ, Sahn SA. Pleural manometry: technique and clinical implications. Chest 2004; 126:1764. Copyright © 2004.</div><div id=\"graphicVersion\">Graphic 58189 Version 3.0</div></div></div>"},"58190":{"type":"graphic_table","displayName":"Spectrum of activity of the tetracyclines","title":"Spectrum of activity of the tetracyclines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Spectrum of activity of the tetracyclines</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Pathogens/syndromes</td>\n</tr>\n<tr>\n<td>Rickettsial infections (doxycycline)</td>\n</tr>\n<tr>\n<td>Chlamydial infections (doxycycline)</td>\n</tr>\n<tr>\n<td>Traveler's diarrhea (doxycycline)</td>\n</tr>\n<tr>\n<td>Early Lyme disease (doxycycline)</td>\n</tr>\n<tr>\n<td>Chloroquine-resistant malaria (doxycycline)</td>\n</tr>\n<tr>\n<td>Acne</td>\n</tr>\n<tr>\n<td>Amebiasis</td>\n</tr>\n<tr>\n<td>Actinomycosis</td>\n</tr>\n<tr>\n<td>Brucellosis</td>\n</tr>\n<tr>\n<td>Borrelia recurrentis</td>\n</tr>\n<tr>\n<td>Legionnaire's disease</td>\n</tr>\n<tr>\n<td>Leptospirosis</td>\n</tr>\n<tr>\n<td>Mycobacterium marinum</td>\n</tr>\n<tr>\n<td>Melioidosis</td>\n</tr>\n<tr>\n<td>Mycoplasma pneumoniae</td>\n</tr>\n<tr>\n<td>Meningococcal prophylaxis (minocycline)</td>\n</tr>\n<tr>\n<td>MRSA (minocycline or tigecycline)</td>\n</tr>\n<tr>\n<td>Nocardiosis</td>\n</tr>\n<tr>\n<td>Pelvic inflammatory disease</td>\n</tr>\n<tr>\n<td>Staphylococcus aureus (minocycline or tigecycline)</td>\n</tr>\n<tr>\n<td>Syphilis</td>\n</tr>\n<tr>\n<td>Tularemia</td>\n</tr>\n<tr>\n<td>Vibrio vulnificus</td>\n</tr>\n<tr>\n<td>VRE (susceptible strains)</td>\n</tr>\n<tr>\n<td>Whipple's disease</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 58190 Version 2.0</div></div></div>"},"58193":{"type":"graphic_picture","displayName":"Massive chronic intervillositis","title":"Massive chronic intervillositis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Massive chronic intervillositis</div><div class=\"cntnt\"><img style=\"width:540px; height:384px;\" src=\"images/OBGYN/58193_Massive_chronic_intervillos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power of a second trimester placenta with mixture of maternal histiocytes (arrow) and fibrinoid material (asterisk) in a case of massive chronic intervillositis.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 58193 Version 2.0</div></div></div>"},"58194":{"type":"graphic_table","displayName":"Chronic abdominal pain history","title":"History to be obtained at the initial visit for children with chronic abdominal pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">History to be obtained at the initial visit for children with chronic abdominal pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Historical feature</td> <td class=\"subtitle1\">Potential significance</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Alarm symptoms:</strong> Involuntary weight loss, difficulty swallowing or painful swallowing, significant vomiting*, chronic severe diarrhea<sup>&#182;</sup>, unexplained fever, urinary symptoms<sup>&#916;</sup>, back pain, blood in stool</td> <td>Increase likelihood of organic etiology</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Pain</td> </tr> <tr> <td class=\"indent1\">Pain triggers (eg, foods, activities, stressors, etc)</td> <td> <p>May identify areas for intervention</p> Prandial or postprandial: Gastroesophageal, pancreatobiliary, functional, carbohydrate intolerance</td> </tr> <tr> <td class=\"indent1\">Onset and course of pain</td> <td> <p>May suggest an organic disorder or category of organic disorders (eg,&nbsp;pain related to&nbsp;lactase deficiency&nbsp;occurs approximately two hours after eating, whereas&nbsp;acid-peptic disease&nbsp;is exacerbated by eating)</p> May suggest a stress-related pain trigger (eg, pain that occurs during academic examinations)</td> </tr> <tr> <td class=\"indent1\">Timing of pain</td> <td> <p>Nighttime and/or early morning&nbsp;&ndash; Abdominal migraine</p> Nighttime&nbsp;&ndash; GERD</td> </tr> <tr> <td class=\"indent1\">Location and radiation of pain</td> <td> <p>May suggest an etiology</p> <p><strong>Location</strong><br /> Periumbilical &ndash; Functional abdominal pain; organic pain in children &#60;8 years<br /> Epigastric &ndash; Pain from esophagus, stomach, duodenum, pancreas; functional dyspepsia<br /> RUQ &ndash; Pain from gallbladder, liver, head of pancreas<br /> RLQ &ndash; Pain from appendix, cecum, terminal ileum<br /> LLQ &ndash; Pain from rectosigmoid (eg, ulcerative proctitis, colitis), functional irritable bowel syndrome</p> <strong>Radiation</strong><br /> Back &ndash; Bancreatic pain<br /> Groin &ndash; Renal colic</td> </tr> <tr> <td class=\"indent1\">Quality of pain</td> <td> <p>Burning &ndash; Acid-peptic disease</p> <p>Crampy &ndash; Gastroenteritis, biliary obstruction, IBS</p> <p>Aching &ndash; Referred</p> </td> </tr> <tr> <td class=\"indent1\">Severity of pain</td> <td>Provides information about how the pain affects the child and family</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">What is the child's and family's response to the pain?</td> <td>May identify reinforcing factors (eg, attention)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Aggravating and relieving factors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Aggravating or relieving factors, including medications and dietary factors (eg, cow's milk)</td> <td> <p>Relief with eating or acid suppression &ndash; Acid-peptic disorders, <em>Helicobacter pylori</em></p> <p>Relief with avoidance of fat &ndash; Cholelithiasis, chronic pancreatitis, IBS</p> Relief with avoidance of cow's milk &ndash; Lactose intolerance</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Associated symptoms</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Associated symptoms (eg, rash, joint pain, anorexia, nausea, bloating, diarrhea, hoarseness, chronic cough)</td> <td>May suggest a specific etiology (eg, IBD, GERD, IBS)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Past history</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">History of trauma or past surgeries</td> <td>May predispose to organic conditions (eg, splenic infarct, adhesions)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Family history</td> </tr> <tr> <td class=\"indent1\">Gastrointestinal disease (eg, IBD, celiac disease, IBS, constipation)</td> <td>May suggest an particular organic or functional condition</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Migraine headaches</td> <td>May be associated with abdominal migraine</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Habits</td> </tr> <tr> <td class=\"indent1\">Dietary history, including fiber intake and juice consumption</td> <td> <p>Low-fiber intake may be associated with constipation</p> <p>Excessive juice consumption may be associated with carbohydrate malabsorption</p> </td> </tr> <tr> <td class=\"indent1\">Restrictive eating behavior/desire to lose weight; purging behavior/self-induced vomiting; excessive exercise</td> <td>May suggest an eating disorder</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Stool habits; ask specifically about stool frequency and size as well as soiling of undergarments (the child and parents may not recognize constipation)</td> <td>Constipation (functional or organic) may cause abdominal pain; chronic diarrhea suggests organic disease</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Review of systems</td> </tr> <tr> <td class=\"indent1\">Dates of three last menstrual periods, relationship of pain with menses</td> <td>May suggest gynecologic cause of abdominal pain</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">History of sexual activity and contraception</td> <td>Sexually transmitted infections and pregnancy (or ectopic pregnancy) may cause abdominal pain</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Psychosocial history</td> </tr> <tr> <td class=\"indent1\">Disruption of normal activities by the pain (eg, sleep, school attendance, sports, social interactions)</td> <td>Provides information about how the pain affects the child and family</td> </tr> <tr> <td class=\"indent1\">Any known stressors for the child and adolescent (eg, school problems, divorce, emotional trauma, or loss)? Is there a temporal relationship between the stressor and symptoms?</td> <td>Stress can affect pain perception (organic or functional)</td> </tr> <tr> <td class=\"indent1\">HEEADSSS<sup>&#9674;</sup> assessment (for adolescents)</td> <td>May identify triggers, stressors, areas for intervention, or provide information about how the pain affects the adolescent and family</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GERD: gastroesophageal reflux disease; RUQ: right upper quadrant; RLQ: right lower quadrant; LLQ: left lower quadrant; IBS: irritable bowel syndrome; IBD inflammatory bowel disease.<br />* Significant vomiting: Bilious, protracted, or otherwise worrisome.<br />¶ Chronic severe diarrhea: ≥3 loose or watery stools per day for ≥2 weeks.<br />Δ Urinary symptoms: Change in bladder function, dysuria, hematuria, flank pain.<br /><FONT class=lozenge>◊</FONT> HEEADSSS: Home, Education/employment, Eating, Activities, Drugs, Sexuality, Suicide/depression, Safety.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Gray L. Chronic abdominal pain in children. Aust Fam Physician 2008; 37:398.</li>&#xD;&#xA;    <li>Lake AM. Chronic abdominal pain in childhood: diagnosis and management. Am Fam Physician 1999; 59:1823.</li>&#xD;&#xA;    <li>Noe JD, Li BU. Navigating recurrent abdominal pain through clinical clues, red flags, and initial testing. Pediatr Ann 2009; 38:259.</li>&#xD;&#xA;    <li>Zeiter DK, Hyams JS. Recurrent abdominal pain in children. Pediatr Clin North Am 2002; 49:53.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 58194 Version 5.0</div></div></div>"},"58197":{"type":"graphic_table","displayName":"Causes of pneumatosis","title":"Diseases associated with pneumatosis intestinalis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diseases associated with pneumatosis intestinalis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Intraabdominal catastrophe:</td> </tr> <tr> <td>Intestinal ischemia</td> </tr> <tr> <td>Intestinal infarction</td> </tr> <tr> <td>Intestinal perforation</td> </tr> <tr> <td>Intestinal obstruction</td> </tr> <tr> <td>Necrotizing enterocolitis</td> </tr> <tr> <td>Typhlitis</td> </tr> <tr> <td class=\"subtitle1_left\">Mucosal disruption:</td> </tr> <tr> <td>Peptic ulcer disease</td> </tr> <tr> <td>Crohn's disease</td> </tr> <tr> <td>Ulcerative colitis</td> </tr> <tr> <td>Feeding jejunostomy tube</td> </tr> <tr> <td>Caustic ingestions</td> </tr> <tr> <td>Ruptured diverticulum</td> </tr> <tr> <td class=\"subtitle1_left\">Infections:</td> </tr> <tr> <td>Clostridium difficile</td> </tr> <tr> <td>Tuberculosis</td> </tr> <tr> <td>Whipples disease</td> </tr> <tr> <td>AIDS entrocolitides</td> </tr> <tr> <td class=\"indent1\">Cryptosporidium</td> </tr> <tr> <td class=\"indent1\">Mycobacterium avium</td> </tr> <tr> <td class=\"indent2\">Intracellulare</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus (CMV)</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Pulmonary disorders:</td> </tr> <tr> <td>Chronic obstructive pulmonary disease</td> </tr> <tr> <td>Asthma</td> </tr> <tr> <td>Cystic fibrosis</td> </tr> <tr> <td>Mechanical ventilation</td> </tr> <tr> <td class=\"subtitle1_left\">Endoscopic procedures:</td> </tr> <tr> <td>Esophagogastroduodenoscopy</td> </tr> <tr> <td>Colonoscopy</td> </tr> <tr> <td>Sclerotherapy</td> </tr> <tr> <td>Endoscopic retrograde cholangiopancreatography (ERCP)</td> </tr> <tr> <td class=\"subtitle1_left\">Diseases affecting gastrointestinal motility:</td> </tr> <tr> <td>Diabetes</td> </tr> <tr> <td>Scleroderma</td> </tr> <tr> <td>Hirschprung's disease</td> </tr> <tr> <td>Intestinal pseudoobstruction</td> </tr> <tr> <td>Jejunoileal bypass</td> </tr> <tr> <td>Pyloric stenosis/obstruction</td> </tr> <tr> <td class=\"subtitle1_left\">Immunological disturbances:</td> </tr> <tr> <td>AIDS</td> </tr> <tr> <td>Steroids</td> </tr> <tr> <td>Chemotherapy</td> </tr> <tr> <td>Lymphoproliferative disorders</td> </tr> <tr> <td>Bone marrow transplantation</td> </tr> <tr> <td>Solid organ transplantation</td> </tr> <tr> <td>Graft versus host disease</td> </tr> <tr> <td>Amyloidosis</td> </tr> <tr> <td>Collagen vascular disease</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58197 Version 2.0</div></div></div>"},"58198":{"type":"graphic_picture","displayName":"Endoscopic treatment bleeding diverticulum","title":"Treatment of a bleeding colonic diverticulum","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Treatment of a bleeding colonic diverticulum</div><div class=\"cntnt\"><img style=\"width:508px; height:164px;\" src=\"images/GAST/58198_Rx_bleeding_tic_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An oozing visible vessel (arrow) can be seen at the mouth of a sigmoid diverticulum (arrowhead, Panel A). The vessel was treated with combination endoscopic therapy using epinephrine injection (1:10,000 dilution) followed by Gold probe electrocautery (Panel B). The area was then tattooed with India ink for easy identification in the event of rebleeding or the need for surgery.</div><div class=\"graphic_reference\">Courtesy of Rome Jutabha, MD.</div><div id=\"graphicVersion\">Graphic 58198 Version 2.0</div></div></div>"},"58199":{"type":"graphic_figure","displayName":"Ischemic MR survival","title":"Survival in ischemic mitral regurgitation is related to the degree of mitral regurgitation","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Survival in ischemic mitral regurgitation is related to the degree of mitral regurgitation</div><div class=\"cntnt\"><img style=\"width:522px; height:228px;\" src=\"images/CARD/58199_Ischemic_MR_survival.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a study of 303 patients with ischemic mitral regurgitation after a myocardial infarction, survival was related to the degree of mitral regurgitation graded by regurgitant volume (RVol) on Doppler echocardiography. In a multivariate analysis, an RVol ≥30 mL/beat was a significant independent predictor of total and cardiac mortality at five years.</div><div class=\"graphic_reference\">Data from Grigioni F, Enriquez-Sorano M, Zehr KJ, et al. Circulation 2001; 103:1759.</div><div id=\"graphicVersion\">Graphic 58199 Version 2.0</div></div></div>"},"58200":{"type":"graphic_table","displayName":"USPSTF grade D recommendations","title":"Adult screening and prevention recommendations of USPSTF D recommendations (discourage use of this service)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adult screening and prevention recommendations of USPSTF D recommendations (discourage use of this service)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"45%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Service</td> <td class=\"subtitle1\">Population</td> <td class=\"subtitle1\">Year</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">CVD</td> </tr> <tr> <td class=\"indent1\">Screening for abdominal aortic aneurysm</td> <td>Women who have never smoked </td> <td class=\"centered\">2014</td> </tr> <tr> <td class=\"indent1\">Screening for asymptomatic carotid artery stenosis</td> <td>Adults with no history of transient ischemic attack, stroke, or other neurologic signs or symptoms</td> <td class=\"centered\">2014</td> </tr> <tr> <td class=\"indent1\">Screening for CHD (resting or exercise ECG)</td> <td>Asymptomatic adults at low risk for CHD events</td> <td class=\"centered\">2012</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Cancer</td> </tr> <tr> <td class=\"indent1\">Chemoprevention of breast cancer</td> <td>Asymptomatic women aged <span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">&#8805; 35 years without prior breast cancer and&nbsp;</span>not at increased risk&nbsp;of breast cancer</td> <td class=\"centered\">2013</td> </tr> <tr> <td class=\"indent1\">Routine genetic counseling or <em>BRCA</em> mutation testing for breast and ovarian cancer</td> <td>Women whose family history is not associated with an increased risk for deleterious mutations in <em>BRCA1</em> or <em>BRCA2</em></td> <td class=\"centered\">2013</td> </tr> <tr> <td class=\"indent1\">Cervical cancer screening</td> <td>Women&nbsp;&#60;21 years; women&nbsp;&#62;65 years who are at average risk&nbsp;and have had adequate prior screens; women who&nbsp;had total hysterectomy for benign disease&nbsp;and&nbsp;no&nbsp;cervical cancer or precancer history&nbsp;</td> <td class=\"centered\">2012</td> </tr> <tr> <td class=\"indent1\">Cervical cancer screening with HPV testing (alone or with&nbsp;cytology)</td> <td>Women&nbsp;&#60;30 years</td> <td class=\"centered\">2012&nbsp;</td> </tr> <tr> <td class=\"indent1\">Screening for ovarian cancer</td> <td> <p>Asymptomatic women who are not known to have a high-risk hereditary cancer syndrome</p> </td> <td class=\"centered\">2018</td> </tr> <tr> <td class=\"indent1\">Screening for pancreatic cancer</td> <td>Asymptomatic adults </td> <td class=\"centered\">2004</td> </tr> <tr> <td class=\"indent1\">Screening for prostate cancer with prostate-specific antigen </td> <td>Men</td> <td class=\"centered\">2012</td> </tr> <tr> <td class=\"indent1\">Screening for testicular cancer </td> <td>Men </td> <td class=\"centered\">2011 </td> </tr> <tr> <td class=\"indent1\">Screening for thyroid cancer </td> <td>Asymptomatic adults </td> <td class=\"centered\">2017 </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Sexually transmitted infections</td> </tr> <tr> <td class=\"indent1\">Screening for bacterial vaginosis in pregnancy to prevent preterm delivery </td> <td>Asymptomatic pregnant women without&nbsp;risk factors for preterm delivery</td> <td class=\"centered\">2008</td> </tr> <tr> <td class=\"indent1\">Serologic screening for genital herpes simplex</td> <td>Asymptomatic pregnant women, adolescents, and adults</td> <td class=\"centered\">2016</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Other conditions</td> </tr> <tr> <td class=\"indent1\">Screening for asymptomatic bacteriuria</td> <td>Men and nonpregnant women</td> <td class=\"centered\">2008</td> </tr> <tr> <td class=\"indent1\">Screening for chronic obstructive pulmonary disease</td> <td>Asymptomatic adults</td> <td class=\"centered\">2016</td> </tr> <tr> <td class=\"indent1\">Postmenopausal hormone&nbsp;therapy with combined estrogen and progestin&nbsp;for prevention of chronic conditions</td> <td>Postmenopausal women</td> <td class=\"centered\">2012</td> </tr> <tr> <td class=\"indent1\">Postmenopausal hormone therapy with estrogen for prevention of chronic conditions</td> <td>Postmenopausal women who have had a hysterectomy</td> <td class=\"centered\">2012&nbsp;</td> </tr> <tr> <td class=\"indent1\">&#8804;400&nbsp;international units&nbsp;D<sub>3</sub> or &#8804;1000 mg calcium for primary prevention of fractures </td> <td>Non-institutionalized postmenopausal women </td> <td class=\"centered\">2013</td> </tr> <tr> <td class=\"indent1\">Beta carotene or vitamin E supplements for the prevention of cardiovascular disease or cancer </td> <td>Healthy adults without special nutritional needs</td> <td class=\"centered\">2014</td> </tr> <tr> <td class=\"indent1\">Screening for elevated blood lead levels</td> <td>Asymptomatic pregnant women</td> <td class=\"centered\">2006</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table covers recommendations for adults &gt;18 years.</div><div class=\"graphic_footnotes\">USPSTF: US&nbsp;Preventive Services Task Force; CVD:&nbsp;cardiovascular disease;&nbsp;CHD: coronary heart disease; ECG: electrocardiogram;&nbsp;HPV: human papillomavirus.</div><div id=\"graphicVersion\">Graphic 58200 Version 29.0</div></div></div>"},"58202":{"type":"graphic_figure","displayName":"Estimated global mortality rates from fire related injuries","title":"Estimated global mortality rates from fire-related burn injuries in 2010, by age and sex","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Estimated global mortality rates from fire-related burn injuries in 2010, by age and sex</div><div class=\"cntnt\"><img style=\"width:552px; height:430px;\" src=\"images/SURG/58202_Global_mortality_by_age.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Graph based on data from the Global Burden of Disease 2010 study. Institute for Health Metrics and Evaluation (IHME). GBD Compare. Seattle, WA: IHME, University of Washington, 2012. Available at: <a href=\"http://viz.healthmetricsandevaluation.org/gbd-compare/\" target=\"_blank\">http://viz.healthmetricsandevaluation.org/gbd-compare/</a> (Accessed on July 1, 2013). Copyright &copy; 2012. Reprinted with permission.</div><div id=\"graphicVersion\">Graphic 58202 Version 3.0</div></div></div>"},"58203":{"type":"graphic_table","displayName":"Skin chromophores","title":"Common chromophore targets in skin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common chromophore targets in skin</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Chromophore</td> <td class=\"subtitle1\">Light absorption range</td> </tr> <tr> <td>DNA, RNA, proteins</td> <td>Ultraviolet</td> </tr> <tr> <td>Oxyhemoglobin</td> <td>Blue-green &#62; yellow &#62;&#62; near infrared</td> </tr> <tr> <td>Red tattoo ink</td> <td>Green</td> </tr> <tr> <td>Green tattoo ink</td> <td>Red</td> </tr> <tr> <td>Aminolevulinic acid</td> <td>Red, blue</td> </tr> <tr> <td>Melanin</td> <td>Ultraviolet &#62; visible light &#62;&#62; near infrared</td> </tr> <tr> <td>Black tattoo ink</td> <td>Visible &#38; near infrared</td> </tr> <tr> <td>Deoxyhemoglobin</td> <td>Near infrared</td> </tr> <tr> <td>Sebaceous gland</td> <td>Near infrared</td> </tr> <tr> <td>Fat (adipocytes)</td> <td>Near infrared</td> </tr> <tr> <td>Water</td> <td>Infrared</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58203 Version 3.0</div></div></div>"},"58204":{"type":"graphic_picture","displayName":"Dracunculiasis papule","title":"Dracunculiasis papule","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Dracunculiasis papule</div><div class=\"cntnt\"><img style=\"width:550px; height:190px;\" src=\"images/ID/58204_Dracunculiasis_papule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The female guinea worm induces a painful blister (A); after rupture of the blister, the worm emerges as a whitish filament (B) in the center of a painful ulcer, which is often secondarily infected.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Dracunculiasis. Available at: <a href=\"http://www.cdc.gov/dpdx/dracunculiasis/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/dracunculiasis/index.html</a>.</div><div id=\"graphicVersion\">Graphic 58204 Version 7.0</div></div></div>"},"58205":{"type":"graphic_figure","displayName":"Treatment of systolic HTN","title":"Benefit of treating isolated systolic hypertension","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Benefit of treating isolated systolic hypertension</div><div class=\"cntnt\"><img style=\"width:400px; height:260px;\" src=\"images/NEPH/58205_Treatment_of_systolic_HTN.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Incidence of stroke in elderly patients with isolated systolic hypertension treated with antihypertensive drugs or placebo. At six years, active therapy prevented strokes in 4 percent of patients compared to the placebo group.</div><div class=\"graphic_reference\">Data from SHEP Cooperative Research Group, JAMA 1991; 265:3255.</div><div id=\"graphicVersion\">Graphic 58205 Version 1.0</div></div></div>"},"58207":{"type":"graphic_diagnosticimage","displayName":"Meconium pseudocyst","title":"Meconium pseudocyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Meconium pseudocyst</div><div class=\"cntnt\"><img style=\"width:396px; height:295px;\" src=\"images/OBGYN/58207_Meconium_pseudocyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Echogenic cystic area in fetal abdomen. After birth, imaging studies identified a meconium pseudocyst.</div><div class=\"graphic_reference\">Courtesy of Stephen T Chasen, MD.</div><div id=\"graphicVersion\">Graphic 58207 Version 3.0</div></div></div>"},"58208":{"type":"graphic_picture","displayName":"Patho nerve sheath B","title":"Intradural nerve sheath tumor: Antoni A (upper right) and B (lower left)","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Intradural nerve sheath tumor: Antoni A (upper right) and B (lower left)</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/ONC/58208_Patho_nerve_sheath_B.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 58208 Version 2.0</div></div></div>"},"58209":{"type":"graphic_figure","displayName":"Childhood immunization schedule 7 through 18 years","title":"Recommended immunization schedule for children and adolescents age 7 through 18 years - United States, 2018 (for those who fall behind or start late, refer to UpToDate content related to the catch-up schedule)","html":"<div class=\"graphic\"><div style=\"width: 1117px\" class=\"figure\"><div class=\"ttl\">Recommended immunization schedule for children and adolescents age 7 through 18 years - United States, 2018 (for those who fall behind or start late, refer to UpToDate content related to the catch-up schedule)</div><div class=\"cntnt\"><img style=\"width:1097px; height:644px;\" src=\"images/PEDS/58209_Chldhdimmnztnschd718yrs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This schedule includes recommendations in effect as of January 1, 2018 and is approved by the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics, the American Academy of Family Physicians, and the American College of Obstetricians and Gynecologists. &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>Consult relevant <A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/index.html\" target=_blank>ACIP statements</A> for detailed recommendations.</LI>&#xD;&#xA;<LI>When a vaccine is not administered at the recommended age, administer at a subsequent visit.</LI>&#xD;&#xA;<LI>Use combination vaccines instead of separate injections when appropriate.</LI>&#xD;&#xA;<LI>Report clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) online at <A href=\"https://vaers.hhs.gov/\" target=_blank>https://vaers.hhs.gov</A> or by telephone, 800-822-7967.</LI>&#xD;&#xA;<LI>Report suspected cases of vaccine-preventable diseases to your state or local health department.</LI>&#xD;&#xA;<LI>For information about precautions and contraindications, refer to <A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html\" target=_blank>https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html</A>.</LI></UL></div><div class=\"graphic_footnotes\">* <STRONG>Tetanus and diphtheria toxoids, and acellular pertussis (Tdap) vaccine</STRONG><br /><EM>(Minimum age: 11 years for routine vaccinations, seven years for catch-up vaccination)</EM> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Adolescents 11 through 12 years of age: One dose.</LI>&#xD;&#xA;<LI>Pregnant adolescents: One dose during each pregnancy (preferably during the early part of gestational weeks 27 through 36).</LI>&#xD;&#xA;<LI>Tdap may be administered regardless of the interval since the last tetanus- and diphtheria-toxoid-containing vaccine.</LI></UL>¶ <STRONG>Human papillomavirus (HPV) vaccines</STRONG><br /><EM>(Minimum age: Nine years)</EM> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Routine vaccination for all adolescents at 11 through 12 years (can start at age nine) and through age 18 if not previously adequately vaccinated. Number of doses dependent on age at initial vaccination: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Age 9 through 14 at initiation: Two-dose series at 0 and 6 to 12 months. Minimum interval: Five months (repeat a dose given too soon at least 12 weeks after the invalid dose and at least five months after the first dose).</LI>&#xD;&#xA;<LI>Age 15 years or older at initiation: Three-dose series at zero, one to two, and six months. Minimum intervals: Four weeks between first and second dose; 12 weeks between second and third dose; five months between first and third dose (repeat dose[s] given too soon at or after the minimum interval since the most recent dose).</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Special populations:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>History of sexual abuse or assault: Begin series at age nine years.</LI>&#xD;&#xA;<LI>Immunocompromised (including human immunodeficiency virus [HIV] infection) aged 9 through 26 years: Three-dose series at zero, one to two, and six months (refer to <A href=\"https://www.cdc.gov/mmwr/volumes/65/wr/mm6549a5.htm\" target=_blank>MMWR Morb Mortal Wkly Rep 2016; 65:1405</A>).</LI>&#xD;&#xA;<LI>Pregnancy: Vaccination not recommended, but there is no evidence the vaccine is harmful. No intervention is needed for women who inadvertently received a dose of HPV vaccine while pregnant. Delay remaining doses until after pregnancy. Pregnancy testing not needed before vaccination.</LI></UL></LI></UL>Δ <STRONG>Serogroup A, C, W, Y meningococcal (MenACWY) vaccines</STRONG><br /><EM>(Minimum age: Two months for MenACWY-CRM [Menveo], nine months for MenACWY-D [Menactra])</EM> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Two-dose series: 11 years and 16 years.</LI>&#xD;&#xA;<LI><STRONG>Special populations and circumstances:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Refer to UpToDate content related to meningococcal vaccines and immunization in the specific high-risk group, and the <A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html\" target=_blank>ACIP recommendations</A>. High-risk conditions include anatomic or functional asplenia, sickle cell disease, HIV infection, persistent complement component deficiency (including eculizumab), travel to or residence in countries where meningococcal disease is hyperendemic or epidemic (including countries in the African meningitis belt or during the Hajj), and exposure to an outbreak attributable to a vaccine serogroup.</LI></UL></LI></UL><FONT class=lozenge>◊</FONT> <STRONG>Serogroup B meningococcal (MenB) vaccines</STRONG><br /><EM>(Minimum age: 10 years for Bexsero or Trumenba)</EM> &#xD;&#xA;<UL>&#xD;&#xA;<LI><STRONG>Clinical discretion:</STRONG> Adolescents not at increased risk of meningococcal B infection who want MenB vaccine: &#xD;&#xA;<UL>&#xD;&#xA;<LI>MenB vaccines may be given at clinical discretion to adolescents 16 through 23 years (preferred age 16 through 18 years) who are not at increased risk.</LI>&#xD;&#xA;<LI>Bexsero: Two doses at least one month apart.</LI>&#xD;&#xA;<LI>Trumenba: Two doses at least six months apart. If the second dose is given earlier than six months, give a third dose at least four months after the second.</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Special populations and situations:</STRONG> Anatomic or functional asplenia, sickle cell disease, persistent complement component deficiency (including eculizumab use), serogroup B meningococcal disease outbreak: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Bexsero: Two-dose series at least one month apart.</LI>&#xD;&#xA;<LI>Trumenba: Three-dose series at zero, one to two, and six months.</LI></UL></LI>&#xD;&#xA;<LI>NOTE: Bexsero and Trumenba are not interchangeable.</LI>&#xD;&#xA;<LI>For additional information, refer to UpToDate content on meningococcal vaccines and immunization in the specific high-risk group, and the <A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html\" target=_blank>ACIP recommendations</A>.</LI></UL>§ <STRONG>Influenza vaccines</STRONG><br /><EM>(Minimum age: Six months for inactivated influenza vaccine [IIV], 18 years for recombinant influenza vaccine [RIV])</EM> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer an age-appropriate formulation and dose of influenza vaccine annually. &#xD;&#xA;<UL>&#xD;&#xA;<LI>Children six months through eight years who did not receive at least two doses of influenza vaccine before July 1, 2017, should receive two doses separated by at least four weeks.</LI>&#xD;&#xA;<LI>Persons nine years and older: One dose.</LI>&#xD;&#xA;<LI>Live attenuated influenza vaccine not recommended for the 2017-2018 influenza season.</LI></UL></LI>&#xD;&#xA;<LI>For additional guidance, refer to UpToDate content on influenza vaccines and the <A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html\" target=_blank>ACIP recommendations</A>.</LI></UL>¥ <STRONG>Pneumococcal vaccines</STRONG><br /><EM>(Minimum age: Six weeks for 13-valent pneumococcal conjugate vaccine [PCV13], two years for 23-valent pneumococcal polysaccharide vaccine [PPSV23])</EM> &#xD;&#xA;<UL>&#xD;&#xA;<LI><STRONG>Vaccination of persons with high-risk conditions:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Refer to UpToDate content on pneumococcal vaccines and immunization in the specific high-risk group, and the <A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html\" target=_blank>ACIP recommendations</A>. High-risk groups include chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure); chronic lung disease (including asthma treated with high-dose, oral, corticosteroids); diabetes mellitus, cerebrospinal fluid leak; cochlear implant; sickle cell disease and other hemoglobinopathies; anatomic or functional asplenia; congenital or acquired immunodeficiency; HIV infection; chronic renal failure; nephrotic syndrome; malignant neoplasms, leukemias, lymphomas, Hodgkin disease, and other diseases associated with treatment with immunosuppressive drugs or radiation therapy; solid organ transplantation; and chronic liver disease and alcoholism.</LI></UL></LI></UL>‡ <STRONG><EM>Haemophilus influenzae</EM> type b (Hib) conjugate vaccines</STRONG><br /><EM>(Minimum age: Six weeks)</EM> &#xD;&#xA;<UL>&#xD;&#xA;<LI><STRONG>Special situations or high-risk conditions:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Refer to UpToDate content related to Hib vaccination and immunization in the specific high-risk group, and the <A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hib.html\" target=_blank>ACIP recommendations</A>. Special situations and high-risk groups include chemotherapy or radiation treatment, hematopoietic stem cell transplant, anatomic or functional asplenia (including sickle cell disease), elective splenectomy, HIV infection, immunoglobulin deficiency, and early component complement deficiency).</LI></UL></LI></UL>† <STRONG>Hepatitis A (HepA) vaccine</STRONG><br /><EM>(Minimum age: 12 months)</EM> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Anyone two years of age or older may receive HepA vaccine if desired. Minimum interval between doses is six months.</LI>&#xD;&#xA;<LI><STRONG>Special populations:</STRONG> Previously unvaccinated persons who should be vaccinated: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Persons traveling to or working in countries with high or intermediate endemicity.</LI>&#xD;&#xA;<LI>Men who have sex with men.</LI>&#xD;&#xA;<LI>Users of injection and noninjection drugs.</LI>&#xD;&#xA;<LI>Persons who work with hepatitis A virus (HAV) in a research laboratory or with nonhuman primates.</LI>&#xD;&#xA;<LI>Persons with clotting-factor disorders.</LI>&#xD;&#xA;<LI>Persons with chronic liver disease.</LI>&#xD;&#xA;<LI>Persons who anticipate close, personal contact (eg, household or regular babysitting) with an international adoptee during the first 60 days after arrival in the United States from a country with high or intermediate endemicity.</LI></UL></LI></UL>** <STRONG>Hepatitis B (HepB) vaccine</STRONG><br /><EM>(Minimum age: Birth)</EM> &#xD;&#xA;<UL class=double_footnote_list>&#xD;&#xA;<LI>Unvaccinated persons should complete a three-dose series at zero, one to two, and six months.</LI>&#xD;&#xA;<LI>Adolescents 11 through 15 years of age may use an alternative two-dose schedule, with at least four months between doses (adult formulation Recombivax HB only).</LI></UL>¶¶ <STRONG>Inactivated poliovirus vaccine (IPV)</STRONG><br /><EM>(Minimum age: Six weeks)</EM> &#xD;&#xA;<UL class=double_footnote_list>&#xD;&#xA;<LI>A fourth dose is not necessary if the third dose was given on after the fourth birthday and at least six months after the previous dose.</LI>&#xD;&#xA;<LI>IPV is not routinely recommended for United States residents 18 years and older.</LI>&#xD;&#xA;<LI><STRONG>Series containing oral polio vaccine (OPV),</STRONG> <EM>either mixed OPV-IPV or OPV-only series:</EM> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Total number of doses needed to complete the series is the same as that recommended for the United States IPV schedule. Refer to <A href=\"https://www.cdc.gov/mmwr/volumes/66/wr/mm6601a6.htm?s_cid=mm6601a6_w\" target=_blank>MMWR Morb Mortal Wkly Rep 2017; 66:23</A>.</LI>&#xD;&#xA;<LI>Only trivalent OPV (tOPV) counts toward the United States vaccination requirements. For guidance to assess doses documented as \"OPV,\" refer to <A href=\"https://www.cdc.gov/mmwr/volumes/66/wr/mm6606a7.htm?s_cid=mm6606a7_w\" target=_blank>MMWR Wkly Rep 2017;66:180</A>.</LI></UL></LI></UL>ΔΔ <STRONG>Measles, mumps, and rubella (MMR) vaccine</STRONG><br /><EM>(Minimum age: 12 months for routine vaccination)</EM> &#xD;&#xA;<UL class=double_footnote_list>&#xD;&#xA;<LI>Unvaccinated children and adolescents: Two doses at least four weeks apart.</LI>&#xD;&#xA;<LI><STRONG>International travel:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Unvaccinated children 12 months and older: Two doses at least four weeks apart before departure.</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Mumps outbreak:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Persons ≥12 months who previously received ≤2 doses of mumps-containing vaccine and are identified by public health authorities to be at increased risk during a mumps outbreak should receive a dose of mumps virus-containing vaccine.</LI></UL></LI></UL><FONT class=double_lozenge>◊◊</FONT> <STRONG>Varicella (VAR) vaccine</STRONG><br /><EM>(Minimum age: 12 months)</EM> &#xD;&#xA;<UL class=double_footnote_list>&#xD;&#xA;<LI>Ensure persons 7 through 18 years without evidence of immunity (refer to <A href=\"https://www.cdc.gov/mmwr/pdf/rr/rr5604.pdf\" target=_blank>MMWR Recomm Rep 2007; 56(RR04):1</A>) have two doses of VAR vaccine. &#xD;&#xA;<UL>&#xD;&#xA;<LI>Ages 7 through 12: Routine interval three months (minimum interval: Four weeks).</LI>&#xD;&#xA;<LI>Ages 13 and older: Minimum interval four weeks.</LI></UL></LI></UL></div><div class=\"graphic_reference\">Adapted from: Centers for Disease Control and Prevention. Immunization schedules. Available at: <A href=\"https://www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html\" target=_blank>www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html</A> (Accessed on February 14, 2018).</div><div id=\"graphicVersion\">Graphic 58209 Version 29.0</div></div></div>"},"58210":{"type":"graphic_waveform","displayName":"Intermediate case 9 with answer","title":"Wandering atrial pacemaker","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Wandering atrial pacemaker</div><div class=\"cntnt\"><img style=\"width:533px; height:99px;\" src=\"images/CARD/58210_Intermediate_case_9_with_an.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram showing prominent beat-to-beat variation in P wave axis or morphology indicative of a wandering (shifting) atrial pacemaker. The P wave is upright in the first and third beats, biphasic in the last beat, and flat or inverted in the other beats. This pattern may occur as a physiologic variant, especially during sleep, or as a manifestation of drug toxicity (digitalis, beta-blockers, calcium channel blockers) or the sick sinus syndrome. The relatively slow rate distinguishes this arrhythmia from multifocal atrial tachycardia.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 58210 Version 2.0</div></div></div>"},"58211":{"type":"graphic_figure","displayName":"Toxic epidermal necrolysis prognosis by SCORTEN","title":"Toxic epidermal necrolysis prognosis by SCORTEN","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Toxic epidermal necrolysis&nbsp;prognosis by SCORTEN</div><div class=\"cntnt\"><img style=\"width:454px; height:312px;\" src=\"images/ALLRG/58211_TEN_prognosis_by_SCORTEN.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier analysis of survival of patients with TEN based upon SCORTEN score, calculated within 24 hours of hospital admission.</div><div class=\"graphic_footnotes\">TEN:&nbsp;toxic epidermal necrolysis. &nbsp;</div><div class=\"graphic_reference\">Adapted with permission from: Auegan S, Bastuji-Garin S, Poszepczynska-Guigne E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006; 126:272.</div><div id=\"graphicVersion\">Graphic 58211 Version 4.0</div></div></div>"},"58218":{"type":"graphic_figure","displayName":"Division of the right gastric and gastroepiploic vessels","title":"Division of the right gastric and gastroepiploic vessels","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Division of the right gastric and gastroepiploic vessels</div><div class=\"cntnt\"><img style=\"width:531px; height:456px;\" src=\"images/SURG/58218_Division_RT_gastrics.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The right gastric and gastroepiploic vessels are double ligated in sequence.</div><div id=\"graphicVersion\">Graphic 58218 Version 2.0</div></div></div>"},"58219":{"type":"graphic_figure","displayName":"Lymphatic drainage of the colon and rectum","title":"Lymphatic drainage of the colon and rectum","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Lymphatic drainage of the colon and rectum</div><div class=\"cntnt\"><img style=\"width:541px; height:546px;\" src=\"images/SURG/58219_Lymphatic-drainage-colon-rectum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the lymphatic drainage of the colon and rectum.</div><div id=\"graphicVersion\">Graphic 58219 Version 1.0</div></div></div>"},"58221":{"type":"graphic_figure","displayName":"Prevalence of HTN in women","title":"Prevalence of hypertension in women in the United States","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prevalence of hypertension in women in the United States</div><div class=\"cntnt\"><img style=\"width:405px; height:314px;\" src=\"images/NEPH/58221_Prevalence_of_HTN_in_women.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prevalence of hypertension in women according to age and race/ethnicity in the United States from the NHANES-III survey. Hypertension occurs earlier and more frequently in African-American women.</div><div class=\"graphic_reference\">Data from: Burt VL, Whelton P, Roccella EJ, et al. Hypertension 1995; 25:305.</div><div id=\"graphicVersion\">Graphic 58221 Version 3.0</div></div></div>"},"58224":{"type":"graphic_table","displayName":"Normal anogenital variants","title":"Normal variants in the anogenital examination","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal variants in the anogenital examination</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Female genitalia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Periurethral bands</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Vestibular bands</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Intravaginal ridge or column</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Linea vestibularis (midline avascular area)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Dilation of the urethral opening with application of labial traction</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Hymen</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Hymenal tags or septal remnants</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Hymenal bump or mound</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Hymenal cleft/notch in the anterior\n(superior) half of the hymenal rim (above the line drawn through 3\no'clock to 9 o'clock, with the patient supine)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">External hymenal ridge</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Septate hymen</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Thickened hymen (may be due to estrogen effect, folded edge of hymen, or swelling from infection or trauma)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Shallow or superficial notch or cleft in the posterior (inferior) rim of hymen (below the line drawn through 3 o'clock to 9 o'clock, with the patient supine)</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Perianal area</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Diastasis ani (smooth area)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Perianal skin tag</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hyperpigmentation of the skin of the labia majora or perianal tissues in Mexican American and African American children</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Adams, JA. Medical evaluation of suspected child sexual abuse. J Pediatr Adolesc Gynecol 2004; 17:191.</div><div id=\"graphicVersion\">Graphic 58224 Version 1.0</div></div></div>"},"58225":{"type":"graphic_figure","displayName":"Causes of upbeat nystagmus","title":"Causes of upbeat nystagmus in 86 patients","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Causes of upbeat nystagmus in 86 patients</div><div class=\"cntnt\"><img style=\"width:504px; height:308px;\" src=\"images/PC/58225_Causes_of_upbeat_nystagmus.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">The numbers in parentheses associated with the pie graph represent the percent of patients with each cause.</div><div id=\"graphicVersion\">Graphic 58225 Version 1.0</div></div></div>"},"58226":{"type":"graphic_diagnosticimage","displayName":"Hemopneumothorax I PA","title":"Chest radiograph of hemopneumothorax due to blunt trauma","html":"<div class=\"graphic\"><div style=\"width: 509px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of hemopneumothorax due to blunt trauma</div><div class=\"cntnt\"><img style=\"width:489px; height:243px;\" src=\"images/PULM/58226_Hemopneumothorax_I_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: Supine chest radiograph shows hyperexpansion of the left hemithorax with filter effect and veil-like opacification due to dorsal blood and ventral gas. Right panel: After insertion of chest tubes, the dorsal component of blood has been drained and only the pneumothorax remains. The contused lung is too rigid and noncompliant to collapse completely.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 58226 Version 4.0</div></div></div>"},"58227":{"type":"graphic_table","displayName":"Distinguishing serotonin and neuroleptic malignant syndromes","title":"Serotonin syndrome and neuroleptic malignant syndrome: Distinguishing features","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Serotonin syndrome and neuroleptic malignant syndrome: Distinguishing features</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Serotonin syndrome (SS)</td> <td class=\"subtitle1\">Neuroleptic malignant syndrome (NMS)</td> </tr> <tr> <td>Onset</td> <td>Within 24 hours</td> <td>Days to weeks</td> </tr> <tr> <td>Neuromuscular findings</td> <td>Hyperreactivity (tremor, clonus, reflexes)</td> <td>Bradyreflexia, severe muscular rigidity</td> </tr> <tr> <td>Causative agents</td> <td>Serotonin agonist</td> <td>Dopamine antagonist</td> </tr> <tr> <td>Treatment agents</td> <td>Benzodiazepine, cyproheptadine</td> <td>Bromocriptine</td> </tr> <tr> <td>Resolution</td> <td>Within 24 hours</td> <td>Days to weeks</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58227 Version 5.0</div></div></div>"},"58228":{"type":"graphic_figure","displayName":"Secretin amino acid sequence","title":"Amino acid sequence of secretin in various animal species","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amino acid sequence of secretin in various animal species</div><div class=\"cntnt\"><img style=\"width:398px; height:167px;\" src=\"images/GAST/58228_Secretin_amino_acid_sequenc.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 58228 Version 1.0</div></div></div>"},"58229":{"type":"graphic_picture","displayName":"Vulva trauma drain","title":"Repair following major vulvar trauma from motor vehicle accident","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Repair following major vulvar trauma from motor vehicle accident</div><div class=\"cntnt\"><img style=\"width:333px; height:504px;\" src=\"images/OBGYN/58229_Vulva_trauma_drain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Appearance of the wound following closure. Note drain in place due to nature of injury.</div><div class=\"graphic_reference\">Courtesy of Marc Laufer, MD.</div><div id=\"graphicVersion\">Graphic 58229 Version 2.0</div></div></div>"},"58231":{"type":"graphic_diagnosticimage","displayName":"Interstitial edema PA","title":"Left ventricular failure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left ventricular failure</div><div class=\"cntnt\"><img style=\"width:336px; height:338px;\" src=\"images/PULM/58231_Interstitial_edema_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows cephalization of pulmonary vascular flow with interstitial pulmonary&nbsp;edema and conspicuous septal lines.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 58231 Version 4.0</div></div></div>"},"58232":{"type":"graphic_picture","displayName":"Silicotic nodule pathology","title":"Silicotic nodule","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Silicotic nodule</div><div class=\"cntnt\"><img style=\"width:430px; height:275px;\" src=\"images/PULM/58232_Silicotic_nodule_path.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The central zone of the silicotic nodule is hyalinized with concentrically arranged collagen fibers. The peripheral zone is whorled and becomes less organized toward the edges. This outer zone contains macrophages, lymphocytes, and lesser amounts of loosely formed collagen and is the site of active enlargement and ongoing inflammation.</div><div class=\"graphic_reference\">Courtesy of Dr. J Parker.</div><div id=\"graphicVersion\">Graphic 58232 Version 3.0</div></div></div>"},"58235":{"type":"graphic_figure","displayName":"Stage II repair for HLHS","title":"Stage II repair for HLHS","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stage II repair for HLHS</div><div class=\"cntnt\"><img style=\"width:429px; height:571px;\" src=\"images/PEDS/58235_StageIIrepairHLHS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Connection of the superior vena cava to the pulmonary arteries and takedown of previous systemic-to-pulmonary artery shunts constitutes the stage II procedure. The bidirectional Glenn shunt is a direct anastomosis of the superior vena cava to the central pulmonary artery. The principle advantage of the bidirectional Glenn shunt is the ease of construction; it can even be accomplished without the use of cardiopulmonary bypass in selected cases.</div><div class=\"graphic_reference\">Reproduced with permission from: Tweddell J, Hoffman G, Ghanayem N, et al. Hypoplastic left heart syndrome. In: Moss and Adams' Heart Disease in Infants, Children and Adolescents: Including the Fetus and Young Adult, 7<SUP>th</SUP> ed, Allen H, Driscoll D, Shaddy R, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 58235 Version 10.0</div></div></div>"},"58237":{"type":"graphic_table","displayName":"Risk factors ERCP pancreatitis","title":"Risk factors for post-ERCP pancreatitis identified by multivariate analysis in large studies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for post-ERCP pancreatitis identified by multivariate analysis in large studies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author</td> <td class=\"subtitle1\">Study</td> <td class=\"subtitle1\">Object of the study</td> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">Post-procedure pancreatitis rate</td> <td class=\"subtitle1\">Independent risk factors</td> </tr> <tr> <td rowspan=\"5\">Freeman et al 1996</td> <td rowspan=\"5\">Prospective multicenter study</td> <td rowspan=\"5\">Endoscopic biliary sphincterotomy</td> <td rowspan=\"5\">2347 patients</td> <td rowspan=\"5\">5.4 percent</td> <td>Suspected sphincter of Oddi dysfunction</td> </tr> <tr> <td>Younger age</td> </tr> <tr> <td>Precut sphincterotomy</td> </tr> <tr> <td>Difficult cannulation</td> </tr> <tr> <td>Number of pancreatic contrast injections</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Loperfido et al 1998</td> <td rowspan=\"3\">Prospective multicenter study</td> <td rowspan=\"3\">Therapeutic ERCP</td> <td rowspan=\"3\">1827 patients</td> <td rowspan=\"3\">1.6 percent*</td> <td>Small bile duct</td> </tr> <tr> <td>Age under 70</td> </tr> <tr> <td>Pancreatic opacification</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Rabenstein et al 2000</td> <td rowspan=\"2\">Prospective multicenter study</td> <td rowspan=\"2\">Endoscopic sphincterotomy</td> <td rowspan=\"2\">438 patients</td> <td rowspan=\"2\">4.3 percent</td> <td>Sphincterotomy rate of the endoscopist (&#60;40 per year)</td> </tr> <tr> <td>Pancreas divisum</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Masci et al 2001</td> <td rowspan=\"3\">Prospective multicenter study</td> <td rowspan=\"3\">Diagnostic and therapeutic ERCP</td> <td rowspan=\"3\">2444 procedures</td> <td rowspan=\"3\">1.8 percent</td> <td>Age under 60</td> </tr> <tr> <td>Precut sphincterotomy</td> </tr> <tr> <td>Failed clearance of biliary stones</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"9\">Freeman et al 2001</td> <td rowspan=\"9\">Prospective multicenter study</td> <td rowspan=\"9\">Diagnostic and therapeutic ERCP</td> <td rowspan=\"9\">1963 procedures</td> <td rowspan=\"9\">6.7 percent</td> <td>Prior post-ERCP pancreatitis</td> </tr> <tr> <td>Suspected dysfunction of sphincter of Oddi</td> </tr> <tr> <td>Female sex</td> </tr> <tr> <td>Normal serum bilirubin</td> </tr> <tr> <td>Absence of chronic pancreatitis</td> </tr> <tr> <td>Biliary sphincter balloon dilation</td> </tr> <tr> <td>Difficult cannulation</td> </tr> <tr> <td>Pancreatic sphincterotomy</td> </tr> <tr> <td>1 or more injections of contrast into the pancreatic duct</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">Vandervoort et al 2002</td> <td rowspan=\"6\">Prospective single center study</td> <td rowspan=\"6\">Diagnostic and therapeutic ERCP</td> <td rowspan=\"6\">1223 patients</td> <td rowspan=\"6\">7.2 percent</td> <td>Recurrent pancreatitis</td> </tr> <tr> <td>Prior post-ERCP pancreatitis</td> </tr> <tr> <td>Difficult cannulation</td> </tr> <tr> <td>Pancreatic brush cytology</td> </tr> <tr> <td>Pain during procedure</td> </tr> <tr> <td>Precut sphincterotomy</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Christensen et al 2004</td> <td rowspan=\"3\">Prospective single center study</td> <td rowspan=\"3\">Diagnostic and therapeutic ERCP</td> <td rowspan=\"3\">1177 patients</td> <td rowspan=\"3\">3.8 percent</td> <td>Age under 40</td> </tr> <tr> <td>Dilated bile duct</td> </tr> <tr> <td>Placement of stent</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">Cheng et al 2006</td> <td rowspan=\"6\">Prospective multicenter study</td> <td rowspan=\"6\">Diagnostic and therapeutic ERCP</td> <td rowspan=\"6\">1115 patients</td> <td rowspan=\"6\">15.1 percent</td> <td>Minor papilla sphincterotomy</td> </tr> <tr> <td>Sphincter of Oddi dysfunction</td> </tr> <tr> <td>Prior post-ERCP pancreatitis</td> </tr> <tr> <td>Age under 70</td> </tr> <tr> <td>2 or more injections of contrast into the pancreatic duct</td> </tr> <tr> <td>Trainee involvement</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Cheon et al 2007</td> <td rowspan=\"2\">Prospective single center study</td> <td rowspan=\"2\">Diagnostic and therapeutic ERCP</td> <td rowspan=\"2\">14,331 procedures</td> <td rowspan=\"2\">4.0 percent</td> <td>Extent of pancreatic opacification</td> </tr> <tr> <td>Sphincter of Oddi dysfunction with manometry</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Williams et al 2008</td> <td rowspan=\"4\">Prospective multicenter study</td> <td rowspan=\"4\">Diagnostic and therapeutic ERCP</td> <td rowspan=\"4\">4561 patients</td> <td rowspan=\"4\">1.6 percent</td> <td>Female sex</td> </tr> <tr> <td>Younger age</td> </tr> <tr> <td>Difficult cannulation</td> </tr> <tr> <td>Performance in a district (as opposed to university)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Wang et al 2009</td> <td rowspan=\"5\">Prospective multicenter study</td> <td rowspan=\"5\">Diagnostic and therapeutic ERCP</td> <td rowspan=\"5\">2691 patients</td> <td rowspan=\"5\">4.3 percent</td> <td>Female sex</td> </tr> <tr> <td>Age under 60</td> </tr> <tr> <td>Difficult cannulation</td> </tr> <tr> <td>&#8805;1 pancreatic deep wire pass</td> </tr> <tr> <td>Precut sphincterotomy</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Cotton et al 2009</td> <td rowspan=\"2\">Retrospective single center study</td> <td rowspan=\"2\">Diagnostic and therapeutic ERCP</td> <td rowspan=\"2\">11,497 procedures</td> <td rowspan=\"2\">2.6 percent</td> <td>Pancreatogram</td> </tr> <tr> <td>Sphincter of Oddi dysfunction</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Glomsaker et al 2013</td> <td rowspan=\"4\">Prospective multicenter study</td> <td rowspan=\"4\">Diagnostic and therapeutic ERCP</td> <td rowspan=\"4\">2808 procedures</td> <td rowspan=\"4\">3.1 percent</td> <td>ASA score III-IV </td> </tr> <tr> <td>Precut sphincterotomy &#62;150 ERCPs/year</td> </tr> <tr> <td>Pancreatic stent placement</td> </tr> <tr> <td>Biliary stent exchange</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ASA: American Society of Anesthesiologists; ERCP: endoscopic retrograde cholangiopancreatography.<br />* Moderate to severe pancreatitis.</div><div id=\"graphicVersion\">Graphic 58237 Version 4.0</div></div></div>"},"58239":{"type":"graphic_picture","displayName":"Transplant glomerulopathy light","title":"Transplant glomerulopathy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transplant glomerulopathy</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/58239_Transplant_glomerulopathy_L.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of transplant glomerulopathy shows a membranoproliferative pattern with capillary wall thickening and a double-contour appearance due to mesangial interposition (arrow).</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 58239 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal glomerulus</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/75094_Normal_glomerulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75094 Version 4.0</div></div></div>"},"58240":{"type":"graphic_figure","displayName":"Classification tooth fractures","title":"Classification of tooth fractures","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Classification of tooth fractures</div><div class=\"cntnt\"><img style=\"width:491px; height:338px;\" src=\"images/PEDS/58240_Classification_tooth_injury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tooth fractures may involve enamel, dentin, or pulp and may occur in the crown or the root.</div><div class=\"graphic_footnotes\">PDL: periodontal ligament.</div><div class=\"graphic_reference\">Reproduced with permission from: McTigue DJ. Managing traumatic injuries in the young permanent dentition. In: Pediatric Dentistry: Infancy through adolescence, 3rd ed, W.B. Saunders, Philadelphia 1999. Copyright &copy; 1999 W.B. Saunders Co.</div><div id=\"graphicVersion\">Graphic 58240 Version 3.0</div></div></div>"},"58241":{"type":"graphic_table","displayName":"New Ballard Score 2","title":"New Ballard score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">New Ballard score</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"14\">Physical maturity</td> </tr> <tr> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\">&ndash;1</td> <td class=\"subtitle2\" colspan=\"2\">0</td> <td class=\"subtitle2\" colspan=\"2\">1</td> <td class=\"subtitle2\" colspan=\"2\">2</td> <td class=\"subtitle2\" colspan=\"2\">3</td> <td class=\"subtitle2\" colspan=\"2\">4</td> <td class=\"subtitle2\" colspan=\"2\">5</td> </tr> <tr> <td><strong>Skin</strong></td> <td>Sticky; friable; transparent</td> <td colspan=\"2\">Gelatinous; red; translucent</td> <td colspan=\"2\">Smooth; pink; visible veins</td> <td colspan=\"2\">Superficial peeling and/or rash; few veins</td> <td colspan=\"2\">Cracking pale areas; rare veins</td> <td colspan=\"2\">Parchment deep cracking; no vessels</td> <td colspan=\"2\">Leathery; cracked; wrinkled</td> </tr> <tr> <td><strong>Lanugo</strong></td> <td>None</td> <td colspan=\"2\">Sparse</td> <td colspan=\"2\">Abundant</td> <td colspan=\"2\">Thinning</td> <td colspan=\"2\">Bald areas</td> <td colspan=\"2\">Mostly bald</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td><strong>Plantar creases</strong></td> <td> <p>Heel-toe</p> <p>40 to 50 mm: &ndash;1</p> &#60;40 mm: &ndash;2</td> <td colspan=\"2\">&#62;50 mm; no crease</td> <td colspan=\"2\">Faint red marks</td> <td colspan=\"2\">Anterior transverse crease only</td> <td colspan=\"2\">Crease anterior 2/3</td> <td colspan=\"2\">Creases over entire sole</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td><strong>Breast</strong></td> <td>Imperceptible</td> <td colspan=\"2\">Barely perceptible</td> <td colspan=\"2\">Flat areola; no bud</td> <td colspan=\"2\">Strippled areola; 1 to 2 mm bud</td> <td colspan=\"2\">Raised areola; 3 to 4 mm bud</td> <td colspan=\"2\">Full areola; 5 to 10 mm bud</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td><strong>Eye/ear</strong></td> <td> <p>Lids fused</p> <p>Loosely: &ndash;1</p> Lightly: &ndash;2</td> <td colspan=\"2\">Lids open; pinna flat, stays folded</td> <td colspan=\"2\">Slightly curved pinna; soft with slow recoil</td> <td colspan=\"2\">Well-curved pinna; soft but ready recoil</td> <td colspan=\"2\">Formed and firm with instant recoil</td> <td colspan=\"2\">Thick cartilage; ear stiff</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td><strong>Genitals (male)</strong></td> <td>Scrotum flat, smooth</td> <td colspan=\"2\">Scrotum empty; faint rugae</td> <td colspan=\"2\">Testes in upper canal; rare rugae</td> <td colspan=\"2\">Testes descending; few rugae</td> <td colspan=\"2\">Testes down; good rugae</td> <td colspan=\"2\">Testes pendulous; deep rugae</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Genitals (female)</strong></td> <td>Clitoris prominent; labia flat</td> <td colspan=\"2\">Prominent clitoris; small labia minora</td> <td colspan=\"2\">Prominent clitoris; enlarging minora</td> <td colspan=\"2\">Majora and minora equally prominent</td> <td colspan=\"2\">Majora large; minora small</td> <td colspan=\"2\">Majora cover clitoris and minora</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"14\">Maturity rating</td> </tr> <tr> <td><strong>Score</strong></td> <td>&ndash;10</td> <td>&ndash;5</td> <td>0</td> <td>5</td> <td>10</td> <td>15</td> <td>20</td> <td>25</td> <td>30</td> <td>35</td> <td>40</td> <td>45</td> <td>50</td> </tr> <tr> <td><strong>Gestational age (weeks)</strong></td> <td>20</td> <td>22</td> <td>24</td> <td>26</td> <td>28</td> <td>30</td> <td>32</td> <td>34</td> <td>36</td> <td>38</td> <td>40</td> <td>42</td> <td>44</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The New Ballard Score is used to estimate gestational age from neuromuscular and physical features. The scores of each feature are added to calculate a maturity rating that correlates with gestational age (see figure 1a).</div><div class=\"graphic_reference\">Adapted with permission from: Ballard JL, Khoury JC, Wedig K, et al. New Ballard Score, expanded to include extremely premature infants. J Pediatr 1991; 119:417. Copyright &copy; 1991 Elsevier.</div><div id=\"graphicVersion\">Graphic 58241 Version 3.0</div></div></div>"},"58242":{"type":"graphic_picture","displayName":"Histology fibrotic foci","title":"Photomicrographs of histologic features of usual interstitial pneumonia of IPF lung","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Photomicrographs of histologic features of usual interstitial pneumonia of IPF lung</div><div class=\"cntnt\"><img style=\"width:516px; height:196px;\" src=\"images/PULM/58242_Histology_fibrotic_foci.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The fibrotic foci (arrows) are hallmarks of usual interstitial pneumonia (Left: H and E stain; Right: Masson's trichrome stain-collagen is stained blue).</div><div class=\"graphic_reference\">Courtesy of Ganesh Raghu, MD.</div><div id=\"graphicVersion\">Graphic 58242 Version 2.0</div></div></div>"},"58243":{"type":"graphic_table","displayName":"Six item screen for confusion in adults","title":"Six item screen for confusion in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Six item screen for confusion in adults</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t<td>1. Give the patient three items to remember (eg, apple, table, and penny), and ask the patient to repeat them aloud.</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>2. Ask the patient to state the current year, month, and day of week.</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>3. Ask the patient to repeat the original three items.</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>One point is given for each correct answer; a score below five connotes cognitive impairment.</strong></td>\n\t\t</tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">3.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=13175&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Six_item_screen.htm</title></head></div><div class=\"graphic_footnotes\">Source: Wilbur et al. An evaluation of two screening tools for cognitive impairment in older emergency department patients. Acad Emerg Med. 2005; 12:612.</div><div id=\"graphicVersion\">Graphic 58243 Version 3.0</div></div></div>"},"58245":{"type":"graphic_figure","displayName":"Actions of cobalamin","title":"Role of cobalamin (vitamin B12) in homocysteine and methylmalonic acid metabolism","html":"<div class=\"graphic\"><div style=\"width: 576px\" class=\"figure\"><div class=\"ttl\">Role of cobalamin (vitamin B12) in homocysteine and methylmalonic acid metabolism</div><div class=\"cntnt\"><img style=\"width:556px; height:378px;\" src=\"images/HEME/58245_Actions_of_cobalamin.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Role of cobalamin in homocysteine and methylmalonic acid metabolism.<br />(Panel A) Methylcobalamin is a cofactor in the synthesis of methionine from homocysteine.<br />(Panel B) Adenosylcobalamin is a cofactor in the synthesis of succinyl-CoA from methylmalonyl-CoA. THF participates in homocysteine but not MMA metabolism. Thus, cobalamin deficiency is characterized by elevations in the serum levels of both homocysteine and MMA metabolism, while only homocysteine levels are elevated in folate deficiency.</div><div class=\"graphic_footnotes\">THF: tetrahydrofolate; MMA: methylmalonic acid.</div><div class=\"graphic_reference\">Reproduced with permission from Tefferi A, Pruthi RK. The Biochemical Basis of Cobalamin Deficiency. Mayo Clin Proc 1994; 69:181.</div><div id=\"graphicVersion\">Graphic 58245 Version 5.0</div></div></div>"},"58246":{"type":"graphic_table","displayName":"Causes of reactive lymphocytosis","title":"Causes of reactive lymphocytosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of reactive lymphocytosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Infections</td> </tr> <tr> <td rowspan=\"7\">Viral</td> <td>Infectious mononucleosis&nbsp;&#8212; Epstein-Barr virus (or&nbsp;other causes: <span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">cytomegalovirus, other herpes viruses, HIV, adenoviruses, toxoplasmosis</span>)</td> </tr> <tr> <td>Cytomegalovirus (CMV)</td> </tr> <tr> <td>Mononucleosis syndrome (adenovirus type 12, herpes virus-6)</td> </tr> <tr> <td>HIV-1 (during early seroconversions associated with CMV) (chronic, associated with post-splenectomy state)</td> </tr> <tr> <td>HTLV-1 associated benign T cell lymphocytosis</td> </tr> <tr> <td>Mumps, varicella, influenza, hepatitis, rubella, roseola</td> </tr> <tr> <td>Infectious lymphocytosis (coxsackie virus B2, enteroviruses including poliovirus, others)</td> </tr> <tr> <td rowspan=\"2\">Bacterial</td> <td>Pertussis</td> </tr> <tr> <td>(Occasional) cat scratch fever, tuberculosis, brucellosis, syphilis</td> </tr> <tr> <td>Protozoal</td> <td>Toxoplasmosis</td> </tr> <tr> <td>Parasitic</td> <td>Babesiosis</td> </tr> <tr> <td>Rickettsial</td> <td>(Occasional) scrub typhus</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" rowspan=\"2\">Hypersensitivity</td> <td>Drug-induced</td> </tr> <tr> <td>Serum sickness</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" rowspan=\"3\">Stress</td> <td>Post-trauma</td> </tr> <tr> <td>Post-splenectomy</td> </tr> <tr> <td>Cigarette smokers</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" rowspan=\"3\">Autoimmune</td> <td>Lymphocytosis of large granular lymphocytes</td> </tr> <tr> <td>Rheumatoid arthritis</td> </tr> <tr> <td>Malignant thymoma</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\">Endocrine</td> <td>Hyperthyroidism</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\">Pre-malignant states</td> <td>Monoclonal B cell lymphocytosis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58246 Version 4.0</div></div></div>"},"58247":{"type":"graphic_table","displayName":"Initiating Rx 12 and up","title":"Classifying asthma severity and initiating treatment in youths greater than or equal to 12 years of age and adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classifying asthma severity and initiating treatment in youths greater than or equal to 12 years of age and adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\" colspan=\"2\">Components of severity</td> <td class=\"subtitle1\" colspan=\"4\">Classification of asthma severity (&#8805;12 years of age)</td> </tr> <tr> <td class=\"subtitle2\" rowspan=\"2\">Intermittent</td> <td class=\"subtitle2\" colspan=\"4\">Persistent</td> </tr> <tr> <td class=\"subtitle3\">Mild</td> <td class=\"subtitle3\">Moderate</td> <td class=\"subtitle3\">Severe</td> </tr> <tr> <td rowspan=\"5\"> <p>Impairment</p> <p>Normal FEV<sub>1</sub>/FVC:</p> <p>8 to 19 years 85 percent</p> <p>20 to 39 years 80 percent</p> <p>40 to 59 years 75 percent</p> <p>60 to 80 years 70 percent</p> </td> <td>Symptoms</td> <td>&#8804;2 days/week</td> <td>&#62;2 days/week but not daily</td> <td>Daily</td> <td>Throughout the day</td> </tr> <tr> <td>Nighttime awakenings</td> <td>&#8804;2x/month</td> <td>3 to 4x/month</td> <td>&#62;1x/week but not nightly</td> <td>Often 7x/week</td> </tr> <tr> <td>Short-acting beta<sub>2</sub>-agonist use for symptom control (not prevention of EIB)</td> <td>&#8804;2 days/week</td> <td>&#62;2 days/week but not daily, and not more than 1x on any day</td> <td>Daily</td> <td>Several times per day</td> </tr> <tr> <td>Interference with normal activity</td> <td>None</td> <td>Minor limitation</td> <td>Some limitation</td> <td>Extremely limited</td> </tr> <tr> <td>Lung function</td> <td> <p>&#8226; Normal FEV<sub>1</sub> between exacerbations</p> <p>&#8226; FEV<sub>1</sub> &#62;80 percent predicted</p> <p>&#8226; FEV<sub>1</sub>/FVC normal</p> </td> <td> <p>&#8226; FEV<sub>1</sub> &#8805;80 percent predicted</p> <p>&#8226; FEV<sub>1</sub>/FVC normal</p> </td> <td> <p>&#8226; FEV<sub>1</sub> &#62;60 but &#60;80 percent predicted</p> <p>&#8226; FEV<sub>1</sub>/FVC reduced 5 percent</p> </td> <td> <p>&#8226; FEV<sub>1</sub> &#60;60 percent predicted</p> <p>&#8226; FEV<sub>1</sub>/FVC reduced &#62;5 percent</p> </td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Risk</td> <td rowspan=\"4\"><strong>Exacerbations requiring oral systemic glucocorticoids</strong></td> <td><strong>0 to 1/year (see footnote)</strong></td> <td colspan=\"3\"><strong>&#8805;2/year (see footnote)</strong></td> </tr> <tr> <td colspan=\"4\"><strong>Consider severity and interval since last exacerbation</strong></td> </tr> <tr> <td colspan=\"4\"><strong>Frequency and severity may fluctuate over time for patients in any severity category</strong></td> </tr> <tr> <td colspan=\"4\"><strong>Relative annual risk of exacerbations may be related to FEV<sub>1</sub></strong></td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\" colspan=\"2\">Recommended step for initiating treatment</td> <td rowspan=\"2\">Step 1</td> <td rowspan=\"2\">Step 2</td> <td>Step 3</td> <td>Step 4 or 5</td> </tr> <tr> <td colspan=\"2\">And consider short course of oral systemic glucocorticoids</td> </tr> <tr> <td colspan=\"4\">In two to six weeks, evaluate level of asthma control that is achieved and adjust therapy accordingly.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>Assessing severity and initiating treatment for patients who are not currently taking long-term control medications.</strong> The stepwise approach is meant to assist, not replace, the clinical decision-making required to meet individual patient needs. Level of severity is determined by assessment of both impairment and risk. Assess impairment domain by patient's/caregiver's recall of previous two to four weeks and spirometry. Assign severity to the most severe category in which any feature occurs. At present, data are inadequate to correlate frequencies of exacerbations with different levels of asthma severity. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate greater underlying disease severity. For treatment purposes, patients who had &ge;2 exacerbations requiring oral systemic glucocorticoids in the past year may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.</div><div class=\"graphic_footnotes\">FEV<sub>1</sub>: forced expiratory volume in one second; FVC: forced vital capacity; ICU: intensive care unit.</div><div class=\"graphic_reference\">Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id=\"graphicVersion\">Graphic 58247 Version 3.0</div></div></div>"},"58248":{"type":"graphic_diagnosticimage","displayName":"SLE with pneumonnia PA","title":"Systemic lupus erythematosus (SLE) with pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Systemic lupus erythematosus (SLE) with pneumonia</div><div class=\"cntnt\"><img style=\"width:354px; height:353px;\" src=\"images/PULM/58248_SLE_with_pneumonitis_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows diffuse faint bilateral linear and reticular opacities consistent with thickened interlobular septa.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 58248 Version 5.0</div></div></div>"},"58250":{"type":"graphic_table","displayName":"High-potassium foods Basic PI","title":"Some foods that are high in potassium","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some foods that are high in potassium</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Fruits</td> <td class=\"subtitle1\">Vegetables</td> <td class=\"subtitle1\">Proteins</td> <td class=\"subtitle1\">Other</td> </tr> <tr> <td>Avocado</td> <td>Artichokes</td> <td>Black beans</td> <td>Chocolate</td> </tr> <tr> <td>Bananas</td> <td>Baked beans</td> <td>Clams</td> <td>Dairy products</td> </tr> <tr> <td>Coconut</td> <td>Beets</td> <td>Ground beef</td> <td>Granola</td> </tr> <tr> <td>Cantaloupe and honeydew melons</td> <td>Broccoli</td> <td>Kidney beans</td> <td>Milk</td> </tr> <tr> <td>Dates</td> <td>Brussels sprouts</td> <td>Lobster</td> <td>Peanut butter</td> </tr> <tr> <td>Dried fruits</td> <td>Cabbage (raw)</td> <td>Navy beans</td> <td>Soups that are salt-free or low-sodium</td> </tr> <tr> <td>Figs</td> <td>Carrots (raw)</td> <td>Pinto beans</td> <td>Soy milk</td> </tr> <tr> <td>Kiwi</td> <td>Chard</td> <td>Salmon</td> <td>Sports drinks</td> </tr> <tr> <td>Mango</td> <td>Olives</td> <td>Sardines</td> <td>Tomato sauce</td> </tr> <tr> <td>Nectarines</td> <td>Potatoes (white and sweet)</td> <td>Scallops</td> <td>Wheat bran and bran products</td> </tr> <tr> <td>Oranges and orange juice</td> <td>Pickles</td> <td>Steak</td> <td>Whole-grain bread</td> </tr> <tr> <td>Prunes and prune juice</td> <td>Pumpkin</td> <td>Whitefish</td> <td>Yogurt</td> </tr> <tr> <td>Raisins</td> <td>Rutabaga</td> <td rowspan=\"3\">&nbsp;</td> <td rowspan=\"3\">&nbsp;</td> </tr> <tr> <td rowspan=\"2\">&nbsp;</td> <td>Squash (acorn, butternut, hubbard)</td> </tr> <tr> <td>Tomatoes and tomato juice</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58250 Version 1.0</div></div></div>"},"58251":{"type":"graphic_figure","displayName":"Endoscopic parathyroid exploration","title":"Endoscopic parathyroid exploration","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Endoscopic parathyroid exploration</div><div class=\"cntnt\"><img style=\"width:454px; height:518px;\" src=\"images/SURG/58251_Endoscopic_parathyroid_exploration_edit.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 58251 Version 1.0</div></div></div>"},"58252":{"type":"graphic_picture","displayName":"Alopecia areata 4","title":"Alopecia areata","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Alopecia areata</div><div class=\"cntnt\"><img style=\"width:350px; height:253px;\" src=\"images/DERM/58252_Alopecia_areata_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patchy hair loss is seen in this patient with alopecia areata.</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology,&nbsp;2nd ed, Lippincott Williams &amp; Wilkins 2001. Copyright © 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58252 Version 2.0</div></div></div>"},"58254":{"type":"graphic_diagnosticimage","displayName":"MPM 55yr man","title":"Epithelial diffuse peritoneal malignant mesothelioma in a 55-year-old man who formerly worked in a shipyard and complained of abdominal discomfort","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epithelial diffuse peritoneal malignant mesothelioma in a 55-year-old man who formerly worked in a shipyard and complained of abdominal discomfort</div><div class=\"cntnt\"><img style=\"width:252px; height:510px;\" src=\"images/ONC/58254_MPM_55yr_man.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A, Panel B) Intravenous contrast-enhanced CT scans show complex ascites, serosal implants on the liver margin (black arrows in Panel A), extension of the tumor across the diaphragm (white arrowheads in Panel A), and extensive tumor encasement of the small bowel (arrowheads in Panel B). The tumor also extends throughout the small bowel mesentery. (Panel C) Photograph of the small bowel and mesentery at autopsy shows thick, nodular tumor on the serosal surface of the bowel and throughout the mesentery. The opened segment of the small bowel (arrowhead) shows tumor thickening the bowel wall.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Levy AD, Arnaiz J, Shaw JC, Sobin LH. From the archives of the AFIP: primary peritoneal tumors: imaging features with pathologic correlation. RadioGraphics 2008; 28:583. Copyright &copy;2008 Radiological Society of North America.</div><div id=\"graphicVersion\">Graphic 58254 Version 4.0</div></div></div>"},"58255":{"type":"graphic_table","displayName":"NSAIDs desmoid Rx","title":"Non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of desmoid tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of desmoid tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agents used</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\"># of patients</td> <td class=\"subtitle1\">Duration of therapy<br /> (in months)</td> <td class=\"subtitle1\">Response</td> <td class=\"subtitle1\">Duration of response</td> <td class=\"subtitle1\">Author, year</td> </tr> <tr class=\"divider_bottom\"> <td>Meloxicam</td> <td>10 mg/day</td> <td>20</td> <td>3 to 66 (median 20)</td> <td> <p>1 CR</p> <p>7 PR</p> <p>11 SD</p> 1 PD</td> <td>NR</td> <td>Nishida Y; 2010</td> </tr> <tr class=\"divider_bottom\"> <td>Sulindac</td> <td>300 mg/day (median)</td> <td>14</td> <td>NR</td> <td> <p>1 CR</p> <p>7 PR</p> <p>4 SD</p> 2 PD</td> <td>NR</td> <td>Tsukada K; 1992</td> </tr> <tr class=\"divider_bottom\"> <td>Indomethacin or sulindac or sulindac with warfarin</td> <td>&nbsp;</td> <td>8</td> <td>2 to 91 (median 20.5)</td> <td> <p>3 PR</p> <p>3 SD</p> 2 PD</td> <td>NR</td> <td>Waddell W; 1991</td> </tr> <tr> <td>Indomethacin</td> <td>100 mg/day</td> <td>3</td> <td>4 to 10 (median 8)</td> <td> <p>1 CR</p> 2 PD</td> <td>NR</td> <td>Klein W; 1987</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OR: overall response; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; NR: not reported.</div><div id=\"graphicVersion\">Graphic 58255 Version 3.0</div></div></div>"},"58256":{"type":"graphic_picture","displayName":"Calcaneovalgus feet","title":"Positional calcaneovalgus feet","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Positional calcaneovalgus feet</div><div class=\"cntnt\"><img style=\"width:389px; height:303px;\" src=\"images/PEDS/58256_Calcaneovalgus_feet.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Gerardo Cabrera-Meza, MD, Baylor College of Medicine.</div><div id=\"graphicVersion\">Graphic 58256 Version 4.0</div></div></div>"},"58257":{"type":"graphic_table","displayName":"Source control in sepsis","title":"Source control methods for common ICU infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Source control methods for common ICU infections</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Source</td> <td class=\"subtitle1\">Interventions</td> </tr> <tr> <td>Pneumonia</td> <td>Chest physiotherapy, suctioning</td> </tr> <tr> <td>Urinary tract</td> <td>Drainage of abscesses, relief of obstruction, removal or changing of infected catheters</td> </tr> <tr> <td>Catheter-related bacteremia</td> <td>Removal of catheter</td> </tr> <tr> <td>Peritonitis</td> <td>Resection, repair, or diversion of ongoing sources of contamination, drainage of abscesses, debridement of necrotic tissue</td> </tr> <tr> <td>Pancreatic infection</td> <td>Drainage or debridement</td> </tr> <tr> <td>Soft tissue infection</td> <td>Debridement of necrotic tissue and drainage of discrete abscesses</td> </tr> <tr> <td>Septic arthritis</td> <td>Joint drainage and debridement</td> </tr> <tr> <td>Endocarditis</td> <td>Valve replacement</td> </tr> <tr> <td>Prosthetic device infection</td> <td>Device removal</td> </tr> <tr> <td>Empyema</td> <td>Drainage, decortication</td> </tr> <tr> <td>Sinusitis</td> <td>Surgical decompression of the sinuses</td> </tr> <tr> <td>Cholangitis</td> <td>Bile duct decompression</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Marshall JC, Lowry SF. Evaluation of the adequacy of source control. In: Clinical Trials for the Treatment of Sepsis, Sibbald WJ, Vincent JL (Eds), Springer-Verlag, Berlin 1995.</div><div id=\"graphicVersion\">Graphic 58257 Version 2.0</div></div></div>"},"58259":{"type":"graphic_diagnosticimage","displayName":"Unstable midshaft fracture","title":"Unstable midshaft fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Unstable midshaft fracture</div><div class=\"cntnt\"><img style=\"width:303px; height:478px;\" src=\"images/EM/58259_Unstablemidshaftfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">12-year-old girl with midshaft both-bone complete forearm fracture.<br />(A) Anterior posterior and lateral injury radiographs.<br />(B) Two-month follow-up radiographs.<br />(C) Six-month follow-up radiographs (ulnar nail removed).</div><div class=\"graphic_reference\">Reproduced with permission from: Mehlman CT, Wall EJ. Injuries to the shafts of the radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 58259 Version 13.0</div></div></div>"},"58261":{"type":"graphic_picture","displayName":"TG lactescent serum sample","title":"Blood sample from a patient with a triglyceride level of 1200 mg/dL in a serum separator tube","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Blood sample from a patient with a triglyceride level of 1200 mg/dL in a serum separator tube</div><div class=\"cntnt\"><img style=\"width:345px; height:470px;\" src=\"images/GAST/58261_TG_lactescent_serum_sample.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd. Tsuang W, Navaneethan U, Ruiz L, et al. Hypertriglyceridemic pancreatitis: Presentation and management. Am J Gastroenterol 2009; 104:984. Copyright © 2009.</div><div id=\"graphicVersion\">Graphic 58261 Version 5.0</div></div></div>"},"58262":{"type":"graphic_diagnosticimage","displayName":"Cauda equina lymphoma","title":"Cauda equina involvement by non-Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cauda equina involvement by non-Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:430px; height:450px;\" src=\"images/HEME/58262_Cauda_equina_lymphoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This T2 sagittal magnetic resonance imaging of the lumbar spine reveals diffuse thickening of nerve roots within the cauda equina (arrows). This finding is suspicious for infiltrative disease, such as lymphoma.</div><div id=\"graphicVersion\">Graphic 58262 Version 3.0</div></div></div>"},"58263":{"type":"graphic_table","displayName":"T cruzi seroprevalence","title":"<EM>Trypanosoma cruzi</EM> infection prevalence estimates for countries in which vector-borne transmission occurs or has occurred in the past","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\"><EM>Trypanosoma cruzi</EM> infection prevalence estimates for countries in which vector-borne transmission occurs or has occurred in the past</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Region</td> <td class=\"subtitle1\">Endemic countries</td> <td class=\"subtitle1\">Estimated seroprevalence, percent*</td> <td class=\"subtitle1\">Estimated number of infected individuals*</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">North America</td> <td>United States<sup>&#182;</sup></td> <td>NDA</td> <td>300,000</td> </tr> <tr class=\"divider_bottom\"> <td>Mexico</td> <td>0.78</td> <td>876,000</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\">Central America</td> <td>Belize<sup>&#916;</sup></td> <td>0.33</td> <td>1000</td> </tr> <tr> <td>Costa Rica<sup>&#916;</sup></td> <td>0.17</td> <td>8,000</td> </tr> <tr> <td>El Salvador<sup>&#916;</sup></td> <td>1.30</td> <td>90,000</td> </tr> <tr> <td>Guatemala<sup>&#916;</sup></td> <td>1.23</td> <td>167,000</td> </tr> <tr> <td>Honduras<sup>&#916;</sup></td> <td>0.92</td> <td>73,000</td> </tr> <tr> <td>Nicaragua<sup>&#916;</sup></td> <td>0.52</td> <td>29,000</td> </tr> <tr class=\"divider_bottom\"> <td>Panama<sup>&#916;</sup></td> <td>0.52</td> <td>18,000</td> </tr> <tr> <td rowspan=\"11\">South America</td> <td>Argentina<sup>&#9674;</sup></td> <td>3.64</td> <td>1,505,000</td> </tr> <tr> <td>Bolivia<sup>&#9674;</sup><sup>&#167;</sup></td> <td>6.10</td> <td>607,000</td> </tr> <tr> <td>Brazil<sup>&#9674;</sup><sup>&#167;</sup></td> <td>0.61</td> <td>1,157,000</td> </tr> <tr> <td>Chile<sup>&#9674;</sup></td> <td>0.70</td> <td>120,000</td> </tr> <tr> <td>Colombia<sup>&#167;</sup><sup>&#165;</sup></td> <td>0.96</td> <td>438,000</td> </tr> <tr> <td>Ecuador<sup>&#167;</sup><sup>&#165;</sup></td> <td>1.38</td> <td>200,000</td> </tr> <tr> <td>French Guiana<sup>&#167;</sup></td> <td>0.84</td> <td>13,000</td> </tr> <tr> <td>Paraguay<sup>&#9674;</sup></td> <td>2.13</td> <td>185,000</td> </tr> <tr> <td>Peru<sup>&#167;</sup><sup>&#165;</sup></td> <td>0.44</td> <td>128,000</td> </tr> <tr> <td>Uruguay<sup>&#9674;</sup></td> <td>0.24</td> <td>8000</td> </tr> <tr> <td>Venezuela<sup>&#167;</sup><sup>&#165;</sup></td> <td>0.71</td> <td>193,000</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NDA: no data available.<br />* Disease burden estimates based on references<SUP>[1,2,3]</SUP>.<br />¶ The United States is not generally considered endemic, but established enzootic transmission cycles exist across the southern half of the country. Documented local transmission to humans is rare, but infected vectors and reservoir hosts are fairly frequent. Nevertheless, the vast majority of infected individuals living in the United States are immigrants who were infected in their country of origin.<br />Δ Member countries of Initiative of the Countries of Central America for Control of Vector-Borne and Transfusional Transmission and Medical Care for Chagas Disease (IPCA).<br /><FONT class=lozenge>◊</FONT> Member countries of the Southern Cone Initiative to Control/Eliminate Chagas Disease (INCOSUR).<br />§ Member countries of Initiative of the Amazon Countries for Surveillance and Control of Chagas Disease (AMCHA).<br />¥ Member countries of Initiative of the Andean Countries to Control Vectoral and Transfusional Transmission of Chagas Disease (IPA).</div><div class=\"graphic_reference\">References:<br /><br /><OL>&#xD;&#xA;<LI>Chagas disease in Latin America: An epidemiological update based on 2010 estimates. Wkly Epidemiol Rec 2015; 90:33. </LI>&#xD;&#xA;<LI>Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis 2009; 49:e52. </LI>&#xD;&#xA;<LI>Manne-Goehler J, Umeh CA, Montgomery SP, Wirtz VJ. Estimating the burden of Chagas disease in the United States. PLoS Negl Trop Dis 2016; 10:e0005033.</LI></OL></div><div id=\"graphicVersion\">Graphic 58263 Version 6.0</div></div></div>"},"58264":{"type":"graphic_figure","displayName":"Mutations in the WAS gene causing X-linked thrombocytopenia","title":"Mutations in the WAS gene causing X-linked thrombocytopenia","html":"<div class=\"graphic\"><div style=\"width: 623px\" class=\"figure\"><div class=\"ttl\">Mutations in the WAS gene causing X-linked thrombocytopenia</div><div class=\"cntnt\"><img style=\"width:603px; height:465px;\" src=\"images/ALLRG/58264_XLT_mutations.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This analysis includes patients worldwide with X-linked thrombocytopenia (XLT). This is a separate analysis from the Wiskott-Aldrich syndrome mutation figure and includes additional patients with XLT. Note that missense mutations predominate and cluster in certain exons, although there is overlap with mutations causing Wiskott-Aldrich syndrome.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Jin Y, Mazza C, Christie JR, et al. Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): Hotspots, effect on transcription, and translation and phenotype/genotype correlation. Blood 2004; 104:4010.</LI>&#xD;&#xA;<LI>Ochs HD, Thrasher AJ. The Wiskott-Aldrich syndrome. J Allergy Clin Immunol 2006; 117:725.</LI>&#xD;&#xA;<LI>Albert MH, Bittner TC, Nonoyama S, et al. X-linked thrombocytopenia (XLT) due to WAS mutations: Clinical characteristics, long-term outcome, and treatment options. Blood 2010; 115:3231.</LI></OL></div><div id=\"graphicVersion\">Graphic 58264 Version 4.0</div></div></div>"},"58265":{"type":"graphic_algorithm","displayName":"Treatment algorithm for neuropathic pain","title":"Neuropathic pain: Pharmacologic approach","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Neuropathic pain: Pharmacologic approach</div><div class=\"cntnt\"><img style=\"width:537px; height:514px;\" src=\"images/PC/58265_Tx_algo_neuropath_pain_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SNRI: serotonin-norepinephrine reuptake inhibitor; TCA: tricyclic antidepressant; NMDA: N-methyl-D-aspartate.</div><div id=\"graphicVersion\">Graphic 58265 Version 1.0</div></div></div>"},"58266":{"type":"graphic_movie","displayName":"Apical 4 chamber normal motion","title":"Apical 4 chamber view with normal cardiac motion","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Apical 4 chamber view with normal cardiac motion</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/58266_Apical4chambnormmovie.mp4\" style=\"width:496px;height:320px\"></div><img style=\"width:504px; height:376px;\" src=\"images/EM/58266_Apical4chambnormimage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video clip shows normal cardiac motion as seen from an apical four chamber view.</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Courtesy of Greg Snead, MD.</div><div id=\"graphicVersion\">Graphic 58266 Version 1.0</div></div></div>"},"58267":{"type":"graphic_picture","displayName":"Pediculosis pubis 2","title":"Pediculosis pubis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pediculosis pubis</div><div class=\"cntnt\"><img style=\"width:379px; height:304px;\" src=\"images/DERM/58267_Pediculosis_pubis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A small brown living crab louse is seen at the base of hairs (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58267 Version 1.0</div></div></div>"},"58268":{"type":"graphic_algorithm","displayName":"Pediatric tachycardia without shock","title":"Pediatric tachycardia without shock","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Pediatric tachycardia without shock</div><div class=\"cntnt\"><img style=\"width:585px; height:530px;\" src=\"images/EM/58268_Tachycardia_no_shock.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ARF: acute rheumatic fever.<br />* Signs of cardiac disease&nbsp;consist of&nbsp;murmur, gallop, or hepatomegaly.<br />• For example, illicit drugs (eg, amphetamines, cocaine, or dextromethorphan), energy drinks, diet supplements with caffeine, or herbal preparations.</div><div id=\"graphicVersion\">Graphic 58268 Version 3.0</div></div></div>"},"58269":{"type":"graphic_diagnosticimage","displayName":"Crossed cerebellar diaschesis in epilepsy","title":"Crossed cerebellar diaschesis in a patient with right hemispheric seizures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Crossed cerebellar diaschesis in a patient with right hemispheric seizures</div><div class=\"cntnt\"><img style=\"width:376px; height:392px;\" src=\"images/NEURO/58269_Cerebellar_diaschesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Images obtained from a 38 year old patient who presented with recurrent right hemispheric seizures. Panels A and B show abnormal signal on fluid attenuated inversion recovery (FLAIR) images in the ipsilateral cortical ribbon and in the contralateral cerebellar hemisphere. Panels C and D show reduced diffusion on diffusion weighted images in corresponding regions.</div><div class=\"graphic_reference\">Reproduced with permission from: Cole, AJ. Status epilepticus and periictal imaging. Epilepsia 2004; 45 Suppl 4:72. Copyright ©2004 Blackwell Science.</div><div id=\"graphicVersion\">Graphic 58269 Version 3.0</div></div></div>"},"58270":{"type":"graphic_figure","displayName":"Outcomes of ART by stage of procedure and maternal age","title":"Outcomes of ART cycles using fresh nondonor eggs or embryos, by stage and age group, 2006","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Outcomes of ART cycles using fresh nondonor eggs or embryos, by stage and age group, 2006</div><div class=\"cntnt\"><img style=\"width:522px; height:455px;\" src=\"images/OBGYN/58270_Outcomesbystageandage.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In 2006, a total of 99,199 cycles using fresh nondonor eggs or embryos were started:<br> • 41,369 in women younger than 35<br> • 23,376 in women 35-37<br> • 19,775 in women 38-40<br> • 9346 in women 41-42<br> • 5333 in women older than 42<br>The above figure shows that a woman's chance of progressing from the beginning of ART to pregnancy and live birth (using her own eggs) decreases at every stage of ART as her age increases. As women get older, the likelihood of a successful response to ovarian stimulation and progression to egg retrieval decreases. As women get older, cycles that have progressed to egg retrieval are slightly less likely to reach transfer. The percentage of cycles that progress from transfer to pregnancy also decreases as women get older. As women get older, cycles that have progressed to pregnancy are less likely to result in a live birth because the risk for miscarriage is greater. Overall, 39 percent of cycles started in 2006 among women younger than 35 resulted in live births. This percentage decreased to 30 percent among women 35-37 years of age, 21 percent among women 38-40, 11 percent among women 41-42, and 4 percent among women older than 42. The proportion of cycles that resulted in singleton live births is even lower for each age group.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention, American Society for Reproductive Medicine, Society for Assisted Reproductive Technology. 2006 Assisted Reproductive Technology Success Rates: National Summary and Fertility Clinic Reports, Atlanta: Centers for Disease Control and Prevention, 2008.</div><div id=\"graphicVersion\">Graphic 58270 Version 2.0</div></div></div>"},"58271":{"type":"graphic_table","displayName":"Catch-up immunization schedule age 4 months through 6 years","title":"Catch-up immunization schedule for children age 4 months through 6 years who start late or who are more than 1 month behind - United States, 2018","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Catch-up immunization schedule for children age 4 months through 6 years who start late or who are more than 1 month behind - United States, 2018</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup span=\"4\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Vaccine</td> <td class=\"subtitle1\" rowspan=\"2\">Minimum age for dose 1</td> <td class=\"subtitle1\" colspan=\"4\">Minimum interval between doses</td> </tr> <tr> <td class=\"subtitle2\">Dose 1 to dose 2</td> <td class=\"subtitle2\">Dose 2 to dose 3</td> <td class=\"subtitle2\">Dose 3 to dose 4</td> <td class=\"subtitle2\">Dose 4 to dose 5</td> </tr> <tr class=\"divider_bottom\"> <td>Hepatitis B*</td> <td>Birth</td> <td>4 weeks</td> <td>8 weeks <strong>and</strong> at least 16 weeks after first dose; minimum age for the final dose is 24 weeks</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Rotavirus<sup>&#182;</sup></td> <td>6 weeks; maximum age for first dose is 14 weeks, 6 days</td> <td>4 weeks</td> <td>4 weeks<sup>&#182;</sup>; maximum age for final dose is 8 months, 0 days</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Diphtheria, tetanus, and acellular pertussis<sup>&#916;</sup></td> <td>6 weeks</td> <td>4 weeks</td> <td>4 weeks</td> <td>6 months</td> <td>6 months<sup>&#916;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><em>Haemophilus influenzae</em> type b<sup>&#9674;</sup></td> <td class=\"divider_bottom\" rowspan=\"3\">6 weeks</td> <td>4 weeks if first dose was administered before the first birthday</td> <td>4 weeks<sup>&#9674;</sup> if current age is younger than 12 months <strong>and</strong> first dose was administered at younger than age 7 months, <strong>and</strong> at least 1 previous dose was PRP-T (ActHIB, Pentacel, Hiberix) or unknown</td> <td class=\"divider_bottom\" rowspan=\"3\">8 weeks (as final dose); this dose only necessary for children age 12 through 59 months who received 3 doses before the first birthday</td> <td class=\"divider_bottom\" rowspan=\"3\">&nbsp;</td> </tr> <tr> <td>8 weeks (as final dose) if first dose administered at age 12 through 14 months</td> <td>8 weeks <strong>and</strong> age 12 months through 59 months (as final dose<sup>&#9674;</sup>) <ul> <li>If current age is younger than 12 months <strong>and</strong> first dose was administered at age 7 through 11 months (wait until at least 12 months old); <strong>or</strong> </li> <li>If current age is 12 through 59 months <strong>and</strong> first dose was administered before the first birthday, <strong>and</strong> second dose administered at younger than 15 months; <strong>or</strong> </li> <li>If both doses were PRP-OMP (PedvaxHIB; Comvax) <strong>and</strong> were administered before the first birthday </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>No further doses needed if first dose was administered at age 15 months or older</td> <td>No further doses needed if previous dose was administered at age 15 months or older</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Pneumococcal conjugate<sup>&#167;</sup></td> <td class=\"divider_bottom\" rowspan=\"3\">6 weeks</td> <td>4 weeks if first dose administered before the first birthday</td> <td>4 weeks if current age is younger than 12 months and previous dose was administered at younger than 7 months old</td> <td class=\"divider_bottom\" rowspan=\"3\">8 weeks (as final dose); this dose only necessary for children age 12 through 59 months who received 3 doses before age 12 months or for children at high risk who received 3 doses at any age</td> <td class=\"divider_bottom\" rowspan=\"3\">&nbsp;</td> </tr> <tr> <td>8 weeks (as final dose for healthy children) if first dose was administered on or after the first birthday</td> <td>8 weeks (as final dose for healthy children) <ul> <li>If previous dose given between 7 and 11 months (wait until at least 12 months old); <strong>or</strong> </li> <li>If current age is 12 months or older and at least 1 dose was given before age 12 months </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>No further doses needed for healthy children if first dose administered at age 24 months or older</td> <td>No further doses needed for healthy children if previous dose administered at age 24 months or older</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Inactivated poliovirus<sup>&#165;</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">6 weeks</td> <td class=\"divider_bottom\" rowspan=\"2\">4 weeks<sup>&#165;</sup></td> <td>4 weeks<sup>&#165;</sup> if current age is younger than 4 years</td> <td class=\"divider_bottom\" rowspan=\"2\">6 months<sup>&#165;</sup> (minimum age 4 years for final dose)</td> <td class=\"divider_bottom\" rowspan=\"2\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>6 months (as final dose) if current age is 4 years or older</td> </tr> <tr class=\"divider_bottom\"> <td>Serogroups A, C, W, Y meningococcal<sup>&#135;</sup></td> <td>6 weeks</td> <td>8 weeks<sup>&#135;</sup></td> <td>Refer to footnote<sup>&#135;</sup></td> <td>Refer to footnote<sup>&#135;</sup></td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Measles, mumps, and rubella<sup>&#134;</sup></td> <td>12 months</td> <td>4 weeks</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Varicella**</td> <td>12 months</td> <td>3 months</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Hepatitis A<sup>&#182;&#182;</sup></td> <td>12 months</td> <td>6 months</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The above table provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use this table in conjunction with its footnotes and related UpToDate content regarding the schedule of recommended childhood immunizations for children 0 through 6 years of age in the United States. This table includes recommendations in effect as of January 1, 2018 and is approved by the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics, the American Academy of Family Physicians, and the American College of Obstetricians and Gynecologists. &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>Consult relevant <A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/index.html\" target=_blank>ACIP statements</A> for detailed recommendations.</LI>&#xD;&#xA;<LI>For calculating intervals between doses, 4 weeks = 28 days. Intervals of ≥4 months are determined by calendar months.</LI>&#xD;&#xA;<LI>Vaccine doses administered ≤4 days before the minimum age or interval are considered valid. Doses of any vaccine administered ≥5 days earlier than the minimum interval or minimum age should not be counted as valid and should be repeated as age-appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. For further details, refer to ACIP's <A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html\" target=_blank>General Best Practice Guidelines for Immunizations</A>.</LI>&#xD;&#xA;<LI>For information about precautions and contraindications, refer to <A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html\" target=_blank>https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html</A>.</LI>&#xD;&#xA;<LI>Report clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) online at <A href=\"https://vaers.hhs.gov/\" target=_blank>https://vaers.hhs.gov</A> or by telephone, 800-822-7967.</LI></UL></div><div class=\"graphic_footnotes\">PRP-T: polyribosylribitol phosphate conjugated to tetanus toxoid; PRP-OMP: polyribosylribitol phosphate conjugated to outer membrane protein complex of <em>Neisseria meningitides</em>.<br />* <strong>Hepatitis B (HepB) vaccine</strong>&#xD;&#xA;<ul>&#xD;&#xA;    <li>Unvaccinated children should complete a three-dose series at zero, one through two, and six months.</li>&#xD;&#xA;</ul>&#xD;&#xA;&para; <strong>Rotavirus (RV) vaccines</strong>&#xD;&#xA;<ul>&#xD;&#xA;    <li>Do not start the series on or after age 15 weeks, 0 days.</li>&#xD;&#xA;    <li>The maximum age for the final dose is eight months, zero days.</li>&#xD;&#xA;    <li>If RV1 (Rotarix) is administered for the first and second doses, a third dose is not indicated. If any dose in the series is either RV5 (RotaTeq) or unknown, default to a three-dose series.</li>&#xD;&#xA;</ul>&#xD;&#xA;&Delta; <strong>Diphtheria and tetanus toxoids, and acellular pertussis (DTaP) vaccine</strong>&#xD;&#xA;<ul>&#xD;&#xA;    <li>The fifth dose of DTaP vaccine is not necessary if the fourth dose was administered at age &ge;4 years.</li>&#xD;&#xA;</ul>&#xD;&#xA;<span class=\"lozenge\">&loz;</span> <strong><em>Haemophilus influenzae</em> type b (Hib) conjugate vaccine</strong>&#xD;&#xA;<ul>&#xD;&#xA;    <li>First dose at 7 through 11 months: Give second dose at least four weeks later and third (final) dose at 12 through 15 months or eight weeks after second dose (whichever is later).</li>&#xD;&#xA;    <li>First dose at 12 through 14 months: Give second (final) dose at least eight weeks after first dose.</li>&#xD;&#xA;    <li>First dose before 12 months and second dose before 15 months: Give third (final) dose eight weeks after second dose.</li>&#xD;&#xA;    <li>Two doses of PedvaxHIB before 12 months: Give third (final) dose at 12 through 59 months and at least eight weeks after second dose.</li>&#xD;&#xA;    <li>Unvaccinated at 15 through 59 months: One dose.</li>&#xD;&#xA;    <li><strong>Catch-up guidance for children with high-risk conditions or special situations:</strong>&#xD;&#xA;    <ul>&#xD;&#xA;        <li>Refer to UpToDate content related to the routine immunization schedule, Hib vaccination, and immunization in the specific high-risk group, and the <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hib.html\" target=\"_blank\">ACIP recommendations</a>. High-risk conditions and special situations include chemotherapy or radiation treatment, hematopoietic stem cell transplant, anatomic or functional asplenia (including sickle cell disease), elective splenectomy, human immunodeficiency virus (HIV) infection, immunoglobulin deficiency, and early complement component deficiency.</li>&#xD;&#xA;    </ul>&#xD;&#xA;    </li>&#xD;&#xA;</ul>&#xD;&#xA;&sect; <strong>Pneumococcal conjugate vaccine (PCV13)</strong>&#xD;&#xA;<ul>&#xD;&#xA;    <li>One dose for healthy children aged 24 through 59 months with any incomplete PCV13 schedule. Incomplete schedules are any schedules where PCV13 doses have not been completed according to ACIP recommended catch-up schedules. The total number and timing of doses are dictated by the age at first vaccination. Refer to UpToDate content on pneumococcal vaccines in children for details.</li>&#xD;&#xA;    <li><strong>Catch-up guidance for children with high-risk conditions:</strong>&#xD;&#xA;    <ul>&#xD;&#xA;        <li>Refer to UpToDate content related to the routine immunization schedule, pneumococcal vaccines in children, and immunization in the specific high-risk group, and the <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html\" target=\"_blank\">ACIP recommendations</a>. High-risk conditions include chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure); chronic lung disease (including asthma if treated with high-dose oral corticosteroids); diabetes mellitus; cerebrospinal fluid leak; cochlear implant; sickle cell disease and other hemoglobinopathies; anatomic or functional asplenia; congenital or acquired immunodeficiency; HIV infection; chronic renal failure; nephrotic syndrome; malignant neoplasms, leukemias, lymphomas, Hodgkin disease, and other diseases associated with treatment with immunosuppressive drugs or radiation therapy; solid organ transplantation; and chronic liver disease.</li>&#xD;&#xA;    </ul>&#xD;&#xA;    </li>&#xD;&#xA;</ul>&#xD;&#xA;&yen; <strong>Inactivated poliovirus (IPV) vaccine</strong>&#xD;&#xA;<ul>&#xD;&#xA;    <li>In the first six months of life, use minimum ages and intervals only for travel to a polio-endemic region or during an outbreak.</li>&#xD;&#xA;    <li>If four or more doses were given before the fourth birthday, give one more dose at age four through six years and at least six months after the previous dose.</li>&#xD;&#xA;    <li>A fourth dose is not necessary if the third dose was given on or after the fourth birthday and at least six months after the previous dose.</li>&#xD;&#xA;    <li><strong>Series containing oral polio vaccine (OPV),</strong> <em>either mixed OPV-IPV or OPV-only series</em>:&#xD;&#xA;    <ul>&#xD;&#xA;        <li>Total number of doses needed to complete the series is the same as that recommended for the United States IPV schedule. Refer to <a href=\"https://www.cdc.gov/mmwr/volumes/66/wr/mm6601a6.htm?s_cid=mm6601a6_w\" target=\"_blank\">MMWR Morb Mortal Wkly Rep 2017; 66:23</a>.</li>&#xD;&#xA;        <li>Only trivalent OPV (tOPV) counts toward the United States vaccination requirements. For guidance to assess doses documented as \"OPV,\" refer to <a href=\"https://www.cdc.gov/mmwr/volumes/66/wr/mm6606a7.htm?s_cid=mm6606a7_w\" target=\"_blank\">MMWR Morb Mortal Wkly Rep 2017; 66:180.</a></li>&#xD;&#xA;    </ul>&#xD;&#xA;    </li>&#xD;&#xA;</ul>&#xD;&#xA;&Dagger; <strong>Serogroups A, C, W, Y meningococcal (MenACWY) vaccines</strong><br /><em>(Minimum age: Two months for Menveo [MenACWY-CRM]; nine months for Menactra [MenACWY-D])</em>&#xD;&#xA;<ul>&#xD;&#xA;    <li><strong>Catch-up guidance for children with high-risk conditions and other children at increased risk of disease:</strong>&#xD;&#xA;    <ul>&#xD;&#xA;        <li>Refer to UpToDate content related to the routine immunization schedule, meningococcal vaccination, and immunization in the specific high-risk condition, and the <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html\" target=\"_blank\">ACIP recommendations</a>. High-risk conditions and conditions that increase the risk of disease include anatomic or functional asplenia, sickle cell disease, HIV infection, persistent complement component deficiency (including eculizumab use), travel to or residence in countries where meningococcal disease is hyperendemic or epidemic (including countries in the African meningitis belt or during the Hajj), or exposure to an outbreak attributable to a vaccine serogroup.</li>&#xD;&#xA;    </ul>&#xD;&#xA;    </li>&#xD;&#xA;</ul>&#xD;&#xA;&dagger; <strong>Measles, mumps, and rubella (MMR) vaccine</strong>&#xD;&#xA;<ul>&#xD;&#xA;    <li>Unvaccinated school-aged children: Two doses at least four weeks apart.</li>&#xD;&#xA;</ul>&#xD;&#xA;** <strong>Varicella (VAR) vaccine</strong>&#xD;&#xA;<ul class=\"double_footnote_list\">&#xD;&#xA;    <li>The minimum interval between the two doses is three months.</li>&#xD;&#xA;</ul>&#xD;&#xA;&para;&para; <strong>Hepatitis A (Hep A) vaccine</strong>&#xD;&#xA;<ul class=\"double_footnote_list\">&#xD;&#xA;    <li>Anyone two years of age or older may receive HepA vaccine if desired. Minimum interval between doses is six months.</li>&#xD;&#xA;    <li><strong>Special populations:</strong> Previously unvaccinated children who should be vaccinated:&#xD;&#xA;    <ul>&#xD;&#xA;        <li>Children traveling to countries with high or intermediate endemicity.</li>&#xD;&#xA;        <li>Children with clotting-factor disorders.</li>&#xD;&#xA;        <li>Children with chronic liver disease.</li>&#xD;&#xA;        <li>Children who anticipate close, personal contact (eg, household or regular babysitting) with an international adoptee during the first 60 days after arrival in the United States from a country with high or intermediate endemicity (administer the first dose as soon as the adoption is planned&ndash;ideally at least two weeks before the adoptee's arrival).</li>&#xD;&#xA;    </ul>&#xD;&#xA;    </li>&#xD;&#xA;</ul></div><div class=\"graphic_reference\">Adapted from: Centers for Disease Control and Prevention. Immunization schedules. Available at: <A href=\"http://www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html\" target=_blank>www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html</A> (Accessed on February 13, 2018).</div><div id=\"graphicVersion\">Graphic 58271 Version 32.0</div></div></div>"},"58273":{"type":"graphic_diagnosticimage","displayName":"Transverse view","title":"Transverse ultrasound view of the region proximal to a second metacarpophalangeal joint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse ultrasound view of the region proximal to a second metacarpophalangeal joint</div><div class=\"cntnt\"><img style=\"width:432px; height:290px;\" src=\"images/RHEUM/58273_Transverse_View.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This transverse ultrasound view of the region proximal to a second metacarpophalangeal joint demonstrates the normal appearance of the flexor tendons and underlying metacarpal bone surface.</div><div class=\"graphic_reference\">Courtesy of George AW Bruyn, MD, PhD.</div><div id=\"graphicVersion\">Graphic 58273 Version 5.0</div></div></div>"},"58275":{"type":"graphic_diagnosticimage","displayName":"Fibula fracture above lateral malleolus - Mortise view","title":"Fibula fracture above lateral malleolus: Mortise view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fibula fracture above lateral malleolus: Mortise view</div><div class=\"cntnt\"><img style=\"width:313px; height:433px;\" src=\"images/EM/58275_Weber_C_mortise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A fibula fracture (arrow) above the joint line is seen on this Mortise view of the ankle.</div><div class=\"graphic_reference\">Courtesy of Scott M Koehler, MD.</div><div id=\"graphicVersion\">Graphic 58275 Version 6.0</div></div></div>"},"58276":{"type":"graphic_picture","displayName":"Anastomosis after bypass","title":"Gastrojejunal anastomosis after gastric bypass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastrojejunal anastomosis after gastric bypass</div><div class=\"cntnt\"><img style=\"width:360px; height:345px;\" src=\"images/GAST/58276_Anastomosis_after_bypass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic appearance of a normal gastrojejunal anastomosis after Roux-en-Y gastric bypass.</div><div class=\"graphic_reference\">Courtesy of Christopher S Huang, MD.</div><div id=\"graphicVersion\">Graphic 58276 Version 3.0</div></div></div>"},"58277":{"type":"graphic_diagnosticimage","displayName":"CT gastric outlet obstruct","title":"CT of the abdomen in a patient with gastric outlet obstruction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT of the abdomen in a patient with gastric outlet obstruction</div><div class=\"cntnt\"><img style=\"width:396px; height:328px;\" src=\"images/GAST/58277_CT_gastric_outlet_obstruct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abdominal CT in a patient with gastric outlet obstruction due to peptic ulcer disease showing a distended and fluid filled stomach.</div><div class=\"graphic_reference\">Courtesy of Ashley Davidoff, MD.</div><div id=\"graphicVersion\">Graphic 58277 Version 2.0</div></div></div>"},"58279":{"type":"graphic_movie","displayName":"Ultrasound normal radial nerve","title":"Ultrasound normal radial nerve","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound normal radial nerve</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/NEURO/58279_USnormradialnerveconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:514px; height:293px;\" src=\"images/NEURO/58279_USnormalradialnerve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an axial image of the normal radial nerve at the level of the antecubital fossa. In this image, the radial nerve is deep to the brachioradialis (B) and appears as two bright rounded fascicles. The fascicle to the right becomes the superficial radial sensory branch (S), and the fascicle to the left, the deep motor branch (M) of the radial nerve. They can be seen to separate in this real-time image as the probe is moved distally. To the lower left the bone shadow is that of the proximal radius and just above it, the supinator.</div><div class=\"graphic_reference\">Courtesy of Francis O Walker, MD.</div><div id=\"graphicVersion\">Graphic 58279 Version 3.0</div></div></div>"},"58280":{"type":"graphic_picture","displayName":"Toxoplasma gondii cysts","title":"Unstained and stained Toxoplasma gondii cysts","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Unstained and stained Toxoplasma gondii cysts</div><div class=\"cntnt\"><img style=\"width:512px; height:257px;\" src=\"images/PEDS/58280_ToxoplasgondiicystPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cysts of Toxoplasma gondii usually range in size from 5-50 micrometers in diameter. They may be found in various sites throughout the body of the host, but are most common in the brain and skeletal and cardiac muscles. Cysts are usually spherical in the brain but more elongated in cardiac and skeletal muscles.<br> (A) Unstained cyst of T. gondii.<br> (B) Toxoplasma gondii cyst in brain tissue stained with hematoxylin and eosin.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention Center for Global Health. Parasite Image Library. Available at: http://www.dpd.cdc.gov/dpdx/HTML/Image_Library.htm. Accessed on December 15, 2010.</div><div id=\"graphicVersion\">Graphic 58280 Version 3.0</div></div></div>"},"58281":{"type":"graphic_figure","displayName":"Normal thromboelastography and parameters","title":"Normal thromboelastography and parameters","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Normal thromboelastography and parameters</div><div class=\"cntnt\"><img style=\"width:593px; height:273px;\" src=\"images/SURG/58281_Norm_thromboelast_param.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal citrated rapid TEG tracing with normal ACT, R time, K time, alpha angle, MA, G, and LY30.</div><div class=\"graphic_footnotes\">R (reaction time): time from sample placement or activation until the tracing amplitude reaches 2 mm; K (clot formation time): time elapsed between the R-time and the point where the tracing amplitude reaches 20 mm; alpha angle: angle between the middle line of the tracing and a tangential line to the developing &quot;body&quot; of the tracing; MA (maximal amplitude): the maximal amplitude reached after clot initiation; G: a calculated measure of total clot strength based on amplitude; LY30: the amount of clot lysis detected 30 minutes after the maximal amplitute (MA) is reached; SP (split point): time from sample placement (or activation with an exogenous procoagulant) until the earliest detectable resistance.</div><div id=\"graphicVersion\">Graphic 58281 Version 2.0</div></div></div>"},"58282":{"type":"graphic_picture","displayName":"Herpes zoster vesicles","title":"Herpes zoster","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Herpes zoster</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ID/58282_Herpes_zoster_pust_vesicles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Grouped vesicles and underlying erythema are present in a dermatomal distribution.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 58282 Version 4.0</div></div></div>"},"58284":{"type":"graphic_diagnosticimage","displayName":"Subtle buckle fx","title":"Subtle distal radial buckle fracture in 10-year-old","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subtle distal radial buckle fracture in 10-year-old</div><div class=\"cntnt\"><img style=\"width:353px; height:525px;\" src=\"images/EM/58284_Subtle_buckle_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Although the anteroposterior view of the radius appears relatively normal, a subtle buckle fracture is present on the lateral view (white arrows).</div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD.</div><div id=\"graphicVersion\">Graphic 58284 Version 3.0</div></div></div>"},"58285":{"type":"graphic_table","displayName":"Misoprostol abortion rupture","title":"Reported cases of uterine rupture with misoprostol induction for pregnancy termination","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Reported cases of uterine rupture with misoprostol induction for pregnancy termination</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Lead author (publication date)</td> <td class=\"subtitle1\">Gestational age, weeks </td> <td class=\"subtitle1\">Previous uterine scar </td> <td class=\"subtitle1\">Gravidity </td> <td class=\"subtitle1\">Misoprostol dose (mcg) </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Ruptures of previously scarred uteri </td> </tr> <tr> <td class=\"indent1\">Jwarah (2007)</td> <td>8</td> <td>Yes</td> <td>G3</td> <td>800 miso PV</td> </tr> <tr> <td class=\"indent1\">Mazouni (2006)</td> <td>16</td> <td>Yes</td> <td>?</td> <td>600 mg mife followed 36 hours later by 200 miso PV every 3 hours up to 3 doses; miso doses repeated 24 hours later as needed</td> </tr> <tr> <td class=\"indent1\">Daskalaikis (2005)</td> <td>23</td> <td>Yes</td> <td>G2</td> <td>400 miso PO plus 400 PV given at first, then 400 PV dose 8 hours later</td> </tr> <tr> <td class=\"indent1\">Berghahn (2001) </td> <td>23</td> <td>Yes</td> <td>G2(?)</td> <td>400 miso PV then 400 buccal 6 hours later</td> </tr> <tr> <td class=\"indent1\">Chen (1999)</td> <td>23</td> <td>Yes</td> <td>G3</td> <td>200 miso PV</td> </tr> <tr> <td class=\"indent1\">Mazouni (2006) </td> <td>24</td> <td>Yes</td> <td>?</td> <td>600 mg mife followed 36 hours later by 200 miso PV every 3 hours up to 3 doses; miso doses repeated 24 hours later as needed</td> </tr> <tr> <td class=\"indent1\">Nayki (2005)</td> <td>26</td> <td>Yes</td> <td>G2(?)</td> <td>200 miso PV every 3 hours up to 4 doses</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Ruptures involving major malformation of uterus </td> </tr> <tr> <td class=\"indent1\">Samuels (2005)</td> <td>18</td> <td>No (pregnancy in noncommunicating rudimentary horn)</td> <td>G1</td> <td>200 miso PV</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Ruptures involving relatively high doses of misoprostol </td> </tr> <tr> <td class=\"indent1\">Phillips (1996)</td> <td>18</td> <td>No</td> <td>G4</td> <td>200 mg mife followed by 600 miso PV every 6 hours for 2 doses</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Ruptures involving high cumulative doses of misoprostol </td> </tr> <tr> <td class=\"indent1\">Bagga (2004)</td> <td>20</td> <td>No</td> <td>G4</td> <td>200 mg mife followed by 200 miso PV every 6 hours for 6 doses</td> </tr> <tr> <td class=\"indent1\">Letourneur (2002)</td> <td>25</td> <td>No</td> <td>G1</td> <td>600 mg mife followed by 200 miso PO for 7 doses</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Miso: misoprostol; Mife: mifepristone; PV: per vaginam; PO: per oral route; ?: indicates that the article is not fully clear on the given point.</div><div id=\"graphicVersion\">Graphic 58285 Version 2.0</div></div></div>"},"58287":{"type":"graphic_table","displayName":"NCI CTCAE v5 pain","title":"NCI CTCAE v5.0 pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Pain</td> <td>Mild pain</td> <td>Moderate pain; limiting instrumental ADL*</td> <td>Severe pain; limiting self-care ADL*</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Pain is graded individually for many sites in the body and is characterized by the sensation of marked discomfort, distress, or agony.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; ADL: activities of daily living.<br />* Instrumental ADLs include preparing meals, shopping, using the telephone, managing money. Self-care ADLs include bathing, dressing/undressing, using the toilet, taking medications, and not bedridden.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <A spellcheck=true href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=_blank>https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</A> (Accessed March 29, 2018).</div><div id=\"graphicVersion\">Graphic 58287 Version 9.0</div></div></div>"},"58288":{"type":"graphic_table","displayName":"Vitamin preparations for CF, fat soluble","title":"Vitamin preparations for cystic fibrosis, fat-soluble vitamin content","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Vitamin preparations for&nbsp;cystic fibrosis, fat-soluble vitamin content</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">AquADEK (drops; chewables)</td> <td class=\"subtitle1\">DEKAs&nbsp;Plus* (liquid, chewables, softgels)&nbsp;</td> <td class=\"subtitle1\">Libertas ABDEK<br /> (D3000&nbsp;chewables;<br /> D3000 softgels)&nbsp;</td> <td class=\"subtitle1\">MVW Complete Formulation (drops, chewables, softgels)</td> <td class=\"subtitle1\"> <p>Poly-Vi-Sol (drops)</p> Centrum Kids (chewable, tablet)&nbsp;</td> <td class=\"subtitle1\">Vitamax (drops, chewables)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Total vitamin A (International Units, IU) (retinol and beta carotene)</td> </tr> <tr> <td class=\"indent1\"> <p>0 to 12 months</p> </td> <td> <p>5751 IU/1 mL</p> 87 percent as beta-carotene</td> <td> <p>5751&nbsp;IU/1 mL&nbsp;</p> <p>87 percent as beta-carotene, remainder as retinol palmitate</p> </td> <td> <p>4627 IU/1 mL</p> <p>100 percent as retinol palmitate</p> </td> <td> <p>4627 IU/0.5 mL</p> 75 percent as beta-carotene</td> <td>750 IU/1 mL100 percent as retinol palmitate</td> <td> <p>3170 IU/1 mL</p> 100 percent as retinol palmitate</td> </tr> <tr> <td class=\"indent1\"> <p>1 to 3 years</p> </td> <td> <p>11,502 IU/2 mL</p> 87 percent as beta-carotene</td> <td> <p>11,502 IU/2 mL&nbsp;</p> <p>87 percent as beta-carotene, remainder as retinol palmitate</p> <p>&nbsp;</p> </td> <td> <p>9254 IU/2 mL</p> <p>100 percent as retinol palmitate&nbsp;</p> </td> <td> <p>9254 IU/1 mL</p> 75 percent as beta-carotene</td> <td> <p>1500 IU/1 mL</p> 100 percent as retinol palmitate&nbsp;</td> <td> <p>6340 IU/2 mL</p> 100 percent as retinol palmitate</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">4 to 10 years</td> <td rowspan=\"2\"> <p>18,167 IU/2 chewables </p> 92 percent as beta-carotene</td> <td rowspan=\"2\"> <p>18,167&nbsp;IU/1&nbsp;chewable</p> <p><strong>or</strong>&nbsp;1 softgel&nbsp;</p> <p>92 percent as beta-carotene, remainder as retinol palmitate</p> </td> <td rowspan=\"2\"> <p>16,000 IU/1 chewable</p> <p>100 percent as beta-carotene</p> <br /> </td> <td> <p>Ages 4 to 8 years:</p> <p>16,000 IU/1 chewable</p> 88 percent as beta-carotene</td> <td> <p>Ages 4 to 8 years:</p> <p>3500 IU/1 chewable</p> 29 percent as beta-carotene&nbsp;</td> <td rowspan=\"2\"> <p>5000 IU/1 chewable</p> 50 percent as beta-carotene</td> </tr> <tr> <td> <p>Ages 9 years and older:</p> <p>32,000 IU/2 chewables,</p> <p><strong>or</strong> 32,000 IU/2 softgels</p> 88 percent as beta-carotene</td> <td> <p>Ages 9 years and older:</p> <p>7000 IU/2 tablets</p> 29 percent as beta-carotene&nbsp;</td> </tr> <tr> <td class=\"indent1\">11 years and older</td> <td> <p>36,334 IU/4 chewables</p> <p>92 percent as beta-carotene</p> </td> <td> <p>36,334&nbsp;IU/2&nbsp;chewables </p> <p><strong>or</strong> 2 softgels</p> <p>92 percent as beta-carotene, remainder as retinol palmitate</p> </td> <td> <p>32,000 IU/2 softgels</p> <p>88 percent as beta-carotene</p> &nbsp;</td> <td> <p>32,000 IU/2 chewables,</p> <p><strong>or</strong> 32,000 IU/2 softgels</p> 88 percent as beta-carotene</td> <td> <p>7000 IU/2 tablets</p> 29 percent as beta-carotene&nbsp;</td> <td> <p>10,000 IU/2 chewables</p> 50 percent as beta-carotene</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Vitamin E (International Units, IU)</td> </tr> <tr> <td class=\"indent1\"> <p>0 to 12 months</p> </td> <td>50 IU/1 mL<sup>&#182;</sup></td> <td>50 IU/1 mL</td> <td>50 IU/1 mL&nbsp;</td> <td>50 IU/0.5 mL</td> <td>5 IU/1 mL&nbsp;</td> <td>50 IU/1 mL</td> </tr> <tr> <td class=\"indent1\">1 to 3 years</td> <td>100 IU/2 mL<sup>&#182;</sup></td> <td>100 IU/2 mL&nbsp;</td> <td>100 IU/2 mL&nbsp;&nbsp;</td> <td>100 IU/1 mL</td> <td>10 IU/2 mL&nbsp;</td> <td>100 IU/2 mL</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">4 to 10 years</td> <td rowspan=\"2\">100 IU/2 chewables<br /> </td> <td rowspan=\"2\"> <p>100 IU/1 chewable&nbsp;</p> <p><strong>or</strong> 150 IU/1 softgel</p> </td> <td rowspan=\"2\">200 IU/1 chewable&nbsp;</td> <td> <p>Ages 4 to 8 years:</p> 200 IU/1 chewable</td> <td> <p>Ages 4 to 8 years:</p> 30 IU/1 chewable&nbsp;</td> <td rowspan=\"2\">200 IU/1 chewable</td> </tr> <tr> <td> <p>Ages 9 years and older:</p> <p>400 IU/2 chewables</p> <strong>or</strong> 400 IU/2 softgels</td> <td>&nbsp;Ages 9 years and older:60 IU/2 tablets</td> </tr> <tr> <td class=\"indent1\">11 years and older</td> <td>200 IU/4 chewables<br /> </td> <td> <p>200 IU/2 chewables</p> <p><strong>or</strong> 300 IU/2 softgels</p> </td> <td>400 IU/2 softgels&nbsp;</td> <td> <p>400 IU/2 chewables</p> <strong>or</strong> 400 IU/2 softgels</td> <td>60 IU/2 tablets&nbsp;</td> <td>400 IU/2 chewables</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Vitamin D (International Units, IU)</td> </tr> <tr> <td class=\"indent1\">0 to 12 months</td> <td>600 IU/1 mL</td> <td>750&nbsp;IU/1 mL&nbsp;</td> <td>500 IU/1 mL&nbsp;</td> <td>750 IU/0.5 mL</td> <td>400 IU/1 mL&nbsp;</td> <td>400 IU/1 mL</td> </tr> <tr> <td class=\"indent1\">1 to 3 years</td> <td>1200 IU/2 mL</td> <td>1500 IU/2 mL&nbsp;</td> <td>1000 IU/2 mL&nbsp;</td> <td>1500 IU/1 mL</td> <td>800 IU/2 mL&nbsp;</td> <td>800 IU/2 mL</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">4 to 10 years</td> <td rowspan=\"2\">1200 IU/2 chewables</td> <td rowspan=\"2\"> <p>2000 IU/1 chewable&nbsp;</p> <p><strong>or </strong>3000 IU/1 softgel</p> </td> <td rowspan=\"2\">1000 IU/1 chewable&nbsp;</td> <td> <p>Ages 4 to 8 years:</p> 1500 IU/1 chewable</td> <td> <p>Ages 4 to 8 years:</p> 400 IU/1 chewable&nbsp;</td> <td rowspan=\"2\">400 IU/1 chewable</td> </tr> <tr> <td> <p>Ages 9 years and older:</p> <p>3000 IU/2 chewables</p> <strong>or</strong> 6000 IU/2 softgels (\"D3000\" type<sup>&#182;</sup>)</td> <td> <p>Ages 9 years and older:</p> 800 IU/2 tablets&nbsp;</td> </tr> <tr> <td class=\"indent1\">11 years and older</td> <td>2400 IU/4 chewables</td> <td> <p>4000 IU/2 chewables&nbsp;</p> <p><strong>or </strong>6000 IU/2 softgels&nbsp;</p> </td> <td>2000 IU/2 softgels&nbsp;</td> <td> <p>3000 IU/2 chewables</p> <strong>or</strong> 6000 IU/2 softgels (\"D3000\" type<sup>&#182;</sup>)</td> <td>800 IU/2 tablets&nbsp;</td> <td>800 IU/2 chewables</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Vitamin K (mcg)</td> </tr> <tr> <td class=\"indent1\">0 to 12 months</td> <td>400 mcg/1 mL</td> <td>500 mcg/1 mL</td> <td>400 mcg/1 mL&nbsp;</td> <td>500 mcg/ 0.5 mL</td> <td>0 mcg&nbsp;</td> <td>300 mcg/1 mL</td> </tr> <tr> <td class=\"indent1\">1 to 3 years</td> <td>800 mcg/2 mL</td> <td>1000&nbsp;mcg/2 mL&nbsp;</td> <td>800 mcg/2 mL&nbsp;</td> <td>1000 mcg/1 mL</td> <td>0 mcg&nbsp;</td> <td>600 mcg/2 mL</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">4 to 10 years</td> <td rowspan=\"2\">700 mcg/2 chewables</td> <td rowspan=\"2\"> <p>1000 mcg/1 chewable&nbsp;</p> <p><strong>or </strong>1 softgel&nbsp;</p> </td> <td rowspan=\"2\">800 mcg/1 chewable&nbsp;</td> <td> <p>Ages 4 to 8 years:</p> 1000 mcg/1 chewable</td> <td> <p>Ages 4 to 8 years:</p> 10 mcg/1 chewable&nbsp;</td> <td rowspan=\"2\">200 mcg/1 chewable</td> </tr> <tr> <td> <p>Ages 9 years and older:</p> <p>2000 mcg/2 chewables</p> <strong>or</strong> 1600 mcg/2 softgels</td> <td> <p>Ages 9 years and older:</p> 50 mcg/2 tablets&nbsp;</td> </tr> <tr> <td class=\"indent1\">11 years and older</td> <td>1400 mcg/4 chewables</td> <td> <p>2000 mcg/2 chewables</p> <p><strong>or </strong>2 softgels&nbsp;</p> </td> <td>1600&nbsp;mcg/2 softgels&nbsp;</td> <td> <p>2000 mcg/2 chewables</p> <strong>or</strong> 1600 mcg/2 softgels</td> <td>50 mcg/2 tablets&nbsp;</td> <td>400 mcg/2 chewables</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>All of the formulations listed above also contain other micronutrients, in addition to the fat-soluble vitamins listed here.*</LI>&#xD;&#xA;<LI>AquADEKs is a registered trademark of Yasoo Health. DEKAs products is a registered trademark of Callion Pharma. Libertas is a registered trademark of Libertas Pharma. MVW Complete Formulation is a registered trademark of MVW Nutritionals. Vitamax is a registered trademark of Shear/Kershman Labs. Poly-Vi-Sol is a registered trademark of Mead Johnson and Company. Centrum is a registered trademark of Wyeth Consumer Care. </LI></UL></div><div class=\"graphic_footnotes\">* A different formulation is also available (DEKAs Essentials), which includes <STRONG>only </STRONG>the four fat-soluble vitamins, in different doses from those in DEKAs Plus. DEKAs Essentials&nbsp;can be used to boost intake of the fat-soluble vitamins for patients with unusually high requirements. <br />¶&nbsp;MVW Complete softgels are available as regular (1500 IU vitamin D);&nbsp;D3000 (3000 IU vitamin D), or D5000 (5000 IU vitamin D). The other components of these softgels are identical.&nbsp;A chewable form is also available (3000 IU vitamin D in 2 chewables).</div><div class=\"graphic_reference\">Reproduced with permission from: Eurand Pharmaceuticals, Inc. All rights reserved. Available at: http://www.sourcecf.com/pdf/VitaminComparisonTablenew.pdf.<br />Updated 12/8/16 with information from manufacturers' websites.</div><div id=\"graphicVersion\">Graphic 58288 Version 10.0</div></div></div>"},"58290":{"type":"graphic_picture","displayName":"Trunk lift PI","title":"Trunk lift","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Trunk lift</div><div class=\"cntnt\"><img style=\"width:504px; height:152px;\" src=\"images/PI/58290_Trunk_lift_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lie face down on a towel or blanket on the floor. Extend hands in front of the body. Lift the arms and upper body away from the floor. Hips should stay in contact with the floor. Hold for 3 to 5 seconds. Rest. Repeat 10 times.</div><div id=\"graphicVersion\">Graphic 58290 Version 3.0</div></div></div>"},"58291":{"type":"graphic_figure","displayName":"CRC in genetic syndromes","title":"Cumulative incidence of colorectal cancer by age in subjects with genetic syndromes compared with the general public","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cumulative incidence of colorectal cancer by age in subjects with genetic syndromes compared with the general public</div><div class=\"cntnt\"><img style=\"width:387px; height:191px;\" src=\"images/GAST/58291_CRC_in_genetic_syndromes.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">FAP: familial adenomatous polyposis; HNPCC: hereditary nonpolyposis colorectal cancer.</div><div class=\"graphic_reference\">Data from: Winawer SW, Fletcher RH, Mille L, et al. AGA guidelines: Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997; 112:594.</div><div id=\"graphicVersion\">Graphic 58291 Version 2.0</div></div></div>"},"58292":{"type":"graphic_figure","displayName":"Posttranslantional processing","title":"Posttranslational processing","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Posttranslational processing</div><div class=\"cntnt\"><img style=\"width:534px; height:192px;\" src=\"images/GAST/58292_Posttranslantional_processi.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of glucagon posttranslational processing that occurs in the pancreas and small intestine. The gene transcript is translated into a preprohormone capable of producing glucagon, glucagon-like peptide (GLP)-I and GLP-II. Only glucagon is produced in the pancreas by tissue specific processing. In the small intestine, GLP-I and GLP-II are the primary products.</div><div id=\"graphicVersion\">Graphic 58292 Version 2.0</div></div></div>"},"58294":{"type":"graphic_table","displayName":"Surgical treatment VAIN","title":"Surgical treatment of vaginal intraepithelial neoplasia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Surgical treatment of vaginal intraepithelial neoplasia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Year</td> <td class=\"subtitle1\">Patients treated</td> <td class=\"subtitle1\">Recurred after first treatment (percent)</td> <td class=\"subtitle1\">Surgical technique</td> <td class=\"subtitle1\">Follow-up range</td> </tr> <tr> <td><strong>Gallup</strong></td> <td>1975</td> <td>24</td> <td>21</td> <td>LE, PV, TV PV, TV</td> <td>1 to 12 years</td> </tr> <tr> <td><strong>Lee</strong></td> <td>1976</td> <td>54</td> <td>4</td> <td>LE, PV, TV</td> <td>NR</td> </tr> <tr> <td><strong>Oliver</strong></td> <td>1979</td> <td>17</td> <td>12</td> <td>LE, PV, TV</td> <td>NR</td> </tr> <tr> <td><strong>Hernandez-Linares</strong></td> <td>1980</td> <td>6</td> <td>0</td> <td>LE, PV, TV</td> <td>&#62;5 years</td> </tr> <tr> <td><strong>Choo</strong></td> <td>1982</td> <td>22</td> <td>0</td> <td>LE, PV, TV</td> <td>8 months to 18 years</td> </tr> <tr> <td><strong>Woodman</strong></td> <td>1984</td> <td>4</td> <td>50</td> <td>LE</td> <td>7 months to 6 years</td> </tr> <tr> <td><strong>Benedet</strong></td> <td>1984</td> <td>81</td> <td>25</td> <td>LE, PV, TV</td> <td>&#62;5 years</td> </tr> <tr> <td><strong>Lenehan</strong></td> <td>1986</td> <td>19</td> <td>16</td> <td>LE, PV, TV</td> <td>5 to 112 months</td> </tr> <tr> <td><strong>Ireland</strong></td> <td>1988</td> <td>25</td> <td>4</td> <td>PV, TV</td> <td>3 months to 11 years</td> </tr> <tr> <td><strong>Curtis</strong></td> <td>1992</td> <td>12</td> <td>17</td> <td>PC</td> <td>9 to 99 months</td> </tr> <tr> <td><strong>Hoffman</strong></td> <td>1992</td> <td>23</td> <td>17</td> <td>PV</td> <td>6 to 73 months</td> </tr> <tr> <td><strong>Julian</strong></td> <td>1992</td> <td>10</td> <td>30</td> <td>PLV</td> <td>NR</td> </tr> <tr> <td rowspan=\"2\"><strong>Sillman</strong></td> <td rowspan=\"2\">1997</td> <td rowspan=\"2\">43</td> <td>21</td> <td>BX, LE, PV, TV</td> <td>&#62;5 years</td> </tr> <tr> <td>27</td> <td>30</td> <td>CS &#62;5 years</td> </tr> <tr> <td><strong>Cheng</strong></td> <td>1999</td> <td>35</td> <td>34</td> <td>LE</td> <td>1 to 124 months</td> </tr> <tr> <td><strong>Dodge</strong></td> <td>2001</td> <td>13</td> <td>0</td> <td>PV</td> <td>&#62;7 months</td> </tr> <tr> <td><strong>Terzakis</strong></td> <td>2010</td> <td>23</td> <td>25</td> <td>LEEP</td> <td>24 months</td> </tr> <tr> <td><strong>Gunderson</strong></td> <td>2013</td> <td>44</td> <td>27</td> <td>LE</td> <td>1 to 194 months</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BX: excisional biopsy; CS: chemosurgery (with 5-FU pretreatment); LE: local excision; LEEP: loop electrosurgical excision procedure; NR: not reported; PC: partial colpectomy; PLV: partial laser vaginectomy; PV: partial vaginectomy; TV: total vaginectomy.</div><div id=\"graphicVersion\">Graphic 58294 Version 4.0</div></div></div>"},"58295":{"type":"graphic_figure","displayName":"Superior flap","title":"Superior flap creation in thyroid surgery","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Superior flap creation in thyroid surgery</div><div class=\"cntnt\"><img style=\"width:492px; height:413px;\" src=\"images/SURG/58295_Superiorflap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Creating superior flap - Kelly clamps on dermis, countertraction with assistant's finger, and electrocautery, also demonstrating anterior jugular veins.</div><div class=\"graphic_reference\">Reproduced with permission from: Clark O. Fine needle aspiration biopsy of the thyroid: Thyroid lobectomy and subtotal and total thyroidectomy. In: Mastery of Surgery, Fischer JE, Bland KI, Callery MP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 58295 Version 11.0</div></div></div>"},"58296":{"type":"graphic_picture","displayName":"AC joint compression test - Part 2","title":"Acromioclavicular joint compression test: Part 2","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acromioclavicular joint compression test: Part 2</div><div class=\"cntnt\"><img style=\"width:432px; height:301px;\" src=\"images/EM/58296_AC_joint_compression_test2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In part two of the acromioclavicular compression test, the patient's arm is fully supinated.</div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 58296 Version 2.0</div></div></div>"},"58298":{"type":"graphic_figure","displayName":"Hyperextension exercise for back pain","title":"Hyperextension exercise","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Hyperextension exercise</div><div class=\"cntnt\"><img style=\"width:524px; height:248px;\" src=\"images/ENDO/58298_Hyperextension-exercise-for-low-back-pain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient should lie face down on the floor or on a firm bed with a pillow under the abdomen and hips. The arms should be resting at the sides. The chin should be held in or neutral. The patient should inhale and raise the head, neck, chest (as a block), and arms a few inches from the floor. Hold for five seconds. Repeat&nbsp;5 to 10 times.</div><div id=\"graphicVersion\">Graphic 58298 Version 3.0</div></div></div>"},"58299":{"type":"graphic_figure","displayName":"3D view of insulin receptor","title":"Insulin receptor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Insulin receptor</div><div class=\"cntnt\"><img style=\"width:357px; height:327px;\" src=\"images/ENDO/58299_3D_view_of_insulin_receptor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A ribbon diagram of the structure of the insulin receptor kinase domain (from Val 978 to Lys 1283) as determined through x-ray crystallography. The alpha helices are shown in red, the &#946; strands in green, the side of chains of tyrosines 1158,1162, and 1163 are in yellow, the nucleotide binding loop is in orange, the catalytic loop is in dark blue, and the activation loop is in violet. The N and C termini are noted by N and C. An N- and a C-terminal lobe with a single connection can be seen.</div><div class=\"graphic_reference\">Courtesy of Jeffrey Flier, MD.</div><div id=\"graphicVersion\">Graphic 58299 Version 1.0</div></div></div>"},"58301":{"type":"graphic_figure","displayName":"Maternal pelvic types","title":"The four maternal pelvic types","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">The four maternal pelvic types</div><div class=\"cntnt\"><img style=\"width:524px; height:430px;\" src=\"images/OBGYN/58301_Pelvic_types.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A line passing through the widest transverse diameter divides the inlet into posterior (P) and anterior (A) segments.</div><div class=\"graphic_reference\">Reproduced with permission from: Pritchard JA, MacDonald PC. Williams Obstetrics, 16th Edition, Appleton-Century-Crofts, New York 1980. Copyright ©1980 McGraw Hill. p.286.</div><div id=\"graphicVersion\">Graphic 58301 Version 4.0</div></div></div>"},"58302":{"type":"graphic_picture","displayName":"Micropapillary ductal carcinoma in situ","title":"Micropapillary ductal carcinoma in situ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Micropapillary ductal carcinoma in situ</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/ONC/58302_Micropapillary_ductal_CIS_L.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a specimen from the breast of a women with micropapillary ductal carcinoma in situ . The tumor cells form tufts which project into the lumen of the involved space. The nuclei are well differentiated (low grade).</div><div class=\"graphic_reference\">Courtesy of Stuart Schnitt, MD.</div><div id=\"graphicVersion\">Graphic 58302 Version 2.0</div></div></div>"},"58304":{"type":"graphic_table","displayName":"BP cuff sizes","title":"Recommended dimensions for blood pressure cuff bladders ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended dimensions for blood pressure cuff bladders </div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Age range</td>\n\n      <td class=\"subtitle1\">Width, cm</td>\n\n      <td class=\"subtitle1\">Length, cm</td>\n\n      <td class=\"subtitle1\">Maximum arm circumference, cm*</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Newborn</td>\n\n      <td>4</td>\n\n      <td>8</td>\n\n      <td>10</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Infant</td>\n\n      <td>6</td>\n\n      <td>12</td>\n\n      <td>15</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Child</td>\n\n      <td>9</td>\n\n      <td>18</td>\n\n      <td>22</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Small adult</td>\n\n      <td>10</td>\n\n      <td>24</td>\n\n      <td>26</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Adult</td>\n\n      <td>13</td>\n\n      <td>30</td>\n\n      <td>34</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Large adult</td>\n\n      <td>16</td>\n\n      <td>38</td>\n\n      <td>44</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Thigh</td>\n\n      <td>20</td>\n\n      <td>42</td>\n\n      <td>52</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* Calculated so that the largest arm would still allow the bladder to encircle arm by at least 80 percent.</div><div class=\"graphic_reference\">Fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. National Heart, Lung and Blood Institute. National Institutes of Health. May 2004.</div><div id=\"graphicVersion\">Graphic 58304 Version 2.0</div></div></div>"},"58305":{"type":"graphic_figure","displayName":"Intragastric balloon","title":"Intragastric balloon","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Intragastric balloon</div><div class=\"cntnt\"><img style=\"width:454px; height:382px;\" src=\"images/SURG/58305_Intragastric_balloon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The intragastric balloon is a temporary alternative for weight loss in moderately obese individuals. It consists of a soft, saline-filled balloon placed endoscopically that promotes a feeling of satiety and restriction.</div><div class=\"graphic_reference\">Reproduced with permission from: Jones DB, Schneider BE, Olbers T. Atlas of Metabolic and Weight Loss Surgery. Cine-Med, North Woodbury, Connecticut 2010. Copyright &#169; 2010 Cine-Med.</div><div id=\"graphicVersion\">Graphic 58305 Version 2.0</div></div></div>"},"58306":{"type":"graphic_figure","displayName":"TURP result","title":"Prostate anatomy after transurethral resection","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Prostate anatomy after transurethral resection</div><div class=\"cntnt\"><img style=\"width:488px; height:668px;\" src=\"images/SURG/58306_TURPresult.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Following TURP, the prostatic fossa bound only by its capsule. The cavity will become lined with a regenerated surface in&nbsp;6 to&nbsp;12 weeks.</div><div class=\"graphic_footnotes\">TURP: transurethral resection of the prostate.</div><div id=\"graphicVersion\">Graphic 58306 Version 3.0</div></div></div>"},"58307":{"type":"graphic_picture","displayName":"Carditis CPC Light","title":"Esophagitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophagitis</div><div class=\"cntnt\"><img style=\"width:238px; height:360px;\" src=\"images/GAST/58307_Carditis_CPC_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power view of a biopsy specimen from the erythematous area of the distal esophagus. The specimen contains cardiac type mucosa with marked chronic inflammation (mononuclear cell infiltrate) diagnostic of chronic carditis. No goblet cells were identified.</div><div class=\"graphic_reference\">Courtesy of Donald Antonioli, MD.</div><div id=\"graphicVersion\">Graphic 58307 Version 1.0</div></div></div>"},"58308":{"type":"graphic_table","displayName":"Common causes LGI bleeding","title":"Common causes of lower gastrointestinal bleeding","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common causes of lower gastrointestinal bleeding</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Anatomic</td> </tr> <tr> <td class=\"indent1\">Diverticulosis</td> </tr> <tr> <td class=\"subtitle1_single\">Vascular</td> </tr> <tr> <td class=\"indent1\">Angiodysplasia</td> </tr> <tr> <td class=\"indent1\">Hemorrhoids</td> </tr> <tr> <td class=\"indent1\">Ischemic</td> </tr> <tr> <td class=\"indent1\">Post biopsy or polypectomy</td> </tr> <tr> <td class=\"indent1\">Radiation-induced telangiectasia</td> </tr> <tr> <td class=\"subtitle1_single\">Inflammatory</td> </tr> <tr> <td class=\"indent1\">Infectious</td> </tr> <tr> <td class=\"indent1\">Inflammatory bowel disease</td> </tr> <tr> <td class=\"indent1\">Ulcer</td> </tr> <tr> <td class=\"subtitle1_single\">Neoplastic</td> </tr> <tr> <td class=\"indent1\">Polyp</td> </tr> <tr> <td class=\"indent1\">Carcinoma</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58308 Version 4.0</div></div></div>"},"58309":{"type":"graphic_diagnosticimage","displayName":"CT scan pneumatosis coli","title":"CT scan of pneumatosis coli","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">CT scan of pneumatosis coli</div><div class=\"cntnt\"><img style=\"width:573px; height:509px;\" src=\"images/RADIOL/58309_Pneumatosis_intestinalis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) imaging of the abdomen is from a 55-year-old female who presented with acute abdominal pain and distension. Image A is a scout film of the abdomen and image B is a magnified view of the small bowel from the scout film. The images reveal air within the wall of the&nbsp;dilated loops of small-bowel, characteristic of pneumatosis intestinalis. The paucity of gas in the colon and rectum suggests SBO or severe ileus. Image C is coronal reformat through the abdomen confirming the accumulation of bubbles of air within the wall of the small bowel (white arrow). Image D is an axial image through the affected small bowel loop that shows more extensive accumulation of air within the wall of the thickened small bowel wall. Associated findings include decompressed large bowel (arrowheads), suggesting small bowel obstruction or severe ileus. In the appropriate clinical setting, the findings are highly suggestive of acute ischemia of the small bowel causing a severe ileus and functional obstruction. Less likely but also possible is small bowel obstruction with secondary ischemia.</div><div class=\"graphic_footnotes\">CT:&nbsp;computed tomography; SBO: small bowel obstruction.</div><div id=\"graphicVersion\">Graphic 58309 Version 3.0</div></div></div>"},"58311":{"type":"graphic_diagnosticimage","displayName":"Angiography during septal ablation for HCM","title":"Angiography during septal ablation for HCM","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Angiography during septal ablation for HCM</div><div class=\"cntnt\"><img style=\"width:404px; height:399px;\" src=\"images/CARD/58311_Angio_septal_abla_HCM_edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Alcohol septal ablation in a patient with hypertrophic cardiomyopathy (HCM). Right anterior oblique cranial coronary angiography shows (top left) baseline appearance of the first septal perforator (arrow; not shown in this still image but seen on cine was clear &quot;milking&quot; of this septal branch during systole owing to the compression of septal contraction), (bottom left) inflation of angioplasty balloon in that branch, (bottom right) contrast injection via balloon central lumen, and (top right) final result with obliteration of septal perforator without compromise or embolization of the left anterior descending artery.</div><div class=\"graphic_reference\">Reproduced with permission from: Baim DS. Grossman's Cardiac Catheterization, Angiography, and Intervention, Seventh Ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58311 Version 6.0</div></div></div>"},"58314":{"type":"graphic_picture","displayName":"Zipper anatomy","title":"Zipper anatomy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Zipper anatomy</div><div class=\"cntnt\"><img style=\"width:504px; height:323px;\" src=\"images/EM/58314_Zipper_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The interlocking dentitions of the zipper are brought together by the zipper fastener which consists of inner and outer faceplates separated by a median bar.</div><div class=\"graphic_reference\">Reproduced with permission from: Raveenthiran V. Releasing of zipper-entrapped foreskin: a novel nonsurgical technique. Pediatr Emerg Care 2007; 23:463. Copyright © 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58314 Version 7.0</div></div></div>"},"58317":{"type":"graphic_diagnosticimage","displayName":"High grade cystic duct leak I","title":"High grade cystic stump leak after cholecystectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">High grade cystic stump leak after cholecystectomy</div><div class=\"cntnt\"><img style=\"width:250px; height:388px;\" src=\"images/GAST/58317_High_grade_cystic_duct_leak.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">ERCP demonstrating extravasation of contrast with minimal filling of the intraheptic bile ducts.</div><div class=\"graphic_reference\">Courtesy of Michael J Bourke, MBBS, FRACP.</div><div id=\"graphicVersion\">Graphic 58317 Version 4.0</div></div></div>"},"58319":{"type":"graphic_figure","displayName":"Water distribution systems for HD","title":"Water distribution systems for hemodialysis","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Water distribution systems for hemodialysis</div><div class=\"cntnt\"><img style=\"width:466px; height:302px;\" src=\"images/NEPH/58319_H20_distribution_systems_in.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of indirect (A, left side) and direct (B, right side) feed water distribution systems. In both examples, reverse osmosis is the last process in a purification cascade.<br />With an indirect feed distribution system (A), product water from the reverse osmosis unit passes into a storage tank. A separate pump circulates water from the storage tank to the point of use (ie, dialysis stations). Water not used for dialysis is returned to the storage tank so that purified water flows in a continuously recirculating loop.<br />With a direct feed distribution system (B), product water from the reverse osmosis unit passes directly to the point of use (ie, dialysis stations). Water not used for dialysis is returned to the feed side of the reverse osmosis system so that purified water flows in a continuously recirculating loop.</div><div id=\"graphicVersion\">Graphic 58319 Version 5.0</div></div></div>"},"58320":{"type":"graphic_figure","displayName":"Intraabdominal version of transverse lie at cesarean","title":"Intraabdominal version of transverse lie at cesarean","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intraabdominal version of transverse lie at cesarean</div><div class=\"cntnt\"><img style=\"width:393px; height:489px;\" src=\"images/OBGYN/58320_Intraabdominal_version_of_transverse_lie_at_cesarean.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The assistant performs intraabdominal version prior to hysterotomy and holds the fetus in its new longitudinal position. The surgeon will then perform the lower-segment uterine incision at the dotted line.</div><div id=\"graphicVersion\">Graphic 58320 Version 3.0</div></div></div>"},"58321":{"type":"graphic_table","displayName":"Risk of a second preterm birth","title":"Risk of recurrent spontaneous preterm birth in a second pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk of recurrent spontaneous preterm birth in a second pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Risk of PTB in next pregnancy<br /> (%)</td> <td class=\"subtitle1\">Risk of PTB before 28 weeks of gestation<br /> (%)</td> </tr> <tr> <td><strong>No prior PTB</strong></td> <td class=\"centered\">9</td> <td class=\"centered\">0.23</td> </tr> <tr> <td><strong>Prior PTB</strong></td> <td class=\"centered\">22</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Prior PTB at 23 to 27 weeks</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">5</td> </tr> <tr> <td><strong>Prior PTB at 28 to 34 weeks</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">3</td> </tr> <tr> <td><strong>Prior PTB at 35 to 36 weeks</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PTB: preterm birth.</div><div class=\"graphic_reference\">Data from: Mercer BM, Goldenberg RL, Moawad AH, et al. The preterm prediction study: Effect of gestational age and cause of preterm birth on subsequent obstetric outcome. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 1999; 181:1216.</div><div id=\"graphicVersion\">Graphic 58321 Version 6.0</div></div></div>"},"58322":{"type":"graphic_picture","displayName":"Inverted papilloma","title":"Inverted papilloma","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Inverted papilloma</div><div class=\"cntnt\"><img style=\"width:521px; height:204px;\" src=\"images/ONC/58322_Inverted_papilloma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A-B, At low power (A, 10x), anastomosing cords of normal appearing urothelium originating from the overlying mucosa are growing downward into the stroma. At higher power (B, 20x), the periphery of the cords displays palisading basal cells, while the central portion contains urothelial cells. The stromal component is mostly minimal and lacks inflammation.</div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 58322 Version 1.0</div></div></div>"},"58323":{"type":"graphic_figure","displayName":"Port sites for laparoscopic hysterectomy","title":"Port sites for laparoscopic hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Port sites for laparoscopic hysterectomy</div><div class=\"cntnt\"><img style=\"width:395px; height:519px;\" src=\"images/OBGYN/58323_Port_sites_for_laparoscopic_hysterectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">5 or 10 mm ports may be placed at any location. Squares indicate typical primary and accessory trocar sites. Circles indicate options for additional accessory trocar sites.</div><div id=\"graphicVersion\">Graphic 58323 Version 5.0</div></div></div>"},"58324":{"type":"graphic_algorithm","displayName":"Treatment of neurosarcoidosis","title":"Neurosarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 578px\" class=\"figure\"><div class=\"ttl\">Neurosarcoidosis</div><div class=\"cntnt\"><img style=\"width:558px; height:442px;\" src=\"images/PULM/58324_Treatment_of_neurosarcoidos.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 58324 Version 2.0</div></div></div>"},"58325":{"type":"graphic_diagnosticimage","displayName":"Hepatorenal recess","title":"Hepatorenal recess on thoracic ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hepatorenal recess on thoracic ultrasound</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/PULM/58325_Hepatorenal_recess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hepatorenal recess is seen as a curvilinear structure between the liver and kidney. Although of similar shape, echogenicity and orientation as the diaphragm, the hepatorenal recess can be easily identified by identification of the adjacent organs. A similar structure may be seen on the left side and represents the splenorenal recess.</div><div id=\"graphicVersion\">Graphic 58325 Version 2.0</div></div></div>"},"58326":{"type":"graphic_figure","displayName":"Schematic of allantoic cyst","title":"Schematic drawing of an expanding allantoic cyst","html":"<div class=\"graphic\"><div style=\"width: 611px\" class=\"figure\"><div class=\"ttl\">Schematic drawing of an expanding allantoic cyst</div><div class=\"cntnt\"><img style=\"width:591px; height:362px;\" src=\"images/OBGYN/58326_Schematic_allantoic_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Primitive umbilical cord with midgut herniation, umbilical vein (in blue), umbilical artery (in red), and the urachus (in yellow).<br> (B) When the urachus remains patent, an allantoic cyst (ac) develops in the center of the umbilical vessels.<br> (C) The expanding allantoic cyst (ac) will push the vessels to the periphery.</div><div id=\"graphicVersion\">Graphic 58326 Version 2.0</div></div></div>"},"58327":{"type":"graphic_diagnosticimage","displayName":"Nondisplaced radial head fracture","title":"Nondisplaced fracture of the radial head","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nondisplaced fracture of the radial head</div><div class=\"cntnt\"><img style=\"width:224px; height:442px;\" src=\"images/EM/58327_Radial_head_fx_nondispl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These radiographs show a minimally displaced radial head fracture (Mason Type I).</div><div class=\"graphic_reference\">Courtesy of Mark Slabaugh, MD.</div><div id=\"graphicVersion\">Graphic 58327 Version 3.0</div></div></div>"},"58328":{"type":"graphic_table","displayName":"Oral tx hypocalcemia in hypoparathyroidism","title":"Oral treatment of chronic hypocalcemia in hypoparathyroidism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral treatment of chronic hypocalcemia in hypoparathyroidism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Treatment </td> <td class=\"subtitle1\">Dose&nbsp;- Adults</td> <td class=\"subtitle1\">&nbsp;Dose - Children</td> </tr> <tr> <td rowspan=\"2\">Calcium </td> <td>1000 to 2000 mg elemental calcium daily (total diet + supplement) in divided doses (calcium carbonate or calcium citrate)*</td> <td>25&nbsp;to&nbsp;50 mg/kg (up to 1000 to 2000 mg) elemental calcium daily (total diet&nbsp;+ supplement)&nbsp;in divided doses (calcium glubionate, calcium carbonate,&nbsp;or calcium citrate)*</td> </tr> <tr> <td colspan=\"2\">For adults and children, adjust dose as needed to control symptoms and maintain low-normal serum calcium concentration</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Vitamin D</td> </tr> <tr> <td class=\"indent1\">Calcitriol<sup>&#182;</sup></td> <td> <p>Initial: 0.25 to&nbsp;0.5 mcg daily</p> <p>Maintenance:&nbsp;0.5 to 2 mcg daily</p> </td> <td> <p>Infants: 0.04 to 0.08 mcg/kg daily</p> <p>Children &#62;1 year:</p> <ul> <li>Initial: 0.25 mcg once daily</li> <li>Maintenance: <ul> <li>Children 1 to 5 years: 0.25 to 0.75 mcg daily </li> <li>Children &#8805;6 years: 0.5 to 2 mcg daily </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Alfacacidol</td> <td> <p>Initial: 0.25 mcg daily</p> Maintenance: 0.5 to 1 mcg daily</td> <td>Insufficient data&nbsp;</td> </tr> <tr> <td class=\"indent1\">Dihydrotachysterol</td> <td colspan=\"2\">&nbsp;0.2 to 1.2 mg daily</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td colspan=\"2\">For each form of vitamin D above&nbsp;that is employed, adjust dose as needed to control symptoms and maintain low-normal serum calcium concentration</td> </tr> <tr> <td class=\"sublist1_start\">Hydrochlorothiazide&nbsp;(if required to control hypercalciuria)<sup>&#916;</sup></td> <td>12.5 to 50 mg daily</td> <td>0.5 to 1.5 mg/kg per day (maximum&nbsp;50 mg daily)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Calcium carbonate absorption is better when taken with meals and has the added benefit of binding phosphate intake. Calcium citrate is absorbed when taken with or without meals, and in achlorhydria and patients taking proton pump inhibitors (PPIs) or H2 agonists. However, calcium citrate does not bind phosphate intake. For additional information refer to UpToDate topic reviews of treatment of hypocalcemia and calcium supplementation.<br />¶ Calcitriol should be administered in divided doses due to its short half-life.<br />Δ Potassium supplementation may be necessary to offset thiazide-induced hypokalemia.</div><div class=\"graphic_reference\">Courtesy of David Goltzman, MD with additional data from: Rubin MR, Levine MA. Hypoparathyroidism and pseudohypoparathyroidism. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 8th ed, Rosen CJ (Ed),&nbsp;American Society of Bone and Mineral Research, Ames, Iowa&nbsp;2013. p.579.</div><div id=\"graphicVersion\">Graphic 58328 Version 5.0</div></div></div>"},"58330":{"type":"graphic_picture","displayName":"Prost intraepithel neopl light","title":"High grade prostatic intraepithelial neoplasia","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">High grade prostatic intraepithelial neoplasia</div><div class=\"cntnt\"><img style=\"width:548px; height:285px;\" src=\"images/ONC/58330_Prost_intraepithel_neopl_li.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-magnification (left panel) and high-magnification (right panel) photomicrographs of high grade PIN. The low magnification view demonstrates the presence of pseudostratified neoplastic epithelial cells in benign-looking large glands. In the high-magnification view, the presence of prominent nuclear atypia (arrows) can be seen.</div><div class=\"graphic_reference\">Courtesy of Ximing Yang, MD.</div><div id=\"graphicVersion\">Graphic 58330 Version 1.0</div></div></div>"},"58331":{"type":"graphic_algorithm","displayName":"Approach to prevention in adolescents","title":"Approach to organizing the preventive health evaluation of the adolescent patient","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Approach to organizing the preventive health evaluation of the adolescent patient</div><div class=\"cntnt\"><img style=\"width:364px; height:419px;\" src=\"images/PEDS/58331_Apprchpreventnadolescnts.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 58331 Version 4.0</div></div></div>"},"58332":{"type":"graphic_diagnosticimage","displayName":"MPS I cord compression A","title":"Spinal cord compression in a patient with mucopolysaccharidosis type I (MPS I, Hurler-Scheie syndrome) A","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spinal cord compression in a patient with mucopolysaccharidosis type I (MPS I, Hurler-Scheie syndrome) A</div><div class=\"cntnt\"><img style=\"width:256px; height:398px;\" src=\"images/PEDS/58332_MPS_I_cord_compression_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A sagittal T2-weighted&nbsp;magnetic resonance&nbsp;image of the spine in a 25 year old with Hurler-Scheie syndrome and spinal cord compression, making him unable to walk. Little or no CSF (white) is anterior to the cord (gray) in the thoracic and cervical region. In the upper cervical region, CSF is completely excluded by meningeal thickening, which also compresses the cord.</div><div class=\"graphic_footnotes\">CSF: cerebrospinal fluid.</div><div class=\"graphic_reference\">Courtesy of Emil Kakkis, MD, PhD.</div><div id=\"graphicVersion\">Graphic 58332 Version 7.0</div></div></div>"},"58335":{"type":"graphic_figure","displayName":"Lung cancer death rate women","title":"Increasing lung cancer death rates in women","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Increasing lung cancer death rates in women</div><div class=\"cntnt\"><img style=\"width:362px; height:276px;\" src=\"images/PULM/58335_Lung_cancer_death_rate_wome.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lung cancer death rates per 100,000 women from 1930 to 1990 showing a dramatic and continuing increase since 1960.</div><div class=\"graphic_reference\">Data from Parker SL, Tong T, Bolden S, et al. CA - A Cancer Journal for Clinicians 1996; 46:5.</div><div id=\"graphicVersion\">Graphic 58335 Version 2.0</div></div></div>"},"58337":{"type":"graphic_figure","displayName":"Cr concentration Heart Tx","title":"Serum creatinine concentrations and heart transplantation","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Serum creatinine concentrations and heart transplantation</div><div class=\"cntnt\"><img style=\"width:504px; height:404px;\" src=\"images/NEPH/58337_Cr_concentration_Heart_Tx.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Graph showing the pooled weighted average serum creatinine concentrations (mg/dL) derived from published studies describing the renal function in heart transplant recipients receiving cyclosporine based immunosuppressive therapy. In general, the serum creatinine level increases early after transplantation and then stabilizes over time.</div><div id=\"graphicVersion\">Graphic 58337 Version 1.0</div></div></div>"},"58340":{"type":"graphic_picture","displayName":"Dry AMD with drusen","title":"Dry type age-related macular degeneration (AMD) with drusen","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dry type age-related macular degeneration (AMD) with drusen</div><div class=\"cntnt\"><img style=\"width:346px; height:295px;\" src=\"images/PC/58340_Dry_AMD_with_drusen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small, bright yellow drusen are visible.</div><div class=\"graphic_reference\">Reproduced with permission from the Massachusetts Eye &amp; Ear Infirmary, Photographer, David Walsh.</div><div id=\"graphicVersion\">Graphic 58340 Version 2.0</div></div></div>"},"58341":{"type":"graphic_figure","displayName":"FBA complicated by pneumonia","title":"73-year-old woman with recurrent right lower lobe pneumonia and bronchiectasis due to airway foreign bodies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">73-year-old woman with recurrent right lower lobe pneumonia and bronchiectasis due to airway foreign bodies</div><div class=\"cntnt\"><img style=\"width:339px; height:301px;\" src=\"images/PULM/58341_FBA_complicated_by_pneumoni.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bronchoscopy revealed a benign granulomatous tumor obstructing the right lower lobe bronchus. After resection of the &quot;tumor&quot; with a large forceps, two peanut fragments were found. The patient did not recall having eaten peanuts for 18 years.</div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 58341 Version 2.0</div></div></div>"},"58342":{"type":"graphic_picture","displayName":"FISH for MCL","title":"FISH analysis for t(11;14)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">FISH analysis for t(11;14)</div><div class=\"cntnt\"><img style=\"width:396px; height:320px;\" src=\"images/HEME/58342_FISHforMCL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">FISH analysis for t(11;14) using a colocalization assay. A normal signal would show two red probes, localizing to the two alleles of the CCND1 gene on chromosome 11 and two green probes localizing to the IGH gene on chromosome 14. In this case of a t(11;14) translocation, the red and green probes are brought in close proximity.</div><div class=\"graphic_footnotes\">FITC: fluorescein isothiocyanate.</div><div class=\"graphic_reference\">Reproduced with permission from: Armitage JO, Mauch PM, Harris NL, et al. Non-Hodgkin Lymphomas, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 58342 Version 10.0</div></div></div>"},"58343":{"type":"graphic_figure","displayName":"Right atrial pressure tracing","title":"Right atrial pressure tracing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right atrial pressure tracing</div><div class=\"cntnt\"><img style=\"width:362px; height:321px;\" src=\"images/PULM/58343_Right_atrial_pressure_traci.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This schematic diagram shows the different components of the right atrial pressure tracing. A simultaneous ECG is shown to demonstrate the timing of the different components.</div><div class=\"graphic_reference\">Redrawn from Gore, JM, Alper, JS, Benotti, JR, et al. Handbook of hemodynamic monitoring, 1st ed, Boston, Little Brown &amp; Co, 1985.</div><div id=\"graphicVersion\">Graphic 58343 Version 1.0</div></div></div>"},"58344":{"type":"graphic_picture","displayName":"Thin-cap fibroatheroma with intraplaque hemorrhage","title":"Thin-cap fibroatheroma with intraplaque hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Thin-cap fibroatheroma with intraplaque hemorrhage</div><div class=\"cntnt\"><img style=\"width:487px; height:384px;\" src=\"images/CARD/58344_Intraplaque_hem_ed.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thin-cap fibroatheroma with recent intraplaque hemorrhage.<br> (1A) Low (x20) and (1B) higher-power (x200) views of a thin-cap fibroatheroma with recent hemorrhage. Note, in 1B there is spillage of erythrocytes from surrounding intraplaque vasa vasorum (arrow).<br> (2A, 2B) Serial section of the lesion in Panel 1A shows a large pool of extravasated erythrocytes with proximate micro-vessels (arrow). Panel 2B is a high-power view of boxed area in Panel 2A.</div><div class=\"graphic_reference\">Reproduced with permission from: Virmani R, Kolodgie FD, Burke AP, et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005; 25:2054. Copyright © 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58344 Version 11.0</div></div></div>"},"58345":{"type":"graphic_table","displayName":"NCI CTCAE v5 heart failure","title":"NCI CTCAE v5.0 heart failure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 heart failure</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Heart failure</td> <td>Asymptomatic with laboratory (eg, BNP [B-Natriuretic Peptide]) or cardiac imaging abnormalities</td> <td>Symptoms with moderate activity or exertion</td> <td>Symptoms at rest or with minimal activity or exertion; hospitalization; new onset of symptoms</td> <td>Life-threatening consequences; urgent intervention indicated (eg, continuous intravenous therapy or mechanical hemodynamic support)</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Heart failure is characterized by the inability of the heart to pump blood at an adequate volume to meet tissue metabolic requirements, or, the ability to do so only at an elevation in the filling pressure. For left-sided heart failure, refer to the table on left ventricular systolic dysfunction; tables on restrictive cardiomyopathy and decreased ejection fraction may also be appropriate.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 58345 Version 7.0</div></div></div>"},"58346":{"type":"graphic_table","displayName":"Emergency management of anaphylaxis in adults","title":"Rapid overview: Emergency management of anaphylaxis in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapid overview: Emergency management of anaphylaxis in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Diagnosis is made clinically:</td> </tr> <tr> <td>The most common signs and symptoms are cutaneous (eg, sudden onset of generalized urticaria, angioedema, flushing, pruritus). However, 10 to 20% of patients have no skin findings.</td> </tr> <tr> <td><strong><span style=\"color: #ff0000;\">Danger signs: Rapid progression of symptoms, respiratory distress (eg, stridor, wheezing, dyspnea, increased work of breathing, persistent cough, cyanosis), vomiting, abdominal pain, hypotension, dysrhythmia, chest pain, collapse.</span></strong></td> </tr> <tr> <td class=\"subtitle1_single\">Acute management:</td> </tr> <tr> <td>The first and most important treatment in anaphylaxis is epinephrine. There are <strong>NO absolute contraindications</strong> <strong>to epinephrine</strong> in the setting of anaphylaxis.</td> </tr> <tr> <td><strong>Airway:</strong> Immediate intubation if evidence of impending airway obstruction from angioedema. Delay may lead to complete obstruction. Intubation can be difficult and should be performed by the most experienced clinician available. Cricothyrotomy may be necessary.</td> </tr> <tr> <td class=\"subtitle2_left\">Promptly and simultaneously, give:</td> </tr> <tr> <td class=\"indent1\"><strong>IM epinephrine (1 mg/mL preparation):</strong> Give epinephrine 0.3 to 0.5 mg intramuscularly, preferably in the mid-outer thigh. Can repeat every 5 to 15 minutes (or more frequently), as needed. If epinephrine is injected promptly IM, most patients respond to one, two, or at most, three doses. If symptoms are not responding to epinephrine injections, prepare IV epinephrine for infusion (see below).</td> </tr> <tr> <td class=\"indent1\"><strong>Place patient in recumbent position</strong>, if tolerated, and elevate lower extremities.</td> </tr> <tr> <td class=\"indent1\"><strong>Oxygen:</strong> Give 8 to 10 L/minute via facemask or up to 100% oxygen, as needed.</td> </tr> <tr> <td class=\"indent1\"><strong>Normal saline rapid bolus:</strong> Treat hypotension with rapid infusion of 1 to 2 liters IV. Repeat, as needed. Massive fluid shifts with severe loss of intravascular volume can occur.</td> </tr> <tr> <td class=\"indent1\"><strong>Albuterol (salbutamol):</strong> For bronchospasm resistant to IM epinephrine, give 2.5 to 5 mg in 3 mL saline via nebulizer. Repeat, as needed.&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\">Adjunctive therapies:</td> </tr> <tr> <td class=\"indent1\"><strong>H1 antihistamine*:</strong> Consider giving diphenhydramine 25 to 50 mg IV (for relief of urticaria and itching only).</td> </tr> <tr> <td class=\"indent1\"><strong>H2 antihistamine<strong>*</strong>:</strong> Consider giving ranitidine 50 mg IV.</td> </tr> <tr> <td class=\"indent1\"><strong>Glucocorticoid<strong>*</strong>:</strong> Consider giving methylprednisolone 125 mg IV.</td> </tr> <tr> <td class=\"indent1\"><strong>Monitoring: </strong>Continuous noninvasive hemodynamic monitoring and pulse oximetry monitoring should be performed. Urine output should be monitored in patients receiving IV fluid resuscitation for severe hypotension or shock.</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment of refractory symptoms:</td> </tr> <tr> <td><strong>Epinephrine infusion<sup>&#182;</sup></strong><strong>:</strong> For patients with inadequate response to IM epinephrine and IV saline, give epinephrine continuous infusion, beginning at <span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\"><strong>0.1 mcg/kg/minute</strong></span> by infusion pump<sup>&#916;</sup>. Titrate the dose continuously according to blood pressure, cardiac rate and function, and oxygenation.</td> </tr> <tr> <td><strong>Vasopressors<sup>&#182;</sup></strong><strong>:</strong> Some patients may require a second vasopressor (in addition to epinephrine). All vasopressors should be given by infusion pump, with the doses titrated continuously according to blood pressure and cardiac rate/function and oxygenation monitored by pulse oximetry.</td> </tr> <tr> <td><strong>Glucagon:</strong> Patients on beta-blockers may not respond to epinephrine and can be given glucagon 1 to 5 mg IV over&nbsp;5 minutes, followed by infusion of 5 to 15 mcg/minute. Rapid administration of glucagon can cause vomiting.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Instructions on how to prepare and administer epinephrine for IV continuous infusions are available as separate tables in UpToDate.</div><div class=\"graphic_footnotes\"><FONT color=black>IM: intramuscular; IV: intravenous.<br />* These medications should not be used as initial or sole treatment.<br />¶&nbsp;All patients receiving an infusion of epinephrine and another vasopressor require continuous noninvasive monitoring of blood pressure, heart rate and function, and oxygen saturation</FONT>. <br /><FONT color=black>Δ For example, the initial infusion rate for a 70 kg patient would be 7 mcg/minute. <FONT color=black>This is consistent with the recommended range for non-weight-based dosing for adults, which is 2 to 10 mcg/minute. Non-weight-based dosing can be used if the patient's weight is not known and cannot be estimated.</FONT></FONT></div><div class=\"graphic_reference\">Adapted from: Simons FER. Anaphylaxis. J Allergy Clin Immunol 2010; 125:S161.</div><div id=\"graphicVersion\">Graphic 58346 Version 27.0</div></div></div>"},"58347":{"type":"graphic_table","displayName":"Penicillin skin test reagents","title":"Penicillin skin test reagents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Penicillin skin test reagents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Reagent</td> <td class=\"subtitle1\">Concentration used for skin testing</td> </tr> <tr> <td>Penicilloyl-polylysine (Pre-Pen)</td> <td>6 x 10<sup>-5</sup> M</td> </tr> <tr> <td>Penicillin G</td> <td>10,000 units/mL</td> </tr> <tr> <td>Penicilloate</td> <td>0.01 M</td> </tr> <tr> <td>Penilloate</td> <td>0.01 M</td> </tr> <tr> <td>Ampicillin/amoxicillin</td> <td>3 to 25 mg/mL</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Commonly used penicillin skin test reagents.</div><div id=\"graphicVersion\">Graphic 58347 Version 5.0</div></div></div>"},"58348":{"type":"graphic_figure","displayName":"Anatomy of cortical bone","title":"Cortical bone and trabecular (cancellous) bone","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Cortical bone and trabecular (cancellous) bone</div><div class=\"cntnt\"><img style=\"width:494px; height:367px;\" src=\"images/ENDO/58348_Anatomy_of_cortical_bone.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Osteon of compact (cortical) bone and trabeculae of spongy (cancellous) bone.</div><div class=\"graphic_reference\">Data from: US National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) Program, http://training.seer.cancer.gov/module_anatomy/unit3_2_bone_tissue.html.</div><div id=\"graphicVersion\">Graphic 58348 Version 1.0</div></div></div>"},"58351":{"type":"graphic_figure","displayName":"Hormonal response hypocalcemia","title":"Hormonal response to hypocalcemia","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Hormonal response to hypocalcemia</div><div class=\"cntnt\"><img style=\"width:479px; height:199px;\" src=\"images/NEPH/58351_Hormonalresponsehypocalce.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Physiologic sequence of events following the development of hypocalcemia. The interaction of parathyroid hormone (PTH) with calcitriol results in an appropriate elevation in the plasma calcium concentration with little or no change in the plasma phosphate concentration.</div><div class=\"graphic_reference\">Adapted from DeLuca, H, Am J Med 1975; 58:39.</div><div id=\"graphicVersion\">Graphic 58351 Version 1.0</div></div></div>"},"58352":{"type":"graphic_table","displayName":"Rx pregnant dialysis patient","title":"Management of the pregnant dialysis patient","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of the pregnant dialysis patient</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Intensification of dialysis</td> </tr> <tr> <td>Blood urea nitrogen should be maintained below 50 mg/dL (17 mmol/L) to avoid polyhydramnios.</td> </tr> <tr> <td>If hemodialysis is used, intensification of the regimen should be considered;&nbsp;five to&nbsp;seven sessions per week&nbsp;are likely to provide more optimal control of uremia and better fetal outcomes. The&nbsp;prescription should include bicarbonate buffer, minimal heparinization and slow-rate ultrafiltration in order to avoid dialysis hypotension and volume contraction.</td> </tr> <tr> <td>If peritoneal dialysis is used, the exchange volumes should be decreased (eg, to 1.5 liters), and the frequency should be increased.</td> </tr> <tr> <td class=\"subtitle1_single\">Adequate supply of calories and protein</td> </tr> <tr> <td>Protein intake should be 1 g/kg per day plus an additional 20 g/day for fetal growth.</td> </tr> <tr> <td>Diet should be supplemented with water-soluble vitamins and zinc.</td> </tr> <tr> <td class=\"subtitle1_single\">Antihypertensive regimen</td> </tr> <tr> <td>Diuretics, ACE inhibitors,&nbsp;angiotensin receptor blockers (ARBs) are avoided. Acceptable antihypertensives&nbsp;include labetalol, Nifedipine XL, methyldopa, and metoprolol.</td> </tr> <tr> <td>The diastolic blood pressure should range between 80 and 90 mmHg.</td> </tr> <tr> <td class=\"subtitle1_single\">Correction of anemia</td> </tr> <tr> <td>Erythropoietin should be given to maintain a hemoglobin level of at least 10 to 11 g/dL.</td> </tr> <tr> <td>Iron and folic acid should be supplemented.</td> </tr> <tr> <td class=\"subtitle1_single\">Avoidance of metabolic acidosis</td> </tr> <tr> <td class=\"subtitle1_single\">Prevention of hypocalcemia</td> </tr> <tr> <td>Oral calcium carbonate should be administered.</td> </tr> <tr> <td>Hypercalcemia should be avoided at the end of hemodialysis treatment.</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment of premature labor</td> </tr> <tr> <td>The use of beta agonists as first-line drug treatment is preferred.</td> </tr> <tr> <td>Nonsteroidal anti-inflammatory drugs are used with great caution and only for a limited duration.</td> </tr> <tr> <td class=\"subtitle1_single\">Reinforced fetal monitoring as soon as viability is reached</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACE: angiotensin-converting enzyme.</div><div class=\"graphic_reference\">Adapted from: Jungers P, Chauveau D. Pregnancy in renal disease. Kidney Int 1997; 52:871.</div><div id=\"graphicVersion\">Graphic 58352 Version 7.0</div></div></div>"},"58353":{"type":"graphic_figure","displayName":"Carotid stenosis in NASCET and ECST","title":"Methods of measuring carotid stenosis in NASCET and ECST","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Methods of measuring carotid stenosis in NASCET and ECST</div><div class=\"cntnt\"><img style=\"width:505px; height:324px;\" src=\"images/NEURO/58353_Carotid_stenosis_in_NASCET.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified from Donnan, GA, Davis, SM, Chambers, BR, Gates, PC, Lancet 1998; 351:1372. NASCET: North American Symptomatic Carotid Endarterectomy Trial; ECST: European Carotid Surgery Trial; CC: Common Carotid Method.</div><div id=\"graphicVersion\">Graphic 58353 Version 2.0</div></div></div>"},"58354":{"type":"graphic_picture","displayName":"HS Crohns2","title":"Crohn's disease mimicking hidradenitis suppurativa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Crohn's disease mimicking hidradenitis suppurativa</div><div class=\"cntnt\"><img style=\"width:396px; height:263px;\" src=\"images/OBGYN/58354_HS_Crohns2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: F William Danby, MD, FRCPC, FAAD&#160;and Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 58354 Version 2.0</div></div></div>"},"58355":{"type":"graphic_picture","displayName":"Posterior impingement test","title":"Posterior impingement test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior impingement test</div><div class=\"cntnt\"><img style=\"width:418px; height:430px;\" src=\"images/EM/58355_Posterior_impingement_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The posterior impingement test is performed by placing the affected shoulder in 90 degrees of abduction, 110 degrees of extension, and maximal external rotation. The test is positive if it recreates the athlete's shoulder pain.</div><div id=\"graphicVersion\">Graphic 58355 Version 2.0</div></div></div>"},"58357":{"type":"graphic_figure","displayName":"Upper cervical spinal nerves","title":"Upper cervical spinal nerves","html":"<div class=\"graphic\"><div style=\"width: 576px\" class=\"figure\"><div class=\"ttl\">Upper cervical spinal nerves</div><div class=\"cntnt\"><img style=\"width:556px; height:339px;\" src=\"images/NEURO/58357_Upper_cervical_spinal_nerv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posterior and lateral views of the upper cervical spine, showing the leading articular sources of cervicogenic headache, the related nerves, and where needles are placed for diagnostic blocks of these structures. Red labels and needles point to target sites for diagnostic blocks.</div><div class=\"graphic_footnotes\">AOJ: atlanto-occipital joint; C3 DMB: C3 deep medial branch block; C4mb: medial branch of the C4 dorsal ramus; dmb: deep medial branch of the C3 dorsal ramus; LAA IAB: intra-articular block of the lateral atlanto-axial joint; LAAJ: lateral atlanto-axial joint; ton: third occipital nerve; TONB: third occipital nerve block; ZJ: zygapophysial joint.</div><div class=\"graphic_reference\">Reproduced from: Bogduk N, Govind J. Cervicogenic headache: an assessment of the evidence on clinical diagnosis, invasive tests, and treatment. Lancet Neurol 2009; 8:959. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 58357 Version 2.0</div></div></div>"},"58359":{"type":"graphic_picture","displayName":"Bullous pemphigoid in childhood","title":"Bullous pemphigoid in childhood","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bullous pemphigoid in childhood</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/58359_Bullous_pemphigoid_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple tense bullae, inflammatory plaques, erosions, and crusts on the skin of this child with bullous pemphigoid.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 58359 Version 5.0</div></div></div>"},"58361":{"type":"graphic_picture","displayName":"Lichen planus hand","title":"Lichen planus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen planus</div><div class=\"cntnt\"><img style=\"width:314px; height:396px;\" src=\"images/DERM/58361_Lichen_planus_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lichen planus of the dorsum of the hand and wrist. Notice the violaceous color of the papules and the linear K&#246;ebner's phenomenon.</div><div class=\"graphic_reference\">Reproduced with permission from: Sauer, GC, Hall, JC. Manual of skin diseases, 7th ed, Lippincott-Raven, Philadelphia 1996. Copyright &#169; 1996 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58361 Version 1.0</div></div></div>"},"58363":{"type":"graphic_figure","displayName":"Causes LGI bleeding children","title":"Major causes of lower gastrointestinal bleeding in children by age group","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Major causes of lower gastrointestinal bleeding in children by age group</div><div class=\"cntnt\"><img style=\"width:515px; height:525px;\" src=\"images/PEDS/58363_Cause_LGI_bleed_child.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the major causes of gastrointestinal bleeding in the pediatric age group. The age categories are approximate, and most of these disorders can occur outside of the given age group.</div><div class=\"graphic_footnotes\">* Rarely, inflammatory bowel disease (IBD) presents before six years of age. This presentation is sometimes termed&nbsp;very early onset IBD (VEO-IBD), or infantile IBD if it presents before two years of age. The disease tends to be severe, with more rapid progression and poor responsiveness to most conventional therapies. The distinct phenotype and early age of onset suggests a pronounced genetic susceptibility and dysregulated immune response.</div><div id=\"graphicVersion\">Graphic 58363 Version 10.0</div></div></div>"},"58364":{"type":"graphic_table","displayName":"Contact allergens children","title":"Common contact allergens in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common contact allergens in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Allergen</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Source</td> <td class=\"subtitle1\">Clinical distribution</td> </tr> <tr> <td>Urushiol</td> <td>Poison ivy, oak, sumac</td> <td>Poison ivy, oak, sumac</td> <td>Linear pattern</td> </tr> <tr> <td>Nickel</td> <td>Metal</td> <td>Jewelry, buckles, clothing snaps</td> <td>Earlobes, neck, wrist periumbilical, base of fingers</td> </tr> <tr> <td>Neomycin</td> <td>Topical antibiotic</td> <td>Topical medications</td> <td>Sites of healing wounds, ear canal</td> </tr> <tr> <td>Potassium dichromate</td> <td>Tanning agent</td> <td>Leather, shoes</td> <td>Dorsum of feet</td> </tr> <tr> <td>Thimerosal</td> <td>Preservative</td> <td>Topical medications</td> <td>Face and eyelids, healing wounds</td> </tr> <tr> <td><em>Myroxylon pereirae</em> (Balsam of Peru)</td> <td>Fragrance</td> <td>Perfumes, soaps, cosmetics, moisturizers</td> <td>Axillae, neck, face, eyelids, site of application of moisturizer</td> </tr> <tr> <td>Formaldehyde</td> <td>Preservative</td> <td>Topical medications, creams, lotions, shampoo</td> <td>Face, eyelids, axillae, hairline</td> </tr> <tr> <td>Quaternium 15</td> <td>Preservative</td> <td>Topical medications, creams, lotions</td> <td>Face, eyelids, axillae</td> </tr> <tr> <td>Colophony</td> <td>Sticky substance from pine and spruce tree trunks</td> <td>Adhesives, glues, sealants, cosmetics, soaps</td> <td>Axillae, neck, face, eyelids</td> </tr> <tr> <td>p-tert-butylphenol formaldehyde</td> <td>Resin</td> <td>Leather glues, adhesives, watch straps</td> <td>Shoes, tape-distribution</td> </tr> <tr> <td>Wool alcohol</td> <td>Lanolin</td> <td>Soaps, emollients, topical medications, cosmetics</td> <td>Face, hands</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Hogan PA, Weston WL. Allergic contact dermatitis in children. Pediatr Rev 1993; 14:240.</div><div id=\"graphicVersion\">Graphic 58364 Version 2.0</div></div></div>"},"58365":{"type":"graphic_figure","displayName":"ME cholesteatoma removal","title":"Removal of a cholesteatoma in the middle ear","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Removal of a cholesteatoma in the middle ear</div><div class=\"cntnt\"><img style=\"width:543px; height:534px;\" src=\"images/ALLRG/58365_MEcholesteatomaremoval.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A) Canal incisions for a middle ear exploration to remove a congenital cholesteatoma. Panel B) The ear canal and half the drum are turned down as a flap to expose the cholesteatoma beneath the malleus; usually the drum is left attached to the end of the malleus. Panel C) The cholesteatoma is detached from its mucosal connections and delivered intact. The drum is then returned to its normal anatomic position.</div><div class=\"graphic_reference\">Panels A and B courtesy of Glenn C Isaacson, MD, FAAP, FACS.<br />Panel C reproduced with permission from Pediatrics, Vol. 120, Pages 603-8, Copyright © 2007 by the AAP.</div><div id=\"graphicVersion\">Graphic 58365 Version 14.0</div></div></div>"},"58366":{"type":"graphic_diagnosticimage","displayName":"Doppler study lower extremity arteriovenous fistula","title":"Doppler study lower extremity arteriovenous fistula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Doppler study lower extremity arteriovenous fistula</div><div class=\"cntnt\"><img style=\"width:342px; height:299px;\" src=\"images/CARD/58366_Lower_extremity_AVF_Doppler.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Duplex Doppler ultrasound image of a relatively small arteriovenous fistula developing after cardiac catheterization. The fistula, seen in red, involves a connection between the common femoral artery (CFA) and a branch of the greater saphenous vein (GSV). The site of the bruit is also noted.</div><div id=\"graphicVersion\">Graphic 58366 Version 4.0</div></div></div>"},"58367":{"type":"graphic_diagnosticimage","displayName":"Anterior junction line CT","title":"Anterior pleural junction line on chest CT scan","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior pleural junction line on chest CT scan</div><div class=\"cntnt\"><img style=\"width:324px; height:316px;\" src=\"images/PULM/58367_Anterior_junction_line_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan shows anterior junction line formed by four layers of pleura. This represents the potential space of the anterior mediastinum.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 58367 Version 4.0</div></div></div>"},"58368":{"type":"graphic_figure","displayName":"Organ reservoirs of urea","title":"Schematic figure showing urea stores versus perfusion in different organs during hemodialysis","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Schematic figure showing urea stores versus perfusion in different organs during hemodialysis</div><div class=\"cntnt\"><img style=\"width:498px; height:256px;\" src=\"images/NEPH/58368_Organ_reservoirs_of_urea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The different tissue compartments represent areas of the body with variable degrees of perfusion from the heart and urea sequestration. Within the gastrointestinal tract and skeletal muscle, the ratio of blood flow to urea content is low. These organs therefore sequester up to 80 percent of the total body urea, leading to urea rebound and reduced dialysis efficiency.</div><div id=\"graphicVersion\">Graphic 58368 Version 3.0</div></div></div>"},"58369":{"type":"graphic_picture","displayName":"Excision ureth diverticulum","title":"Transvaginal excision of a small urethral diverticulum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transvaginal excision of a small urethral diverticulum</div><div class=\"cntnt\"><img style=\"width:432px; height:314px;\" src=\"images/OBGYN/58369_Excision_ureth_diverticulum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The forceps is on the diverticulum which has been dissected intact to the connection with the urethra just prior to transection. Additional Allis clamps have been placed on the vaginal epithelium to improve exposure. The white arrow points to the urethral catheter.</div><div class=\"graphic_reference\">Courtesy of Robert E Gutman, MD.</div><div id=\"graphicVersion\">Graphic 58369 Version 1.0</div></div></div>"},"58373":{"type":"graphic_diagnosticimage","displayName":"RP Tracheal stenosis CT","title":"Relapsing polychondritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Relapsing polychondritis</div><div class=\"cntnt\"><img style=\"width:260px; height:434px;\" src=\"images/PULM/58373_RP_Tracheal_stenosis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiplanar computed tomographic reformatting of the trachea demonstrates a long segment stenosis involving the entire trachea.</div><div id=\"graphicVersion\">Graphic 58373 Version 2.0</div></div></div>"},"58375":{"type":"graphic_picture","displayName":"Coronary artery after DES","title":"Coronary artery at long-term follow-up after drug eluting stent implantation","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Coronary artery at long-term follow-up after drug eluting stent implantation</div><div class=\"cntnt\"><img style=\"width:514px; height:514px;\" src=\"images/CARD/58375_Coronary_artery_DES.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The individual stent struts can be recognized as signal rich, bright yellow structures casting a dorsal shadow on the vessel wall. All stent struts are covered towards the lumen by a thin, homogenous bright yellow layer, corresponding to neointima. (IC) OCT imaging catheter in the center of the lumen; asterisk indicates the angioplasty guide wire artefact.</div><div class=\"graphic_footnotes\">OCT: St. Jude/Lightlab Imaging C7XR.</div><div class=\"graphic_reference\">Courtesy of Dr. Evelyn Regar, Thoraxcenter.</div><div id=\"graphicVersion\">Graphic 58375 Version 2.0</div></div></div>"},"58376":{"type":"graphic_figure","displayName":"Achilles tendon and superficial calf muscle anatomy","title":"Anatomy of the Achilles tendon and superficial posterior calf muscles","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Anatomy of the Achilles tendon and superficial posterior calf muscles</div><div class=\"cntnt\"><img style=\"width:549px; height:597px;\" src=\"images/EM/58376_Achilles_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note that the subtendinous bursa is also referred to as the retrocalcaneal bursa.</div><div id=\"graphicVersion\">Graphic 58376 Version 8.0</div></div></div>"},"58377":{"type":"graphic_picture","displayName":"Anatomy left pelvic vessels","title":"Anatomy of left pelvic vessels","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of left pelvic vessels</div><div class=\"cntnt\"><img style=\"width:370px; height:277px;\" src=\"images/OBGYN/58377_Anatomy_left_pelvic_vessels.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Ken Hatch, MD.</div><div id=\"graphicVersion\">Graphic 58377 Version 1.0</div></div></div>"},"58379":{"type":"graphic_picture","displayName":"Broth dilution test","title":"Broth microdilution test of Candida glabrata at 48 hours","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Broth microdilution test of Candida glabrata at 48 hours</div><div class=\"cntnt\"><img style=\"width:480px; height:350px;\" src=\"images/ID/58379_Broth_dilution_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Minimum inhibitory concentration (MIC) determinations can be made using standardized panels of antifungals in a 96-well plate. Wells of broth are inoculated with a concentrated antifungal solution in serial two-fold dilutions. All wells are then inoculated with a specified amount of the fungal suspension of interest, suspended in an equal volume, and incubated at a given temperature and for a given length of time. The tubes are then examined for turbidity, which represents fungal growth. The MIC is the first well that is clear or that shows a significant diminution in turbidity relative to the control well. For example, the MICs for rows A, B, and C are observed in A9, B8, and C9, respectively. Row H is the control well.</div><div class=\"graphic_reference\">Courtesy of Michael Pfaller, MD.</div><div id=\"graphicVersion\">Graphic 58379 Version 1.0</div></div></div>"},"58380":{"type":"graphic_picture","displayName":"Janeway lesion in infective endocarditis","title":"Janeway lesion in infective endocarditis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Janeway lesion in infective endocarditis</div><div class=\"cntnt\"><img style=\"width:390px; height:252px;\" src=\"images/ID/58380_Janeway_lesion_IE_edt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A Janeway lesion (arrow) occurred on the palm in this patient with bacterial endocarditis due to <EM>Streptococcus bovis</EM>. These lesions are macular, nonpainful, and erythematous; they are located on the palms and soles.</div><div class=\"graphic_reference\">Courtesy of Jan V Hirschmann. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 58380 Version 15.0</div></div></div>"},"58383":{"type":"graphic_diagnosticimage","displayName":"Rejection drug withdrawal CT","title":"Allograft rejection after immunosuppression withdrawal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Allograft rejection after immunosuppression withdrawal</div><div class=\"cntnt\"><img style=\"width:360px; height:244px;\" src=\"images/NEPH/58383_Rejection_drug_withdrawal_C.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abdominal and pelvic CT scan shows ill-defined margins and heterogenous enhancement of renal allograft (arrow), findings that represent rejection. The surrounding mesenteric fat and abdominal wall musculature have inflammatory changes. This patient, in whom immunosuppression had been completely withdrawn, eventually required a transplant nephrectomy.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Brent Miller, MD.</div><div id=\"graphicVersion\">Graphic 58383 Version 3.0</div></div></div>"},"58384":{"type":"graphic_table","displayName":"Computed tomography signs of appendicitis","title":"Computed tomography signs of acute appendicitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Computed tomography signs of acute appendicitis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Wall thickness &#62;2 mm</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Appendicolith</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Enlargement of the appendix</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Target sign (concentric thickening of the appendiceal wall)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Phlegmon</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Abscess</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Free fluid</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Thickening of the mesentery, fat stranding (peri-appendiceal inflammation)</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 58384 Version 2.0</div></div></div>"},"58385":{"type":"graphic_figure","displayName":"Haplotypes coupling repulsion","title":"Haplotypes, coupling, and repulsion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Haplotypes, coupling, and repulsion</div><div class=\"cntnt\"><img style=\"width:377px; height:165px;\" src=\"images/ALLRG/58385_Haplotypes_coupling_repulsi.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of two pairs of chromosomes, to illustrate that the coupling and repulsion relationships of the alleles affect the haplotypes. In the top pair of chromosomes, the B1 and C1 alleles are in coupling, while they are in repulsion in the bottom pair of chromosomes. The individual marker genotypes are the same in both cases, but the haplotypes differ. A, B, and C each represent loci, while the subscripts represent alleles at these loci.</div><div id=\"graphicVersion\">Graphic 58385 Version 1.0</div></div></div>"},"58386":{"type":"graphic_picture","displayName":"Mohs surgery 2","title":"Mohs surgery of squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mohs surgery of squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:371px; height:727px;\" src=\"images/DERM/58386_Mohs_surgery_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The excised tissue is subdivided, sequentially numbered, and inked.<br> (B) A Mohs map of the excised tissue with anatomic landmarks, location of reference nicks, and subdivision and inking.<br> (C) The excised Mohs tissue is inverted, the angled skin edge is flattened and oriented such that the deep margin and skin edges are aligned in a horizontal plane, embedded in OCT&#169;, and placed on a cryostat chuck.<br> (D) Tissue is sectioned in a cryostat into thin frozen sections.<br> (E) Mohs frozen sections stained with hematoxylin and eosin are examined and residual tumor is marked on the Mohs map.</div><div id=\"graphicVersion\">Graphic 58386 Version 1.0</div></div></div>"},"58389":{"type":"graphic_figure","displayName":"Heart chamber anatomy PI","title":"Chambers and valves of the heart","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Chambers and valves of the heart</div><div class=\"cntnt\"><img style=\"width:536px; height:526px;\" src=\"images/PI/58389_Heart_chamber_anatomy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The heart has four main sections, or \"chambers.\" The top two chambers are called the right atrium and left atrium. The bottom two chambers are called the right and left ventricles. Each of these chambers has a valve that keeps blood flowing in one direction. The valves in this picture appear in gray. When the heart is working normally, blood comes in from the body through the right atrium and into the right ventricle. From there it goes to the lungs, where it picks up oxygen. Then the blood comes back through the left atrium, into the left ventricle, and back out to the body through a blood vessel called the aorta. The aorta appears in red. If a valve doesn't work properly, it will either let blood flow backwards in the wrong direction or not let enough blood flow forwards.</div><div id=\"graphicVersion\">Graphic 58389 Version 12.0</div></div></div>"},"58390":{"type":"graphic_picture","displayName":"Pancreas histology in SDS","title":"Pancreas histology in Shwachman-Diamond Syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreas histology in Shwachman-Diamond Syndrome</div><div class=\"cntnt\"><img style=\"width:370px; height:576px;\" src=\"images/PEDS/58390_Pancreas_histology_in_SDS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A pancreatic duct is shown (center). <br />(A) Pancreatic biopsy in a six-year-old boy with Shwachman-Diamond Syndrome shows extensive replacement of the exocrine pancreas by adipose tissue with remaining small islands of parenchyma. <br />(B) Extensive fat surrounding acini (large arrows) with poorly granulated exocrine cells and naked islets (small arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Shimamura A. Shwachman-Diamond Syndrome. Seminars in Hematology 2006; 43:178. Copyright ©2006 Elsevier.</div><div id=\"graphicVersion\">Graphic 58390 Version 3.0</div></div></div>"},"58391":{"type":"graphic_table","displayName":"Genetic neuropathies","title":"Genetically determined neuropathies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetically determined neuropathies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Genetic disorder</td> <td class=\"subtitle1\">Basic process</td> <td class=\"subtitle1\">Other features</td> <td class=\"subtitle1\">Other systems involved</td> </tr> <tr> <td>CMT type 1</td> <td>Demyelinating</td> <td>Hypertrophic change with onion bulbs; severe slowing of conduction velocity in both the motor and sensory nerves </td> <td>--</td> </tr> <tr> <td>CMT type 2</td> <td>Axonal</td> <td>Normal or mildly reduced nerve conduction velocity with decreased amplitude </td> <td>--</td> </tr> <tr> <td>Hereditary amyloid polyneuropathies</td> <td>Axonal</td> <td>Small-fiber involvement; endoneurial amyloid deposition</td> <td>In some families: cornea, kidneys, heart</td> </tr> <tr> <td>Hereditary sensory neuropathy type I</td> <td>Neuronopathic</td> <td>Dorsal root ganglia neurons selectively involved</td> <td>Sensorineural deafness (some families)</td> </tr> <tr> <td>Porphyric neuropathy</td> <td>Axonal</td> <td>Neuropathy part of attacks; may be recurrent</td> <td>Widespread cellular abnormality</td> </tr> <tr> <td>Hereditary liability to pressure palsy</td> <td>Demyelinating</td> <td>Tomaculous changes in myelin</td> <td>--</td> </tr> <tr> <td>Fabry disease</td> <td>Neuronopathic</td> <td>Sensory neuropathy, small dorsal root ganglia neurons</td> <td>Kidney, skin, lung</td> </tr> <tr> <td>CMT 1, X-linked</td> <td>Demyelinating</td> <td>Heterozygote females have symptoms</td> <td>--</td> </tr> <tr> <td>Adrenomyeloneuropathy</td> <td>?Axonal</td> <td>Mild neuropathy, spastic paraparesis, baldness, hypogonadism</td> <td>Adrenal cortex, cerebral white matter, spinal cord</td> </tr> <tr> <td>Hereditary sensory neuropathy type II</td> <td>Neuronopathic</td> <td>Dorsal root ganglia neurons selectively involved</td> <td>--</td> </tr> <tr> <td>D&#233;j&#233;rine-Sottas syndrome</td> <td>Demyelinating</td> <td>Hypertrophic change with onion bulb formation</td> <td>May be mentally retarded</td> </tr> <tr> <td>CMT type 4A</td> <td>Demyelinating</td> <td>Hypomyelination</td> <td>--</td> </tr> <tr> <td>Refsum disease</td> <td>Demyelinating</td> <td>Hypertrophic change with onion bulb formation</td> <td>Retinitis pigmentosa, ichthyosis, sensorineural deafness</td> </tr> <tr> <td>Ataxia-telangiectasia</td> <td>Axonal</td> <td>Neuropathy moderate</td> <td>Cell nuclear aneuploidy, skin and scleral telangiectasia, cerebellar atrophy, immunopathy</td> </tr> <tr> <td>Abetalipoproteinemia</td> <td>Neuronopathic</td> <td>Large dorsal root ganglia neurons</td> <td>Retinitis pigmentosa, acanthocytosis of red blood cells</td> </tr> <tr> <td>Giant axonal neuropathy</td> <td>Axonal</td> <td>Massive segmented accumulation of neurofilaments in axons</td> <td>Slowly progressive encephalopathy with Rosenthal fibers</td> </tr> <tr> <td>Metachromatic leukodystrophy</td> <td>Demyelinating</td> <td>Schwannopathy with cerebroside accumulation</td> <td>Cerebral white matter disease predominates</td> </tr> <tr> <td>Friedrich ataxia</td> <td>Axonal</td> <td>Spinocerebellar and corticospinal tracts involved; also primary sensory neurons</td> <td>Cardiomyopathy (usual cause of death)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CMT: Charcot-Marie-Tooth disease</div><div class=\"graphic_reference\">Modified with data from: Fauci AS, Braunwald E, Isselbacher KJ, et al (Eds). Harrison's Principles of Internal Medicine, 14th ed, McGraw-Hill Company, Inc., New York, 1998, p.2460.</div><div id=\"graphicVersion\">Graphic 58391 Version 4.0</div></div></div>"},"58392":{"type":"graphic_figure","displayName":"Air exchange lungs","title":"How air is exchanged in the lungs","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">How air is exchanged in the lungs</div><div class=\"cntnt\"><img style=\"width:460px; height:443px;\" src=\"images/PULM/58392_Air_exchange_lungs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts how oxygen (02) and carbon dioxide (CO2) pass between the alveloi (inside the lung) and the capillaries (the blood stream).</div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Co. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58392 Version 1.0</div></div></div>"},"58394":{"type":"graphic_diagnosticimage","displayName":"Pulmonary edema PA","title":"Hydrostatic pulmonary edema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hydrostatic pulmonary edema</div><div class=\"cntnt\"><img style=\"width:365px; height:298px;\" src=\"images/PULM/58394_Pulmonary_edema_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pulmonary edema in a &quot;butterfly distribution&quot; due to left ventricular failure. Chest radiograph shows large perihilar opacities in patient with enlarged cardiac silhouette.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 58394 Version 5.0</div></div></div>"},"58395":{"type":"graphic_diagnosticimage","displayName":"Thoracic aortic dissection on reconstructed computed tomography","title":"Thoracic aortic dissection on reconstructed computed tomography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thoracic aortic dissection on reconstructed computed tomography</div><div class=\"cntnt\"><img style=\"width:360px; height:259px;\" src=\"images/CARD/58395_Aortic_dissection_Spiral_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal plane reconstruction of transverse and descending thoracic aorta showing the true (TL) and false (FL) lumens of the same patient as the previous CT.</div><div class=\"graphic_reference\">Courtesy of Vassilios Raptopoulos, MD.</div><div id=\"graphicVersion\">Graphic 58395 Version 3.0</div></div></div>"},"58396":{"type":"graphic_figure","displayName":"Survival decompensated HBV","title":"Survival after decompensation in HBV-related cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Survival after decompensation in HBV-related cirrhosis</div><div class=\"cntnt\"><img style=\"width:351px; height:213px;\" src=\"images/GAST/58396_Survival_decompensated_HBV.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative probability of survival in patients with cirrhosis related to hepatitis B virus (HBV) infection after the first major complication.</div><div class=\"graphic_reference\">Data from: Fattovich G, Giustina G, Schalm SW, et al. Hepatology 1995; 21:77.</div><div id=\"graphicVersion\">Graphic 58396 Version 2.0</div></div></div>"},"58397":{"type":"graphic_figure","displayName":"Malaria life cycle","title":"<EM>Plasmodium</EM> life cycle","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\"><EM>Plasmodium</EM> life cycle</div><div class=\"cntnt\"><img style=\"width:542px; height:579px;\" src=\"images/ID/58397_Malaria_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><STRONG>(1)</STRONG> <EM>Plasmodium</EM>-infected <EM>Anopheles </EM>mosquito bites a human and transmits sporozoites into the bloodstream. <STRONG>(2)</STRONG> Sporozoites migrate through the blood to the liver where they invade hepatocytes and divide to form multinucleated schizonts (preerythrocytic stage). <STRONG>(3) </STRONG>Hypnozoites are a quiescent stage in the liver that exist only in the setting of <EM>P. vivax </EM>and <EM>P. ovale </EM>infection. This liver stage does not cause clinical symptoms, but with reactivation and release into the circulation, late onset or relapsed disease can occur up to many months after initial infection. <STRONG>(4)</STRONG> The schizonts rupture and release merozoites into the circulation where they invade red blood cells. Within red cells, merozoites mature from ring forms to trophozoites to multinucleated schizonts (erythrocytic stage). <STRONG>(5)</STRONG> Some merozoites differentiate into male or female gametocytes. These cells are ingested by the <EM>Anopheles</EM> mosquito and mature in the midgut, where sporozoites develop and migrate to the salivary glands of the mosquito. The mosquito completes the cycle of transmission by biting another host.</div><div id=\"graphicVersion\">Graphic 58397 Version 4.0</div></div></div>"},"58400":{"type":"graphic_figure","displayName":"Normal permanent tooth eruption","title":"Age of normal permanent tooth eruption","html":"<div class=\"graphic\"><div style=\"width: 656px\" class=\"figure\"><div class=\"ttl\">Age of normal permanent tooth eruption</div><div class=\"cntnt\"><img style=\"width:636px; height:322px;\" src=\"images/PEDS/58400_Norm_perm_tooth_eruptn_ed1.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Wright JT. Normal formation and development defects of the human dentition. Pediatr Clin North Am 2000; 47:975. Copyright © 2000 WB Saunders.</div><div id=\"graphicVersion\">Graphic 58400 Version 5.0</div></div></div>"},"58401":{"type":"graphic_table","displayName":"Tips for specific patient impairments","title":"Tips to address specific impairments that may impede patient-physician communication","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tips to address specific impairments that may impede patient-physician communication</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Impairment</td> <td class=\"subtitle1\">Recommendations</td> <td class=\"subtitle1\">Helpful material, resources, or personnel</td> </tr> <tr class=\"divider_bottom\"> <td>Hearing</td> <td> <p>Ask the patient: \"Can you hear me okay the way I'm speaking now?\"</p> <p>Speak slowly and clearly, but don't over-exaggerate words.</p> <p>Face the patient to allow lip-reading.</p> <p>As you increase the volume of your voice, try to keep pitch low (higher frequencies are more impaired in presbycusis).</p> <p>Minimize ambient noise.</p> </td> <td> <p>Portable amplifiers*</p> <p>Written instructions or educational material</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Vision</td> <td> <p>Avoid communication that relies on gestures: \"Place your urine sample over there\" or \"Can you do this with your hands?\"</p> <p>Be aware that the patient may miss subtle body language or facial expressions (a smile or an empathic nod). Use words to share those emotions.</p> <p>If you offer a hand, tell the patient so he/she can return the gesture. Likewise, tell the patient when you enter and leave the room.</p> <p>If there are multiple people in the room, speak the patient's name to signify that you are addressing him/her.</p> </td> <td> <p>Large-print forms and patient education material</p> <p>Reading glasses/magnifiers available</p> <p>Audio-recorded information or personnel to read consent forms or other materials</p> </td> </tr> <tr> <td>Cognitive</td> <td> <p>Stick to the point.</p> <p>When questions are repeated, answer them again, just as you did the first time.</p> <p>Involve caregiver or companion when available and appropriate, but avoid excluding the patient.</p> <p>Write down key instructions and findings for the patient to take home and refer to later.</p> </td> <td> <p>Take-home education materials</p> <p>Nurses or other extended care providers to reinforce teaching and assess patient's understanding on issues discussed</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* If an amplifier is unavailable, you can place the ear pieces of your stethoscope into the patient's ears and speak into the bell.</div><div id=\"graphicVersion\">Graphic 58401 Version 2.0</div></div></div>"},"58402":{"type":"graphic_diagnosticimage","displayName":"Normal foot lateral","title":"Standard lateral radiograph of foot","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Standard lateral radiograph of foot</div><div class=\"cntnt\"><img style=\"width:540px; height:312px;\" src=\"images/EM/58402_Normal_foot_lateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 58402 Version 2.0</div></div></div>"},"58403":{"type":"graphic_table","displayName":"Changing practice behavior","title":"Options for changing clinicians' practice behavior*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Options for changing clinicians' practice behavior*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Education</td> </tr> <tr> <td>Passive: Providing information by CME, journals, books, electronic media</td> </tr> <tr> <td>Active: Provide answers to questions as they arise (\"just-in-time learning\")</td> </tr> <tr> <td class=\"subtitle1_single\">Change the work environment</td> </tr> <tr> <td>Make it easier to do the right thing</td> </tr> <tr> <td>Case managers</td> </tr> <tr> <td class=\"subtitle1_single\">Feedback on performance</td> </tr> <tr> <td>Practice pattern reports for physician's use only</td> </tr> <tr> <td>Public report cards: HEDIS and others</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical practice guidelines</td> </tr> <tr> <td>Authoritative, recommendations, tailored to local situation</td> </tr> <tr> <td>Should include an evidence-based rationale</td> </tr> <tr> <td class=\"subtitle1_single\">Local opinion leaders</td> </tr> <tr> <td>Informal, disease-specific network of respected colleagues</td> </tr> <tr> <td class=\"subtitle1_single\">Persuasion</td> </tr> <tr> <td>\"Academic detailing\" methods similar to advertisements</td> </tr> <tr> <td class=\"subtitle1_single\">Economic incentives/disincentives</td> </tr> <tr> <td>Capitation, risk contracts</td> </tr> <tr> <td>Tying compensation to performance</td> </tr> <tr> <td class=\"subtitle1_single\">Change patients' expectations</td> </tr> <tr> <td>Popular media, books, patient help hotlines</td> </tr> <tr> <td>Direct-to-patient marketing</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CME: Continuing Medical Education;&nbsp;HEDIS: Healthcare Effectiveness Data and Information Set.<br />* In descending order of strength.</div><div id=\"graphicVersion\">Graphic 58403 Version 2.0</div></div></div>"},"58405":{"type":"graphic_figure","displayName":"ACE inhibitors improve outcome after MI","title":"ACE inhibitors improve outcome after a myocardial infarction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">ACE inhibitors improve outcome after a myocardial infarction</div><div class=\"cntnt\"><img style=\"width:369px; height:247px;\" src=\"images/CARD/58405_Meta_analysis_ACEI_LV_dysfn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A meta-analysis of 5966 patients with left ventricular dysfunction after a myocardial infarction enrolled in the SAVE, AIRE, and TRACE trials shows that after a median follow-up of 31 months there is a significant reduction in mortality with an angiotensin converting enzyme (ACE) inhibitor (23.4 versus 29 percent, odds ratio 0.74, p &lt;0.0001). There is a continuing divergence in the mortality curves during follow-up that exceeds four years.</div><div class=\"graphic_reference\">Data from Flather MD, Yusuf S, Kober L, et al. Lancet 2000; 355:1575.</div><div id=\"graphicVersion\">Graphic 58405 Version 3.0</div></div></div>"},"58406":{"type":"graphic_table","displayName":"Indications for bronchoscopy","title":"Indications for bronchoscopy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for bronchoscopy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Inspection</td> </tr> <tr> <td class=\"indent1\">Cough (persistent, unexplained)</td> </tr> <tr> <td class=\"indent1\">Hemoptysis</td> </tr> <tr> <td class=\"indent1\">Wheeze (localized/fixed)</td> </tr> <tr> <td class=\"indent1\">Diaphragmatic paralysis*</td> </tr> <tr> <td class=\"indent1\">Unexplained hoarseness and/or vocal cord paralysis/stridor</td> </tr> <tr> <td class=\"indent1\">Suspected tracheo-esophageal fistula</td> </tr> <tr> <td class=\"indent1\">Chest trauma</td> </tr> <tr> <td class=\"indent1\">Suspected tracheomalacia</td> </tr> <tr> <td class=\"indent1\">Toxic inhalation or burn injury</td> </tr> <tr> <td class=\"indent1\">Verify tracheostomy or endotracheal tube placement</td> </tr> <tr> <td class=\"indent1\">Evaluate precancerous lesions (autofluorescence)</td> </tr> <tr> <td class=\"indent1\">Donor transplant lung evaluation</td> </tr> <tr> <td class=\"subtitle1_single\">May require biopsy, BAL, or other procedure</td> </tr> <tr> <td class=\"indent1\">Focal/unilateral hyperinflation or hyperlucency</td> </tr> <tr> <td class=\"indent1\">Localization of broncho-pleural fistula</td> </tr> <tr> <td class=\"indent1\">Atelectasis (persistent)</td> </tr> <tr> <td class=\"sublist2_start\">Abnormal chest radiograph</td> </tr> <tr> <td class=\"sublist2\">Pleural effusion<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist2\">Paratracheal/mediastinal/hilar mass</td> </tr> <tr> <td class=\"sublist2\">Parenchymal mass/nodule</td> </tr> <tr> <td class=\"sublist2\">Diagnosis of etiology of pneumonia</td> </tr> <tr> <td class=\"sublist3\">Recurrent/nonresolving (imunocompetent host)</td> </tr> <tr> <td class=\"sublist3\">Nosocomial</td> </tr> <tr> <td class=\"sublist3\">Immunocompromised host</td> </tr> <tr> <td class=\"indent1\">Foreign body in airway (known or suspected)</td> </tr> <tr> <td class=\"indent1\">Evaluation for rejection in lung transplant recipient</td> </tr> <tr> <td class=\"indent1\">Delivery of brachytherapy</td> </tr> <tr> <td class=\"indent1\">Research</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Utility/yield for this indication are controversial.<br />&para; Diagnostic yield &ge;40 percent only when effusion is massive or associated with hemoptysis, mass, or atelectasis.</div><div id=\"graphicVersion\">Graphic 58406 Version 3.0</div></div></div>"},"58407":{"type":"graphic_figure","displayName":"Anatomy of the foot","title":"Anatomy of the foot","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Anatomy of the foot</div><div class=\"cntnt\"><img style=\"width:498px; height:717px;\" src=\"images/SURG/58407_Anatomy_of_the_foot.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 58407 Version 5.0</div></div></div>"},"58408":{"type":"graphic_figure","displayName":"The law of Laplace","title":"Law of Laplace","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Law of Laplace</div><div class=\"cntnt\"><img style=\"width:342px; height:97px;\" src=\"images/CARD/58408_The_law_of_Laplace.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">According to the law of Laplace, left ventricular (LV) wall stress is directly proportional to the product of cavity pressure and radius and inversely proportional to wall thickness. An elevation in LV cavity pressure (as with aortic stenosis or hypertension) causes an increase in wall stress. If a hypertrophic response occurs, increasing thickness can return wall stress to normal. With LV chamber enlargement (as with mitral regurgitation, dilated cardiomyopathy, or infarct expansion) wall stress increases, unless there is an appropriate hypertrophic response.</div><div id=\"graphicVersion\">Graphic 58408 Version 2.0</div></div></div>"},"58409":{"type":"graphic_table","displayName":"Causes of diarrhea in AIDS","title":"Causes of diarrhea in patients with AIDS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of diarrhea in patients with AIDS</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Protozoal</td> </tr> <tr> <td>Microsporidium*</td> </tr> <tr> <td>Cryptosporidium*</td> </tr> <tr> <td>Isospora belli</td> </tr> <tr> <td>Giardia lamblia</td> </tr> <tr> <td>Entamoeba histolytica</td> </tr> <tr> <td>Leishmania donovani</td> </tr> <tr> <td>Blastocystis hominis</td> </tr> <tr> <td>Cyclospora sp</td> </tr> <tr> <td class=\"subtitle1_single\">Viral</td> </tr> <tr> <td>Cytomegalovirus*</td> </tr> <tr> <td>Herpes simplex</td> </tr> <tr> <td>Adenovirus</td> </tr> <tr> <td>Rotavirus</td> </tr> <tr> <td>Norwalk</td> </tr> <tr> <td>HIV</td> </tr> <tr> <td class=\"subtitle1_single\">Gut neoplasms</td> </tr> <tr> <td>Lymphoma</td> </tr> <tr> <td>Kaposi's sarcoma</td> </tr> <tr> <td class=\"subtitle1_single\">Pancreatic insufficiency</td> </tr> <tr> <td class=\"subtitle2_single\">Infectious pancreatitis</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus</td> </tr> <tr> <td class=\"indent1\">Mycobacterium avium complex</td> </tr> <tr> <td class=\"subtitle2_single\">Drug-induced pancreatitis</td> </tr> <tr> <td class=\"indent1\">Didanosine</td> </tr> <tr> <td class=\"indent1\">Pentamidine</td> </tr> <tr> <td class=\"subtitle2_single\">Tumor invasion</td> </tr> <tr> <td class=\"indent1\">Lymphoma</td> </tr> <tr> <td class=\"indent1\">Kaposi's sarcoma</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Bacterial</td> </tr> <tr> <td>Salmonella*</td> </tr> <tr> <td>Campylobacter*</td> </tr> <tr> <td>Mycobacterium avium complex</td> </tr> <tr> <td>Mycobacterium tuberculosis</td> </tr> <tr> <td>Clostridium difficile</td> </tr> <tr> <td>Shigella</td> </tr> <tr> <td>Small bowel bacterial overgrowth</td> </tr> <tr> <td>Vibrio sp</td> </tr> <tr> <td class=\"subtitle1_single\">Fungal</td> </tr> <tr> <td>Histoplasmosis</td> </tr> <tr> <td>Coccidiomycosis</td> </tr> <tr> <td class=\"subtitle1_single\">Idiopathic</td> </tr> <tr> <td>\"AIDS enteropathy\"</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* More frequent.</div><div id=\"graphicVersion\">Graphic 58409 Version 3.0</div></div></div>"},"58411":{"type":"graphic_table","displayName":"Renal dosing of cephalosporins","title":"Dose of parenteral cephalosporins with adjustments for renal failure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dose of parenteral cephalosporins with adjustments for renal failure</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Drug</td> <td class=\"subtitle1\" colspan=\"3\">Glomerular filtration rate (GFR) mL/min*</td> <td class=\"subtitle1\" rowspan=\"2\">Removal by dialysis</td> </tr> <tr> <td class=\"subtitle2\">&#62;50 (normal renal function)</td> <td class=\"subtitle2\">10-50</td> <td class=\"subtitle2\">&#60;10</td> </tr> <tr> <td>Cefazolin</td> <td>1-2 g Q 8 h</td> <td>0.5-1 g Q 12 h</td> <td>0.5-1 g Q 24 h</td> <td>Yes (HD), No (PD)</td> </tr> <tr> <td>Cefuroxime</td> <td>0.75-1.5 g Q 6-8 h</td> <td>0.75-1.5 g Q 8-12 h</td> <td>0.75 g Q 24 h</td> <td>Yes (HD, PD)</td> </tr> <tr> <td>Cefoxitin</td> <td>1-2 g Q 4-6 h</td> <td>1-2 g Q 8-12 h</td> <td>0.5-1 g Q 24 h</td> <td>Yes (HD), No (PD)</td> </tr> <tr> <td>Cefotetan</td> <td>1-2 g Q 12 h</td> <td>1-2 g Q 24 h</td> <td>1-2 g Q 48 h</td> <td>Yes (HD)</td> </tr> <tr> <td>Cefotaxime</td> <td>1-2 g Q 6 h</td> <td>1-2 g Q 8-12 h</td> <td>1-2 g Q 12-24 h</td> <td>Yes (HD), No (PD)</td> </tr> <tr> <td>Ceftriaxone</td> <td>1-2 g Q 12-24 h</td> <td>NC</td> <td>NC</td> <td>No (HD)</td> </tr> <tr> <td>Ceftazidime</td> <td>1-2 g Q 8 h</td> <td>1-2 g Q 12-24 h</td> <td>0.5-1 g Q 24-48 h</td> <td>Yes (HD, PD)</td> </tr> <tr> <td>Cefepime</td> <td>1-2 g Q 8-12 h</td> <td>0.5-2 g Q 12-24 h</td> <td>0.25-1 g Q 24 h</td> <td>Yes (HD)</td> </tr> <tr> <td>Ceftaroline<sup>&#916;</sup></td> <td>600 mg Q 12 h</td> <td>300-400 mg Q 12 h</td> <td>200-400 mg Q 12 h</td> <td>Yes (HD)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">HD: hemodialysis; PD: peritoneal dialysis; NC: no change.</div><div class=\"graphic_footnotes\">* Usual adult dosing and renal adjustments shown are for moderate to severe infections. For specific dosing recommendations, see related disease treatment topics and Lexi-Comp drug information included with UpToDate.<br />&para; Not available in the United States or Canada.<br />&Delta; 1 hour infusion.</div><div id=\"graphicVersion\">Graphic 58411 Version 9.0</div></div></div>"},"58414":{"type":"graphic_picture","displayName":"Electron microscopy in minimal change disease","title":"Electron microscopy in minimal change disease","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electron microscopy in minimal change disease</div><div class=\"cntnt\"><img style=\"width:396px; height:252px;\" src=\"images/NEPH/58414_Minimal_change_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph in minimal change disease showing a normal glomerular basement membrane (GBM), no immune deposits, and the characteristic widespread fusion of the epithelial cell foot processes (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 58414 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Electron micrograph of a normal glomerulus</div><div class=\"cntnt\"><img style=\"width:377px; height:266px;\" src=\"images/NEPH/50018_Normal_glomerulus_EM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron-dense deposits are present. Two normal platelets are seen in the capillary lumen.</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 50018 Version 7.0</div></div></div>"},"58418":{"type":"graphic_table","displayName":"Examples of patterns of tryptase elevations and interpretations","title":"Examples of patterns of tryptase elevations and interpretations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of patterns of tryptase elevations and interpretations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"4\">If acute levels of total and mature tryptase are available:</td> </tr> <tr> <td class=\"subtitle2\">Total<br /> (normal 1 to 15 ng/mL)</td> <td class=\"subtitle2\">Mature<br /> (&#60;1 ng/mL)</td> <td class=\"subtitle2\">Total/mature</td> <td class=\"subtitle2\">Findings are consistent with:</td> </tr> <tr> <td class=\"centered\">3</td> <td class=\"centered\">&#60;1</td> <td class=\"centered\">ND</td> <td class=\"centered\">Normal</td> </tr> <tr> <td class=\"centered\">10</td> <td class=\"centered\">&#60;1</td> <td class=\"centered\">ND</td> <td class=\"centered\">Normal*</td> </tr> <tr> <td class=\"centered\">15</td> <td class=\"centered\">5</td> <td class=\"centered\">3</td> <td class=\"centered\">Anaphylaxis</td> </tr> <tr> <td class=\"centered\">75</td> <td class=\"centered\">65</td> <td class=\"centered\">1.2</td> <td class=\"centered\">Anaphylaxis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\"><span style=\"color: black;\">39</span></td> <td class=\"centered\"><span style=\"color: black;\">&#60;1</span></td> <td class=\"centered\"><span style=\"color: black;\">&#62;20</span></td> <td class=\"centered\">Systemic mastocytosis*</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"4\">If acute and baseline levels of total tryptase (only) are available:</td> </tr> <tr> <td class=\"subtitle2\">Acute total tryptase</td> <td class=\"subtitle2\" colspan=\"2\">Baseline total tryptase either before onset or at least<br /> 24 hours after resolution of signs and symptoms</td> <td class=\"subtitle2\">Interpretation consistent with:</td> </tr> <tr> <td class=\"centered\" rowspan=\"2\">5</td> <td class=\"centered\" colspan=\"2\">4</td> <td class=\"centered\">Normal</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">1</td> <td class=\"centered\">Anaphylaxis</td> </tr> <tr> <td class=\"centered\" rowspan=\"2\">10</td> <td class=\"centered\" colspan=\"2\">9</td> <td class=\"centered\">Normal*</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">5</td> <td class=\"centered\">Anaphylaxis</td> </tr> <tr> <td class=\"centered\" rowspan=\"2\">15</td> <td class=\"centered\" colspan=\"2\">14</td> <td class=\"centered\">Normal*</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">5</td> <td class=\"centered\">Anaphylaxis</td> </tr> <tr> <td class=\"centered\" rowspan=\"2\">75</td> <td class=\"centered\" colspan=\"2\">15</td> <td class=\"centered\">Anaphylaxis*</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">65</td> <td class=\"centered\">Systemic mastocytosis</td> </tr> <tr> <td class=\"centered\" rowspan=\"2\">22</td> <td class=\"centered\" colspan=\"2\">13</td> <td class=\"centered\">Anaphylaxis*</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">25</td> <td class=\"centered\">Systemic mastocytosis*</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Measurements of total and mature tryptase (top table) or total alone (bottom table) can provide support to the clinical diagnosis of anaphylaxis. Tryptase values alone are not sufficient to make the diagnosis, however. If only measurements of total tryptase are available, a baseline sample occurring prior to the acute events should be retrieved or a follow-up sample should be drawn after full resolution of symptoms in order to accurately interpret the findings. High baseline tryptase levels increase the risk for more severe anaphylaxis and increase the likelihood of underlying clonal mast cell disorders when higher than 11.4 ng/mL.</div><div class=\"graphic_footnotes\"><FONT color=black>*Alpha-trypasemia can be considered where baseline total tryptase levels are between 8 and 40 ng/mL.</FONT><br />ND: not determined due to a denominator <SPAN style=\"COLOR: black\">of &lt;1 and a normal total tryptase level.</SPAN></div><div id=\"graphicVersion\">Graphic 58418 Version 6.0</div></div></div>"},"58420":{"type":"graphic_figure","displayName":"Removal cholesteatoma with extension","title":"Removal of cholesteatoma with extension beyond the middle ear","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Removal of cholesteatoma with extension beyond the middle ear</div><div class=\"cntnt\"><img style=\"width:274px; height:480px;\" src=\"images/PEDS/58420_Removal_chlstma_w_extension.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When a cholesteatoma has extended beyond the accessible confines of the middle ear, it is necessary to remove cranial bone to reach the temporal bone spaces above and behind the middle ear. Panel A) The mastoid cortex is removed with a drill. Panel B) The mastoid cortex has been removed to expose a cholesteatoma of the middle ear, attic (pneumatized space just superior to the middle ear), and mastoid. The canal wall is left intact to separate the middle ear and mastoid (a canal-wall-up mastoidectomy).</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 58420 Version 3.0</div></div></div>"},"58421":{"type":"graphic_table","displayName":"Depression in AD","title":"Depression in Alzheimer-type dementia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Depression in Alzheimer-type dementia</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"sublist1_start\" rowspan=\"1\" colspan=\"1\">A. Three or more of the following\nsymptoms, present during the same two-week period, and representing a\nchange from a previous level of functioning. Either item-one or\nitem-two must be included:</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">1. Clinically significant depressed mood</td>\n\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">2. Decreased positive affect or pleasure in response to social contacts and usual activities</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">3. Social isolation or withdrawal </td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">4. Disturbed appetite </td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">5. Disturbed sleep </td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">6. Psychomotor retardation or agitation</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\"> 7. Irritability</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">8. Fatigue or loss of energy </td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\"> 9. Feelings of worthlessness, hopelessness, or inappropriate guilt</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">10. Recurrent thoughts of death or suicidal ideation, plan, or any attempt&nbsp;</td>\n    </tr>\n    <tr>\n\n      <td>B. Meets criteria for Alzheimer-type dementia</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td rowspan=\"1\" colspan=\"1\">C. Depressive symptoms cause clinically significant distress or disruption in function</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>D. Symptoms do not occur exclusively during an episode of delirium</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td rowspan=\"1\" colspan=\"1\">E. Symptoms are not due to a direct physiological effect from a substance (medication or drug of abuse)</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">F. Symptoms are not better accounted for by another condition</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Specify if: </td>\n\n      \n\n    </tr>\n\n    <tr>\n      <td class=\"sublist2\">Co-occuring onset: onset antedates or co-occurs with AD symptoms</td>\n    </tr>\n    <tr><td class=\"sublist2\">Post-AD onset: onset occurs after AD diagnosis</td></tr><tr>\n\n      <td class=\"sublist1\">Specify if: </td>\n\n      \n\n    </tr>\n    <tr>\n      <td class=\"sublist2\" rowspan=\"1\">With psychosis of AD</td>\n    </tr>\n    <tr><td class=\"sublist2\">With other significant behaviorial signs or symptoms</td></tr><tr>\n      <td class=\"sublist2\">With past history of mood disorder</td>\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 58421 Version 1.0</div></div></div>"},"58422":{"type":"graphic_picture","displayName":"Finkelstein test de Quervain","title":"Finkelstein test for de Quervain tendinopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Finkelstein test for de Quervain tendinopathy</div><div class=\"cntnt\"><img style=\"width:418px; height:284px;\" src=\"images/RHEUM/58422_Finkelstein_test_deQuervain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The examiner gently rotates the patient's wrist ulnarly (arrow) while the patient's fingers are folded over the thumb.</div><div class=\"graphic_reference\">From Sheon, RP, Moskowitz, RW, Goldberg, VM, Soft Tissue Rheumatic Pain: Recognition, Management, Prevention. 3rd ed, Williams &amp; Wilkins, Baltimore 1996.</div><div id=\"graphicVersion\">Graphic 58422 Version 5.0</div></div></div>"},"58427":{"type":"graphic_picture","displayName":"PKDL plaques","title":"Post-kala-azar dermal leishmaniasis (PKDL) plaque-like lesions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Post-kala-azar dermal leishmaniasis (PKDL) plaque-like lesions</div><div class=\"cntnt\"><img style=\"width:350px; height:270px;\" src=\"images/ID/58427_PKDL_plaques.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Raised plaque-like lesions of PKDL on the face of a 60-year-old Bangladeshi man. The perioral location is frequently the first area affected in PKDL.</div><div class=\"graphic_reference\">Reproduced with permission from: Caryn Bern, MD.</div><div id=\"graphicVersion\">Graphic 58427 Version 3.0</div></div></div>"},"58428":{"type":"graphic_table","displayName":"Characteristics of RTA","title":"Characteristics of the different types of renal tubular acidosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of the different types of renal tubular acidosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Hypokalemic RTA</td> <td class=\"subtitle1\" colspan=\"2\">Hyperkalemic RTA</td> </tr> <tr> <td class=\"subtitle1\">Type 1 RTA</td> <td class=\"subtitle1\">Type 2 RTA</td> <td class=\"subtitle1\">Hypoaldosteronism (Type 4 RTA)</td> <td class=\"subtitle1\">Distal tubule volume defects</td> </tr> <tr> <td><strong>Primary defect</strong></td> <td>Impaired distal acidification.</td> <td>Reduced proximal&nbsp;HCO<sub>3</sub> reabsorption.</td> <td>Decreased aldosterone secretion or aldosterone resistance.</td> <td>Reduced sodium reabsorption.</td> </tr> <tr> <td><strong>Plasma HCO<sub>3</sub></strong></td> <td> <p>Variable.</p> May be below 10 mEq/L. </td> <td>Usually 12 to 20 mEq/L.</td> <td>Usually greater than 17 mEq/L.</td> <td>Usually greater than 17 mEq/L.</td> </tr> <tr> <td><strong>Urine pH</strong></td> <td>Greater than 5.3.</td> <td> <p>Variable.</p> Greater than 5.3 if the serum HCO<sub>3</sub> exceeds the tubule's&nbsp;HCO<sub>3</sub> reabsorptive threshold. Less than 5.3 when the serum HCO<sub>3</sub> is reduced to levels that can be largely reabsorbed despite defective proximal tubule reabsorptive mechanisms. </td> <td> <p>Variable.</p> Usually greater than 5.3. </td> <td> <p>Variable.</p> Usually greater than 5.3. </td> </tr> <tr> <td><strong>Plasma potassium</strong></td> <td>Usually reduced, but hyperkalemic forms exist; hypokalemia largely corrects with alkali therapy.</td> <td>Reduced; made worse by bicarbonaturia induced by alkali therapy.</td> <td>Increased; correcting the hyperkalemia alone will improve the acidosis by increasing ammonium availability.</td> <td>Increased; correcting the hyperkalemia alone will improve the acidosis by increasing ammonium availability.</td> </tr> <tr> <td><strong>Urine anion gap</strong></td> <td>Positive</td> <td>Negative</td> <td>Positive</td> <td>Positive</td> </tr> <tr> <td><strong>Urine calcium/creatinine ratio</strong></td> <td>Increased</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> </tr> <tr> <td><strong>Nephrolithiasis/nephrocalcinosis</strong></td> <td>Yes</td> <td>No</td> <td>No</td> <td>No</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RTA: renal tubular acidosis; HCO<SUB>3</SUB>: bicarbonate.</div><div id=\"graphicVersion\">Graphic 58428 Version 8.0</div></div></div>"},"58432":{"type":"graphic_table","displayName":"Supplies for skin biopsy","title":"Supplies for skin biopsy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Supplies for skin biopsy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td>Isopropyl alcohol, povidone-iodine, or chlorhexadine</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Sterile gauze, 3x3 or 4x4, and sterile cotton-tip\napplicators</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cloth or plastic fenestrated drape</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Syringes, 1 and 3 mL</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Needles, 22-gauge (to draw up solutions), 30-gauge (for\ninjection)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lidocaine, 1 or 2 percent, with and without\nepinephrine. May buffer with 1 part NaHCO3 to 9 parts lidocaine, but\nmust be refrigerated and disposed after 30 days</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Disposable surgical blades, 15 or 15c</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Disposable punches, 4, 6, and 8 mm</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Double-edge razor blade cut in half</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Small tissue forceps (Adson 4 3/4 inch, 1x2 teeth, 1 mm\ntip)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Small tissue scissors (Grade 3 3/4 inch or tenotomy)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Needle holders, 4 1/2 or 5 inch, smooth jaws, small tip\n(Webster 4 1/2 inch). Consider purchase of disposable suture kits with\nneedle holders, forceps, and scissors included.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>20 percent aluminum chloride</td>\n\n    </tr>\n\n    <tr>\n\n      <td>4-0 or 5-0 Nylon on C-17 or P-3 needles (4-0 for scalp)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Packaged alcohol swabs or tissues</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Antibiotic ointment or plain petrolatum</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Spot and rectangular Band-Aid</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Nonadherent dressings</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Paper tape</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Elastic wrap</td>\n\n    </tr>\n\n    <tr>\n\n      <td>10 percent formalin specimen bottle</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Surgical marking pen</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pathology request forms</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Patient instructions</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=61449&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Supplies_for_skin_biopsy.htm</title></head></div><div class=\"graphic_reference\">With permission from Alguire, PC, Mathes, BM, J Gen Intern Med 1998; 13:46.</div><div id=\"graphicVersion\">Graphic 58432 Version 1.0</div></div></div>"},"58434":{"type":"graphic_table","displayName":"Evaluation for transtracheal O2","title":"Patient evaluation for transtracheal oxygen","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient evaluation for transtracheal oxygen</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Assessment</td> <td class=\"subtitle1\">Rationale/decision making</td> </tr> <tr> <td>Is patient receiving optimal therapy?</td> <td>If not, optimize and reevaluate.</td> </tr> <tr> <td>Is disease process/O<sub>2</sub> requirement relatively stable or rapidly progressing suggesting a preterminal phase?</td> <td>If patient is in a preterminal phase of the disease, benefits of transtracheal oxygen may be short-term. TTO care may add to family burden, rather than help.</td> </tr> <tr> <td>What PaO<sub>2</sub> is achieved with 100 percent O<sub>2</sub>?</td> <td>Evaluate ability of 100 percent O<sub>2</sub> to raise PaO<sub>2</sub>. If 100 percent O<sub>2</sub> does not increase the PaO<sub>2</sub>, TTO is not indicated.</td> </tr> <tr> <td>Can the patient walk?</td> <td>Ability to walk without severe decompensation typically indicates sufficient airflow to clear mucus balls with coughing.</td> </tr> <tr> <td>Can periodic stripping be done, if needed?</td> <td>High TTO flows promote formation of mucus balls on the outside of the catheter. Airway obstruction can occur if this mucus is not removed by coughing or stripping. During Phase III when the tract is immature, patients using high-flow oxygen should have their catheter stripped (removed over guide wire) at periodic intervals to assess risk of mucus ball formation.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">O<sub>2</sub>: oxygen; PaO<sub>2</sub>: arterial tension of oxygen; TTO: transtracheal oxygen.</div><div id=\"graphicVersion\">Graphic 58434 Version 4.0</div></div></div>"},"58435":{"type":"graphic_movie","displayName":"Back leg raise video","title":"Strength exercise video: Back leg raise","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Strength exercise video: Back leg raise</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PC/58435_Backlegraisevideo.mp4\" style=\"width:480px;height:336px\"></div><img style=\"width:369px; height:297px;\" src=\"images/PC/58435_BacklegraiseexerimgPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This exercise strengthens your buttocks and lower back. For an added challenge, you can modify the exercise to improve your balance.<br> <ol> <li>Stand behind a sturdy chair, holding on for balance. Breathe in slowly. </li> <li>Breathe out and slowly lift one leg straight back without bending your knee or pointing your toes. Try not to lean forward. The leg you are standing on should be slightly bent. </li> <li>Hold position for one second. </li> <li>Breathe in as you slowly lower your leg. </li> <li>Repeat 10 to 15 times. </li> <li>Repeat 10 to 15 times with other leg. </li> <li>Repeat 10 to 15 more times with each leg. </li> </ol> As you progress, you may want to add ankle weights.</div><div class=\"graphic_reference\">Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: http://go4life.niapublications.org (Accessed December 2, 2011).</div><div id=\"graphicVersion\">Graphic 58435 Version 1.0</div></div></div>"},"58438":{"type":"graphic_diagnosticimage","displayName":"FNH Bopta scan","title":"Focal nodular hyperplasia of the liver seen on Gd-BOPTA scan","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Focal nodular hyperplasia of the liver seen on Gd-BOPTA scan</div><div class=\"cntnt\"><img style=\"width:432px; height:330px;\" src=\"images/GAST/58438_FNH_Bopta_scan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial T1-weighted magnetic resonance (MR) image of the liver showing focal nodular hyperplasia in the left lateral segment of the liver (arrow). This image was acquired three hours following intravenous administration of gadobenate dimeglumine&nbsp;(Gd-BOPTA). The bright signal intensity of the lesion is due to accumulation of the contrast agent to a greater extent within the lesion than in the adjacent liver parenchyma, and is not due to increased vascularity.</div><div class=\"graphic_reference\">Courtesy of Jonathan B Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 58438 Version 4.0</div></div></div>"},"58440":{"type":"graphic_figure","displayName":"Ig class switching","title":"Immunoglobulin class-switching","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Immunoglobulin class-switching</div><div class=\"cntnt\"><img style=\"width:477px; height:251px;\" src=\"images/ALLRG/58440_Class_switching.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Before class-switching. A rearranged VDJH gene is at the left, the first five CH genes are shown (and the&nbsp;ε pseudogene). All CH genes, except Cδ, have a 5' associated sequence called the switch (S) region, or switch sequence. These are the sites where DNA is cut during the switching process. <br />(B) The class-switching intermediate. Two switch sequences are juxtaposed, in this case Sµ and Sγ1. The intervening DNA is excised in a fashion similar to V gene recombination.</div><div class=\"graphic_footnotes\">D: diversity; J<SUB>H</SUB>: joining region of heavy chain; V<SUB>H</SUB>: joining segment of heavy chain.</div><div class=\"graphic_reference\">Reproduced with permission from Bona C, Bonilla FA. Textbook of Immunology, 2nd ed. Harwood Academic Publishers GmbH, Amsterdam 1996. Copyright © 1996 Overseas Publishers Association, NV. Permission granted by Gordon and Breach Publishers.</div><div id=\"graphicVersion\">Graphic 58440 Version 4.0</div></div></div>"},"58441":{"type":"graphic_diagnosticimage","displayName":"MRI Heidenhain CJD","title":"MRI of heidenhain variant CJD","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI of heidenhain variant CJD</div><div class=\"cntnt\"><img style=\"width:355px; height:373px;\" src=\"images/NEURO/58441_MRI_Heidenhain_CJD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Head MRI of a 65-year-old man with biopsy proven sporadic CJD (Heidenhain variant). Figure A is a T2 MRI that shows essentially normal signal intensity within the basal ganglia and throughout the brain. Figure B is a proton density MRI that shows increased cortical signal intensity within the right frontal lobe and bilateral medial occipital lobes. Figure C is a diffusion weighted MRI (DWI) that reveals more conspicuous involvement of the right frontal lobe and more extensive hyperintensities of the bilateral occipital lobes with no involvement of the basal ganglia. Figure D is a DWI rostral to the basal ganglia that shows extensive cortical involvement throughout the brain with more prominence posteriorly, as may be expected with the Heidenhain variant.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; CJD: Creutzfeldt-Jakob Disease.</div><div class=\"graphic_reference\">Courtesy of Eric D Schwartz, MD.</div><div id=\"graphicVersion\">Graphic 58441 Version 3.0</div></div></div>"},"58442":{"type":"graphic_figure","displayName":"Concentration of PIGF in pregnancy","title":"Concentration of PIGF in various groups","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Concentration of PIGF in various groups</div><div class=\"cntnt\"><img style=\"width:525px; height:278px;\" src=\"images/OBGYN/58442_Concentration_PIGF_preeclam.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified from: Levine, RJ, Maynard, SE, Qian, C, et al. N Engl J Med 2004; 350:672.</div><div id=\"graphicVersion\">Graphic 58442 Version 2.0</div></div></div>"},"58443":{"type":"graphic_table","displayName":"Early primary tooth loss","title":"Conditions associated with premature primary tooth exfoliation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with premature primary tooth exfoliation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Oral manifestations</td> <td class=\"subtitle1\">Systemic manifestations</td> <td class=\"subtitle1\">Cause</td> </tr> <tr> <td>Hypophosphatasia (MIM #<a href=\"http://omim.org/entry/146300\" target=\"_blank\">146300</a> &#38; #<a href=\"http://omim.org/entry/241500\" target=\"_blank\">241500</a>)</td> <td>Tooth loss as early as one year of age, minimal soft-tissue inflammation, large dental pulp chambers, variable enamel hypoplasia</td> <td>Decreased alkaline phosphatase, severe cases can have bone manifestations, bowing of legs, short stature</td> <td>Autosomal dominant and recessive forms, mutations in tissue-nonspecific alkaline phosphatase gene</td> </tr> <tr> <td>Papillon-Lef&#232;vre syndrome (MIM #<a href=\"http://omim.org/entry/245000\" target=\"_blank\">245000</a>)</td> <td>Tooth loss beginning second to third year of life, marked soft-tissue inflammation, generalized alveolar bone loss</td> <td>Hyperkeratosis of palmar and plantar surfaces</td> <td>Autosomal recessive trait, mutation in cathepsin gene</td> </tr> <tr> <td>Cyclic neutropenia (MIM #<a href=\"http://omim.org/entry/162800\" target=\"_blank\">162800</a>)</td> <td>Severe erythematous gingivitis, can have rapid periodontal breakdown and bone loss</td> <td>Recurrent fevers, malaise, sore throat, anorexia, 21-day periodicity of decreased neutrophils</td> <td>Autosomal dominant trait, defect in neutrophil elastase</td> </tr> <tr> <td>Chediak-Higashi syndrome (MIM #<a href=\"http://omim.org/entry/214500\" target=\"_blank\">214500</a>)</td> <td>Ulcerations of oral mucosa, severe gingivitis, glossitis, periodontal breakdown and bone loss</td> <td>Partial albinism, neutropenia, recurrent infections of skin and respiratory tract, frequently lethal before age seven years</td> <td>Autosomal recessive trait, deficiency of natural killer lymphocytes</td> </tr> <tr> <td>Langerhans cell histiocytosis (histiocytosis X) (MIM <a href=\"http://omim.org/entry/604856\" target=\"_blank\">604856</a>)</td> <td>Ulcerative gingivitis, root exposure, and premature tooth mobility, typically starting with posterior teeth</td> <td>Bone lesions, multiorgan involvement, seborrheic scalp rash, diabetes insipidus, growth retardation</td> <td>Proliferation of Langerhans cell (dendritic histiocytes), immunologic dysregulation</td> </tr> <tr> <td>Aggressive&nbsp;periodontitis (MIM #<a href=\"http://omim.org/entry/170650\" target=\"_blank\">170650</a>)</td> <td>Variable gingival inflammation (localized minor to generalized severe), alveolar bone loss, typically starting with posterior teeth</td> <td>&nbsp;</td> <td>Autosomal dominant trait, leukocyte defect involving chemotaxis or phagocytosis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Wright JT. Pediatr Clin North Am 2000; 47:986. Copyright 2000 WB Saunders Company.</div><div id=\"graphicVersion\">Graphic 58443 Version 9.0</div></div></div>"},"58444":{"type":"graphic_figure","displayName":"Long term follow up iliac stenting","title":"Long term follow up iliac stenting","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Long term follow up iliac stenting</div><div class=\"cntnt\"><img style=\"width:453px; height:253px;\" src=\"images/CARD/58444_Stenting_iliac_stenosis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this trial, 279 patients with intermittent claudication due to iliac artery stenosis were randomized to primary stenting or selective stenting for a residual gradient after angioplasty. The two groups had the same hemodynamic parameters at baseline, as determined by ankle-brachial index (ABI) measured after treadmill testing. At two years, the distribution of ABI was similar in the two groups.</div><div class=\"graphic_reference\">Data from Tetteroo, E, van der Graaf, Y, Bosch, JL, et al, for the Dutch Iliac Stent Trial Study Group, Lancet 1998; 351:1153.</div><div id=\"graphicVersion\">Graphic 58444 Version 2.0</div></div></div>"},"58445":{"type":"graphic_picture","displayName":"Seborrheic keratosis superficial","title":"Seborrheic keratosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Seborrheic keratosis</div><div class=\"cntnt\"><img style=\"width:504px; height:387px;\" src=\"images/DERM/58445_Seborrheic_keratosis_super.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large superficial seborrheic keratosis on the cheek of a 56-year-old woman.</div><div class=\"graphic_reference\">Reproduced with permisison from: the Dermatology Online Atlas, <a href=\"http://www.dermis.net/\" target=\"_blank\">www.dermis.net</a>. Copyright &#169; 2011. All rights reserved.</div><div id=\"graphicVersion\">Graphic 58445 Version 1.0</div></div></div>"},"58446":{"type":"graphic_picture","displayName":"Diffuse astrocytoma","title":"Diffuse astrocytoma","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Diffuse astrocytoma</div><div class=\"cntnt\"><img style=\"width:503px; height:376px;\" src=\"images/ONC/58446_Diffuse_astrocytoma_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histological features include the prominent eosinophilic cytoplasm in some astrocytic tumor cells (gemistocytes) as well as the fibrillary background.</div><div class=\"graphic_reference\">Courtesy of Dr. David Louis.</div><div id=\"graphicVersion\">Graphic 58446 Version 1.0</div></div></div>"},"58448":{"type":"graphic_algorithm","displayName":"Medical management of GERD","title":"Medical management of gastroesophageal reflux disease","html":"<div class=\"graphic\"><div style=\"width: 756px\" class=\"figure\"><div class=\"ttl\">Medical management of gastroesophageal reflux disease</div><div class=\"cntnt\"><img style=\"width:736px; height:550px;\" src=\"images/GAST/58448_Medical_treatment_of_GERD.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">GERD: gastroesophageal reflux disease; EGD: esophagogastroduodenoscopy.</div><div id=\"graphicVersion\">Graphic 58448 Version 3.0</div></div></div>"},"58449":{"type":"graphic_table","displayName":"Immunodeficiency cancer risk","title":"Immune deficiency diseases predisposing to neoplastic disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immune deficiency diseases predisposing to neoplastic disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>X-linked lymphoproliferative disease</td>\n</tr>\n<tr>\n<td>Bruton agammaglobulinemia</td>\n</tr>\n<tr>\n<td>Severe combined immunodeficiency</td>\n</tr>\n<tr>\n<td>Wiskott-Aldrich syndrome</td>\n</tr>\n<tr>\n<td>IgA deficiency</td>\n</tr>\n<tr>\n<td>Common variable immunodeficiency</td>\n</tr>\n<tr>\n<td>DiGeorge syndrome</td>\n</tr>\n<tr>\n<td>Ataxia-telangiectasia</td>\n</tr>\n<tr>\n<td>Chediak-Higashi syndrome</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 58449 Version 1.0</div></div></div>"},"58450":{"type":"graphic_picture","displayName":"Irritated skin tag","title":"Irritated skin tag","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Irritated skin tag</div><div class=\"cntnt\"><img style=\"width:347px; height:294px;\" src=\"images/PC/58450_Irritated_skin_tag.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 58450 Version 2.0</div></div></div>"},"58452":{"type":"graphic_table","displayName":"2010 revised criteria for diagnosis of ARVC","title":"2010 revised Task Force criteria for the diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">2010 revised Task Force criteria for the diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"90%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Revised Task Force criteria</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">I. Global or regional dysfunction and structural alterations*</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\"><strong>Major</strong></td> <td><strong>By 2D echo:</strong> <ul> <li>Regional RV akinesia, dyskinesia, or aneurysm </li> <li><em>and</em> 1 of the following (end diastole): <ul> <li>PLAX RVOT &#8805;32 mm (corrected for body size [PLAX/BSA] &#8805;19 mm/m<sup>2</sup>) </li> <li>PSAX RVOT &#8805;36 mm (corrected for body size [PSAX/BSA] &#8805;21 mm/m<sup>2</sup>) </li> <li><em>or</em> fractional area change &#8804;33 percent </li> </ul> </li> </ul> </td> </tr> <tr> <td><strong>By MRI:</strong> <ul> <li>Regional RV akinesia or dyskinesia or dyssynchronous RV contraction </li> <li><em>and</em> 1 of the following: <ul> <li>Ratio of RV end-diastolic volume to BSA &#8805;110 mL/m<sup>2</sup> (male) or &#8805;100 mL/m<sup>2</sup> (female) </li> <li><em>or</em> RV ejection fraction &#8804;40 percent </li> </ul> </li> </ul> </td> </tr> <tr> <td><strong>By RV angiography:</strong> <ul> <li>Regional RV akinesia, dyskinesia, or aneurysm </li> </ul> </td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\"><strong>Minor</strong></td> <td><strong>By 2D echo:</strong> <ul> <li>Regional RV akinesia or dyskinesia </li> <li><em>and</em> 1 of the following (end diastole): <ul> <li>PLAX RVOT &#8805;29 to &#60;32 mm (corrected for body size [PLAX/BSA] &#8805;16 to &#60;19 mm/m<sup>2</sup>) </li> <li>PSAX RVOT &#8805;32 to &#60;36 mm (corrected for body size [PSAX/BSA] &#8805;18 to &#60;21 mm/m<sup>2</sup>) </li> <li><em>or</em> fractional area change &#62;33 percent to &#8804;40 percent </li> </ul> </li> </ul> </td> </tr> <tr> <td><strong>By MRI:</strong> <ul> <li>Regional RV akinesia or dyskinesia or dyssynchronous RV contraction </li> <li><em>and</em> 1 of the following: <ul> <li>Ratio of RV end-diastolic volume to BSA &#8805;100 to &#60;110 mL/m<sup>2</sup> (male) or &#8805;90 to &#60;100 mL/m<sup>2</sup> (female) </li> <li><em>or</em> RV ejection fraction &#62;40 percent to &#8804;45 percent </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">II. Tissue characterization of wall</td> </tr> <tr> <td class=\"indent1\"><strong>Major</strong></td> <td> <ul> <li>Residual myocytes &#60;60 percent by morphometric analysis (or &#60;50 percent if estimated), with fibrous replacement of the RV free wall myocardium in &#8805;1 sample, with or without fatty replacement of tissue on endomyocardial biopsy </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Minor</strong></td> <td> <ul> <li>Residual myocytes 60 percent to 75 percent by morphometric analysis (or 50 percent to 65 percent if estimated), with fibrous replacement of the RV free wall myocardium in &#8805;1 sample, with or without fatty replacement of tissue on endomyocardial biopsy </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">III. Repolarization abnormalities</td> </tr> <tr> <td class=\"indent1\"><strong>Major</strong></td> <td> <ul> <li>Inverted T waves in right precordial leads (V<sub>1</sub>, V<sub>2</sub>, and V<sub>3</sub>) or beyond in individuals &#62;14 years of age (in the absence of complete right bundle-branch block QRS &#8805;120 ms) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Minor</strong></td> <td> <ul> <li>Inverted T waves in leads V<sub>1</sub> and V<sub>2</sub> in individuals &#62;14 years of age (in the absence of complete right bundle-branch block) or in V<sub>4</sub>, V<sub>5</sub>, or V<sub>6</sub> </li> <li>Inverted T waves in leads V<sub>1</sub>, V<sub>2</sub>, V<sub>3</sub>, and V<sub>4</sub> in individuals &#62;14 years of age in the presence of complete right bundle-branch block </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">IV. Depolarization/conduction abnormalities</td> </tr> <tr> <td class=\"indent1\"><strong>Major</strong></td> <td> <ul> <li>Epsilon wave (reproducible low-amplitude signals between end of QRS complex to onset of the T wave) in the right precordial leads (V<sub>1</sub> to V<sub>3</sub>) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Minor</strong></td> <td> <ul> <li>Late potentials by SAECG in &#8805;1 of the following 3 parameters in the absence of a QRS duration of &#8805;110 ms on the standard ECG <ul> <li>Filtered QRS duration (fQRS) &#8805;114 ms </li> <li>Duration of terminal QRS &#60;40 &#181;V (low-amplitude signal duration) &#8805;38 ms </li> <li>Root-mean-square voltage of terminal 40 ms &#8804;20 &#181;V </li> </ul> </li> <li>Terminal activation duration of QRS &#8805;55 ms measured from the nadir of the S wave to the end of the QRS, including R', in V<sub>1</sub>, V<sub>2</sub>, or V<sub>3</sub>, in the absence of complete right bundle-branch block </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">V. Arrhythmias</td> </tr> <tr> <td class=\"indent1\"><strong>Major</strong></td> <td> <ul> <li>Nonsustained or sustained ventricular tachycardia of left bundle-branch morphology with superior axis (negative or indeterminate QRS in leads II, III, and aVF and positive in lead aVL) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Minor</strong></td> <td> <ul> <li>Nonsustained or sustained ventricular tachycardia of RV outflow configuration, left bundle-branch block morphology with inferior axis (positive QRS in leads II, III, and aVF and negative in lead aVL) or of unknown axis </li> <li>&#62;500 ventricular extrasystoles per 24 hours (Holter) </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">VI. Family history</td> </tr> <tr> <td class=\"indent1\"><strong>Major</strong></td> <td> <ul> <li>ARVC/D confirmed in a first-degree relative who meets current Task Force criteria </li> <li>ARVC/D confirmed pathologically at autopsy or surgery in a first-degree relative </li> <li>Identification of a pathogenic mutation<sup>&#182;</sup> categorized as associated or probably associated with ARVC/D in the patient under evaluation </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Minor</strong></td> <td> <ul> <li>History of ARVC/D in a first-degree relative in whom it is not possible or practical to determine whether the family member meets current Task Force criteria </li> <li>Premature sudden death (&#60;35 years of age) due to suspected ARVC/D in a first-degree relative </li> <li>ARVC/D confirmed pathologically or by current Task Force Criteria in second-degree relative </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Diagnostic terminology for revised criteria:&#xD;&#xA;<ul>&#xD;&#xA;    <li>Definite diagnosis: 2 Major, OR 1 Major and 2 Minor criteria, OR 4 Minor from different categories</li>&#xD;&#xA;    <li>Borderline diagnosis: 1 Major and 1 Minor, OR 3 Minor criteria from different categories</li>&#xD;&#xA;    <li>Possible diagnosis: 1 Major, OR 2 Minor criteria from different categories</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">PLAX: parasternal long-axis view; RVOT: RV outflow tract; BSA: body surface area; PSAX: parasternal short-axis view; aVF: augmented voltage unipolar left foot lead; aVL: augmented voltage unipolar left arm lead.<br />* Hypokinesis is not included in this or subsequent definitions of RV regional wall motion abnormalities for the proposed modified criteria.<br />&#182; A pathogenic mutation is a DNA alteration associated with ARVC/D that alters or is expected to alter the encoded protein, is unobserved or rare in a large non-ARVC/D control population, and either alters or is predicted to alter the structure or function of the protein or has demonstrated linkage to the disease phenotype in a conclusive pedigree.</div><div class=\"graphic_reference\">Modified with permission from: Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force criteria. Circulation 2010; 121:1533. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58452 Version 12.0</div></div></div>"},"58453":{"type":"graphic_table","displayName":"Developmental reflexes","title":"Common developmental reflexes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common developmental reflexes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"55%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Reflex</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Age at appearance</td> <td class=\"subtitle1\">Age at resolution</td> </tr> <tr class=\"divider_bottom\"> <td>Moro (startle)</td> <td>The examiner holds the infant supine in his or her arms, then drops the infant's head slightly but suddenly. This leads to the infant extending and abducting the arms, with the palms open, and sometimes crying. Alternatively, the examiner may lift the infant's head off the bed by 1 to 2 inches and allow it to gently drop back; this maneuver elicits a similar response.</td> <td>34 to 36 weeks PCA</td> <td>5 to 6 months</td> </tr> <tr class=\"divider_bottom\"> <td>Asymmetric tonic neck reflex</td> <td>With the infant relaxed and lying supine, the examiner rotates the head to one side. The infant extends the leg or arm on the side towards which the head has been turned, while flexing the arm on the contralateral side (fencing posture).</td> <td>38 to 40 weeks PCA</td> <td>2 to 3 months</td> </tr> <tr class=\"divider_bottom\"> <td>Trunk incurvation (Galant)</td> <td>With the infant in a prone position, the examiner strokes or taps along the side of the spine. The infant twitches his or her hips toward the side of the stimulus.</td> <td>38 to 40 weeks PCA</td> <td>1 to 2 months</td> </tr> <tr class=\"divider_bottom\"> <td>Palmar grasp</td> <td>The examiner places a finger in the infant's open palm. The infant closes his or her hand around the finger, tightens the grip if the examiner attempts to withdraw the finger.</td> <td>38 to 40 weeks PCA</td> <td>5 to 6 months</td> </tr> <tr class=\"divider_bottom\"> <td>Plantar grasp</td> <td>The examiner places a finger under the infant's toes. The infant flexes the toes downwards to \"grasp\" the finger.</td> <td>38 to 40 weeks PCA</td> <td>9 to 10 months</td> </tr> <tr class=\"divider_bottom\"> <td>Rooting</td> <td>The examiner strokes the infant's cheek. The infant turns the head toward the side that is stroked, and makes sucking motions.</td> <td>38 to 40 weeks PCA</td> <td>2 to 3 months</td> </tr> <tr> <td>Parachute</td> <td>The infant is held upright, back to the examiner. The body is rotated quickly forward (as if falling). The infant reflexively extends the upper extremities towards the ground as if to break a fall.</td> <td>8 to 9 months of age</td> <td>Persists throughout life</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PCA: post-conceptional age.</div><div class=\"graphic_reference\">Courtesy of Suresh Kotagal, MD.</div><div id=\"graphicVersion\">Graphic 58453 Version 5.0</div></div></div>"},"58454":{"type":"graphic_picture","displayName":"Hutchinson teeth","title":"Congenital syphilis: Hutchinson teeth","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital syphilis: Hutchinson teeth</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/PEDS/58454_Hutchinson_teeth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hutchinson teeth are smaller and more widely spaced than normal and are notched on their biting surfaces. The sides of the teeth taper toward the biting edges. The upper central incisors of the permanent (not the deciduous) teeth are most often affected.</div><div class=\"graphic_reference\">Reproduced with permission from: Robinson HBG, Miller AS. Colby, Kerr, and Robinson's Color Atlas of Oral Pathology. JB Lippincott, Philadelphia 1990. Copyright &#169; 1990 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58454 Version 2.0</div></div></div>"},"58455":{"type":"graphic_picture","displayName":"Cryptococcus neoformans in CSF","title":"Cryptococcus neoformans in cerebrospinal fluid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cryptococcus neoformans in cerebrospinal fluid</div><div class=\"cntnt\"><img style=\"width:368px; height:240px;\" src=\"images/ID/58455_Cryptococcusneoformansin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of cerebrospinal fluid (x1000) shows likely yeast forms, a few with cell walls and budding. These forms can be confused with host cells on Gram stain and are more easily identified by India ink. The most definitive procedures are testing for cryptococcal antigen and culture. <EM>Cryptococcus neoformans </EM>grew from this specimen.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 58455 Version 2.0</div></div></div>"},"58456":{"type":"graphic_movie","displayName":"TEE mitral valve vegetation","title":"Transesophageal echocardiogram (TEE) showing mitral valve vegetation in patient with endocarditis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiogram (TEE) showing mitral valve vegetation in patient with endocarditis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/58456_endmvteeconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:276px; height:438px;\" src=\"images/CARD/58456_endmvtee.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transesophageal echocardiogram shows a large vegetation of the anterior mitral valve leaflet. The posterior leaflet appears to have limited mobility, suggesting mitral stenosis.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 58456 Version 3.0</div></div></div>"},"58458":{"type":"graphic_figure","displayName":"Relationship between sodium intake and excretion in steady state","title":"Relationship between sodium intake and excretion in the steady state","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Relationship between sodium intake and excretion in the steady state</div><div class=\"cntnt\"><img style=\"width:404px; height:229px;\" src=\"images/NEPH/58458_Na_intake_and_Na_excretion.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relation between sodium intake (solid line) and urinary sodium excretion (dashed line) as sodium intake is progressively increased from 10 to 350 meq/day in normal subjects. Although excretion rises in parallel to intake, there is a slight lag in equilibration, and the area under the curve represents the net amount of sodium retained. This volume expansion constitutes the signal to maintain sodium excretion at a high level.</div><div class=\"graphic_reference\">Data from Sagnella GA, Markandu ND, Buckley MG, et al. Am J Physiol 1989; 256:R1171.</div><div id=\"graphicVersion\">Graphic 58458 Version 3.0</div></div></div>"},"58460":{"type":"graphic_picture","displayName":"Tympanosclerosis","title":"Tympanosclerosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tympanosclerosis</div><div class=\"cntnt\"><img style=\"width:396px; height:399px;\" src=\"images/PEDS/58460_Tympanosclerosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tympanosclerosis, asymptomatic whitish plaques of calcium and phosphate crystals, as depicted above, is common in children with middle ear disease and more common after tympanostomy tube placement.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 58460 Version 5.0</div></div></div>"},"58461":{"type":"graphic_figure","displayName":"Relationship between ST depression and mortality unstable angina","title":"ST segment depression on the initial ECG is associated with mortality in unstable angina","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">ST segment depression on the initial ECG is associated with mortality in unstable angina</div><div class=\"cntnt\"><img style=\"width:444px; height:350px;\" src=\"images/CARD/58461_ST_depression_mortality_UAP.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the GUSTO-IIb trial of 8001 patients with unstable angina, the presence of &ge;2 mm ST segment depression in &ge;2 contiguous leads on the initial ECG was associated with an increased one-year mortality (14 versus 4.4 percent without ST segment depression, p&lt;0.05).</div><div class=\"graphic_reference\">Data from: Kaul P, Fu Y, Chang WC, et al. J Am Coll Cardiol 2001; 38:64.</div><div id=\"graphicVersion\">Graphic 58461 Version 4.0</div></div></div>"},"58462":{"type":"graphic_figure","displayName":"Flow cytometry for X-linked lymphoproliferative disease","title":"Flow cytometric analysis for SAP deficiency (XLP1) and XIAP deficiency (XLP2)","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Flow cytometric analysis for SAP deficiency (XLP1) and XIAP deficiency (XLP2)</div><div class=\"cntnt\"><img style=\"width:529px; height:279px;\" src=\"images/ALLRG/58462_Flow_cyto_XLP_XIAP_deficien.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood mononuclear cells were stained with antibodies to SAP (left) or XIAP (right).</div><div class=\"graphic_footnotes\">SAP: signaling lymphocyte activation molecule (SLAM)-associated protein; XLP1: X-linked lymphoproliferative disease type 1; XIAP: X-linked inhibitor of apoptosis; XLP2: X-linked lymphoproliferative disease type 2.</div><div id=\"graphicVersion\">Graphic 58462 Version 3.0</div></div></div>"},"58463":{"type":"graphic_diagnosticimage","displayName":"ERC anastomosis stricture","title":"Severe anastomotic stricture in the distal biliary tract following liver transplantation","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Severe anastomotic stricture in the distal biliary tract following liver transplantation</div><div class=\"cntnt\"><img style=\"width:491px; height:319px;\" src=\"images/GAST/58463_ERC_anastomosis_stricture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic retrograde cholangiogram (ERC) image of the distal biliary tract in a patient who developed abnormal liver enzymes one month after liver transplantation. Panel A) The ERC shows a severe anastomotic stricture. Panel B) shows a thru-the scope (TTS) balloon being inserted across the stricture to dilate the anastomosis stricture. The stricture was dilated followed by placement of a plastic stent.</div><div class=\"graphic_reference\">Courtesy of Karen Krok, MD and Paul J Thuluvath, MBBS, MD, FRCP.</div><div id=\"graphicVersion\">Graphic 58463 Version 3.0</div></div></div>"},"58465":{"type":"graphic_picture","displayName":"Advanced stasis dermatitis","title":"Advanced stasis dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Advanced stasis dermatitis</div><div class=\"cntnt\"><img style=\"width:228px; height:271px;\" src=\"images/PC/58465_Advanced_stasis_dermatitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Advanced pigment changes of stasis dermatitis are characterized by red oozing skin (worse on the left anterior leg) with some scaling on the ankle.</div><div class=\"graphic_reference\">Courtesy of Patrick C Alguire, MD.</div><div id=\"graphicVersion\">Graphic 58465 Version 2.0</div></div></div>"},"58468":{"type":"graphic_picture","displayName":"Ureteral stent placement","title":"Ureteral stent placement","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Ureteral stent placement</div><div class=\"cntnt\"><img style=\"width:520px; height:661px;\" src=\"images/SURG/58468_Ureteral_stent_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ureteral orifice is first identified (A), and cannulated with a guidewire (B). The guidewire is placed beyond the area of obstruction and into the renal pelvis (C). A ureteral access catheter is placed over the guidewire, the guidewire is removed and contrast is injected to opacify the renal pelvis aiding accurate stent placement (D). The guidewire is replaced into the renal pelvis through the access catheter, which is then removed (not shown). The red metal-tipped pusher is used to maneuver the stent over the wire and up the ureter (E). The end of the ureteral stent can be seen at the bladder neck. Finally, the wire is removed and the stent is fully deployed (F). A full pigtail curl should be visualized in the bladder. Fluoroscopy can also be used to verify an adequate curl in the renal pelvis (not shown).</div><div class=\"graphic_reference\">Courtesy of Sutchin Patel, MD.</div><div id=\"graphicVersion\">Graphic 58468 Version 2.0</div></div></div>"},"58469":{"type":"graphic_table","displayName":"Causes of lymphocytopenia","title":"Causes of lymphocytopenia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of lymphocytopenia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Infection</td> </tr> <tr> <td class=\"indent1\">Bacterial (eg, tuberculosis, typhoid fever, brucellosis)</td> </tr> <tr> <td class=\"indent1\">Viral (eg, HIV, severe acute respiratory syndrome [SARS], measles, hepatitis)</td> </tr> <tr> <td class=\"indent1\">Fungal (eg, histoplasmosis)</td> </tr> <tr> <td class=\"indent1\">Parasitic (eg, malaria)</td> </tr> <tr> <td class=\"subtitle1_single\">Congenital immunodeficiency disorders</td> </tr> <tr> <td class=\"subtitle1_single\">Iatrogenic</td> </tr> <tr> <td class=\"indent1\">Immunosuppressive agents (eg, glucocorticoids, antilymphocyte globulin, alemtuzumab, rituximab)</td> </tr> <tr> <td class=\"indent1\">Chemotherapy (eg, fludarabine, cladribine), hematopoietic cell transplantation</td> </tr> <tr> <td class=\"indent1\">Radiation therapy (eg, total body irradiation, radiation injury)</td> </tr> <tr> <td class=\"subtitle1_single\">Systemic disease</td> </tr> <tr> <td class=\"indent1\">Autoimmune disorders (eg, systemic lupus erythematosus, rheumatoid arthritis, Sj&#246;gren syndrome)</td> </tr> <tr> <td class=\"indent1\">Lymphoma</td> </tr> <tr> <td class=\"indent1\">Other malignancies</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"indent1\">Renal failure</td> </tr> <tr> <td class=\"indent1\">Aplastic anemia, pancytopenia</td> </tr> <tr> <td class=\"indent1\">Cushing's syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Other causes</td> </tr> <tr> <td class=\"indent1\">Alcohol abuse</td> </tr> <tr> <td class=\"indent1\">Zinc deficiency</td> </tr> <tr> <td class=\"indent1\">Malnutrition, stress, exercise, trauma</td> </tr> <tr> <td class=\"indent1\">Thoracic duct leak, rupture, diversion</td> </tr> <tr> <td class=\"indent1\">Protein-losing enteropathy</td> </tr> <tr> <td class=\"indent1\">Idiopathic CD4+ lymphocytopenia</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.</div><div id=\"graphicVersion\">Graphic 58469 Version 10.0</div></div></div>"},"58470":{"type":"graphic_diagnosticimage","displayName":"VCUG Grade II reflux","title":"Voiding cystourethrogram (VCUG) demonstrating unilateral Grade II vesicoureteral reflux","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Voiding cystourethrogram (VCUG) demonstrating unilateral Grade&nbsp;II vesicoureteral reflux</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/PEDS/58470_VCUG_grade_II_reflux.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 58470 Version 4.0</div></div></div>"},"58471":{"type":"graphic_waveform","displayName":"Basic case 7 with answer","title":"Ventricular fibrillation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ventricular fibrillation</div><div class=\"cntnt\"><img style=\"width:436px; height:100px;\" src=\"images/CARD/58471_Basic_case_7_with_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extremely rapid, erratic ventricular activity due to ventricular fibrillation during cardiac arrest.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 58471 Version 2.0</div></div></div>"},"58474":{"type":"graphic_figure","displayName":"DCM anatomy PI","title":"Heart with dilated cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\">Heart with dilated cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:568px; height:398px;\" src=\"images/PI/58474_DCM_anatomy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The heart on the left is normal. The heart on the right has dilated cardiomyopathy. The condition causes the walls of heart to become thin, and the heart itself to become enlarged.</div><div id=\"graphicVersion\">Graphic 58474 Version 7.0</div></div></div>"},"58475":{"type":"graphic_table","displayName":"Cytokeratin stain pattern CUP","title":"Differential diagnosis of unknown primary cancers based upon immunostaining for cytokeratin (CK) 7 and 20","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of unknown primary cancers based upon immunostaining for cytokeratin (CK) 7 and 20</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">CK7+ CK20+</td> </tr> <tr> <td>Urothelial tumors</td> </tr> <tr> <td>Mucinous ovarian cancer</td> </tr> <tr> <td>Pancreatic or biliary cancer</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">CK7+ CK20-</td> </tr> <tr> <td>Non-small cell lung cancer</td> </tr> <tr> <td>Small cell lung cancer</td> </tr> <tr> <td>Breast cancer</td> </tr> <tr> <td>Endometrial cancer</td> </tr> <tr> <td>Nonmucinous ovarian cancer</td> </tr> <tr> <td>Mesothelioma</td> </tr> <tr> <td>Squamous cancer of cervix</td> </tr> <tr> <td>Pancreatic or biliary cancer</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">CK7- CK20+</td> </tr> <tr> <td>Colorectal cancer</td> </tr> <tr> <td>Merkel cell cancer</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">CK7- CK20-</td> </tr> <tr> <td>Hepatocellular cancer</td> </tr> <tr> <td>Renal cell cancer</td> </tr> <tr> <td>Prostate cancer</td> </tr> <tr> <td>Squamous cell lung cancer</td> </tr> <tr> <td>Head and neck cancer</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified from: Dabbs D. Diagnostic Immunohistochemistry, 2nd ed, Churchill Livingstone, 2006.</div><div id=\"graphicVersion\">Graphic 58475 Version 3.0</div></div></div>"},"58477":{"type":"graphic_table","displayName":"PECARN decision rule for minor head trauma in children","title":"PECARN rule: Findings associated with very low risk of significant traumatic brain injury in children*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">PECARN rule: Findings associated with very low risk of significant traumatic brain injury in children*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Age (years)</td> <td class=\"subtitle1\">Clinical criteria</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">&#60;2</td> <td>Normal mental status</td> </tr> <tr> <td>Normal behavior per routine caregiver</td> </tr> <tr> <td>No LOC<sup>&#182;</sup></td> </tr> <tr> <td>No severe mechanism of injury<sup>&#916;</sup></td> </tr> <tr> <td>No nonfrontal scalp hematoma</td> </tr> <tr class=\"divider_bottom\"> <td>No evidence of skull fracture</td> </tr> <tr> <td rowspan=\"6\">&#8805;2 to 18</td> <td>Normal mental status<sup>&#9674;</sup></td> </tr> <tr> <td>No LOC</td> </tr> <tr> <td>No severe mechanism of injury<sup>&#167;</sup></td> </tr> <tr> <td>No vomiting</td> </tr> <tr> <td>No severe headache</td> </tr> <tr> <td>No signs of basilar skull fracture<sup>&#165;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TBI: traumatic brain injury; GCS: Glasgow coma scale; LOC: loss of consciousness.<br />* Significant TBI such as death or injury that requires neurosurgical intervention, endotracheal intubation for longer than 24 hours, or hospitalization for 2 or more nights is very unlikely if all of the clinical criteria are present. Thus, computed tomography of the head is usually not necessary in such patients. When individual criteria are not met, observation or neuroimaging may be indicated. Refer to topics on minor head trauma in infants and children for further discussion.<br />¶ For the purposes of this criterion, loss of consciousness does <STRONG>not</STRONG> include very brief (&lt;5 seconds) loss of consciousness associated with low risk mechanisms for head trauma.<br />Δ Severe mechanism of injury: fall &gt;0.9 m (3 feet); head struck by high impact object; motor vehicle collision with patient ejection, death of another passenger, or rollover; pedestrian or bicyclist without helmet struck by a motorized vehicle.<br /><FONT class=lozenge>◊</FONT> Signs of altered mental status: agitation, somnolence, repetitive questioning, or slow response to verbal questioning.<br />§ As for children under 2 years of age except fall &gt;1.5 m (5 feet) considered severe.<br />¥ Early signs of basilar skull fracture at presentation include hemotympanum, CSF rhinorrhea, and CSF otorrhea; late signs of basilar skull fracture, occurring up to 24 hours after injury, include raccoon eyes and post auricular hematoma (Battle sign).</div><div class=\"graphic_reference\">Data from: Kuppermann N, Holmes JF, Dayan PS, et al. Identification of children at very low risk of clinically-important brain injuries after head trauma: a prospective cohort study. Lancet 2009; 374:1160.</div><div id=\"graphicVersion\">Graphic 58477 Version 7.0</div></div></div>"},"58478":{"type":"graphic_figure","displayName":"Structure calcium receptor","title":"Schematic representation of the proposed structure of the calcium receptor cloned from bovine parathyroid tissue","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Schematic representation of the proposed structure of the calcium receptor cloned from bovine parathyroid tissue</div><div class=\"cntnt\"><img style=\"width:469px; height:415px;\" src=\"images/ENDO/58478_Structure_calcium_receptor.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The structure of the human receptor is very similar.</div><div class=\"graphic_footnotes\">SP: signal peptide; HS: hydrophobic substance; PKC: protein kinase C. </div><div class=\"graphic_reference\">Adapted with permission from: Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993; 366:575.</div><div id=\"graphicVersion\">Graphic 58478 Version 3.0</div></div></div>"},"58479":{"type":"graphic_diagnosticimage","displayName":"Conduit leak B","title":"Conduit leak at urethral anastomosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Conduit leak at urethral anastomosis</div><div class=\"cntnt\"><img style=\"width:259px; height:381px;\" src=\"images/OBGYN/58479_Conduit_leak_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiograph showing percutaneous stent placed into conduit, which allowed drainage and subsequent healing.</div><div id=\"graphicVersion\">Graphic 58479 Version 3.0</div></div></div>"},"58480":{"type":"graphic_picture","displayName":"Schiller-Duval body","title":"A Schiller-Duval body in yolk sac tumor","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">A Schiller-Duval body in yolk sac tumor</div><div class=\"cntnt\"><img style=\"width:468px; height:314px;\" src=\"images/OBGYN/58480_Schiller-Duval_body.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Crum CP. The Female Genital Tract. In: Pathologic Basis of Disease, 6th ed, Cotran RS, Kumar V, Collins T (Eds), WB Saunders Company, Pennsylvania 1999. Copyright &#169; 1999 Elsevier.</div><div id=\"graphicVersion\">Graphic 58480 Version 3.0</div></div></div>"},"58481":{"type":"graphic_picture","displayName":"Umbilical granuloma","title":"Umbilical granuloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Umbilical granuloma</div><div class=\"cntnt\"><img style=\"width:360px; height:270px;\" src=\"images/PEDS/58481_Umbilical_granuloma.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Mary L Brandt, MD.</div><div id=\"graphicVersion\">Graphic 58481 Version 2.0</div></div></div>"},"58483":{"type":"graphic_table","displayName":"Weight based heparin nomogram","title":"Example of a weight-based nomogram for intravenous unfractionated heparin infusion for treatment of venous thromboembolism and/or pulmonary embolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Example of a weight-based nomogram for intravenous unfractionated heparin infusion for treatment of venous thromboembolism and/or pulmonary embolism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Initial dose</td> <td colspan=\"2\">80 units/kg bolus, then 18 units/kg per hour*</td> </tr> <tr> <td><strong>aPTT result</strong></td> <td><strong>Action</strong></td> <td><strong>Next aPTT<sup>&#916;</sup></strong></td> </tr> <tr> <td>aPTT &#60;35 seconds (&#60;1.2 x control)</td> <td>80 units/kg bolus, then increase infusion rate by 4 units/kg per hour</td> <td>6 hours</td> </tr> <tr> <td>aPTT 35 to 45 seconds (1.2 to 1.5 x control)</td> <td>40 units/kg bolus, then increase infusion rate by 2 units/kg per hour</td> <td>6 hours</td> </tr> <tr> <td>aPTT 46 to 70 seconds<sup>&#182; </sup>(1.5 to 2.3 x control)</td> <td>No change (therapeutic range)</td> <td>6 hours (when two consecutive values are within therapeutic range, then next aPTT in morning)</td> </tr> <tr> <td>aPTT 71 to 90 seconds (2.3 to 3.0 x control)</td> <td>Decrease infusion rate by 2 units/kg per hour</td> <td>6 hours</td> </tr> <tr> <td>aPTT &#62;90 seconds (&#62;3.0 x control)</td> <td>Hold infusion 1 hour, then decrease infusion rate by 3 units/kg per hour</td> <td>6 hours</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">aPTT: activated partial thromboplastin time.<br /><STRONG>This table is provided as an example of a locally developed and validated unfractionated heparin weight-based dose adjustment nomogram. </STRONG>It reflects the original aPTT ranges, bolus sizes, and suggested changes in infusion rate that were present at the time the study was performed.<SUP>[1]</SUP> The therapeutic ranges (ie, relationship between the aPTT and anti-factor Xa activity), initial and subsequent bolus sizes, and sizes of the infusion rate changes, as well as dosing differences depending on the disorder under treatment (eg, venous thromboembolism, stroke, acute coronary syndrome) should be established separately for each institution.</div><div class=\"graphic_footnotes\">* Use of total body weight (TBW) is suggested for calculating the initial bolus dose and infusion rate for most obese patients. For additional information refer to \"Management of the critically ill obese patient\", section \"Anticoagulants\".<br />&para; Therapeutic aPTT range of 46 to 70 seconds corresponded to anti-Xa activity of 0.3 to 0.7 units/mL. The target aPTT range in a particular institution should reflect what is known about the local reagents and equipment to perform the assay<sup>[2]</sup>.<br />&Delta; The first aPTT should be obtained 4 to 6 hours after the initial heparin bolus.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a \"standard care\" nomogram. A randomized controlled trial. Ann Intern Med 1993; 119:874.</li>&#xD;&#xA;    <li>Garcia DA, Baglin TP, Weitz JI A, et al. Parenteral Anticoagulants: Antithrombotic therapy and Prevention of Thrombosis, American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition). Chest 2012; 141:e24S-e43S.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 58483 Version 8.0</div></div></div>"},"58484":{"type":"graphic_diagnosticimage","displayName":"Normal adult scaphoid radiograph","title":"Scaphoid view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scaphoid view</div><div class=\"cntnt\"><img style=\"width:316px; height:326px;\" src=\"images/EM/58484_Normal_adult_scaphoid_Xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This posterior anterior (PA) radiograph of the wrist taken with ulnar deviation of the hand serves to isolate the scaphoid (arrow) from overlapping shadows.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 58484 Version 4.0</div></div></div>"},"58485":{"type":"graphic_picture","displayName":"Female genital HSV","title":"Female genital herpes simplex virus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Female genital herpes simplex virus</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/ID/58485_Female_genital_HSV.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 58485 Version 3.0</div></div></div>"},"58486":{"type":"graphic_picture","displayName":"Nevus multicomponent pattern","title":"Dermoscopic image of a nevus with a symmetric multicomponent pattern","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of a nevus with a symmetric multicomponent pattern</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/58486_Nevus_mult_comp_pattern_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nevi with a multicomponent pattern should be considered suspicious, since melanoma may present with a similar pattern.</div><div class=\"graphic_reference\">Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 58486 Version 4.0</div></div></div>"},"58487":{"type":"graphic_table","displayName":"HIV prophylaxis guidelines percutaneous injury","title":"Recommended HIV postexposure prophylaxis (PEP) for percutaneous injuries","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended HIV postexposure prophylaxis (PEP) for percutaneous injuries</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Exposure type</td> <td class=\"subtitle1\" colspan=\"5\">Infection status of source</td> </tr> <tr> <td class=\"subtitle2\">HIV-positive class 1*</td> <td class=\"subtitle2\">HIV-positive class 2*</td> <td class=\"subtitle2\">Source of unknown HIV status<sup>&#182;</sup></td> <td class=\"subtitle2\">Unknown source<sup>&#916;</sup></td> <td class=\"subtitle2\">HIV-negative</td> </tr> <tr> <td>Less severe<sup>&#9674;</sup></td> <td>Recommend basic 2 drug PEP</td> <td>Recommend expanded &#8805;3 drug PEP</td> <td>Generally, no PEP warranted; however, consider basic 2-drug PEP<sup>&#167;</sup> for source with HIV risk factors<sup>&#165;</sup></td> <td>Generally, no PEP warranted; however, consider basic 2-drug PEP<sup>&#167;</sup> in settings in which exposure to HIV-infected persons is likely</td> <td>No PEP warranted</td> </tr> <tr> <td>More severe<sup>&#167;</sup></td> <td>Recommend expanded &#8805;3 drug PEP</td> <td>Recommend expanded &#8805;3 drug PEP</td> <td>Generally, no PEP warranted; however, consider basic 2-drug PEP<sup>&#167;</sup> for source with HIV risk factors<sup>&#165;</sup></td> <td>Generally, no PEP warranted; however, consider basic 2-drug PEP<sup>&#167;</sup> in settings in which exposure to HIV-infected persons is likely</td> <td>No PEP warranted</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* HIV-positive, Class 1: asymptomatic HIV infection or known low viral load (eg, &lt;1500 ribonucleic acid copies/mL). HIV-positive, Class 2: symptomatic HIV infection, acquired immunodeficiency syndrome, acute seroconversion, or known high viral load. If drug resistance is a concern, obtain expert consultation. Initiation of PEP should not be delayed pending expert consultation, and, because expert consultation alone cannot substitute for face-to-face counseling, resources should be available to provide immediate evaluation and follow-up care for all exposures.<br />¶ For example, deceased source person with no samples available for HIV testing.<br />Δ For example, a needle from a sharps disposal container.<br /><FONT class=lozenge>◊</FONT> For example, solid needle or superficial injury.<br />§ The recommendation \"consider PEP\" indicates that PEP is optional; a decision to initiate PEP should be based on a discussion between the exposed person and the treating clinician regarding the risks versus benefits of PEP.<br />¥ If PEP is offered and administered and the source is later determined to be HIV-negative, PEP should be discontinued.</div><div class=\"graphic_reference\">MMWR Recomm Rep 2005; 54(RR-9):1.</div><div id=\"graphicVersion\">Graphic 58487 Version 3.0</div></div></div>"},"58488":{"type":"graphic_figure","displayName":"Big endothelin outcome HF","title":"Big endothelin-1 predicts outcome in heart failure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Big endothelin-1 predicts outcome in heart failure</div><div class=\"cntnt\"><img style=\"width:396px; height:271px;\" src=\"images/CARD/58488_BigendothelinoutcomeHF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier analysis shows that the cumulative event-free survival (free of death or prioritization for urgent transplant) in 218 patients with stable, chronic heart failure is higher in those with a big endothelin (ET)-1 concentration &lt;4.3 fmol/mL compared to those with a concentration ≥4.3 fmol/mL (p &lt;0.0001).</div><div class=\"graphic_reference\">Data from: Hulsmann M, Stanek B, Frey B. J Am Coll Cardiol 1998; 32:1695.</div><div id=\"graphicVersion\">Graphic 58488 Version 3.0</div></div></div>"},"58493":{"type":"graphic_picture","displayName":"Vessel loop system for staged abdominal wall closure","title":"Vessel loop system for staged abdominal wall closure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vessel loop system for staged abdominal wall closure</div><div class=\"cntnt\"><img style=\"width:298px; height:223px;\" src=\"images/SURG/58493_Vessel_loop_system.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 58493 Version 1.0</div></div></div>"},"58494":{"type":"graphic_movie","displayName":"Membranous VSD subcostal parasagittal 2D","title":"Membranous VSD subcostal parasagittal 2D","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Membranous VSD subcostal parasagittal 2D</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/58494_MembrVSDparasagitmovie.mp4\" style=\"width:496px;height:384px\"></div><img style=\"width:540px; height:363px;\" src=\"images/CARD/58494_MembrVSDparasagitposter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this subcostal parsagittal movie clip demonstrating a membranous ventricular septal defect, the movement and proximity of the aortic and tricuspid valves can be seen.</div><div class=\"graphic_footnotes\">PA: pulmonary artery; AO: aorta; LA: left atrium; RV: right ventricle; TV: tricuspid valve; RA: right atrium; IVC: inferior vena cava; arrow: VSD.</div><div id=\"graphicVersion\">Graphic 58494 Version 3.0</div></div></div>"},"58495":{"type":"graphic_figure","displayName":"Sports mechanism for proximal humeral fracture","title":"Sports mechanism for proximal humeral fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sports mechanism for proximal humeral fracture</div><div class=\"cntnt\"><img style=\"width:351px; height:418px;\" src=\"images/EM/58495_Mechhumeralfx2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blunt trauma from contact sports may result in fracture of the proximal humerus in children.</div><div class=\"graphic_reference\">Reproduced with permission from: Sarwark JF, King EC, Luhmann SJ. Proximal humerus, scalpula, and clavicle. In: Rockwood and Wilkins' Fractures in Children, 6th edition, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 58495 Version 13.0</div></div></div>"},"58499":{"type":"graphic_picture","displayName":"Lip swelling CD","title":"Lip swelling with fissures in a child with Crohn disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lip swelling with fissures in a child with Crohn disease</div><div class=\"cntnt\"><img style=\"width:360px; height:231px;\" src=\"images/PEDS/58499_Lip_swelling_CD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lip swelling of one or both lips may occur in patients with Crohn disease. Persistent enlargment may lead to the development of fissures.</div><div class=\"graphic_reference\">Reproduced with permission from: Hardy S, Fleming P, Rowland M, et al. A prospective study of the oral manefestations of Crohn's disease. Clin Gastroenterol Hepatol 2005; 3:886. Copyright © 2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 58499 Version 3.0</div></div></div>"},"58500":{"type":"graphic_picture","displayName":"Palpation trochanteric bursa","title":"Palpation of the trochanteric bursa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palpation of the trochanteric bursa</div><div class=\"cntnt\"><img style=\"width:324px; height:303px;\" src=\"images/EM/58500_Palpation_trochanteric_burs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The trochanteric bursae are palpated to assess for tenderness. The trochanter can be palpated either in the sitting or the lateral decubitus position. In either case, the hip must be flexed to 90 degrees&nbsp;to be able to adequately identify the superior aspect of the trochanteric process. The trochanteric process is the most prominent portion of the femur. Firm pressure must be applied to determine local tenderness in the obese patient. Bursitis is the most common cause of local tenderness; other causes include occult fracture, stress fracture, and metastatic disease.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 58500 Version 3.0</div></div></div>"},"58502":{"type":"graphic_diagnosticimage","displayName":"Osteonecrosis of knee MRI","title":"Osteonecrosis of the femoral condyle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Osteonecrosis of the femoral condyle</div><div class=\"cntnt\"><img style=\"width:312px; height:544px;\" src=\"images/RHEUM/58502_Osteonecrosis_of_knee_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MRI of&nbsp;a young woman on prednisone for inflammatory bowel disease who developed knee pain due to osteonecrosis of the femoral condyle without collapse (marrow infarction).<br />(Top panel) Sagittal proton density MRI of the knee shows a serpentine \"double-line sign\" (concentric high and low signal at the periphery) (arrow) that represents hypervascular granulation tissue and is pathognomonic of osteonecrosis.<br />(Bottom panel) Coronal inversion recovery image (a fat saturation MRI sequence) again demonstrates serpentine intramedullary pattern of decreased signal intensity.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Mark Robbins, MD.</div><div id=\"graphicVersion\">Graphic 58502 Version 6.0</div></div></div>"},"58503":{"type":"graphic_table","displayName":"Increase in infant blood lead concentration from breast milk","title":"Estimated* increase in infant blood lead concentration<sup>¶</sup> associated with different maternal blood lead concentrations at 1 month postpartum","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated* increase in infant blood lead concentration<sup>&#182;</sup> associated with different maternal blood lead concentrations at 1 month postpartum</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Maternal blood lead concentration (&#181;g/dL)</td> <td class=\"subtitle1\">Estimated breast milk lead concentration (&#181;g/L)</td> <td class=\"subtitle1\">Estimated associated increase in infant blood lead at age 1 month (&#181;g/dL)<sup>&#916;</sup></td> </tr> <tr class=\"centered\"> <td>1</td> <td>0.3</td> <td>0.12</td> </tr> <tr class=\"centered\"> <td>2</td> <td>0.6</td> <td>0.25</td> </tr> <tr class=\"centered\"> <td>3</td> <td>0.9</td> <td>0.37</td> </tr> <tr class=\"centered\"> <td>4</td> <td>1.2</td> <td>0.49</td> </tr> <tr class=\"centered\"> <td>5</td> <td>1.5</td> <td>0.62</td> </tr> <tr class=\"centered\"> <td>8</td> <td>2.4</td> <td>0.98</td> </tr> <tr class=\"centered\"> <td>10</td> <td>3</td> <td>1.2</td> </tr> <tr class=\"centered\"> <td>20</td> <td>6</td> <td>2.5</td> </tr> <tr class=\"centered\"> <td>30</td> <td>9</td> <td>3.7</td> </tr> <tr class=\"centered\"> <td>40<sup>&#9674;</sup></td> <td>12</td> <td>4.9</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* This estimation integrates absorption, distribution, and excretion.<br />¶ These values are estimations based upon ICP-MS laboratory analysis and increments of less than 2 μg/dL would not necessarily be detectable in clinical laboratories.<br />Δ Calculated based upon the observation that a 2 μg/L increase in breast milk lead is associated with an increase of 0.82 μg/dL in the blood lead of the nursing infant<SUP>[1]</SUP>.<br /><FONT class=lozenge>◊</FONT> Extrapolation beyond the range of observed data from Ettinger et al 2004<SUP>[1]</SUP> (where maternal BLLs ranged from 1-30 μg/dL).</div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Ettinger AS, Tellez-Rojo MM, Amarasiriwardena C, et al. Effect of breast milk lead on infant blood lead levels at 1 month of age. Environ Health Perspect 2004; 112:1381. </LI></OL>Reproduced from: Ettinger AS, Gurthrie Wengrovitz A (Eds). Guidelines for the identification and management of lead exposure in pregnant and lactating women. National Center for Environmental Health/Agency for Toxic Substances and Disease Registry; Centers for Disease Control and Prevention, Atlanta, GA, 2010. Available at <A href=\"http://www.cdc.gov/nceh/lead/publications/LeadandPregnancy2010.pdf\" target=_blank>http://www.cdc.gov/nceh/lead/publications/LeadandPregnancy2010.pdf</A>.</div><div id=\"graphicVersion\">Graphic 58503 Version 8.0</div></div></div>"},"58504":{"type":"graphic_picture","displayName":"Alcoholic hepatitis Light","title":"Alcoholic hepatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Alcoholic hepatitis</div><div class=\"cntnt\"><img style=\"width:288px; height:336px;\" src=\"images/GAST/58504_AlcoholichepatitisLight.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power view of a liver biopsy from a patient with alcoholic hepatitis shows the classic changes of hepatocellular steatosis, neutrophilic infiltration (in contrast to the mononuclear cell infiltration in other forms of chronic hepatitis), and focal hepatocyte necrosis. These changes are indistinguishable from those in nonalcoholic steatohepatitis.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 58504 Version 1.0</div></div></div>"},"58505":{"type":"graphic_table","displayName":"Diagnostic criteria paroxysmal hemicrania","title":"Diagnostic criteria for paroxysmal hemicrania","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for paroxysmal hemicrania</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>A. At least 20 attacks fulfilling B-E</td> </tr> <tr> <td>B. Severe unilateral orbital, supra-orbital, and/or temporal pain lasting 2 to 30 minutes</td> </tr> <tr> <td class=\"sublist1_start\">C. Headache is accompanied by at least one of the following signs or symptoms, ipsilateral to the pain:</td> </tr> <tr> <td class=\"sublist2\">1. Conjunctival injection and/or lacrimation</td> </tr> <tr> <td class=\"sublist2\">2. Nasal congestion and/or rhinorrhea</td> </tr> <tr> <td class=\"sublist2\">3. Eyelid edema</td> </tr> <tr> <td class=\"sublist2\">4. Forehead and facial sweating</td> </tr> <tr> <td class=\"sublist2\">5. Forehead and facial flushing</td> </tr> <tr> <td class=\"sublist2\">6. Ipsilateral miosis and/or ptosis</td> </tr> <tr> <td>D. Attacks have a frequency &#62;5 per day for more than half the time</td> </tr> <tr> <td>E. Attacks are prevented absolutely by therapeutic doses of indomethacin</td> </tr> <tr> <td>F. Not better accounted for by another ICHD-3 disorder</td> </tr> <tr> <td class=\"subtitle2_single\">Episodic paroxysmal headache</td> </tr> <tr> <td class=\"indent1\">Attacks of paroxysmal hemicrania occurring in periods lasting from&nbsp;seven days to one year, separated by pain free periods lasting at least one month</td> </tr> <tr> <td class=\"subtitle2_single\">Chronic paroxysmal headache</td> </tr> <tr> <td class=\"indent1\">Attacks of paroxysmal hemicrania occurring for more than one year without remission, or with remission periods&nbsp;lasting less than one month</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">ICHD-3: International Classification of Headache Disorders, 3rd edition</div><div class=\"graphic_reference\">Data from: Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013; 33:629.</div><div id=\"graphicVersion\">Graphic 58505 Version 12.0</div></div></div>"},"58506":{"type":"graphic_table","displayName":"Vaginal estrogen","title":"Vaginal estrogen preparations available in the United States for treatment of vaginal atrophy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Vaginal estrogen preparations available in the United States for treatment of vaginal atrophy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Preparation (US trade name)</td> <td class=\"subtitle1\">Available strengths</td> <td class=\"subtitle1\">Regimen<br /> (FDA-approved prescribing information)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Vaginal ring</td> </tr> <tr> <td class=\"indent1\">Estring</td> <td>7.5 mcg estradiol/day, released over 90 days</td> <td>Ring is inserted into the vagina by the patient or clinician. Ring is removed and replaced with a new ring every 90 days.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Vaginal insert</td> </tr> <tr> <td class=\"indent1\">Vagifem</td> <td>10 mcg estradiol per vaginal insert</td> <td>Insert&nbsp;one tablet intravaginally daily for&nbsp;two weeks, followed by twice weekly.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Vaginal cream</td> </tr> <tr> <td class=\"indent1\">Premarin</td> <td>0.625 mg conjugated estrogens per gram of cream</td> <td>0.5 gram of cream intravaginally administered twice weekly. Cyclic regimen also listed in&nbsp;approved product information, but not commonly used.</td> </tr> <tr> <td class=\"indent1\">Estrace</td> <td>100 mcg estradiol per gram of cream</td> <td>0.5&nbsp;grams of cream intravaginally administered daily for one or&nbsp;two weeks, then reduce to twice weekly.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FDA: US Food and&nbsp;Drug Administration.</div><div class=\"graphic_reference\">Prepared with data from: FDA prescribing information available at US National Library of Medicine NIH DailyMed website <A href=\"http://dailymed.nlm.nih.gov/dailymed/index.cfm\">http://dailymed.nlm.nih.gov/dailymed/index.cfm</A> (accessed on April 3, 2015).</div><div id=\"graphicVersion\">Graphic 58506 Version 17.0</div></div></div>"},"58508":{"type":"graphic_picture","displayName":"Spindle cell carcinoma Light","title":"Spindle cell carcinoma of the head and neck","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Spindle cell carcinoma of the head and neck</div><div class=\"cntnt\"><img style=\"width:537px; height:266px;\" src=\"images/ONC/58508_Spindle_cell_carcinoma_Ligh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph of a spindle cell carcinoma (left panel). The growth pattern is one of interlacing fascicles or pinwheel (storiform) arrangements. These tumors need to be distinguished from sarcomas and melanomas, and immunostains for cytokeratin (right panel) are useful in this regard.</div><div class=\"graphic_reference\">Courtesy of G Kenneth Haines, MD.</div><div id=\"graphicVersion\">Graphic 58508 Version 3.0</div></div></div>"},"58509":{"type":"graphic_figure","displayName":"Overactive thyroid PI","title":"Overactive thyroid","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Overactive thyroid</div><div class=\"cntnt\"><img style=\"width:472px; height:336px;\" src=\"images/PI/58509_Overactive_thyroid_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperthyroidism can cause the thyroid gland to enlarge. This causes a swelling in the neck called a \"goiter.\" Hyperthyroidism caused by Graves' disease can also make the eyes bulge.</div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Company. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58509 Version 6.0</div></div></div>"},"58510":{"type":"graphic_algorithm","displayName":"Difficult airway management outside OR","title":"Difficult airway management outside the operating room","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Difficult airway management outside the operating room</div><div class=\"cntnt\"><img style=\"width:400px; height:586px;\" src=\"images/EM/58510_DiffairwaymgmtoutsideOR.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BMV: bag-mask ventilation; EGD: extra-glottic device; ILMA: intubating laryngeal mask airway; OR:&nbsp;operating room;&nbsp;PIM: post intubation management; RSI: rapid sequence intubation.</div><div class=\"graphic_reference\">Reproduced with permission from: The Difficult Airway Course®: Emergency and Brown III CA, Walls RM. The Emergency Airway Algorithms. In: The Walls Manual of Emergency Airway Management, 5th ed, Brown III CA, Sakles JC, Mick NW (Eds), Wolters Kluwer, Philadelphia 2018. Copyright © 2018 Wolters Kluwer.</div><div id=\"graphicVersion\">Graphic 58510 Version 21.0</div></div></div>"},"58511":{"type":"graphic_figure","displayName":"Decreasing T with age","title":"Longitudinal effects of aging","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Longitudinal effects of aging</div><div class=\"cntnt\"><img style=\"width:354px; height:410px;\" src=\"images/ENDO/58511_Decreasing_T_with_age.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear segment plots for total T and free T index versus age are shown for men with T and SHBG values on at least two visits. Each linear segment has a slope equal to the mean of the individual longitudinal slopes in each decade, and is centered on the median age, for each cohort of men from the second to the ninth decade. Numbers in parentheses represent the number of men in each cohort. With the exception of free T index in the ninth decade, segments show significant change in slopes for T or free T index over the entire age range.<br />(Top panel) To convert T from&nbsp;nmol/L to ng/dL,&nbsp;multiply by 28.84.</div><div class=\"graphic_footnotes\">T: testosterone; SHBG: sex hormone-binding globulin.</div><div class=\"graphic_reference\">Reproduced with permission from: Harman SM, Metter EJ, Tobin JD, Pearson J. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86:724. http://jcem.endojournals.org/. Copyright &copy; 2001 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 58511 Version 9.0</div></div></div>"},"58512":{"type":"graphic_table","displayName":"Prolonged fast I","title":"Results of a prolonged fast in a patient with suspected insulinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Results of a prolonged fast in a patient with suspected insulinoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Time, hours</td> <td class=\"subtitle1\">Serum glucose, mg/dL</td> <td class=\"subtitle1\">Serum insulin, microU/mL</td> <td class=\"subtitle1\">Serum C-peptide, pmol/L</td> <td class=\"subtitle1\">Serum proinsulin, pmol/L</td> </tr> <tr> <td>3</td> <td>61</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>48</td> <td>42</td> <td>13</td> <td>510</td> <td>55</td> </tr> <tr> <td>60</td> <td>40</td> <td>8</td> <td>330</td> <td>37</td> </tr> <tr> <td>66</td> <td>33</td> <td>13</td> <td>480</td> <td>50</td> </tr> <tr> <td>68</td> <td>31</td> <td>5</td> <td>310</td> <td>34</td> </tr> <tr> <td>72</td> <td>32</td> <td>11</td> <td>360</td> <td>37</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">To convert serum glucose values to mmol/L, multiply by 0.056; to convert serum insulin values to pmol/L, multiply by 6.0.</div><div id=\"graphicVersion\">Graphic 58512 Version 3.0</div></div></div>"},"58513":{"type":"graphic_diagnosticimage","displayName":"Pancreatic stent migration","title":"Proximal migration of a pancreatic stent","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proximal migration of a pancreatic stent</div><div class=\"cntnt\"><img style=\"width:362px; height:300px;\" src=\"images/GAST/58513_Pancreatic_stent_migration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This pancreatogram demonstrates a pancreatic stent that has migrated into the pancreatic body. A mini-snare has been advanced into the pancreatic duct and is opened beyond the stent to capture its proximal end.</div><div class=\"graphic_reference\">Courtesy of Marc Catalano, MD.</div><div id=\"graphicVersion\">Graphic 58513 Version 2.0</div></div></div>"},"58514":{"type":"graphic_table","displayName":"Lead poisoning evaluation","title":"Evaluation of the child with an elevated venous blood lead level","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of the child with an elevated venous blood lead level</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\r\n \r\n <tr>\r\n \r\n <td class=\"container\"><table cellspacing=\"0\">\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle1_single\">\r\n \r\n History\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"sublist1_start\">The presence of symptoms:</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"sublist1\">Lethargy</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"sublist1\">Decreased appetite</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"sublist1\">Intermittent abdominal pain</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"sublist1\">Vomiting</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Pica</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Nutritional status (particularly iron and calcium)</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Family history of lead poisoning</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>History of lead poisoning in playmates</td>\r\n \r\n </tr>\r\n\r\n <tr>\r\n \r\n <td>Foreign birthplace or recent foreign residence</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle1_single\">\r\n \r\n Physical examination\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Growth parameters</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Blood pressure</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Neurologic assessment</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Neurobehavioral assessment</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Language development</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Abdominal tenderness</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle1_single\">\r\n \r\n Radiographic evaluation\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>For children with symptoms, pica, or acute ingestion of lead containing objects:</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Abdominal radiograph</td>\r\n \r\n </tr>\r\n \r\n </table></td>\r\n \r\n <td class=\"container\"><table cellspacing=\"0\">\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle1_single\">\r\n \r\n Environmental history\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Age of housing</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Home renovations</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Work history of parents</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Hobbies of all family members</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Water source</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Play areas</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Daycare</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle1_single\">\r\n \r\n Laboratory evaluation\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Repeat (confirm) venous lead level</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Venous lead level in siblings</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>CBC, reticulocyte count, serum iron, iron binding capacity, and ferritin</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"sublist1_start\">\r\n \r\n Pre-treatment evaluation\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"sublist1\">\r\n \r\n Serum electrolytes\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"sublist1\">\r\n \r\n BUN, creatinine\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"sublist1\">\r\n \r\n Calcium, magnesium\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"sublist1\">\r\n \r\n AST/ALT, alkaline phosphatase,\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"sublist1\">\r\n \r\n Urinalysis\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n </table></td>\r\n \r\n </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 58514 Version 1.0</div></div></div>"},"58515":{"type":"graphic_table","displayName":"Nebulizer performance","title":"Factors affecting aerosol delivery by nebulizer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors affecting aerosol delivery by nebulizer</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Technical factors</td> </tr> <tr> <td class=\"indent1\">Mechanism and manufacturer</td> </tr> <tr> <td class=\"indent1\">Flow rate</td> </tr> <tr> <td class=\"indent1\">Fill volume</td> </tr> <tr> <td class=\"indent1\">Solution characteristics</td> </tr> <tr> <td class=\"indent1\">Characteristics of driving gas</td> </tr> <tr> <td class=\"indent1\">Designs to enhance output</td> </tr> <tr> <td class=\"indent1\">Continuous versus intermittent delivery</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Patient factors</td> </tr> <tr> <td class=\"indent1\">Breathing pattern</td> </tr> <tr> <td class=\"indent1\">Nose versus mouth breathing</td> </tr> <tr> <td class=\"indent1\">Artificial airway</td> </tr> <tr> <td class=\"indent1\">Airway obstruction</td> </tr> <tr> <td class=\"indent1\">Positive pressure level</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58515 Version 4.0</div></div></div>"},"58516":{"type":"graphic_table","displayName":"Chompret diagn criteria Li-Fraumeni syndrome and TP53 testing","title":"Chompret diagnostic criteria for Li-Fraumeni syndrome and TP53 testing<sup>[1,2]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chompret diagnostic criteria for Li-Fraumeni syndrome and TP53 testing<sup>[1,2]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">One of the following:</td> </tr> <tr> <td class=\"sublist_other_start\">&#8226; A proband who has:</td> </tr> <tr> <td class=\"indent1\">- A tumor belonging to the LFS tumor spectrum (soft tissue sarcoma, osteosarcoma, pre-menopausal breast cancer, brain tumor, adrenocortical carcinoma, leukemia, or lung bronchoalveolar cancer) before age 46 years <strong>AND</strong></td> </tr> <tr> <td class=\"indent1\">- At least one first- or second-degree relative with an LFS tumor (except breast cancer if the proband has breast cancer) before age 56 years or with multiple tumors;</td> </tr> <tr> <td>&#8226; A proband with multiple tumors (except multiple breast tumors), two of which belong to the LFS tumor spectrum and the first of which occurred before age 46 years;</td> </tr> <tr> <td>&#8226; A proband who is diagnosed with adrenocortical carcinoma or choroid plexus tumor, irrespective of family history</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">11</mso:Specialty>\r\n<mso:Media_Notes msdt:dt=\"string\"></mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=77965&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">References:<br> <ol> <li>Tinat J, Bougeard G, Baert-Desurmont S, et al. 2009 Version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 2009; 27:e108. </li> <li>Li-Fraumeni Syndrome. Schneider K, Garber J. In: Pagon RA, Bird TC, Dolan CR, Stephens K, editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-1999 Jan 19 [updated 2010 Feb 9]. </li> </ol></div><div id=\"graphicVersion\">Graphic 58516 Version 8.0</div></div></div>"},"58517":{"type":"graphic_figure","displayName":"Oblique abdominal incisions","title":"Oblique abdominal incisions","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Oblique abdominal incisions</div><div class=\"cntnt\"><img style=\"width:492px; height:629px;\" src=\"images/SURG/58517_Oblique_abdominal_incisions.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 58517 Version 3.0</div></div></div>"},"58519":{"type":"graphic_waveform","displayName":"Exercise testing in LEMS","title":"Exercise testing in Lambert-Eaton myasthenic syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Exercise testing in Lambert-Eaton myasthenic syndrome</div><div class=\"cntnt\"><img style=\"width:312px; height:244px;\" src=\"images/NEURO/58519_Exercise_testing_LEMS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Exercise testing in Lambert-Eaton myasthenic syndrome, with the median nerve stimulated supramaximally at the wrist and the abductor pollicis brevis muscle recorded. (Top) Baseline. (Bottom) Immediately after 10 seconds of maximal voluntary exercise. Note marked increase in compound muscle action potential amplitude (postexercise facilitation). Preexercise and postexercise testing, looking for an increment, always is better tolerated by patients than is 50-Hz repetitive nerve stimulation.</div><div class=\"graphic_reference\">Reproduced with permission from: Preston DC, Shapiro BE. Electromyography and Neuromuscular Disorders, 2nd ed, Butterworth-Heinemann, Boston 1998. Copyright © 1998 Elsevier.</div><div id=\"graphicVersion\">Graphic 58519 Version 2.0</div></div></div>"},"58520":{"type":"graphic_table","displayName":"AASLD Rx chronic HBV recs","title":"Recommendations for initial treatment of chronic hepatitis B in nonpregnant adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for initial treatment of chronic hepatitis B in nonpregnant adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"12%\"></colgroup><colgroup width=\"64%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">HBeAg</td> <td class=\"subtitle1\">HBV DNA<br /> (PCR)</td> <td class=\"subtitle1\">ALT</td> <td class=\"subtitle1\">Treatment strategy</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Patients without cirrhosis*</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\" rowspan=\"2\">+</td> <td rowspan=\"2\">&#62;20,000 int. units/mL</td> <td rowspan=\"2\">&#8804;2 x ULN<sup>&#182;</sup></td> <td>Treatment is not recommended, because current treatment has low efficacy in inducing HBeAg seroconversion. Treatment may be considered in older patients (&#62;40 years) and in those with family history of HCC.</td> </tr> <tr class=\"highlight_gray_text\"> <td>Patients should be monitored<sup>&#916;</sup> and treatment considered if ALT becomes elevated &#62;2 x ULN, liver biopsy shows moderate/severe inflammation or fibrosis<sup>&#9674;</sup> (eg, METAVIR score &#8805;F2), and/or noninvasive testing suggests moderate/severe fibrosis.</td> </tr> <tr> <td class=\"centered\" rowspan=\"7\">+</td> <td rowspan=\"7\">&#62;20,000 int. units/mL</td> <td rowspan=\"7\">&#62;2 x ULN<sup>&#182;</sup></td> <td>Observe for 3 to 6 months if compensated and treat if no spontaneous HBeAg loss.</td> </tr> <tr> <td>Immediate treatment if icteric or clinical decompensation (eg, hepatitis B flare).</td> </tr> <tr> <td>ETV, TAF, TDF, or PegIFN alfa&nbsp;are preferred for initial therapy.<sup>&#167;</sup><sup>&#165;</sup></td> </tr> <tr> <td>End-point of treatment&nbsp;<span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">&ndash;</span> Seroconversion from HBeAg to anti-HBe.<sup>&#135;</sup></td> </tr> <tr> <td class=\"sublist1_start\">Duration of therapy:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>PegIFN alfa: 48 weeks. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>ETV, TAF, or TDF: Continue for at least 12 months after HBeAg seroconversion. </li> </ul> </td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\" rowspan=\"5\">&ndash;</td> <td rowspan=\"5\">&#62;2000 int. units/mL</td> <td rowspan=\"5\"> <p>&#62;2 x ULN<sup>&#182;</sup></p> <p>OR</p> 1 to 2 x ULN<sup>&#182;</sup> if liver biopsy shows moderate/severe necroinflammation or significant fibrosis<sup>&#9674;</sup> (eg, METAVIR score &#8805;F2) or non-invasive testing shows significant fibrosis</td> <td>ETV, TAF, TDF, or PegIFN alfa&nbsp;are preferred for initial therapy.<sup>&#167;</sup><sup>&#165;</sup></td> </tr> <tr class=\"highlight_gray_text\"> <td>End-point of treatment&nbsp;<span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">&ndash;</span> HBsAg loss.</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"sublist1_start\">Duration of therapy:</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\"> <ul> <li>PegIFN alfa: One year. </li> </ul> </td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\"> <ul> <li>ETV, TAF, or TDF: Several years or indefinite.<sup>&#134;</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">&ndash;</td> <td>&#8804;2000 int. units/mL</td> <td>&#8804;ULN<sup>&#182;</sup></td> <td>Monitor and treat if HBV DNA and ALT increase as described above.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Patients with cirrhosis*</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\" rowspan=\"5\">+/&ndash;</td> <td rowspan=\"5\">Detectable</td> <td rowspan=\"5\">Any ALT</td> <td class=\"sublist1_start\">Compensated:</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\"> <ul> <li>HBV DNA &#62;2000 int. units/mL&nbsp;<span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">&ndash;</span> Treat with ETV, TAF, or TDF.<sup>&#167;</sup><sup>&#165;</sup> Treatment should be continued indefinitely.** </li> </ul> </td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\"> <ul> <li>HBV DNA &#60;2000 int. units/mL&nbsp;<span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">&ndash;</span> Consider treatment particularly if ALT elevated; close monitoring if treatment is not initiated. </li> </ul> </td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"sublist1_start\">Decompensated:</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\"> <ul> <li>Treat immediately, regardless of ALT or HBV DNA levels. ETV preferred.<sup>&#167;</sup><sup>&#165;</sup> TDF may be used with close monitoring of renal function. Refer for liver transplant. </li> </ul> </td> </tr> <tr> <td class=\"centered\" rowspan=\"2\">+/&ndash;</td> <td rowspan=\"2\">Undetectable</td> <td rowspan=\"2\">Any ALT</td> <td>Compensated: Observe.</td> </tr> <tr> <td>Decompensated: Refer for liver transplant, recheck HBV DNA during follow-up, evaluate for other causes of cirrhosis.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ALT: alanine aminotransferase; anti-HBe: antibody to hepatitis B e antigen; ETV: entecavir; HBeAg: Hepatitis B e antigen; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; PegIFN alfa: pegylated interferon alfa; TAF: tenofovir alafenamide; TDF: tenofovir disoproxil fumarate; ULN: upper limit of normal.<br />* Based upon findings on noninvasive testing or liver biopsy performed during the initial evaluation. Patients with advanced fibrosis determined by noninvasive methods should be evaluated using a second method, and if results are concordant, consider managing the same way as patients with cirrhosis.<br />¶ The American Association for the Study of Liver Diseases (AASLD) recommends using an ALT &gt;30 U/L for men and &gt;19 U/L for women as the upper limit of normal (ULN) rather than local laboratory values.<br />Δ Refer to UpToDate topic on \"Hepatitis B virus: Overview of management\" for a discussion of monitoring.<br /><FONT class=lozenge>◊</FONT> Refer to UpToDate topic on \"Hepatitis B virus: Overview of management\" for a discussion of indications for biopsy.<br />§ Adefovir, lamivudine, and telbivudine are not typically used for initial treatment, due to a high rate of resistance after the first year and/or weak antiviral activity.<br />¥ Refer to UpToDate topic on \"Hepatitis B virus: Overview of management\" for a discussion of which agent to use.<br />‡ Up to 50% of patients who achieve HBeAg seroconversion can experience a virologic relapse after discontinuing treatment with oral agents. Thus, some providers prefer to treat until HBsAg-loss.<br />† For most patients, antiviral therapy should be continued indefinitely. However, treatment discontinuation may be considered in persons without cirrhosis who have demonstrated loss of HBsAg. Persons who stop antiviral therapy should be monitored every month for the first&nbsp;six months.<br />** This includes HBeAg-positive adults with cirrhosis who seroconvert to anti-HBe on therapy.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016 Jan; 63:261.</li>&#xD;&#xA;    <li>Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009; 50:661. Available online at http://publish.aasld.org/Pages/Default.aspx. Accessed September 8th 2009. Copyright &copy; 2009 American Association for the Study of Liver Diseases.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 58520 Version 18.0</div></div></div>"},"58521":{"type":"graphic_diagnosticimage","displayName":"Cryptosporidium cholangitis","title":"Cryptosporidium cholangitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cryptosporidium cholangitis</div><div class=\"cntnt\"><img style=\"width:307px; height:324px;\" src=\"images/GAST/58521_Cryptosporidium_cholangitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic retrograde cholangiopancreatography in a patient with AIDS and a CD4 cell count of 30/mm3 shows sclerosing cholangitis, characterized by multiple irregular strictures throughout the medium size and large ducts, due to Cryptosporidium.</div><div class=\"graphic_reference\">Courtesy of Vivek Raj, MD.</div><div id=\"graphicVersion\">Graphic 58521 Version 2.0</div></div></div>"},"58524":{"type":"graphic_picture","displayName":"Intraoperative congenital diaphragmatic hernia","title":"Intraoperative view of a congenital diaphragmatic hernia prior to primary repair in an infant","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Intraoperative view of a congenital diaphragmatic hernia prior to primary repair in an infant</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/OBGYN/58524_Primary_repair_of_CDH.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Holly L Hedrick, MD.</div><div id=\"graphicVersion\">Graphic 58524 Version 2.0</div></div></div>"},"58528":{"type":"graphic_figure","displayName":"Standard cricothyrotomy step six","title":"Standard cricothyrotomy step six","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Standard cricothyrotomy step six</div><div class=\"cntnt\"><img style=\"width:373px; height:631px;\" src=\"images/EM/58528_Cric_standard_step_six.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><FONT color=black><FONT class=red><FONT color=black>A) Rotate the dilator 90 degrees. B) Insert the tracheostomy tube, and advance the tube into the trachea.</FONT></FONT></FONT></div><div class=\"graphic_reference\">Reproduced with permission from: Custalow CB. Color Atlas of Emergency Department Procedures, Elsevier Saunders, Philadelphia 2005. Copyright &#169;2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 58528 Version 2.0</div></div></div>"},"58529":{"type":"graphic_table","displayName":"Regulation of T4 5 deiodinase","title":"Conditions affecting thyroxine 5'-deiodinase activity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions affecting thyroxine 5'-deiodinase activity</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td colspan=\"1\" rowspan=\"2\" class=\"subtitle1\">Condition</td>\n<td colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">Enzyme type affected*</td>\n\n</tr>\n<tr>\n\n<td class=\"subtitle2\">Type 1</td>\n<td class=\"subtitle2\">Type 2</td>\n</tr>\n<tr>\n<td>Fetus</td>\n<td>Decreased</td>\n<td>Decreased</td>\n</tr>\n<tr>\n<td>Hypothyroidism</td>\n<td>Decreased</td>\n<td>Increased</td>\n</tr>\n<tr>\n<td>Hyperthyroidism</td>\n<td>Increased</td>\n<td>Decreased</td>\n</tr>\n<tr>\n<td>Starvation</td>\n<td>Decreased</td>\n<td>Normal</td>\n</tr>\n<tr>\n<td>Diabetes mellitus</td>\n<td>Decreased</td>\n<td>Normal</td>\n</tr>\n<tr>\n<td>Uremia</td>\n<td>Decreased</td>\n<td>Normal</td>\n</tr>\n<tr>\n<td>Propylthiouracil</td>\n<td>Decreased</td>\n<td>Normal</td>\n</tr>\n<tr>\n<td>Amiodarone</td>\n<td>Decreased</td>\n<td>Decreased</td>\n</tr>\n<tr>\n<td>Propranolol</td>\n<td>Decreased</td>\n<td>?</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_footnotes\">* Type 1 deiodinase predominates in the liver, kidneys, and thyroid; type 2 deiodinase in the brain, pituitary, and skin.</div><div id=\"graphicVersion\">Graphic 58529 Version 1.0</div></div></div>"},"58531":{"type":"graphic_figure","displayName":"Diagram colon rectum PI","title":"Diagram of the colon and rectum","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Diagram of the colon and rectum</div><div class=\"cntnt\"><img style=\"width:459px; height:561px;\" src=\"images/PI/58531_Diagram_colon_rect_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the different parts of the colon (also known as the large intestine), the rectum, and the anus.</div><div id=\"graphicVersion\">Graphic 58531 Version 7.0</div></div></div>"},"58533":{"type":"graphic_table","displayName":"Oral treatment osteoarticular infections children","title":"Doses of oral antibiotics commonly used in the treatment of osteoarticular infections in infants and children >1 month of age*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Doses of oral antibiotics commonly used in the treatment of osteoarticular infections in infants and children &gt;1 month of age*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Oral agent </td> <td class=\"subtitle1\">Dose<sup>&#182;</sup> </td> </tr> <tr> <td>Amoxicillin<sup>&#916;</sup></td> <td>100 mg/kg per day divided in 4 doses</td> </tr> <tr> <td>Cefixime</td> <td>8 mg/kg per day&nbsp;divided in 1 or 2 doses; maximum dose 400 mg/day</td> </tr> <tr> <td>Cephalexin<sup>&#916;</sup></td> <td>100 to 150 mg/kg per day divided in 3 or 4 doses; maximum dose 4 g/day</td> </tr> <tr> <td>Clindamycin</td> <td>25 to 40<sup>&#9674;</sup>&nbsp;mg/kg per day divided in 3 doses; maximum dose&nbsp;2.7 g/day</td> </tr> <tr> <td>Cloxacillin<sup>&#916;&#167;</sup></td> <td>125 mg/kg per day divided in 4 doses</td> </tr> <tr> <td>Dicloxacillin<sup>&#916;</sup></td> <td>100 mg/kg per day divided in 4 doses</td> </tr> <tr> <td>Linezolid </td> <td> <p>&#60;12 years: 30 mg/kg per day divided in 3 doses; maximum dose 1.8 g/day</p> <p>&#8805;12 years: 600 mg twice per day</p> </td> </tr> <tr> <td>Penicillin V<sup>&#916;</sup></td> <td>150 mg/kg per day divided in 6 doses</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Refer to UpToDate topics on treatment of bacterial arthritis and osteomyelitis in children for&nbsp;details regarding indications for particular drugs.<br />¶&nbsp;Recommended doses are for patients with normal renal function. Antibiotics administered orally for&nbsp;osteoarticular infections&nbsp;generally are given in higher doses than those used for treatment of other infections and recommended in package inserts.<br />Δ&nbsp;To achieve adequate serum levels, doses can be increased to 150 to 200 mg/kg per day without serious adverse side effects. Diarrhea can be mitigated by using the doses above and, for children&nbsp;&gt;2 years,&nbsp;adding probenecid 40 mg/kg per day in 4 divided doses (maximum of 2 grams per day).<br />◊ 40 mg/kg per day is preferred for children ≥3 months.<br />§ Cloxacillin is not available in the United States.</div><div id=\"graphicVersion\">Graphic 58533 Version 6.0</div></div></div>"},"58537":{"type":"graphic_table","displayName":"Respiratory signs symptoms ALS","title":"Respiratory signs and symptoms associated with amyotrophic lateral sclerosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Respiratory signs and symptoms associated with amyotrophic lateral sclerosis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td class=\"container\"><table cellspacing=\"0\">\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Lower motor neuron signs\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Tachypnea</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Vocal and speech\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Reduced vocal volume\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Shortened sentences\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Frequent breath pauses\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Use of accessory respiratory muscles</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Abdominal paradox</td>\r\n  \r\n   </tr>\r\n  \r\n   </table></td>\r\n  \r\n   <td class=\"container\"><table cellspacing=\"0\">\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Lower motor neuron symptoms\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Dyspnea and/or orthopnea</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Low speech volume</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Weak cough</td>\r\n  \r\n   </tr>\r\n\r\n   <tr>\r\n  \r\n   <td class=\"sublist1_start\">Sleep disordered breathing</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Frequent nocturnal awakenings, possibly with note of dyspnea\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Excessive daytime sleepiness and/or fatigue\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Morning headache</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Confusion</td>\r\n  \r\n   </tr>\r\n\r\n   <tr>\r\n  \r\n   <td>Hallucinations</td>\r\n  \r\n   </tr>\r\n  \r\n   </table></td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 58537 Version 1.0</div></div></div>"},"58538":{"type":"graphic_diagnosticimage","displayName":"Radiograph of ectopic ureter","title":"Radiograph of ectopic ureter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiograph of ectopic ureter</div><div class=\"cntnt\"><img style=\"width:274px; height:358px;\" src=\"images/OBGYN/58538_Radiograph_of_ectopic_urete.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><SPAN style=\"COLOR: black\">(A) Dye injected via spinal needle (arrow) placed in the suprapubic area under cystoscopic visualization, illustrating left ectopic ureter (B) and extension down the vaginal wall to introitus.</SPAN></div><div id=\"graphicVersion\">Graphic 58538 Version 3.0</div></div></div>"},"58539":{"type":"graphic_table","displayName":"Total fetal loss rate CVS compared with amniocentesis","title":"Total fetal loss rate: CVS compared with amniocentesis in randomized trials","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Total fetal loss rate: CVS compared with amniocentesis in randomized trials</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Study, year </td> <td class=\"subtitle1\" colspan=\"2\">Total loss rate, percent </td> <td class=\"subtitle1\" rowspan=\"2\">Difference, percentage </td> <td class=\"subtitle1\" rowspan=\"2\">Relative risk (95 percent CI) </td> </tr> <tr> <td class=\"subtitle2\">CVS </td> <td class=\"subtitle2\">Amniocentesis </td> </tr> <tr> <td>MRC (1991)</td> <td>13.7 (220/1609)</td> <td>9.0 (144/1592)</td> <td>4.6</td> <td>1.5 (1.2-1.8)</td> </tr> <tr> <td>Smidt-Jensen (1992)</td> <td>9.1 (195/2144)</td> <td>7.0 (81/1158)</td> <td>2.1</td> <td>1.3 (1.1-1.7)</td> </tr> <tr> <td>Overall</td> <td>11.06</td> <td>8.18</td> <td>2.9</td> <td>1.4 (1.2-1.6)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CVS: chorionic villus sampling; MRC: Medical Research Council; CI: confidence interval.</div><div id=\"graphicVersion\">Graphic 58539 Version 6.0</div></div></div>"},"58540":{"type":"graphic_figure","displayName":"Acquired methemoglobinemia","title":"Methemoglobinemia","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Methemoglobinemia</div><div class=\"cntnt\"><img style=\"width:600px; height:174px;\" src=\"images/PEDS/58540_Acq_methemoglobinemia_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Samples of blood with varying methemoglobin levels displayed on white absorbent material.</div><div class=\"graphic_reference\">Reproduced from: Shihana F, Dissanayake DM, Buckley NA, Dawson AH. A simple quantitative bedside test to determine methemoglobin. Ann Emerg Med 2010; 55:184. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 58540 Version 5.0</div></div></div>"},"58541":{"type":"graphic_picture","displayName":"Auricular cellulitis","title":"Auricular cellulitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Auricular cellulitis</div><div class=\"cntnt\"><img style=\"width:269px; height:342px;\" src=\"images/PEDS/58541_Auricular_cellulitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 19-month-old child with a red, swollen, anteriorly displaced auricle after 10 days of treatment with amoxicillin. The posterior aspect of his auricle was erythematous, but his mastoid process was nontender, and his tympanic membrane was normal. Computed tomography demonstrated normal mastoid air cells, and his cellulitis responded to antistaphylococcal antibiotics.</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR, Ludwig W, Baskin MN. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58541 Version 2.0</div></div></div>"},"58542":{"type":"graphic_picture","displayName":"Herpetic stomatitis","title":"Herpetic stomatitis","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Herpetic stomatitis</div><div class=\"cntnt\"><img style=\"width:514px; height:496px;\" src=\"images/PEDS/58542_Herpetic_stomatitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These three children demonstrate the spectrum of oral infection with herpes simplex virus, which ranges from asymptomatic to severe.<br />(A) The first patient has a single vesicle on his tongue.<br />(B) The second manifests widespread labial lesions.<br />(C) The third patient shows dissemination to the face. In the young girl with facial involvement, fluorescein dye is dripping from the left eye after its instillation in an attempt to identify the typical dendritic ulcer seen with herpetic keratitis.</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR, Ludwig W, Baskin MN. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58542 Version 3.0</div></div></div>"},"58544":{"type":"graphic_diagnosticimage","displayName":"XRT variable dose neck","title":"External radiation therapy for thyroid cancer: Variable dose to the neck","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">External radiation therapy for thyroid cancer: Variable dose to the neck</div><div class=\"cntnt\"><img style=\"width:443px; height:430px;\" src=\"images/ENDO/58544_XRT_variable_dose_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiation treatment plan for a 47-year-old woman who presented with locally advanced MTC involving the left recurrent nerve and with esophageal and tracheal invasion. She had bilateral neck dissection: 4 out of 24 nodes were involved on the right and 20 out of 23 on the left with extracapsular invasion. IMRT allows for giving variable dose to the neck depending on the risk of recurrence, while sparing as much normal tissue as possible. The red shaded area represents the volume where there was gross disease before surgery; orange represents the area of potential residual disease; the blue and green shaded area represents the volume of potential residual nodal disease. The volume of tissue within each line (isodose line) receives a minimum dose represented by that line. The yellow line is the 66 Gy isodose line (eg, the orange and red volumes within that line receive a minimum of 66 Gy). The mauve line is the 53.2 Gy isodose line (blue and green volumes receive a minimum of 53.4 Gy). Similar technique may be used for differentiated thyroid cancer.</div><div class=\"graphic_footnotes\">IMRT: intensity modulated radiation therapy; MTC: medullary thyroid cancer.</div><div class=\"graphic_reference\">Courtesy of James D Brierley, MB, BS, FRCP, FRCR, FRCPC.</div><div id=\"graphicVersion\">Graphic 58544 Version 6.0</div></div></div>"},"58546":{"type":"graphic_figure","displayName":"Pap test liquid-based","title":"Liquid-based cervical cytology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Liquid-based cervical cytology</div><div class=\"cntnt\"><img style=\"width:406px; height:434px;\" src=\"images/OBGYN/58546_Pap_test_liquid-based.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Obtaining endocervical portion of Pap test. B) Placement of specimens in liquid collection medium.</div><div class=\"graphic_reference\">Reproduced with permission from: Beckmann CRB, Ling FW, Barzansky BM, et al. Obstetrics and Gynecology, Fifth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright ©2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58546 Version 2.0</div></div></div>"},"58548":{"type":"graphic_figure","displayName":"Neural circuitry of panic attacks","title":"Neural circuitry of panic attacks","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Neural circuitry of panic attacks</div><div class=\"cntnt\"><img style=\"width:495px; height:434px;\" src=\"images/PSYCH/58548_Neur_circuit_panic_attacks.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Original figure modified for this publication. Roy-Byrne, P, Craske, MG, Stein, MB. Panic disorder. Lancet 2006; 368:1023. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 58548 Version 1.0</div></div></div>"},"58549":{"type":"graphic_figure","displayName":"Segmental pressure examination","title":"Segmental pressure examination","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">Segmental pressure examination</div><div class=\"cntnt\"><img style=\"width:602px; height:492px;\" src=\"images/SURG/58549_Segmental_pressure_exam.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A high thigh pressure that differs from the higher brachial systolic value by more than 30 mmHg is considered abnormal. A 20 mmHg or greater reduction between segments in the same leg or compared with the opposite leg at the same level (ie, right thigh/left thigh, right calf/left calf) is indicative of a flow-limiting lesion at that level.<br />In this patient, the right high thigh pressure is abnormal and pressure gradients are present from the high to low thigh, low thigh to calf and calf to ankle indicative of multilevel disease. The ankle-brachial index of 0.17 is consistent with critical limb ischemia. The left extremity demonstrates mild tibial vessel disease with adequate collateralization. The left ankle-brachial index of 0.84 may be consistent with claudication.</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Courtesy of the Division of Vascular Surgery at OHSU.</div><div id=\"graphicVersion\">Graphic 58549 Version 4.0</div></div></div>"},"58550":{"type":"graphic_figure","displayName":"Reconstruction with free TRAM flap PI","title":"Reconstruction with free TRAM flap","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Reconstruction with free TRAM flap</div><div class=\"cntnt\"><img style=\"width:547px; height:698px;\" src=\"images/PI/58550_Reconstr_free_TRAM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Women who have reconstruction with a free TRAM have a flap of tissue cut out of their belly. The flap is made up of skin, fat, and a chunk of muscle. In this surgery, the flap is completely detached from the belly and then attached to the chest. Because the flap is completely detached, surgeons have to reconnect blood vessels that were cut. Unlike the pedicled TRAM surgery, this surgery does not involve creating a tunnel under the skin to put the flap in place. Later, surgeons can also reconstruct a nipple. TRAM stands for &quot;transverse rectus abdominus myocutaneous.&quot;</div><div id=\"graphicVersion\">Graphic 58550 Version 2.0</div></div></div>"},"58552":{"type":"graphic_picture","displayName":"Central line suture","title":"Central venous catheter sutured in place","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Central venous catheter sutured in place</div><div class=\"cntnt\"><img style=\"width:432px; height:232px;\" src=\"images/EM/58552_Central_line_suture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When suturing central venous catheters in place, avoid knots that place excessive pressure on the skin, which can lead to skin necrosis.</div><div class=\"graphic_reference\">UpToDate acknowledges the invaluable assistance of the University of Massacusetts Medical School, Department of Anatomy and Department of Emergency Medicine, including Thomas Ellis, MD and Jean Marcelin, MD, for the photographs of central venous catheter placement.</div><div id=\"graphicVersion\">Graphic 58552 Version 2.0</div></div></div>"},"58553":{"type":"graphic_diagnosticimage","displayName":"MRI schwannoma","title":"A schwannoma of the brachial plexus by MRI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">A schwannoma of the brachial plexus by MRI</div><div class=\"cntnt\"><img style=\"width:240px; height:540px;\" src=\"images/NEURO/58553_MRISchwannoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) T1 showing a rounded mass with homogeneous signal intensity similar to muscle.<br />(B) T2 showing the same mass with high signal intensity, especially on the periphery.<br />(C) T1 with gadolinium showing homogeneous enhancement except for a small rim, suggesting encapsulation.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of James M Gilchrist, MD.</div><div id=\"graphicVersion\">Graphic 58553 Version 4.0</div></div></div>"},"58555":{"type":"graphic_figure","displayName":"Laryngeal anatomy coronal","title":"Laryngeal anatomy in the coronal plane from a posterior view","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Laryngeal anatomy in the coronal plane from a posterior view</div><div class=\"cntnt\"><img style=\"width:519px; height:460px;\" src=\"images/ONC/58555_Laryngeal_anatomy_coronal.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Garrett CG, Ossoff RH. Hoarseness. Med Clin N Am 1999; 83:115. Copyright 1999 W.B. Saunders Company.</div><div id=\"graphicVersion\">Graphic 58555 Version 2.0</div></div></div>"},"58556":{"type":"graphic_table","displayName":"Prog brain mets trip-neg BC","title":"Prognosis of patients with brain metastases from triple-negative breast cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prognosis of patients with brain metastases from triple-negative breast cancer</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Study\n   </td>\n   <td  class=\"subtitle1\">\n   Time period\n   </td>\n   <td  class=\"subtitle1\">\n   Number of patients\n   </td>\n   <td  class=\"subtitle1\">\n   Median survival after CNS recurrence\n   </td>\n   </tr>\n   <tr>\n   <td>Dawood et al<sup>[1]</sup></td>\n   <td>1980-2006</td>\n   <td>42</td>\n   <td>2.9 months</td>\n   </tr>\n   <tr>\n   <td>Lin et al<sup>[2]</sup></td>\n   <td>2000-2006</td>\n   <td>53</td>\n   <td>4.9 months</td>\n   </tr>\n   <tr>\n   <td>Eichler et al<sup>[3]</sup></td>\n   <td>2001-2005</td>\n   <td>21</td>\n   <td>4.0 months</td>\n   </tr>\n   <tr>\n   <td>Nam et al<sup>[4]</sup></td>\n   <td>2001-2006</td>\n   <td>47</td>\n   <td>3.4 months</td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">CNS: central nervous system.</div><div class=\"graphic_reference\">1. Dawood S, Broglio K, Esteva FJ, et al. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 2009; 20:621.<BR>2. Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008; 113:2638.<BR>3. Eichler AF, Kuter I, Ryan P, et al. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 2008; 112:2359.<BR>4. Nam BH, Kim SY, Han HS, et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 2008; 10:R20.</div><div id=\"graphicVersion\">Graphic 58556 Version 2.0</div></div></div>"},"58558":{"type":"graphic_figure","displayName":"Relationship of hypothalamic set-point to body temperature","title":"Relationship of hypothalamic set-point to body temperature","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Relationship of hypothalamic set-point to body temperature</div><div class=\"cntnt\"><img style=\"width:421px; height:344px;\" src=\"images/PEDS/58558_Hypothsetptvstempedt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Euthermia: Hypothalamic set-point is normal, and body temperature approximates set-point and is also normal.<br />Fever: Hypothalamic set-point is elevated, and body temperature follows set-point and is also elevated.<br />Heat illness: Hypothalamic set-point is normal, and body temperature is elevated despite normal set-point.</div><div id=\"graphicVersion\">Graphic 58558 Version 5.0</div></div></div>"},"58561":{"type":"graphic_diagnosticimage","displayName":"Jejunum adeno CA SBFT","title":"Adenocarcinoma of the jejunum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Adenocarcinoma of the jejunum</div><div class=\"cntnt\"><img style=\"width:276px; height:287px;\" src=\"images/GAST/58561_Jejunum_adeno_CA_SBFT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small bowel follow through examination demonstrates a circumferential apple-core lesion of the jejunum (arrow), producing distension of the proximal small bowel.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 58561 Version 3.0</div></div></div>"},"58563":{"type":"graphic_table","displayName":"Pathophysiology respiratory failure in neuromuscular disease","title":"Pathophysiology of neuromuscular respiratory failure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pathophysiology of neuromuscular respiratory failure</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Inadequate ventilation</td> <td class=\"subtitle1\">Hypoxemia</td> <td class=\"subtitle1\">Ineffective cough</td> <td class=\"subtitle1\">Risk for aspiration</td> </tr> <tr> <td>Inspiratory muscle weakness*</td> <td>X</td> <td>X</td> <td>X</td> <td>&nbsp;</td> </tr> <tr> <td>Expiratory muscle weakness<sup>&#182;</sup></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X</td> <td>&nbsp;</td> </tr> <tr> <td>Upper airway muscle weakness<sup>&#916;</sup></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X</td> <td>X</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Inspiratory muscles: diaphgragm, external intercostals, scalenes, sternocleidomastoids, trapezii.<br />¶ Expiratory muscles: abdominals (internal and external oblique, rectus abdominus, transverse abdominus), internal intercostals.<br />Δ Upper airway muscles: abductors and adductors (pharyngeal, laryngeal).</div><div id=\"graphicVersion\">Graphic 58563 Version 3.0</div></div></div>"},"58566":{"type":"graphic_picture","displayName":"Hand-foot-and-mouth disease - buccal","title":"Hand-foot-and-mouth disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hand-foot-and-mouth disease</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/58566_Hand_foot_mouth_dis_buccal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small ulcers are present on the oral mucosa.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 58566 Version 5.0</div></div></div>"},"58567":{"type":"graphic_figure","displayName":"Pain scale PI","title":"Pain scale","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pain scale</div><div class=\"cntnt\"><img style=\"width:430px; height:228px;\" src=\"images/PI/58567_Pain_scale_PI.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 58567 Version 1.0</div></div></div>"},"58569":{"type":"graphic_table","displayName":"Causes of Q waves on the electrocardiogram","title":"Causes of Q waves on the electrocardiogram","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of Q waves on the electrocardiogram</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Physiologic or positional factors</td> </tr> <tr> <td>Normal variant \"septal\" q waves</td> </tr> <tr> <td>Normal variant Q waves in leads V1,V2, aVL, III, and aVF</td> </tr> <tr> <td>Left pneumothorax or dextrocardia: loss of lateral precordial R wave progression</td> </tr> <tr> <td class=\"subtitle1_single\">Myocardial injury or infiltration</td> </tr> <tr> <td>Acute processes: myocardial ischemia or infarction, myocarditis, hyperkalemia</td> </tr> <tr> <td>Chronic processes: myocardial infarction, idiopathic cardiomyopathy, myocarditis, amyloidosis, tumor, sarcoid, scleroderma, Chagas' disease, echinococcus cyst</td> </tr> <tr> <td class=\"subtitle1_single\">Ventricular hypertrophy or enlargement</td> </tr> <tr> <td>Left ventricle: slow R wave progression in which there are small or absent R waves in the mid-precordial leads</td> </tr> <tr> <td>Right ventricle: reversed R wave progression in which there is a progressive decrease in R wave amplitude from V1 to the mid-lateral precordial leads, or slow R wave progression, particularly with chronic obstructive lung disease or acute pulmonary embolism</td> </tr> <tr> <td>Hypertrophic cardiomyopathy - may simulate anterior, inferior, posterior, or lateral infarcts</td> </tr> <tr> <td class=\"subtitle1_single\">Conduction abnormalities</td> </tr> <tr> <td>Left bundle branch block - slow R wave progression in which there are small or absent R waves in the mid-precordial leads</td> </tr> <tr> <td>Wolff-Parkinson-White patterns</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58569 Version 2.0</div></div></div>"},"58574":{"type":"graphic_table","displayName":"Caffeine source amount PI","title":"Caffeine source and amount*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Caffeine source and amount*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Source </td> <td class=\"subtitle1\">Caffeine (mg) </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Coffee </td> </tr> <tr> <td class=\"indent1\">Drip (8 ounces) </td> <td>234</td> </tr> <tr> <td class=\"indent1\">Percolated (8 ounces) </td> <td>176</td> </tr> <tr> <td class=\"indent1\">Regular instant (8 ounces) </td> <td>85</td> </tr> <tr> <td class=\"indent1\">Decaffeinated instant (8 ounces) </td> <td>3</td> </tr> <tr> <td class=\"indent1\">Espresso (1 to 2 ounces) </td> <td>45 to 100</td> </tr> <tr> <td class=\"indent1\">Starbucks grande (16 ounces) </td> <td>330</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Cocoa and chocolate </td> </tr> <tr> <td class=\"indent1\">Cocoa from mix (6 ounces) </td> <td>10</td> </tr> <tr> <td class=\"indent1\">Milk chocolate (1 ounce) </td> <td>6</td> </tr> <tr> <td class=\"indent1\">Baking chocolate (1 ounce) </td> <td>35</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Soft drinks (12 ounces) </td> </tr> <tr> <td class=\"indent1\">Dr. Pepper </td> <td>39.6</td> </tr> <tr> <td class=\"indent1\">Regular cola </td> <td>46</td> </tr> <tr> <td class=\"indent1\">Diet cola </td> <td>46</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Tea </td> </tr> <tr> <td class=\"indent1\">One-minute brew </td> <td>9 to 33</td> </tr> <tr> <td class=\"indent1\">Three-minute brew </td> <td>20 to 46</td> </tr> <tr> <td class=\"indent1\">Instant </td> <td>12 to 28</td> </tr> <tr> <td class=\"indent1\">Canned iced tea (12 ounces) </td> <td>22 to 36</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* It is important to remember that these figures are approximate and vary among products. In addition, different types of beans and teas have different caffeine contents, and the way the beverage is brewed also affects the caffeine content.</div><div id=\"graphicVersion\">Graphic 58574 Version 3.0</div></div></div>"},"58575":{"type":"graphic_diagnosticimage","displayName":"CT enteric fistula","title":"Entero-enteric fistula in Crohn disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Entero-enteric fistula in Crohn disease</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/GAST/58575_CT_enteric_fistula.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal reformat computed tomography (CT) scan with both intravenous and oral contrast demonstrates an entero-enteric fistula between the ileum and cecum in this patient with Crohn disease.</div><div class=\"graphic_reference\">Courtesy of J Pierre Sasson, MD.</div><div id=\"graphicVersion\">Graphic 58575 Version 3.0</div></div></div>"},"58576":{"type":"graphic_diagnosticimage","displayName":"Forearm bowing fracture","title":"Forearm bowing fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Forearm bowing fracture</div><div class=\"cntnt\"><img style=\"width:237px; height:432px;\" src=\"images/EM/58576_Forearmbowingfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bowing fracture with approximately 15 degrees of apex dorsal bowing of the radius and ulna.</div><div class=\"graphic_reference\">Reproduced with permission from: Mehlman CT, Wall EJ. Injuries to the shafts of the radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 58576 Version 12.0</div></div></div>"},"58577":{"type":"graphic_figure","displayName":"Average annual fracture rate","title":"Annual fracture rate in men and women","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Annual fracture rate in men and women</div><div class=\"cntnt\"><img style=\"width:509px; height:300px;\" src=\"images/ENDO/58577_Average_annual_fracture_rat.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Average annual fracture incidence rate per 10,000 men and women in Leicester, United Kingdom. The rate begins to increase in women after age 44 years as they enter menopause and in men after age 74 years.</div><div class=\"graphic_reference\">Reproduced with permission from: Donaldson LJ, Cook A, Thomson RG. Incidence of fractures in a geographically defined population.&nbsp;J Epidemiol Community Health 1990; 44:241.</div><div id=\"graphicVersion\">Graphic 58577 Version 2.0</div></div></div>"},"58578":{"type":"graphic_table","displayName":"MEN2 genotype timing progression","title":"RET mutation-related youngest age of onset of MTC","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">RET mutation-related youngest age of onset of MTC</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Age-related progression of hereditary MTC depends on RET genotype</td> </tr> <tr> <td class=\"subtitle2\">RET genotype of MTC</td> <td class=\"subtitle2\">Youngest age at first diagnosis</td> </tr> <tr> <td>918</td> <td>9&nbsp;months</td> </tr> <tr> <td>630</td> <td>12 months</td> </tr> <tr> <td>634</td> <td>15 months</td> </tr> <tr> <td>609</td> <td>5&nbsp;years</td> </tr> <tr> <td>620</td> <td>6&nbsp;years</td> </tr> <tr> <td>804</td> <td>6&nbsp;years</td> </tr> <tr> <td>611</td> <td>7&nbsp;years</td> </tr> <tr> <td>618</td> <td>7&nbsp;years</td> </tr> <tr> <td>790</td> <td>10 years</td> </tr> <tr> <td>891</td> <td>13 years</td> </tr> <tr> <td>912</td> <td>14 years</td> </tr> <tr> <td>533</td> <td>21 years</td> </tr> <tr> <td>791</td> <td>21 years</td> </tr> <tr> <td>768</td> <td>22 years</td> </tr> <tr> <td>666</td> <td>35 years</td> </tr> <tr> <td>649</td> <td>44 years</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MTC: medullary thyroid cancer.</div><div class=\"graphic_reference\">Data from: de Groot JW, Links TP, Plukker JT, et al. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 2006; 27:535.</div><div id=\"graphicVersion\">Graphic 58578 Version 3.0</div></div></div>"},"58579":{"type":"graphic_table","displayName":"Best pract infection prevention","title":"Best practices for preventing surgical site infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Best practices for preventing surgical site infections</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Evidence category IA - Well designed studies</td> </tr> <tr> <td class=\"indent1\">Cancel elective surgery if the patient has an infection at or remote from the surgical site</td> </tr> <tr> <td class=\"indent1\">Achieve maximal subcutaneous concentration of perioperative antibiotics</td> </tr> <tr> <td class=\"indent1\">Maintain prophylactic antibiotics for only a few hours after closing incisions</td> </tr> <tr> <td class=\"indent1\">If it is necessary to remove hair, use clippers, not shaving, immediately before operation</td> </tr> <tr> <td class=\"subtitle1_single\">Evidence category IB - Good evidence and expert consensus</td> </tr> <tr> <td class=\"indent1\">Control glucose levels in diabetic patients and avoid perioperative hyperglycemia</td> </tr> <tr> <td class=\"indent1\">Encourage patients who use tobacco products to quit using or to abstain for 30 days prior to surgery</td> </tr> <tr> <td class=\"indent1\">Have the patient shower or bathe with an antiseptic agent on at least the night before surgery</td> </tr> <tr> <td class=\"indent1\">Follow strict standards for sterilizing instruments, disinfecting operating room, and air circulation</td> </tr> <tr> <td class=\"indent1\">Do not routinely use vancomycin for prophylaxis if other agents are appropriate</td> </tr> <tr> <td class=\"indent1\">Do not use UV radiation in the operating room for infection prophylaxis</td> </tr> <tr> <td class=\"indent1\">Surgical staff who have draining skin lesions are excluded from duty</td> </tr> <tr> <td class=\"indent1\">Surgical staff should wear sterile clothing and gloves</td> </tr> <tr> <td class=\"indent1\">Surgical team hand hygiene to include keeping fingernails short, scrubing with antiseptic to elbows for two to five minutes, using sterile towels</td> </tr> <tr> <td class=\"indent1\">Use appropriate topical microbicides during surgery</td> </tr> <tr> <td class=\"indent1\">Use proper surgical technique</td> </tr> <tr> <td class=\"indent1\">Apply sterile dressing to incision for 24 to 48 hours postoperatively and wash hands before contact with surgical site</td> </tr> <tr> <td class=\"indent1\">Perform hospital surveillance for surgical site infection</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: the Centers for Disease Control Guidelines for Prevention of Surgical Site Infection (www.cdc.gov/ncidod/dhqp/gl_surgicalsite.html).</div><div id=\"graphicVersion\">Graphic 58579 Version 4.0</div></div></div>"},"58580":{"type":"graphic_table","displayName":"LN metastases in endometrial CA","title":"Incidence of pelvic and para-aortic lymph node metastases in clinical stage I endometrial carcinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incidence of pelvic and para-aortic lymph node metastases in clinical stage I endometrial carcinoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Histologic grade</td> <td class=\"subtitle1\" rowspan=\"2\">n</td> <td class=\"subtitle1\" colspan=\"4\">Depth of myometrial invasion</td> </tr> <tr> <td class=\"subtitle2\">None</td> <td class=\"subtitle2\">Inner third</td> <td class=\"subtitle2\">Middle third</td> <td class=\"subtitle2\">Outer third</td> </tr> <tr> <td class=\"subtitle3\" colspan=\"2\">&nbsp;</td> <td class=\"subtitle3\" colspan=\"4\">Percent pelvic lymph nodes involved</td> </tr> <tr> <td>1</td> <td>180</td> <td>0</td> <td>3</td> <td>0</td> <td>11</td> </tr> <tr> <td>2</td> <td>288</td> <td>3</td> <td>5</td> <td>9</td> <td>19</td> </tr> <tr> <td>3</td> <td>153</td> <td>0</td> <td>9</td> <td>4</td> <td>34</td> </tr> <tr> <td class=\"subtitle3\" colspan=\"2\">&nbsp;</td> <td class=\"subtitle3\" colspan=\"4\">Percent para-aortic lymph nodes involved</td> </tr> <tr> <td>1</td> <td>180</td> <td>0</td> <td>1</td> <td>5</td> <td>6</td> </tr> <tr> <td>2</td> <td>288</td> <td>3</td> <td>4</td> <td>0</td> <td>14</td> </tr> <tr> <td>3</td> <td>153</td> <td>0</td> <td>4</td> <td>0</td> <td>24</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Creasman WT, Morrow CP, Bundy BN, et al, Cancer 1987; 60(8 Suppl):2035.</div><div id=\"graphicVersion\">Graphic 58580 Version 3.0</div></div></div>"},"58581":{"type":"graphic_picture","displayName":"Infant status post frenulotomy","title":"Infant status post-frenulotomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infant status post-frenulotomy</div><div class=\"cntnt\"><img style=\"width:325px; height:354px;\" src=\"images/PEDS/58581_Post_frenulotomy_infant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photo shows an infant whose short frenulum has been clipped (frenulotomy).</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 58581 Version 3.0</div></div></div>"},"58583":{"type":"graphic_picture","displayName":"Fibrosing NSIP histology","title":"Nonspecific interstitial pneumonia, fibrosing pattern","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Nonspecific interstitial pneumonia, fibrosing pattern</div><div class=\"cntnt\"><img style=\"width:458px; height:290px;\" src=\"images/PULM/58583_Fibrosing_NSIP_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The alveolar walls show diffuse thickening by fibrosis and mild interstitial inflammation. No fibroblastic foci are present. The alveolar walls are thickened by dense collagen and a few lymphocytes and plasma cells.</div><div id=\"graphicVersion\">Graphic 58583 Version 2.0</div></div></div>"},"58584":{"type":"graphic_diagnosticimage","displayName":"Digital angiogram in MCTD","title":"Digital angiogram in mixed connective tissue disease (MCTD) vasculopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Digital angiogram in mixed connective tissue disease (MCTD) vasculopathy</div><div class=\"cntnt\"><img style=\"width:303px; height:360px;\" src=\"images/RHEUM/58584_Digital_angiogram_in_MCTD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Digital angiogram in a patient with mixed connective tissue disease shows an attenuated distal ulnar artery (arrow), absence of the deep palmar arch, and absence or compromise of several digital arteries including that to the fifth digit. Such medium-sized arterial disease is common in this disorder.</div><div class=\"graphic_reference\">Courtesy of Robert M Bennett, MD.</div><div id=\"graphicVersion\">Graphic 58584 Version 2.0</div></div></div>"},"58586":{"type":"graphic_picture","displayName":"Cryoglobulinemic vasculitis","title":"Cryoglobulinemic vasculitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cryoglobulinemic vasculitis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/58586_Cryoglobulinemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ulcers are present on the lower legs in this patient with cryoglobulinemic vasculitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 58586 Version 4.0</div></div></div>"},"58587":{"type":"graphic_table","displayName":"Risk factors for dengue HF","title":"Factors that influence the risk for dengue hemorrhagic fever","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors that influence the risk for dengue hemorrhagic fever</div><div class=\"cntnt\"><table cellspacing=\"0\"> <tbody>\n<tr> <td class=\"subtitle1\">Factor</td> <td class=\"subtitle1\">Low risk</td> <td class=\"subtitle1\">High risk</td> </tr> <tr>\n<td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">Viral\nfactors</td> </tr> <tr> <td class=\"indent1\">Viral\nserotype</td> <td>&nbsp;</td> <td>Dengue-2\nvirus</td> </tr> <tr> <td class=\"indent1\">Viral\ngenotype</td> <td>&nbsp;</td> <td>\"Asian\"\ngenotypes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">Host\nfactors</td> </tr> <tr> <td class=\"indent1\">Immunity</td>\n<td>&nbsp;</td> <td>Prior dengue virus infection</td>\n</tr> <tr> <td class=\"indent1\">Age</td>\n<td>Adult</td> <td>&nbsp;</td> </tr>\n<tr> <td class=\"indent1\">Nutrition</td> <td>Malnourished</td>\n<td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Genetics</td> <td>Black</td>\n<td>&nbsp;</td> </tr> </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 58587 Version 1.0</div></div></div>"},"58588":{"type":"graphic_picture","displayName":"Wrights stain yeast","title":"Wright's-stained peripheral blood smear showing intracellular elongated yeast-like organisms with clear central septum, a typical characteristic of <em>Penicillium marneffei</em>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Wright's-stained peripheral blood smear showing intracellular elongated yeast-like organisms with clear central septum, a typical characteristic of <em>Penicillium marneffei</em></div><div class=\"cntnt\"><img style=\"width:396px; height:328px;\" src=\"images/ID/58588_Wrights_stain_yeast.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Drs. Khuanchai Supparatpinyo and Thira Sirisanthana.</div><div id=\"graphicVersion\">Graphic 58588 Version 1.0</div></div></div>"},"58590":{"type":"graphic_table","displayName":"Indications for OB ultrasound","title":"Indications for ultrasound examination during pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for ultrasound examination during pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">First-trimester ultrasonography</td> </tr> <tr> <td class=\"subtitle2_single\">Indications for first-trimester ultrasonography include, but are not limited to the following:</td> </tr> <tr> <td class=\"indent2\">To confirm the presence of an intrauterine pregnancy</td> </tr> <tr> <td class=\"indent2\">To evaluate a suspected ectopic pregnancy</td> </tr> <tr> <td class=\"indent2\">To evaluate vaginal bleeding</td> </tr> <tr> <td class=\"indent2\">To evaluate&nbsp;pelvic pain</td> </tr> <tr> <td class=\"indent2\">To estimate&nbsp;gestational age</td> </tr> <tr> <td class=\"indent2\">To diagnose&nbsp;or evaluate multiple gestations</td> </tr> <tr> <td class=\"indent2\">To confirm&nbsp;cardiac activity</td> </tr> <tr> <td class=\"indent2\">As adjunct&nbsp;to chorionic villus sampling, embryo transfer, or localization and removal of an intrauterine device</td> </tr> <tr> <td class=\"indent2\">To assess&nbsp;for certain fetal anomalies, such as anencephaly, in patients at high risk</td> </tr> <tr> <td class=\"indent2\">To evaluate&nbsp;maternal pelvic or adnexal masses or uterine abnormalities</td> </tr> <tr> <td class=\"indent2\">To screen for fetal aneuploidy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">To evaluate&nbsp;suspected hydatidiform mole</td> </tr> <tr> <td class=\"subtitle1_single\">Second- and third-trimester ultrasonography</td> </tr> <tr> <td class=\"subtitle2_single\">Indications for second- and third-trimester ultrasonography include, but are not limited to the following:</td> </tr> <tr> <td class=\"indent2\">Screening for fetal anomalies</td> </tr> <tr> <td class=\"indent2\">Evaluation of fetal anatomy</td> </tr> <tr> <td class=\"indent2\">Estimation of gestational age</td> </tr> <tr> <td class=\"indent2\">Evaluation of fetal growth</td> </tr> <tr> <td class=\"indent2\">Evaluation of vaginal bleeding</td> </tr> <tr> <td class=\"indent2\">Evaluation of abdominal or pelvic pain</td> </tr> <tr> <td class=\"indent2\">Evaluation of cervical insufficiency</td> </tr> <tr> <td class=\"indent2\">Determination of fetal presentation</td> </tr> <tr> <td class=\"indent2\">Evaluation of suspected multiple gestation</td> </tr> <tr> <td class=\"indent2\">Adjunct to amniocentesis or other procedure</td> </tr> <tr> <td class=\"indent2\">Evaluation of a significant discrepancy between uterine size and clinical dates</td> </tr> <tr> <td class=\"indent2\">Evaluation of a pelvic mass</td> </tr> <tr> <td class=\"indent2\">Evaluation of a suspected hydatidiform mole</td> </tr> <tr> <td class=\"indent2\">Adjunct to cervical cerclage placement</td> </tr> <tr> <td class=\"indent2\">Suspected ectopic pregnancy</td> </tr> <tr> <td class=\"indent2\">Suspected fetal death</td> </tr> <tr> <td class=\"indent2\">Suspected uterine abnormalities</td> </tr> <tr> <td class=\"indent2\">Evaluation of fetal well-being</td> </tr> <tr> <td class=\"indent2\">Suspected amniotic fluid abnormalities</td> </tr> <tr> <td class=\"indent2\">Suspected placental abruption</td> </tr> <tr> <td class=\"indent2\">Adjunct to external cephalic version</td> </tr> <tr> <td class=\"indent2\">Evaluation of prelabor rupture of membranes or premature labor</td> </tr> <tr> <td class=\"indent2\">Evaluation of abnormal biochemical markers</td> </tr> <tr> <td class=\"indent2\">Follow-up evaluation of a fetal anomaly</td> </tr> <tr> <td class=\"indent2\">Follow-up evaluation of placental location for suspected placenta previa</td> </tr> <tr> <td class=\"indent2\">History of previous congenital anomaly</td> </tr> <tr> <td class=\"indent2\">Evaluation of the fetal condition in late registrants for prenatal care</td> </tr> <tr> <td class=\"indent2\">Assessment for findings that may increase the risk of aneuploidy</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A sonographic study should only be performed for a valid medical indication. Nonmedical use of obstetric ultrasonography has been discouraged by major societies, including the American College of Obstetricians and Gynecologists (ACOG), the American Institute of Ultrasound in Medicine (AIUM), and the International Society of Ultrasound in Obstetrics and Gynecology.</div><div class=\"graphic_reference\">Reprinted with permission from: Ultrasound in pregnancy. Practice Bulletin No. 175. American College of Obstetricians and Gynecologists. Obstet Gynecol 2016; 128:e241-56.</div><div id=\"graphicVersion\">Graphic 58590 Version 4.0</div></div></div>"},"58592":{"type":"graphic_table","displayName":"Definitions for estimating magnitude of effects","title":"Definitions for estimating magnitude of effects","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definitions for estimating magnitude of effects</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Size of effect</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td rowspan=\"3\">Small/slight</td> <td><strong>Pain scales:</strong> Mean 5 to 10 mm improvement on a 100 mm visual analogue scale (VAS), or equivalent</td> </tr> <tr> <td><strong>Back-specific functional status:</strong> Mean 5 to 10 mm improvement on the Oswestry Disability Index (ODI), 1 to 2 points on the Roland-Morris Disability Questionnaire (RDQ), or equivalent</td> </tr> <tr> <td><strong>All outcomes:</strong> Standardized mean difference (SMD) 0.2 to 0.5</td> </tr> <tr> <td rowspan=\"3\">Moderate</td> <td><strong>Pain scales:</strong> Mean 10 to 20 mm improvement on a 100 mm VAS, or equivalent</td> </tr> <tr> <td><strong>Back-specific functional status:</strong> Mean 10 to 20 mm improvement on the ODI, 2 to 5 points on the RDQ, or equivalent</td> </tr> <tr> <td><strong>All outcomes:</strong> SMD 0.5 to 0.8</td> </tr> <tr> <td rowspan=\"3\">Large/substantial</td> <td><strong>Pain scales:</strong> Mean &#62;20 mm improvement on a 100 mm VAS, or equivalent</td> </tr> <tr> <td><strong>Back-specific functional status:</strong> Mean &#62;20 mm improvement on the ODI, &#62;5 points on the RDQ, or equivalent</td> </tr> <tr> <td><strong>All outcomes:</strong> SMD &#62;0.8</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58592 Version 2.0</div></div></div>"},"58593":{"type":"graphic_figure","displayName":"Tompkins metroplasty E","title":"Tompkins metroplasty (E)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tompkins metroplasty (E)</div><div class=\"cntnt\"><img style=\"width:450px; height:357px;\" src=\"images/OBGYN/58593_Tompkins_metroplasty_E.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(E) After which the superficial myometrium and serosa are closed with an imbricating suture.</div><div id=\"graphicVersion\">Graphic 58593 Version 1.0</div></div></div>"},"58594":{"type":"graphic_waveform","displayName":"Advanced case 4","title":"Advanced case 4","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Advanced case 4</div><div class=\"cntnt\"><img style=\"width:408px; height:360px;\" src=\"images/CARD/58594_Advanced_case_4.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 58594 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"58596":{"type":"graphic_table","displayName":"Types of airway stents","title":"Advantages and disadvantages of different airway stents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Advantages and disadvantages of different airway stents</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n      <td class=\"subtitle1\">Advantages</td>\n\n      <td class=\"subtitle1\">Disadvantages</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"1\">Silicone stents</td>\n\n      <td colspan=\"1\" rowspan=\"1\"><p>Easily inserted</p>\n\t\t<p>Repositioning and removal are easily accomplished</p></td>\n\n      <td colspan=\"1\" rowspan=\"1\"><p>Rigid bronchoscopy and general anesthesia required</p>\n\t\t<p>Stent migration is common</p>\n\t\t<p>Granulation tissue may obstruct proximal or distal ends of stent</p></td>\n\n    </tr>\n\n\n    \n\n    \n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"1\">Metal stents</td>\n\n      <td colspan=\"1\" rowspan=\"1\"><p>May be introduced with fiberoptic scope without general anesthesia</p>\n\t\t<p>Self-expanding; resist extrinsic compression</p>\n\t\t<p>Minimal migration after placement</p></td>\n\n      <td colspan=\"1\" rowspan=\"1\"><p>Cannot be easily removed or repositioned</p>\n\t\t<p>Granulation tissue or tumor easily grows through spaces between metal struts</p>\n\t\t<p>Expansile force may rupture airways and vascular structures</p>\n\t\t<p>More expensive than silicone stents</p></td>\n\n    </tr>\n\n    \n\n\n    \n\n    \n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"1\">Hybrid stents</td>\n\n      <td colspan=\"1\" rowspan=\"1\"><p>Resist extrinsic compression</p>\n\t\t<p>Silicone membrane resists ingrowth of tumor or granulation tissue</p></td>\n\n      <td colspan=\"1\" rowspan=\"1\"><p>Cannot be easily removed or repositioned</p>\n\t\t<p>Most expensive</p></td>\n\n    </tr>\n\n    \n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 58596 Version 1.0</div></div></div>"},"58598":{"type":"graphic_table","displayName":"Major language milestones","title":"Major speech, language, and communication milestones*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major speech, language, and communication milestones*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Expressive language skill</td> <td class=\"subtitle1\">Receptive language skill</td> <td class=\"subtitle1\">Gestural communication skill</td> </tr> <tr class=\"divider_bottom\"> <td>Birth to 2 months</td> <td>Cries</td> <td>Turns toward sound</td> <td>-</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">2 to 4 months</td> <td class=\"divider_bottom\" rowspan=\"2\">Coos (makes open vowel sounds: \"ooh\"; \"aah\")</td> <td>Social smile</td> <td class=\"divider_bottom\" rowspan=\"2\">-</td> </tr> <tr class=\"divider_bottom\"> <td>Watches faces intently</td> </tr> <tr class=\"divider_bottom\"> <td>6 months</td> <td>Babbles (repetitive consonant-vowel combinations (\"bababa\"; \"mamama\")</td> <td>Responds to name</td> <td>-</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">12 months</td> <td>Says first word/word approximation</td> <td>Follows one-step verbal command with gesture (eg, \"Give me the ball\")</td> <td>Visually follows adult's pointing</td> </tr> <tr> <td>Uses jargon/babbles with inflection</td> <td class=\"divider_bottom\" rowspan=\"2\">Responds to \"no\" (eg, stops activity)</td> <td>Points to request (12 to 14 months)</td> </tr> <tr class=\"divider_bottom\"> <td>Repeats sounds or gestures to get attention</td> <td>Starts to use gestures (eg, shaking head \"no\")</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">15 to 18 months</td> <td class=\"divider_bottom\" rowspan=\"2\">Points to common body parts when named</td> <td class=\"divider_bottom\" rowspan=\"2\">Follows one-step verbal command without gesture</td> <td>Points to share attention/enjoyment with another person (not just to request things)</td> </tr> <tr class=\"divider_bottom\"> <td>Shows objects to another person</td> </tr> <tr class=\"divider_bottom\"> <td>18 to 24 months</td> <td>Uses<sup>&#182;</sup> two-word phrases (\"Mommy milk\"; \"go outside\")</td> <td>Points to objects or people when named</td> <td>-</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">24 to 36 months</td> <td>Answers simple questions (\"What's your name?\"; \"Who's that?\")</td> <td class=\"divider_bottom\" rowspan=\"2\">Follows two-step verbal command</td> <td class=\"divider_bottom\" rowspan=\"2\">-</td> </tr> <tr class=\"divider_bottom\"> <td>50% intelligible</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">36 to 48 months</td> <td>Uses four- to five-word sentences</td> <td class=\"divider_bottom\" rowspan=\"3\">Understands placement in space (on, in, under)</td> <td class=\"divider_bottom\" rowspan=\"3\">-</td> </tr> <tr> <td>Uses pronouns and some plurals</td> </tr> <tr class=\"divider_bottom\"> <td>75% intelligible</td> </tr> <tr> <td rowspan=\"2\">48 to 72 months</td> <td>Uses full sentences with grammatical markings (eg, plurals, verb endings)</td> <td rowspan=\"2\">Follows three-step verbal command</td> <td rowspan=\"2\">-</td> </tr> <tr> <td>100% intelligible</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* A general knowledge of skills that are typical for age (milestones/50th percentile skills) is important in order to conduct general developmental surveillance in primary care. However, milestones are not particularly helpful in making decisions about which children may require more formal evaluation or closer monitoring. This is because of the significant variability in the normal range of development of different skills in young children. Red flags (usually the 90th percentile for skill attainment) are more helpful in clinical decision-making<sup>[1]</sup>.<br />&para; Young children's use of words implies spontaneous expression of words or word approximation to communicate a request or to interact with another person. Echoing or immediately repeating words spoken by a caregiver does not constitute having or using words in the meaning of the milestone.</div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Sices L. Use of developmental milestones in pediatric residency training and practice: time to rethink the meaning of the mean. J Dev Behav Pediatr 2007; 28:47. </LI></OL></div><div id=\"graphicVersion\">Graphic 58598 Version 5.0</div></div></div>"},"58600":{"type":"graphic_table","displayName":"Indications endometrial evaluation","title":"Women who should undergo evaluation for endometrial hyperplasia or endometrial cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Women who should undergo evaluation for endometrial hyperplasia or endometrial cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Abnormal uterine bleeding</strong></td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Postmenopausal women &ndash; Any uterine bleeding, regardless of volume (including spotting or staining). Pelvic ultrasound to evaluate endometrial thickness is an&nbsp;alternative to endometrial sampling in appropriately selected women.&nbsp;A thickened endometrium should be further evaluated with endometrial sampling. </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Age 45 years to menopause&nbsp;&ndash; In any woman, bleeding that is frequent (interval between the onset of bleeding episodes is &#60;21 days), heavy, or prolonged (&#62;5 days). In women who are ovulatory, this includes intermenstrual bleeding.<span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\"> </span></li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Younger than 45 years&nbsp;&ndash; Any abnormal uterine bleeding in obese women (BMI &#8805;30). In non-obese women, abnormal uterine bleeding that is persistent and occurs in the setting of one of the following: chronic ovulatory dysfunction, other exposure to estrogen unopposed by progesterone, failed medical management of the bleeding, or women at high risk of endometrial cancer (eg, Lynch syndrome, Cowden syndrome).</li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>In addition, endometrial neoplasia should be suspected in premenopausal women who are anovulatory and have prolonged periods of amenorrhea (six or more months). </li> </ul> </td> </tr> <tr> <td><strong>Cervical cytology results</strong></td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Presence of AGC-endometrial. </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Presence of AGC-all subcategories other than endometrial &ndash; If &#8805;35 years&nbsp;of&nbsp;age&nbsp;OR at risk for endometrial cancer (risk factors or symptoms). </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Presence of benign-appearing endometrial cells in women &#8805;40 years of age who also have abnormal uterine bleeding or risk factors for endometrial cancer. </li> </ul> </td> </tr> <tr> <td><strong>Other indications</strong></td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Monitoring of women with endometrial pathology (eg, endometrial hyperplasia). </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Screening in women at high risk of endometrial cancer (eg, Lynch syndrome). </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These recommendations are based on an average age of menopause of 51 years. Evaluation of women who undergo menopause earlier should be individualized based upon gynecologic history and risk of endometrial neoplasia.</div><div class=\"graphic_footnotes\">BMI: body mass index; AGC: atypical glandular cells.</div><div id=\"graphicVersion\">Graphic 58600 Version 11.0</div></div></div>"},"58601":{"type":"graphic_picture","displayName":"Trypanosomiasis Romanas sign","title":"Romaña’s sign","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Romaña’s sign</div><div class=\"cntnt\"><img style=\"width:381px; height:193px;\" src=\"images/ID/58601_TrypanosomiasisRomanassig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Unilateral eyelid edema is the Romaña's sign of <EM>Trypanosoma cruzi</EM> infection. This agent causes Chagas' disease and is found in Central and South America.</div><div class=\"graphic_reference\">Courtesy of Joy D Jester, Rolando E Saenz, Lee T Nesbitt, Jr, and WA Krotoski. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 58601 Version 9.0</div></div></div>"},"58602":{"type":"graphic_figure","displayName":"Effacement and dilatation","title":"Effacement and dilatation of the cervix","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Effacement and dilatation of the cervix</div><div class=\"cntnt\"><img style=\"width:472px; height:303px;\" src=\"images/OBGYN/58602_Effacement_and_dilatation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Cervix is uneffaced and minimally dilated.<br />(B) Cervix is almost completely effaced and dilated.</div><div id=\"graphicVersion\">Graphic 58602 Version 3.0</div></div></div>"},"58603":{"type":"graphic_table","displayName":"Cetuximab dose modify derm tox","title":"Dose modification guidelines for cetuximab (Erbitux) based upon cutaneous adverse reaction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dose modification guidelines for cetuximab (Erbitux) based upon cutaneous adverse reaction</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Severe acneiform rash</td> <td class=\"subtitle1\">Initial management</td> <td class=\"subtitle1\">Outcome </td> <td class=\"subtitle1\">Dose modification</td> </tr> <tr> <td rowspan=\"2\">First occurrence</td> <td rowspan=\"2\">Delay infusion 1 to 2 weeks</td> <td>Improvement</td> <td>Continue at 250 mg/m<sup>2</sup></td> </tr> <tr> <td>No improvement</td> <td>Discontinue cetuximab</td> </tr> <tr> <td rowspan=\"2\">Second occurrence</td> <td rowspan=\"2\">Delay infusion 1 to 2 weeks</td> <td>Improvement</td> <td>Reduce dose to 200 mg/m<sup>2</sup></td> </tr> <tr> <td>No improvement</td> <td>Discontinue cetuximab</td> </tr> <tr> <td rowspan=\"2\">Third occurrence</td> <td rowspan=\"2\">Delay infusion 1 to 2 weeks</td> <td>Improvement</td> <td>Reduce dose to 150 mg/m<sup>2</sup></td> </tr> <tr> <td>No improvement</td> <td>Discontinue cetuximab</td> </tr> <tr> <td>Fourth occurrence</td> <td>Discontinue cetuximab</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Erbitux (cetuximab) package insert, ImClone LLC, August, 2013.</div><div id=\"graphicVersion\">Graphic 58603 Version 5.0</div></div></div>"},"58605":{"type":"graphic_form","displayName":"Diet diary PI","title":"Diet diary","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Diet diary</div><div class=\"cntnt\"><img style=\"width:599px; height:788px;\" src=\"images/PI/58605_Diet_diary_PI_edt.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 58605 Version 5.0</div></div></div>"},"58606":{"type":"graphic_picture","displayName":"Necrotizing periodontal dis","title":"Necrotizing periodontal disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Necrotizing periodontal disease</div><div class=\"cntnt\"><img style=\"width:427px; height:575px;\" src=\"images/PC/58606_Necrotizing_periodontal_dis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Presence of alveolar bone sequestrum in an HIV-positive 35-year-old Caucasian male.</div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.</div><div id=\"graphicVersion\">Graphic 58606 Version 2.0</div></div></div>"},"58607":{"type":"graphic_table","displayName":"Surgical risk groups","title":"Categories of risk for venous thromboembolism in surgical patients (From the 2004 ACCP Guidelines)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Categories of risk for venous thromboembolism in surgical patients (From the 2004 ACCP Guidelines)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Low risk:</td> </tr> <tr> <td class=\"sublist1_start\">Minor surgery in patients &#60;40 years of age with no additional risk factors present*</td> </tr> <tr> <td class=\"sublist1\">Risk of calf DVT: 2 percent</td> </tr> <tr> <td class=\"sublist1\">Risk of proximal DVT: 0.4 percent</td> </tr> <tr> <td class=\"sublist1\">Risk of clinical PE: 0.2 percent</td> </tr> <tr> <td class=\"sublist1\">Risk of fatal PE: &#60;0.01 percent</td> </tr> <tr> <td class=\"subtitle1_single\">Moderate risk:</td> </tr> <tr> <td>Minor surgery in patients with additional risk factor present*, <strong>or</strong> </td> </tr> <tr> <td class=\"sublist1_start\">Surgery in patients aged 40 to 60 with no additional risk factor</td> </tr> <tr> <td class=\"sublist1\">Risk of calf DVT: 10 to 20 percent</td> </tr> <tr> <td class=\"sublist1\">Risk of proximal DVT: 2 to 4 percent</td> </tr> <tr> <td class=\"sublist1\">Risk of clinical PE: 1 to 2 percent</td> </tr> <tr> <td class=\"sublist1\">Risk of fatal PE: 0.1 to 0.4 percent</td> </tr> <tr> <td class=\"subtitle1_single\">High risk:</td> </tr> <tr> <td>Surgery in patients &#62;60, <strong>or</strong></td> </tr> <tr> <td class=\"sublist1_start\">Surgery in patients aged 40 to 60 with additional risk factor*</td> </tr> <tr> <td class=\"sublist1\">Risk of calf DVT: 20 to 40 percent</td> </tr> <tr> <td class=\"sublist1\">Risk of proximal DVT: 4 to 8 percent</td> </tr> <tr> <td class=\"sublist1\">Risk of clinical PE: 2 to 4 percent</td> </tr> <tr> <td class=\"sublist1\">Risk of fatal PE: 0.4 to 1.0 percent</td> </tr> <tr> <td class=\"subtitle1_single\">Highest risk:</td> </tr> <tr> <td>Surgery in patients &#62;40 with multiple risk factors*, <strong>or</strong></td> </tr> <tr> <td>Hip or knee arthroplasty, hip fracture surgery, <strong>or</strong></td> </tr> <tr> <td class=\"sublist1_start\">Major trauma, spinal cord injury</td> </tr> <tr> <td class=\"sublist1\">Risk of calf DVT: 40 to 80 percent</td> </tr> <tr> <td class=\"sublist1\">Risk of proximal DVT: 10 to 20 percent</td> </tr> <tr> <td class=\"sublist1\">Risk of clinical PE: 4 to 10 percent</td> </tr> <tr> <td class=\"sublist1\">Risk of fatal PE: 0.2 to 5 percent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DVT: deep vein thrombosis; PE: pulmonary embolism.<br>* Additional risk factors include one or more of the following: advanced age, cancer, prior venous thromboembolism, obesity, heart failure, paralysis, or presence of a molecular hypercoagulable state (eg, protein C deficiency, factor V Leiden).</div><div class=\"graphic_reference\">Data from Geerts WH, et al. Chest 2004; 126:338S.</div><div id=\"graphicVersion\">Graphic 58607 Version 4.0</div></div></div>"},"58609":{"type":"graphic_diagnosticimage","displayName":"Acromioclavicular injury Type I","title":"Acromioclavicular injury Type I","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acromioclavicular injury Type I</div><div class=\"cntnt\"><img style=\"width:360px; height:319px;\" src=\"images/EM/58609_AC_type_I_XR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Type I acromioclavicular (AC) injuries represent a sprain of the AC ligaments, while the coracoclavicular ligaments remain intact. Often no abnormality is seen on x-ray, but a&nbsp;slight widening of the AC joint may be apparent.</div><div class=\"graphic_reference\">Courtesy of Scott M Koehler, MD.</div><div id=\"graphicVersion\">Graphic 58609 Version 3.0</div></div></div>"},"58610":{"type":"graphic_table","displayName":"NSAID oral challenge protocols","title":"Oral challenges to detect reactions induced by acetylsalicylic acid (ASA) and other nonsteroidal anti-inflammatory drugs (NSAIDs)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral challenges to detect reactions induced by acetylsalicylic acid (ASA) and other nonsteroidal anti-inflammatory drugs (NSAIDs)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"34%\"></colgroup><colgroup span=\"6\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Suspected reaction type<br /> (based upon detailed history of past reactions and underlying conditions)</td> <td class=\"subtitle1\">Symptoms of past reaction(s)</td> <td class=\"subtitle1\">Starting dose for ASA, in mg</td> <td class=\"subtitle1\">Increase per step</td> <td class=\"subtitle1\">Interval between steps</td> <td class=\"subtitle1\">Dose range in which reactions usually occur, in mg</td> <td class=\"subtitle1\">Usual time between administration and onset of symptoms</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Respiratory reaction induced by multiple NSAIDs (cross-reacting) in patient with underlying AERD (<strong>type 1</strong>)</p> Also appropriate for <strong>type 4</strong> reactions</td> <td>Rhinitis/ocular symptoms, bronchospasm</td> <td>40.5</td> <td>Double</td> <td>Three hours</td> <td>60 to 100</td> <td>One to three hours</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Urticaria/angioedema induced by multiple NSAIDs (cross-reacting) in patient with chronic urticaria (<strong>type 2</strong>)</p> Also appropriate for <strong>type 3</strong> reactions</td> <td>Urticaria/angioedema</td> <td>81 to 162</td> <td>Double</td> <td>Three hours</td> <td>162 to 650</td> <td>One to three hours</td> </tr> <tr class=\"divider_bottom\"> <td>Urticaria/angioedema induced by one NSAID (no underlying conditions) (<strong>type 5</strong>)*</td> <td>Urticaria/angioedema</td> <td>162</td> <td>Double</td> <td>Three hours</td> <td>Not applicable<sup>&#182;</sup></td> <td>Not applicable<sup>&#182;</sup></td> </tr> <tr> <td>Anaphylaxis induced by one NSAID (no underlying conditions) (<strong>type 6</strong>)*</td> <td>Anaphylaxis</td> <td>162</td> <td>Double</td> <td>Three hours</td> <td>Not applicable<sup>&#182;</sup></td> <td>Not applicable<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The challenge is terminated when either the patient reacts or the desired therapeutic dose of ASA/NSAID is reached without a reaction. The challenge is continued beyond the reaction in order to desensitize patients with AERD.<br />Aspirin is most often used for these protocols, and the doses cited here apply to aspirin. Refer to the UpToDate topic for a discussion of performing challenges with other NSAIDs.</div><div class=\"graphic_footnotes\">AERD: aspirin-exacerbated respiratory disease.<br />* These patients should avoid the suspected NSAID and be challenged with ASA or another NSAID (chemically different from the one that caused the reaction) to prove drug tolerance.<br />¶ Patients are challenged with aspirin to confirm that they do&nbsp;<STRONG>not</STRONG> have a pseudoallergic reaction, and symptoms during challenge are not anticipated.</div><div id=\"graphicVersion\">Graphic 58610 Version 10.0</div></div></div>"},"58611":{"type":"graphic_figure","displayName":"Low dose step up gonadotropins","title":"Step-up protocol for ovulation induction","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Step-up protocol for ovulation induction</div><div class=\"cntnt\"><img style=\"width:459px; height:199px;\" src=\"images/ENDO/58611_Low_dose_step_up_gonadotrop.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the low-dose, step-up protocol of gonadotropin administration for ovulation induction. The initial subcutaneous or intramuscular dose of FSH is 37.5 to 75 IU/day; the dose is increased only if, after 14 days, no response is documented on ultrasonography and serum estradiol monitoring. Increments of 37.5 IU then are given at weekly intervals up to a maximum of 225 IU/day. Detection of an ovarian response is an indication to continue the current dose until hCG can be given to stimulate ovulation.</div><div class=\"graphic_footnotes\">FSH: follicle-stimulating hormone; hCG: human chorionic gonadotropin; IU: international units.</div><div id=\"graphicVersion\">Graphic 58611 Version 2.0</div></div></div>"},"58612":{"type":"graphic_figure","displayName":"Effector systems","title":"Second messenger systems associated with G proteins","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Second messenger systems associated with G proteins</div><div class=\"cntnt\"><img style=\"width:458px; height:307px;\" src=\"images/GAST/58612_Effector_systems.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">G proteins initiate cellular changes by acting directly on processes (such as ion channels) or through second messengers, which then affect cell proteins to alter function.</div><div class=\"graphic_reference\">Courtesy of Michael A Shetzline, MD, PhD and Rodger A Liddle, MD.</div><div id=\"graphicVersion\">Graphic 58612 Version 1.0</div></div></div>"},"58616":{"type":"graphic_table","displayName":"Pharmacologic cardioversion AF","title":"ACC/AHA/ESC guideline summary: Pharmacologic cardioversion of atrial fibrillation (AF)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACC/AHA/ESC guideline summary: Pharmacologic cardioversion of atrial fibrillation (AF)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Class I - There is evidence and/or general agreement that the following drugs are effective for cardioversion of AF</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>&#8226;&nbsp; Flecainide.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>&#8226;&nbsp; Dofetilide.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>&#8226;&nbsp; Propafenone.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>&#8226;&nbsp; Ibutilide.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Class IIa - The weight of evidence\nor opinion is in favor of the usefulness of the following drugs for\ncardioversion of AF</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>&#8226;&nbsp; Amiodarone, including use as an out-patient when rapid restoration of sinus rhythm does not appear to be necessary.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">&#8226;&nbsp; A single oral bolus (\"pill-in-the-pocket\") of propafenone or flecainide in the out-patient setting in selected patients in whom the safety and efficacy of this approach has been demonstrated in hospital and who meet the following criteria:</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">1. The absence of sinus and atrioventricular (AV) node dysfunction, bundle branch block, QT interval prolongation, Brugada syndrome, and structural heart disease.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">2. The presence of AV nodal blockade with a beta blocker or nondihydropyridine calcium channel blocker to prevent rapid AV conduction if atrial flutter occurs.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Class IIb - The weight of evidence\nor opinion is less well established for the usefulness of the following\ndrugs for cardioversion of AF</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>&#8226;&nbsp; Quinidine.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>&#8226;&nbsp; Procainamide.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Class III - There is evidence and/or\ngeneral agreement that the following drugs for cardioversion of AF are\nnot useful or may be harmful</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>&#8226;&nbsp; Digoxin.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>&#8226;&nbsp; Sotalol.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>&#8226;&nbsp; For out-of-hospital cardioversion, quinidine, procainamide, disopyramide, and dofetilide.</td>\n\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Data from Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol 2006; 48:e149.</div><div id=\"graphicVersion\">Graphic 58616 Version 2.0</div></div></div>"},"58618":{"type":"graphic_figure","displayName":"Ced genes phagocytosis","title":"Ced genes and their mammalian homologs that encode proteins responsible for phagocytosis of apoptotic cells","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">Ced genes and their mammalian homologs that encode proteins responsible for phagocytosis of apoptotic cells</div><div class=\"cntnt\"><img style=\"width:610px; height:237px;\" src=\"images/RHEUM/58618_ced_genes_phagocytosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Keith Elkon, MD.</div><div id=\"graphicVersion\">Graphic 58618 Version 4.0</div></div></div>"},"58619":{"type":"graphic_picture","displayName":"Peritonsillar abscess with exudate","title":"Peritonsillar abscess with exudate","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Peritonsillar abscess with exudate</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/EM/58619_Peritonsill_abscess_exudate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the bulging of the soft palate and increased tonsillar hypertrophy on the left.</div><div class=\"graphic_reference\">Courtesy of Diane Heatley, MD.</div><div id=\"graphicVersion\">Graphic 58619 Version 1.0</div></div></div>"},"58621":{"type":"graphic_picture","displayName":"Giemsa stain bartonellosis","title":"Giemsa stain bartonellosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Giemsa stain bartonellosis</div><div class=\"cntnt\"><img style=\"width:432px; height:309px;\" src=\"images/ID/58621_Giemsa_stain_bartonellosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Maguina C, Garcia PJ, Gotuzzo E, et al. Bartonellosis (Carrion's disease) in the modern era. Clin Infect Dis 2001; 33:772. Copyright © 2001 University of Chicago's Press.</div><div id=\"graphicVersion\">Graphic 58621 Version 3.0</div></div></div>"},"58623":{"type":"graphic_figure","displayName":"Response to steroids in MCD","title":"Cumulative rate of remission in response to steroids in MCD","html":"<div class=\"graphic\"><div style=\"width: 641px\" class=\"figure\"><div class=\"ttl\">Cumulative rate of remission in response to steroids in MCD</div><div class=\"cntnt\"><img style=\"width:621px; height:313px;\" src=\"images/NEPH/58623_ResponsetosteroidsinMCD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The rate of response of minimal change disease (MCD) to corticosteroid therapy is lower in adults compared with children, and more prolonged therapy is required to achieve a remission.</div><div class=\"graphic_footnotes\">ISKDC: International Study of Kidney Disease in Children.</div><div class=\"graphic_reference\">Adapted with permission from: Nakayama M, Katafuchi R, Yanase T, et al. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am J Kidney Dis 2002; 39:503.</div><div id=\"graphicVersion\">Graphic 58623 Version 5.0</div></div></div>"},"58624":{"type":"graphic_diagnosticimage","displayName":"Osteoid osteoma CT","title":"Osteoid osteoma computed tomography","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Osteoid osteoma computed tomography</div><div class=\"cntnt\"><img style=\"width:468px; height:304px;\" src=\"images/PEDS/58624_Osteoid_osteoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography demonstrates the lucent nidus characteristic of osteoid osteoma with surrounding cortical thickening and periosteal reaction.</div><div class=\"graphic_reference\">Courtesy of the Department of Diagnostic Imaging, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 58624 Version 3.0</div></div></div>"},"58626":{"type":"graphic_picture","displayName":"Cutaneous small vessel vasculitis - lower leg","title":"Cutaneous small vessel vasculitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutaneous small vessel vasculitis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/58626_Leukocytoclastic_vasculitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous petechiae are present on the lower leg.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 58626 Version 4.0</div></div></div>"},"58630":{"type":"graphic_diagnosticimage","displayName":"Bronchial atresia CXR II","title":"Left upper lobe bronchial atresia seen on a chest radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left upper lobe bronchial atresia seen on a chest radiograph</div><div class=\"cntnt\"><img style=\"width:432px; height:432px;\" src=\"images/PULM/58630_Bronchial_atresia_CXR_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The radiograph demonstrates a tubular mass in the left hilar region with hyperexpansion and hyperlucency of the left upper lobe.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 58630 Version 2.0</div></div></div>"},"58632":{"type":"graphic_figure","displayName":"WHO head circumference for age boys 0 to 24 months","title":"Head circumference-for-age percentiles, boys 0 to 24 months, WHO growth standards","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Head circumference-for-age percentiles, boys 0 to 24 months, WHO growth standards</div><div class=\"cntnt\"><img style=\"width:562px; height:423px;\" src=\"images/PEDS/58632_WHO_head_circum_boys_0_to_24.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">WHO: World Health Organization.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention based on data from the WHO Child Growth Standards.</div><div id=\"graphicVersion\">Graphic 58632 Version 3.0</div></div></div>"},"58634":{"type":"graphic_figure","displayName":"Hamartin tuberin complex","title":"Hamartin-tuberin complex: Central regulator of cell-signalling","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Hamartin-tuberin complex: Central regulator of cell-signalling</div><div class=\"cntnt\"><img style=\"width:480px; height:743px;\" src=\"images/NEURO/58634_Hamartin_tuberin_complex_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After growth-factor stimulation, the hamartin-tuberin complex is phosphorylated and its GTPase-activating protein activity is decreased, whereas in response to stimuli such as hypoxia or low energy it is phosphorylated and its GTPase-activating protein activity increased. The complex deactivates RHEB by causing GTP to be cleaved from it. Activated RHEB stimulates mTOR, which has a crucial role in the translation of proteins such as c-Myc or ornithine decarboxylase, and participates in cell-cycle control. mTOR binds to raptor and G&#946;L to exert its effect, which is mediated by S6K1 and 4E-BP1, proteins that participate in ribosome biogenesis and translation initiation, respectively. Nutrients might boost translation through PI3KIII, which phosphorylates mTOR. TSC1 and TSC2 interact also with other proteins, such as ER&#945;, calmodulin, p27, SMAD2, 14-3-3 proteins, and PAM.</div><div class=\"graphic_footnotes\">4E-BP1: eukaryotic translation initiation factor 4E binding protein 1; AKT: protein kinase B; AMPK: AMP-activated protein kinase; CDK1: cyclin-dependent kinase 1; ERK: extracellular signal-regulated protein kinase; G&#946;L: G protein &#946;-subunit like; GSK3&#946;: glycogen synthase kinase 3&#946;; PAM: protein associated with Myc; PI3KIII: PtdIns 3-kinase; REDD1: regulated in development and DNA damage responses; RHEB: Ras homologue enriched in brain; RSK1: ribosomal S6 kinase 1; S6K1: kinase that activates ribosomal subunit S6.</div><div class=\"graphic_reference\">Reproduced from: Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008; 372:657. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 58634 Version 1.0</div></div></div>"},"58635":{"type":"graphic_table","displayName":"Evaluation of infants with WNV","title":"Recommended clinical evaluation of infants with clinical or laboratory evidence of possible congenital West Nile virus (WNV) infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended clinical evaluation of infants with clinical or laboratory evidence of possible congenital West Nile virus (WNV) infection</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td>Computerized tomography (CT) scan of the head and\nbrain. If abnormal, a pediatric neurologist should be consulted.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pediatric ophthalmologic evaluation, including\nexamination of the retina.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Complete blood count, platelet count, and liver\nfunction tests, including alanine aminotransferase (ALT) and aspartate\naminotransferase (AST). Examination of the CSF should be considered,\nand if done, should include testing of the CSF for IgM to WNV.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Evaluation by a dysmorphologist or clinical geneticist.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Further evaluation of any congenital abnormalities to\ndetermine alternative causes, including genetic, infectious, or other\nteratogenic causes.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Repeat hearing screen at age 6 months.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Careful evaluation of head circumference, physical\ncharacteristics, and developmental milestones throughout the first year\nof life.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Repeat examination of infant serum for IgG and IgM\nantibody to WNV at age 6 months.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Histopathologic examination of the placenta and\numbilical cord, testing of frozen placental tissue and cord tissue for\nWNV nucleic acid, and testing of cord serum for IgM and IgG antibody to\nWNV.</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">www.cdc.gov.</div><div id=\"graphicVersion\">Graphic 58635 Version 1.0</div></div></div>"},"58638":{"type":"graphic_figure","displayName":"Arm position","title":"Position of the arm for implanon insertion","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Position of the arm for implanon insertion</div><div class=\"cntnt\"><img style=\"width:528px; height:456px;\" src=\"images/OBGYN/58638_Arm_position.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 58638 Version 1.0</div></div></div>"},"58639":{"type":"graphic_table","displayName":"Factors high-risk delivery","title":"Factors associated with a high-risk delivery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors associated with a high-risk delivery</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Antepartum</td> </tr> <tr> <td class=\"subtitle2_single\">Maternal conditions</td> </tr> <tr> <td class=\"indent1\">Age (&#62;40 years, &#60;16 years)</td> </tr> <tr> <td class=\"indent1\">Poor socioeconomic status (poverty, malnutrition)</td> </tr> <tr> <td class=\"indent1\">Detrimental habits (smoking, drug and/or alcohol abuse)</td> </tr> <tr> <td class=\"sublist2_start\">Medical conditions</td> </tr> <tr> <td class=\"sublist2\">&#8226; Diabetes mellitus</td> </tr> <tr> <td class=\"sublist2\">&#8226; Hypertension</td> </tr> <tr> <td class=\"sublist2\">&#8226; Chronic heart and/or lung diseases</td> </tr> <tr> <td class=\"sublist2\">&#8226; Kidney diseases/urinary tract infections</td> </tr> <tr> <td class=\"sublist2\">&#8226; Blood disorders (thrombocytopenia, anemia, blood group incompatibilities)</td> </tr> <tr> <td class=\"sublist2_start\">Obstetric conditions</td> </tr> <tr> <td class=\"sublist2\">&#8226; Prior stillbirth/fetal loss/early neonatal death</td> </tr> <tr> <td class=\"sublist2\">&#8226; Prior birth of a high-risk infant</td> </tr> <tr> <td class=\"sublist2\">&#8226; Antepartum hemorrhage</td> </tr> <tr> <td class=\"sublist2\">&#8226; Premature rupture of membranes</td> </tr> <tr> <td class=\"sublist2\">&#8226; Serious infection during pregnancy</td> </tr> <tr> <td class=\"sublist2\">&#8226; Placental anomalies: praevia, polyhydramnios or oligohydramnios, pregnancy-induced hypertension, group B streptococcus carrier</td> </tr> <tr> <td class=\"subtitle2_single\">Fetal conditions</td> </tr> <tr> <td class=\"indent1\">Prematurity</td> </tr> <tr> <td class=\"indent1\">Postmaturity</td> </tr> <tr> <td class=\"indent1\">Intrauterine growth retardation</td> </tr> <tr> <td class=\"indent1\">Macrosomia</td> </tr> <tr> <td class=\"indent1\">Multiple gestation</td> </tr> <tr> <td class=\"indent1\">Congenital anomalies</td> </tr> <tr> <td class=\"indent1\">Hydrops</td> </tr> <tr> <td class=\"subtitle1_single\">During birth</td> </tr> <tr> <td class=\"indent1\">Complications of maternal medical disease</td> </tr> <tr> <td class=\"indent1\">Preterm labor</td> </tr> <tr> <td class=\"indent1\">Prolapsed cord</td> </tr> <tr> <td class=\"indent1\">Utero-placental bleeding</td> </tr> <tr> <td class=\"indent1\">Abnormalities of presentation (transverse lie, breech, etc)</td> </tr> <tr> <td class=\"indent1\">Chorioamnionitis or systemic maternal infection</td> </tr> <tr> <td class=\"indent1\">Foul-smelling or meconium-stained amniotic fluid</td> </tr> <tr> <td class=\"indent1\">Abnormal fetal heart rate patterns</td> </tr> <tr> <td class=\"indent1\">Instrumented delivery (forceps or&nbsp;vacuum deliveries)</td> </tr> <tr> <td class=\"indent1\">Cesarean delivery for maternal or fetal compromise</td> </tr> <tr> <td class=\"indent1\">Narcotic administered to mother within four hours of birth</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Fernandes CJ. Care of the High-Risk Neonate. In: Conn's Current Therapy 2005, 57th ed, Rakel RE, Bope ET (Eds), WB Saunders, Philadelphia 2005. Copyright &copy; 2005 Elsevier Science, Inc.</div><div id=\"graphicVersion\">Graphic 58639 Version 5.0</div></div></div>"},"58640":{"type":"graphic_figure","displayName":"Trans-urethral bladder catheterization labial traction","title":"Gentle traction of the labia majora in females to visualize the urethra","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gentle traction of the labia majora in females to visualize the urethra</div><div class=\"cntnt\"><img style=\"width:356px; height:338px;\" src=\"images/PEDS/58640_TUBC_labial_traction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gentle traction of the labia majora in girls facilitates the visualization of the urethra for transurethral bladder catheterizaton.</div><div class=\"graphic_reference\">Adapted from King C, Henreting FM. Pocket Atlas of Pediatric Emergency Procedures, Lippincott Williams and Wilkins, Philadelphia 2000.</div><div id=\"graphicVersion\">Graphic 58640 Version 2.0</div></div></div>"},"58641":{"type":"graphic_figure","displayName":"Manual compression of the liver for hemostasis","title":"Manual compression of the liver for hemostasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Manual compression of the liver for hemostasis</div><div class=\"cntnt\"><img style=\"width:447px; height:417px;\" src=\"images/SURG/58641_Liver-compression.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Manual compression of the liver parenchyma is accomplished by pressing the injured surfaces firmly together.</div><div id=\"graphicVersion\">Graphic 58641 Version 3.0</div></div></div>"},"58642":{"type":"graphic_table","displayName":"Eosinophilic esophagitis recommendations summary TIGERS 2011","title":"The International Gastrointestinal Eosinophil Researchers (TIGERS) Summary of 2011 eosinophilic esophagitis updated consensus recommendations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The International Gastrointestinal Eosinophil Researchers (TIGERS) Summary of 2011 eosinophilic esophagitis updated consensus recommendations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Below is a summary version of the 2011 consensus recommendations for eosinophilic esophagitis (EoE) diagnosis and treatment.<sup>[1]</sup> Since 2007, the number of EoE publications doubled, providing new disease insight. A panel of 33 physicians with expertise in pediatric and adult allergy/immunology, gastroenterology and pathology conducted a systematic review of the EoE literature (since September 2006) using electronic databases. Based on the literature review and expertise of the panel, a summary of the recommendations is provided here.</td> </tr> <tr> <td><strong>Conceptual definition</strong> - To refine perceptions and hypotheses for future EoE studies, the following conceptual definition was developed: \"Eosinophilic esophagitis represents a chronic, immune/antigen mediated, esophageal disease characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation.\"</td> </tr> <tr> <td><strong>Diagnostic guidelines</strong> - Taking into account increasing clinical experiences and research, the following guidelines were proposed: \"Eosinophilic esophagitis is a clinico-pathological disease. Clinically, EoE is characterized by symptoms related to esophageal dysfunction. Pathologically, one or more biopsies must show eosinophil predominant inflammation.* With few exceptions, 15 eosinophils/hpf (peak value) is considered a minimum threshold for a diagnosis of EoE. The disease is isolated to the esophagus and other causes of esophageal eosinophilia should be excluded, specifically proton pump inhibitor (PPI)-responsive esophageal eosinophilia.<sup>&#182;</sup> (Table A). The disease should remit with treatments of dietary exclusion and/or topical corticosteroids. EoE should be diagnosed by clinicians taking into consideration all clinical and pathologic information; neither of these parameters should be interpreted in isolation.</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Summary statements</strong></td> </tr> <tr> <td class=\"indent1\"><strong>History and physical</strong> - History should focus on difficulties with eating and swallowing (Table B) and a thorough physical examination should focus on growth and nutrition parameters and to assess potential other causes of esophagitis (Table A).</td> </tr> <tr> <td class=\"indent1\"><strong>Endoscopy</strong> - Endoscopy with esophageal biopsy is considered the only reliable EoE diagnostic. Two to four biopsies each from the proximal and distal esophagus should be obtained. Gastric and duodenal biopsies should be examined to exclude other potential causes of eosinophil associated gastrointestinal disease (Table A). Endoscopic features can suggest but cannot diagnose EoE.</td> </tr> <tr> <td class=\"indent1\"><strong>Radiography</strong> - An upper gastrointestinal series is useful to characterize anatomic abnormalities that may escape endoscopic detection such as proximal strictures and long segment narrowing.</td> </tr> <tr> <td class=\"indent1\"><strong>Histopathology</strong> - See Diagnostic guidelines and Table C.</td> </tr> <tr> <td class=\"indent1\"><strong>Allergic evaluation</strong> - An evaluation by an allergist or immunologist is recommended to document aeroallergen sensitization and seasonal variability as it may pertain to EoE and to control concurrent atopic diseases. Serum IgE and/or skin prick testing for immediate type hypersensitivity reactions to foods are warranted to help identify food allergic disease in patients with EoE. Medically supervised food reintroduction may be necessary for patients with previous allergic reactions to a food or IgE-mediated sensitivity documented by IgE testing. Skin prick tests, serum IgE tests, and food patch tests may be used to help identify foods that are associated with EoE, but are <strong>not</strong> sufficient to make the diagnosis of food allergy driven EoE. Foods that trigger EoE can only be identified by documenting disease remission and recrudescence after specific food elimination and addition.</td> </tr> <tr> <td class=\"indent1\"><strong>Genetics</strong> - EoE runs in families and although specific genes that pre-dispose to EoE susceptibility have been identified (thymic stromal lymphopoietin [TSLP], eotaxin-3), they are not yet ready for usage in clinical settings.</td> </tr> <tr> <td class=\"sublist2_start\"><strong>Treatments</strong> - (Table D).</td> </tr> <tr> <td class=\"sublist2\"><strong>Dietary therapy</strong> - Amino acid based formulas and dietary elimination are effective therapies for children with EoE and their use in adults requires further study. Patient's lifestyle, adherence to therapy and family resources should be considered when instituting these treatments. Consultation with a registered dietitian is strongly encouraged. EoE foods triggers may need to be restricted indefinitely.</td> </tr> <tr> <td class=\"sublist2\"><strong>Steroids</strong> - Topical corticosteroids are effective therapy for EoE in children and adults. Systemic corticosteroids may be used for emergent situations (severe dysphagia, hospitalization, weight loss) but caution is warranted for chronic management of EoE.</td> </tr> <tr> <td class=\"sublist2\"><strong>Other treatments</strong> - Cromolyn sodium, leukotriene receptor antagonists, and immunosuppressives (azathioprine or 6-mercaptopurine) are not recommended treatments for EoE. Biologic agents require further clinical studies and are currently not recommended for routine use.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\"><strong>Dilation</strong> - Esophageal dilation can provide relief of dysphagia in selected EoE patients. If high-grade esophageal stenosis is not present, a trial of medical or dietary therapy prior to esophageal dilation is reasonable.</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Table A.<sup>[1]</sup> Conditions associated with esophageal eosinophilia</strong></td> </tr> <tr> <td class=\"indent1\">Gastroesophageal reflux disease (GERD)</td> </tr> <tr> <td class=\"indent1\">Eosinophilic esophagitis (EoE)</td> </tr> <tr> <td class=\"indent1\">Eosinophilic gastrointestinal diseases (EGIDs)</td> </tr> <tr> <td class=\"indent1\">Celiac disease</td> </tr> <tr> <td class=\"indent1\">Crohn's disease</td> </tr> <tr> <td class=\"indent1\">Infection</td> </tr> <tr> <td class=\"indent1\">Hypereosinophilic syndrome (HES)</td> </tr> <tr> <td class=\"indent1\">Achalasia</td> </tr> <tr> <td class=\"indent1\">Drug hypersensitivity</td> </tr> <tr> <td class=\"indent1\">Vasculitis</td> </tr> <tr> <td class=\"indent1\">Pemphigoid vegetans</td> </tr> <tr> <td class=\"indent1\">Connective tissue disease</td> </tr> <tr> <td class=\"indent1\">Graft versus host disease</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Table B.<sup>[1]</sup> Symptoms related to EoE</strong></td> </tr> <tr> <td class=\"sublist2_start\">Dysphagia and feeding dysfunction</td> </tr> <tr> <td class=\"sublist2\">Coping mechanisms - Avoiding highly textured foods such as meats and bulky foods such as bagels, cutting food in small pieces, lubricating foods before eating with liquids or butter, extensive chewing of foods, washing food down with liquids, prolongation of mealtimes</td> </tr> <tr> <td class=\"sublist2_start\">Food impaction</td> </tr> <tr> <td class=\"sublist2\">Coping mechanisms - Drinking liquid to wash food down, raising hands above head, jumping up and down, waiting for food to dissolve or to pass</td> </tr> <tr> <td class=\"sublist2_start\">Chest pain</td> </tr> <tr> <td class=\"sublist2\">Coping mechanisms - Avoiding foods or liquids that exacerbate pain such as highly textured or bulky foods, alcohol or acidic drinks</td> </tr> <tr> <td class=\"indent1\">GERD like symptoms recalcitrant to medical and surgical GERD management</td> </tr> <tr> <td class=\"indent1\">Abdominal pain</td> </tr> <tr> <td class=\"indent1\">Vomiting</td> </tr> <tr> <td class=\"indent1\">Anorexia and early satiety</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Table C.<sup>[1]</sup> Histological characteristics of EoE</strong></td> </tr> <tr> <td class=\"indent1\">Mucosal eosinophilia</td> </tr> <tr> <td class=\"indent1\">Eosinophil microabscesses</td> </tr> <tr> <td class=\"indent1\">Superficial layering of eosinophils</td> </tr> <tr> <td class=\"indent1\">Extracellular eosinophil granules</td> </tr> <tr> <td class=\"indent1\">Surface epithelial desquamation</td> </tr> <tr> <td class=\"indent1\">Basal zone hyperplasia</td> </tr> <tr> <td class=\"indent1\">Rete peg elongation</td> </tr> <tr> <td class=\"indent1\">Dilated intercellular spaces</td> </tr> <tr> <td class=\"indent1\">Subepithelial fibrosis/sclerosis/lamina propria fibrosis</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Table D.<sup>[1]</sup> Recommended initial treatments for EoE</strong></td> </tr> <tr> <td class=\"sublist2_start\">Topical swallowed corticosteroids (initial doses)<sup>[2-4]</sup></td> </tr> <tr> <td class=\"sublist2\">Fluticasone (spray metered dose inhaler directly in mouth then swallow)</td> </tr> <tr> <td class=\"sublist3\">Adults: 440 to 880 mcg twice daily</td> </tr> <tr> <td class=\"sublist3\">Children: 88 to 440 mcg twice to four times daily (maximum 1760 mcg per day)</td> </tr> <tr> <td class=\"sublist2\">Budesonide (as a compounded viscous suspension<sup>&#916;</sup>)</td> </tr> <tr> <td class=\"sublist3\">Children (&#60;10 years): 1 mg daily</td> </tr> <tr> <td class=\"sublist3\">Older children and adults: 2 mg daily</td> </tr> <tr> <td class=\"sublist3\">Following administration, patients should not rinse the mouth or eat or drink for 30 minutes</td> </tr> <tr> <td class=\"sublist2_start\">Systemic corticosteroids (severe disease)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\">Prednisone: 1 to 2 mg/kg per day by mouth in one or two divided doses (maximum 60 mg per day), taper after week 4<sup>[4]</sup></td> </tr> <tr> <td class=\"sublist1_start\"><strong>Education, advocacy, and/or research support resources:</strong></td> </tr> <tr> <td class=\"indent1\">American Academy of Allergy, Asthma, and Immunology: <a href=\"http://www.aaaai.org/\" target=\"_blank\">www.aaaai.org</a></td> </tr> <tr> <td class=\"indent1\">American Partnership for Eosinophilic Disorders: <a href=\"http://www.apfed.org/\" target=\"_blank\">www.apfed.org</a></td> </tr> <tr> <td class=\"indent1\">Campaign Urging Research for Eosinophilic Disorders: <a href=\"http://www.curedfoundation.org/\" target=\"_blank\">www.curedfoundation.org</a></td> </tr> <tr> <td class=\"indent1\">Children's Digestive Health and Nutrition Foundation: <a href=\"http://www.cdhnf.org/\" target=\"_blank\">www.cdhnf.org</a></td> </tr> <tr> <td class=\"indent1\">Food Allergy &#38; Anaphylaxis Network: <a href=\"http://www.foodallergy.org/\" target=\"_blank\">www.foodallergy.org</a></td> </tr> <tr> <td class=\"indent1\">North American Society of Pediatric Gastroenterology and Nutrition: <a href=\"http://www.naspghan.org/\" target=\"_blank\">www.naspghan.org</a></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Registry for Eosinophilic Gastrointestinal Disorders: <a href=\"http://www.rarediseasesnetwork.org/cms/cegir/Get-Involved/Contact-Registry\" spellcheck=\"true\">http://www.rarediseasesnetwork.org/cms/cegir/Get-Involved/Contact-Registry</a></td> </tr> <tr> <td class=\"sublist_other_centered\">TIGERS is grateful to the American Partnership for Eosinophilic Disorders for providing financial support of this summary document. APFED (www.apfed.org) is a 501(c)3 non-profit dedicated to education, advocacy, support and advancing research to improve the lives of those with eosinophil associated diseases. Content summarized by TIGERS.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EoE: eosinophilic esophagitis.<br />* For optimal pathological evaluation, multiple biopsies from the proximal and distal esophagus should be obtained and evaluated for a variety of pathological features. Pathologists should report all abnormalities associated with EoE such as the peak eosinophil count (obtained from the area with the highest density of eosinophils), eosinophilic microabscesses, surface layering of eosinophils, extracellular eosinophil granules, basal cell hyperplasia, dilated intercellular spaces, and lamina propria fibrosis. In a few circumstances, patients may have strong clinical evidence for EoE and have less than 15 eosinophils/hpf with other histological features indicative of eosinophilic inflammation.<br />&#182; An emerging body of literature and clinical experience describes a subset of patients whose symptoms and histopathologic findings are responsive to PPI treatment and who may, or may not, have well documented gastroesophageal reflux disease (GERD). Until more is known, these patients should be diagnosed as \"PPI-responsive esophageal eosinophilia.\"<br />&Delta; Viscous budesonide can be compounded by mixing two 0.5 mg/2 mL budesonide inhalation (Pulmicort Respule) ampules for nebulization with sucralose (Splenda), ten 1-gram packets per 1 mg of budesonide, creating a volume of approximately 8 mL<sup>[3]</sup>.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: Updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011; 128:3. </li>&#xD;&#xA;    <li>Konikoff MR, Noel RJ, Blanchard C, et al. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology 2006; 131:1381. </li>&#xD;&#xA;    <li>Dohil R, Newbury R, Fox L, Bastian J, Aceves SS. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology 2010; 139:418. </li>&#xD;&#xA;    <li>Schaefer ET, Fitzgerald JF, Molleston JP, et al. Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol 2008; 6:165. </li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: The International Gastrointestinal Eosinophil Researchers (TIGERS). Dosing recommendations modified for this publication.</div><div id=\"graphicVersion\">Graphic 58642 Version 4.0</div></div></div>"},"58644":{"type":"graphic_picture","displayName":"Gastric varix Endosc","title":"Gastric varix","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric varix</div><div class=\"cntnt\"><img style=\"width:320px; height:320px;\" src=\"images/GAST/58644_Gastric_varix_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper endoscopy of a gastric varix in the fundus of the stomach. Gastric varices can arise in conjunction with esophageal varices. They can also be isolated when they result from segmental portal hypertension due to obstruction of the splenic vein by pancreatic carcinoma or chronic pancreatitis.</div><div class=\"graphic_reference\">Courtesy of Rome Jutabha, MD, and Dennis M Jensen, MD.</div><div id=\"graphicVersion\">Graphic 58644 Version 1.0</div></div></div>"},"58646":{"type":"graphic_picture","displayName":"AML FAB M4","title":"Acute myelomonocytic leukemia (M4)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute myelomonocytic leukemia (M4)</div><div class=\"cntnt\"><img style=\"width:381px; height:288px;\" src=\"images/HEME/58646_AML_FAB_M4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow smear from a patient with acute myelomonocytic leukemia (FAB classification M4). (Wright-Giemsa stain). The two promyelocytes on the left (black arrows) with basophilic cytoplasm containing coarse azurophilic granules contrast with the two promonocytes on the right (blue arrows) which have abundant pale cytoplasm and delicate nuclear folds.</div><div class=\"graphic_reference\">From Brunning, RD, McKenna, RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 58646 Version 1.0</div></div></div>"},"58648":{"type":"graphic_picture","displayName":"Acute eosinophilic pneum High","title":"Acute eosinophilic pneumonia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute eosinophilic pneumonia</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/PULM/58648_Acute_eosinophilic_pneum_Hi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power photomicrograph of acute eosinophilic pneumonia shows a mixed inflammatory infiltrate expanding the alveolar septa and spilling into adjacent air spaces. The inflammatory infiltrate contains numerous eosinophils and mononuclear cells and is accompanied by a fibrinous exudate resembling hyaline membranes (arrow).</div><div class=\"graphic_reference\">Courtesy of Jeffrey L Myers, MD.</div><div id=\"graphicVersion\">Graphic 58648 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal lung</div><div class=\"cntnt\"><img style=\"width:360px; height:330px;\" src=\"images/PULM/80140_Normal_lung_High.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power photomicrograph shows alveoli containing capillaries within a narrow interstitium. The alveoli are lined with thin, elongated type I pneumocytes (arrow) and smaller numbers of cuboidal type II pneumocytes (dashed arrow).</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 80140 Version 2.0</div></div></div>"},"58649":{"type":"graphic_waveform","displayName":"Mobitz type II second degree atrioventricular block","title":"Mobitz type II second degree atrioventricular (AV) block","html":"<div class=\"graphic normal\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Mobitz type II second degree atrioventricular (AV) block</div><div class=\"cntnt\"><img style=\"width:487px; height:142px;\" src=\"images/CARD/58649_Mobitz_II_AV_block_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The third and sixth P waves are not conducted through the AV node (there is no associated QRS complex). The PR interval is constant prior to and after the non-conducted beats.</div><div id=\"graphicVersion\">Graphic 58649 Version 3.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"58651":{"type":"graphic_table","displayName":"Preventing fatal asthma","title":"Steps to prevent fatal and nonfatal asthma exacerbations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Steps to prevent fatal and nonfatal asthma exacerbations</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>Provide verbal and written education about trigger avoidance (eg, aeroallergens, aspirin, NSAIDs)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Educate about early warning signs of deterioration</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Use objective measures of airflow limitation</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Review prednisone based action plan at each visit</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Arrange frequent visits to assess asthma control</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Optimize controller therapy</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Encourage adherence to medications</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Encourage smoking cessation</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Address illicit drug use</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Provide annual influenza vaccination</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 58651 Version 1.0</div></div></div>"},"58653":{"type":"graphic_table","displayName":"Drug regimens TB in HIV","title":"Regimens for treatment of drug-susceptible pulmonary tuberculosis in HIV-infected adults receiving antiretroviral therapy*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Regimens for treatment of drug-susceptible pulmonary tuberculosis in HIV-infected adults receiving antiretroviral therapy*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Intensive phase</td> <td class=\"subtitle1\" colspan=\"2\">Continuation phase</td> </tr> <tr> <td class=\"subtitle2\">Drugs</td> <td class=\"subtitle2\">Interval and doses<sup>&#182;</sup><br /> minimal duration</td> <td class=\"subtitle2\">Drugs</td> <td class=\"subtitle2\">Interval and doses<sup>&#182;</sup><sup>&#916;</sup><br /> minimal duration</td> </tr> <tr> <td colspan=\"4\"><strong>Regimen 1:</strong> Preferred regimen for HIV-infected adults with newly diagnosed tuberculosis</td> </tr> <tr> <td class=\"indent1\">INH</td> <td class=\"divider_bottom\" rowspan=\"4\"> <p><strong>Daily for 8 weeks</strong></p> <p>7 days per week for 56 doses (8 weeks), or</p> 5 days per week for 40 doses (8 weeks)<sup>&#9674;</sup></td> <td class=\"divider_bottom\" rowspan=\"4\">INH/RIF</td> <td class=\"divider_bottom\" rowspan=\"4\"> <p>7 days per week for 126 doses (18 weeks), or</p> 5 days per week for 90 doses (18 weeks)<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">RIF</td> </tr> <tr> <td class=\"indent1\">PZA</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">EMB</td> </tr> <tr> <td colspan=\"4\"><strong>Regimen 2:</strong> Alternative regimen for HIV-infected adults in setting of resistance or intolerance to PZA</td> </tr> <tr> <td class=\"indent1\">INH</td> <td rowspan=\"3\"> <p><strong>Daily for 8 weeks</strong></p> <p>7 days per week for 56 doses (8 weeks), or</p> 5 days per week for 40 doses (8 weeks)<sup>&#9674;</sup></td> <td rowspan=\"3\">INH/RIF</td> <td rowspan=\"3\"> <p>7 days per week for 217 doses (31 weeks), or</p> 5 days per week for 155 doses (31 weeks)<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">RIF</td> </tr> <tr> <td class=\"indent1\">EMB</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: If rifampin is replaced with rifabutin, refer to UpToDate table on rifabutin and antiretroviral therapy for dosing recommendations.</div><div class=\"graphic_footnotes\">INH: isoniazid; RIF: rifampin; PZA: pyrazinamide; EMB: ethambutol; DOT: directly observed therapy.<br />* For HIV-infected patients who are not receiving antiretroviral therapy, the continuation phase should be extended by three months (or 90 doses) for regimen 1 (above) and for at least three months for regimen 2.<sup>[1]</sup><br />&para; When DOT is used, drugs may be given five days/week, and the necessary number of doses adjusted accordingly. Although there are no studies that compare five with seven daily doses, extensive experience indicated this would be an effective practice.<br />&Delta; To help evaluate treatment effectiveness, sputum smears and mycobacterial cultures should be obtained at least monthly until at least two sequential cultures are negative and the patient is responding clinically to antituberculous therapy. Patients treated with regimen 1 with positive cultures at completion of two months of therapy should receive a seven-month (31-week; 217 doses [daily]) continuation phase; those receiving regimen 2 without PZA should probably have their continuation phase extended by three months as well (one year total). Patients with a positive sputum culture after three months of therapy should be evaluated for possible treatment failure.<sup>[1]</sup><br /><span class=\"lozenge\">&loz;</span> Five-day-a-week administration is always given by DOT.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.</li>&#xD;&#xA;</ol>&#xD;&#xA;Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>.</li>&#xD;&#xA;    <li>Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf</a>.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 58653 Version 13.0</div></div></div>"},"58656":{"type":"graphic_figure","displayName":"Upper extremity nerve roots","title":"Nerve roots and peripheral nerves corresponding to the principal movements of the upper extremity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nerve roots and peripheral nerves corresponding to the principal movements of the upper extremity</div><div class=\"cntnt\"><img style=\"width:350px; height:602px;\" src=\"images/NEURO/58656_Upper_extremity_nerve_roots.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The letters labeling the movements form a spiral down the extremity. The nerve roots and peripheral nerves corresponding to each movement are listed below. Figure redrawn with permission from Gelb, DJ. The Neurologic Examination.</div><div class=\"graphic_reference\">In: Introduction to Clinical Neurology. Woburn, MA, Butterworth-Heinemann 2000.</div><div id=\"graphicVersion\">Graphic 58656 Version 1.0</div></div></div>"},"58657":{"type":"graphic_diagnosticimage","displayName":"Functional constipation barium","title":"Functional constipation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Functional constipation</div><div class=\"cntnt\"><img style=\"width:320px; height:320px;\" src=\"images/PEDS/58657_Functional_constipation_bar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This unprepped barium enema is compatible with functional constipation. The rectum is mildly dilated with stool and there is no evidence of obstruction.</div><div class=\"graphic_reference\">Courtesy of George D Ferry, MD.</div><div id=\"graphicVersion\">Graphic 58657 Version 2.0</div></div></div>"},"58658":{"type":"graphic_figure","displayName":"Heart failure predicts sudden cardiac death and mortality","title":"Heart failure predicts increased sudden cardiac death and overall mortality","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Heart failure predicts increased sudden cardiac death and overall mortality</div><div class=\"cntnt\"><img style=\"width:406px; height:256px;\" src=\"images/CARD/58658_HF_and_SCD_total_mortality.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During a 38-year old follow-up of subjects in the Framingham Heart Study, the presence of heart failure (HF) significantly increased sudden death and overall mortality in both men and women.</div><div class=\"graphic_footnotes\">* p &lt;0.01.<BR>• p &lt;0.001.</div><div class=\"graphic_reference\">Data from: Kannel WB, Wilson PWF, D'Agostino RB, et al. Am Heart J 1998; 136:205.</div><div id=\"graphicVersion\">Graphic 58658 Version 4.0</div></div></div>"},"58659":{"type":"graphic_algorithm","displayName":"ETT confirm capnography","title":"Universal tube placement confirmation with capnography","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Universal tube placement confirmation with capnography</div><div class=\"cntnt\"><img style=\"width:471px; height:459px;\" src=\"images/EM/58659_ETT_confirm_capnography.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Based on the clinical situation, provider may choose to remove the tube or obtain a secondary confirmation measure.<br>• Clinical maneuvers, such as auscultation (chest, epigastric) and direct laryngoscopy may be utilized at physician discretion, but clinicians must be aware of their limitations in discriminating between esophageal and tracheal intubation.</div><div id=\"graphicVersion\">Graphic 58659 Version 2.0</div></div></div>"},"58661":{"type":"graphic_picture","displayName":"Crusted scabies scalp","title":"Crusted scabies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Crusted scabies</div><div class=\"cntnt\"><img style=\"width:396px; height:277px;\" src=\"images/PC/58661_Crusted_scabies_scalp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Crusted scabies in a patient with acquired immunodeficiency syndrome (AIDS). The lesions resemble solar keratoses.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright ©2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58661 Version 4.0</div></div></div>"},"58662":{"type":"graphic_diagnosticimage","displayName":"Alveolar proteinosis CT","title":"Pulmonary alveolar proteinosis chest CT scan","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary alveolar proteinosis chest CT scan</div><div class=\"cntnt\"><img style=\"width:288px; height:319px;\" src=\"images/PULM/58662_Alveolar_proteinosis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ground-glass opacification and thickened intralobular structures and interlobular septa, in typical polygonal shapes referred to as \"crazy-paving.\"</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King, Jr, MD.</div><div id=\"graphicVersion\">Graphic 58662 Version 4.0</div></div></div>"},"58663":{"type":"graphic_table","displayName":"Clinical presentation of BO","title":"Clinical presentation of bronchiolitis obliterans after lung transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical presentation of bronchiolitis obliterans after lung transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Early</td> <td class=\"subtitle1\">Late</td> </tr> <tr> <td>Symptoms</td> <td>Nonproductive cough; dyspnea on exertion</td> <td>Productive cough; dyspnea at rest</td> </tr> <tr> <td>Physical examination</td> <td>Clear chest</td> <td>\"Pops and squeaks\"</td> </tr> <tr> <td>Chest radiograph</td> <td>Clear</td> <td>Bronchiectasis, hyperinflation</td> </tr> <tr> <td>Pulmonary function tests</td> <td>Obstruction; most marked in mid flows FEF<sub>25-75</sub></td> <td>Severe obstruction</td> </tr> <tr> <td>Sputum culture</td> <td>Negative</td> <td>Pseudomonas</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FEF<sub>25-75</sub>: forced expiratory flow between 25 and 75 percent of vital capacity.</div><div id=\"graphicVersion\">Graphic 58663 Version 3.0</div></div></div>"},"58664":{"type":"graphic_diagnosticimage","displayName":"Pulmonary vein invasion","title":"Pulmonary vein invasion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary vein invasion</div><div class=\"cntnt\"><img style=\"width:432px; height:352px;\" src=\"images/PULM/58664_Pulmonary_vein_invasion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The axial CT scan shows a right lower lobe bronchogenic carcinoma invading the right inferior pulmonary vein, with extension into the left atrium. Transseptal invasion of the right atrium ensued.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 58664 Version 3.0</div></div></div>"},"58665":{"type":"graphic_figure","displayName":"Skin healing","title":"Skin healing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin healing</div><div class=\"cntnt\"><img style=\"width:447px; height:669px;\" src=\"images/SURG/58665_Skin_healing_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) In any wound, the initial gap is filled by blood that, upon clotting (formation of fibrin polymers), provides the initial stability to the wound. Plasma fibronectin, present in the clot, can be cross-linked with extracellular matrix components and fibrin to bridge the clot and tissues.<br> (B) The epidermal cells at the edges of the wound lose contact with other epithelial cells and with their basement membranes. At the same time, this loss of contact probably acts as a signal to trigger migration of the cells. Concurrently, basal epidermal cells adjacent to the migrating cells undergo division. The result of this coordinated migration and cell division is the gradual covering of the epidermal defect. The breakdown products from the injured cells, fibronectin, and lysosomal enzymes from leukocytes act as chemoattractants, resulting in an influx of macrophages, myofibroblasts, and fibroblasts. Simultaneously, endothelial cells proliferate and neovascularization begins. The phagocytic cells attracted to the wound remove part of the clot, while fibroblasts and myofibroblasts begin to deposit a new extracellular matrix.<br> (C) The concentric migration of epidermal cells, sustained by the mitotic activity of the trailing cells, fills the wound gap and displaces the remnants of the original clot (scab) toward the surface. Contact with other epidermal cells is the signal that stops migration. The trailing cells not only divide but also secrete basement membrane components. In this manner, the continuity of the epidermal basement membrane is restored. In a similar fashion, the concerted activity of fibroblasts, myofibroblasts, macrophages, and endothelial cells fills the dermal gap. At this point, the number of macrophages and myofibroblasts declines. Those capillaries that failed to establish a definitive flow pattern begin to be obliterated, and accumulation of the definitive extracellular matrix is initiated.<br> (D) The gap created by the wound has been repaired. The mitotic activity of the epidermal cells will restore the epidermal thickness. Most capillaries of the initial granulation tissue have been reabsorbed, and the dermal gap has been filled with a dense, almost avascular, extracellular matrix, composed predominantly of type I collagen.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58665 Version 1.0</div></div></div>"},"58666":{"type":"graphic_figure","displayName":"Normal IgG subclass levels in infants and children","title":"Serum immunoglobulin G (IgG) subclass levels in healthy infants and children","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Serum immunoglobulin G (IgG) subclass levels in healthy infants and children</div><div class=\"cntnt\"><img style=\"width:452px; height:380px;\" src=\"images/ALLRG/58666_IgG_levels_infants_children.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Time 0 represents the cord blood values. The means for each age group were obtained from data published by Oxelius.</div><div class=\"graphic_reference\">Reproduced with permission from: Immunologic Disorders in Infants and Children (5th Ed), Ochs HD, Stiehm ER, Winkelstein JA (Eds), Elsevier, Philadelphia 2004. Copyright &copy; 2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 58666 Version 5.0</div></div></div>"},"58668":{"type":"graphic_algorithm","displayName":"Use of IFNa in chronic HBV","title":"Strategy for the treatment of HBeAg positive chronic HBV infection with interferon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Strategy for the treatment of HBeAg positive chronic HBV infection with interferon</div><div class=\"cntnt\"><img style=\"width:440px; height:346px;\" src=\"images/GAST/58668_Use_of_IFNa_in_chronic_HBV.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* FDA approved dose and duration, a shorter duration of treatment may be sufficient.</div><div id=\"graphicVersion\">Graphic 58668 Version 3.0</div></div></div>"},"58669":{"type":"graphic_table","displayName":"Clues for anaerobic infection","title":"Clues to probability of anaerobic bacteria at infection site","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clues to probability of anaerobic bacteria at infection site</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Infection adjacent to surfaces that normally harbor anaerobes as normal flora</td> </tr> <tr> <td>Abscess formation or tissue necrosis</td> </tr> <tr> <td>Putrid odor</td> </tr> <tr> <td>Gas formation</td> </tr> <tr> <td>Gram stain of exudate showing polymicrobial flora or organisms with morphologic features of anaerobes</td> </tr> <tr> <td>Classic features of histotoxic clostridial syndromes: tetanus, botulism, <em>Clostridium perfringens</em> food poisoning, gas gangrene, <em>Clostridium difficile-</em>induced diarrhea or colitis, enteritis necroticans</td> </tr> <tr> <td>Infections that, by prior experience, usually involve anaerobic bacteria</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58669 Version 3.0</div></div></div>"},"58671":{"type":"graphic_table","displayName":"Sinusitis features","title":"Persistent symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Persistent symptoms</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>Nasal discharge and congestion</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Facial pressure/pain (especially one sided)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Decreased or absent ability to smell</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pain in the teeth</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ear pressure/fullness</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">8.00000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=32213&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Persistent_symptoms.htm</title></head></div><div class=\"graphic_lgnd\">Patients with symptoms that persist (no improvement after 10 days) or worsen (after 5 to 7 days) may require additional treatment. A health care provider should be consulted in all cases.</div><div id=\"graphicVersion\">Graphic 58671 Version 2.0</div></div></div>"},"58674":{"type":"graphic_diagnosticimage","displayName":"MRI Listeria rhombencephalitis","title":"Brain magnetic resonance imaging of a patient with rhombencephalitis due to <em>Listeria monocytogenes</em>","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Brain magnetic resonance imaging of a patient with rhombencephalitis due to <em>Listeria monocytogenes</em></div><div class=\"cntnt\"><img style=\"width:545px; height:356px;\" src=\"images/ID/58674_MRI_listeria_rhombenceph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Axial&nbsp;fluid-attenuated inversion recovery image shows a homogenous hyperintense area in the central portion of the midbrain. The anterior part of the peduncles and the collicular area are spared.<br />(B) Axial T1-weighted image following contrast administration shows a nodular area of enhancement with poorly defined margins within the lesion. Note the small anterior satellite nodule (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Moragas M, Martinez-Yelamos S, Majos C, et al. Rhombencephalitis. Medicine 2011; 90:256. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58674 Version 10.0</div></div></div>"},"58675":{"type":"graphic_diagnosticimage","displayName":"TEE right left outflow tracts","title":"Left and right ventricular outflow tracts and aortic root on transesophageal echocardiogram","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Left and right ventricular outflow tracts and aortic root on transesophageal echocardiogram</div><div class=\"cntnt\"><img style=\"width:584px; height:425px;\" src=\"images/CARD/58675_TEE_right_left_outflow_trac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Imaging from the vertical (90º) plane demonstrates the left atrium (LA), mitral valve leaflets (MV), aortic root (AoR), left ventricular outflow tract (LVOT, panel A). In panel B, the transducer has been rotated slightly more anteriorly to display the aortic valve (AoV), proximal AoR, and right ventricular outflow tract (RVOT). Multiplane (134º) imaging (panel C) may allow for imaging of the LVOT, AoR, and ascending aorta in some patients.</div><div class=\"graphic_reference\">Courtesy of Warren Manning, MD.</div><div id=\"graphicVersion\">Graphic 58675 Version 2.0</div></div></div>"},"58676":{"type":"graphic_picture","displayName":"Arm curl exercise","title":"Strength exercise: Arm curl","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Strength exercise: Arm curl</div><div class=\"cntnt\"><img style=\"width:374px; height:306px;\" src=\"images/PC/58676_Arm_curl_exercise_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After a few weeks of doing this exercise for your upper arm muscles, lifting that gallon of milk will be much easier. &#xD;&#xA;<OL>&#xD;&#xA;<LI>Stand with your feet shoulder-width apart. </LI>&#xD;&#xA;<LI>Hold weights* straight down at your sides, palms facing forward. Breathe in slowly. </LI>&#xD;&#xA;<LI>Breathe out as you slowly bend your elbows and lift weights toward chest. Keep elbows at your sides. </LI>&#xD;&#xA;<LI>Hold the position for&nbsp;one second. </LI>&#xD;&#xA;<LI>Breathe in as you slowly lower your arms. </LI>&#xD;&#xA;<LI>Repeat 10 to 15 times. </LI>&#xD;&#xA;<LI>Rest; then repeat 10 to 15 more times. </LI></OL>As you progress, use a heavier weight and alternate arms until you can lift the weight comfortably with both arms.</div><div class=\"graphic_footnotes\">* Handheld weights or household items (soup cans, bottles of water).</div><div class=\"graphic_reference\">Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: http://go4life.niapublications.org (Accessed December 2, 2011).</div><div id=\"graphicVersion\">Graphic 58676 Version 4.0</div></div></div>"},"58677":{"type":"graphic_figure","displayName":"Greenstick mechanism","title":"Greenstick mechanism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Greenstick mechanism</div><div class=\"cntnt\"><img style=\"width:418px; height:356px;\" src=\"images/EM/58677_Greenstickmechanism.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Forearm shaft fractures typically have a rotational mechanism. Panel A) A supinating force accompanies an apex-volar midshaft fracture (blue circular arrow). During reduction, this rotary force is reversed by pronating the thumb and hand towards the deformity (red circular arrow) while stabilizing just proximal to the fracture site (large red arrow). Panel B) A pronating force accompanies an apex-dorsal midshaft fracture (blue circular arrow). During reduction, this rotary force is reversed by supinating the thumb and hand (red circular arrow) while stabilizing just proximal to the fracture site (large red arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Mehlman CT, Wall EJ. Diaphyseal Radius and Ulna Fractures. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins 2014. Copyright © 2014 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 58677 Version 12.0</div></div></div>"},"58678":{"type":"graphic_figure","displayName":"Structure recombinant TPO","title":"Structure of the recombinant thrombopoietins","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Structure of the recombinant thrombopoietins</div><div class=\"cntnt\"><img style=\"width:418px; height:306px;\" src=\"images/HEME/58678_Structure_recombinant_TPO.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: rHuTPO (recombinant human thrombopoietin) (left) has a molecular structure identical to native thrombopoietin and is fully glycoslyated. It consists of a carbohydrate-rich terminal domain (upper box) and an \"erythropoietin-like\" domain (lower box) which contains the receptor-binding region. Right panel: PEG-rHuMGDF (pegylated recombinant human megakaryocyte growth and development factor) consists of the \"erythropoietin-like\" domain only and is stabilized by the presence of a 20 kDa polyethylene glycol (PEG)&nbsp;moiety on the amino terminus.</div><div class=\"graphic_reference\">Courtesy of Amgen, Inc, Thousand Oaks, California.</div><div id=\"graphicVersion\">Graphic 58678 Version 2.0</div></div></div>"},"58679":{"type":"graphic_figure","displayName":"Hydrocele","title":"Hydrocele","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hydrocele</div><div class=\"cntnt\"><img style=\"width:331px; height:439px;\" src=\"images/PEDS/58679_Hydrocele.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A hydrocele is a fluid accumulation between the parietal and visceral layers of the tunica vaginalis. The hydrocele depicted above is noncommunicating (there is no connection between the hydrocele and the peritoneum; the fluid comes from the mesothelial lining of the tunica vaginalis).</div><div id=\"graphicVersion\">Graphic 58679 Version 2.0</div></div></div>"},"58680":{"type":"graphic_waveform","displayName":"Intermediate case 18 answer","title":"Severe myocardial ischemia","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Severe myocardial ischemia</div><div class=\"cntnt\"><img style=\"width:540px; height:284px;\" src=\"images/CARD/58680_Intermediate_case_18_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sinus rhythm is present with a prolonged PR interval (first degree AV block). Severe myocardial ischemia is indicated by prominent ST depressions, except, notably, lead aVR which shows ST segment elevations. This combination of findings may be due to extensive ischemia (subendocardial and possibly basal transmural), raising concern for high-grade three-vessel and/or left main coronary artery disease.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 58680 Version 3.0</div></div></div>"},"58682":{"type":"graphic_figure","displayName":"Placement of endotracheal tube anterior view","title":"Placement of endotracheal tube anterior view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Placement of endotracheal tube anterior view</div><div class=\"cntnt\"><img style=\"width:348px; height:472px;\" src=\"images/PC/58682_Endotracheal_intubation_ant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note that the tongue is swept to the left side by the curved blade.</div><div id=\"graphicVersion\">Graphic 58682 Version 3.0</div></div></div>"},"58683":{"type":"graphic_picture","displayName":"Talocrural joint line","title":"Talocrural joint line","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Talocrural joint line</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/EM/58683_Talocrural_joint_line.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The talocrural joint line is indicated by the transverse lines on the skin at the point of the pen. Effusion and pain on palpation of the talocrural joint line suggest an osteochondral talar dome fracture resulting from direct trauma between the talus and the fibula or tibia.</div><div class=\"graphic_reference\">Courtesy of Karen Maughan, MD.</div><div id=\"graphicVersion\">Graphic 58683 Version 2.0</div></div></div>"},"58684":{"type":"graphic_table","displayName":"Causes of hypothermia","title":"Causes of hypothermia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of hypothermia</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td class=\"container\"><table cellspacing=\"0\">\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Mechanism\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Clinical disorder\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"14\">\r\n  \r\n   Increased heat loss\r\n  \r\n   </td>\r\n  \r\n   <td>Environmental exposure</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Induced vasodilation\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Drugs\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Alcohol\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Toxins\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Skin disorders\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Burns\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Psoriasis\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Exfoliative dermatitis\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Iatrogenic\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Cold infusion\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Emergent deliveries\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Cardiopulmonary bypass\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Continuous renal replacement therapy\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"11\">\r\n  \r\n   Decreased heat production\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Endocrinologic disease\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Hypopituitarism\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Hypoadrenalism\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Hypothyroidism\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Insufficient fuel\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Hypoglycemia\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Malnutrition\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Neuromuscular inefficiency\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Extremes of age\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Impaired shivering\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Inactivity\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   </table></td>\r\n  \r\n   <td class=\"container\"><table cellspacing=\"0\">\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Mechanism\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Clinical disorder\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"12\">\r\n  \r\n   Impaired regulation\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Peripheral\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Spinal-cord transection\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Neuropathies\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Diabetes mellitus\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Central\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Cerebrovascular accident\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Subarachnoid hemorrhage\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Parkinsonism\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Hypothalamic dysfunction\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Multiple sclerosis\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Anorexia nervosa\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Drugs: Intoxicants, anxiolytics, antidepressants, antimanic agents, antipsychotics, opioids, oral antihyperglycemics, beta blockers\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"6\">\r\n  \r\n   Other\r\n  \r\n   </td>\r\n  \r\n   <td>Sepsis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pancreatitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Carcinomatosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Uremia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Vascular insufficiency</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Trauma</td>\r\n  \r\n   </tr>\r\n  \r\n   </table></td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">14.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=64302&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Differential_dx_for_hypothe.htm</title></head></div><div class=\"graphic_reference\">Reproduced with permission from Hanania, NA, Zimmerman, JL. Accidental hypothermia. Critical Care Clinincs 1999; 15:235. Copyright ©1999 WB Saunders Company.</div><div id=\"graphicVersion\">Graphic 58684 Version 2.0</div></div></div>"},"58685":{"type":"graphic_picture","displayName":"Candida endophthalmitis","title":"<EM>Candida</EM> endophthalmitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Candida</EM> endophthalmitis</div><div class=\"cntnt\"><img style=\"width:375px; height:270px;\" src=\"images/ID/58685_Candida_endophthalmitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endogenous <EM>Candida</EM> endophthalmitis with multiple focal white lesions within the choroid and extension of the two largest lesions through the retina into the vitreous.</div><div class=\"graphic_reference\">Courtesy of Carol Kauffman, MD.</div><div id=\"graphicVersion\">Graphic 58685 Version 3.0</div></div></div>"},"58686":{"type":"graphic_table","displayName":"Oral rx renal abscess in adults","title":"Oral antibiotic therapy of renal or perinephric abscess in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral antibiotic therapy of renal or perinephric abscess in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antibiotic</td> <td class=\"subtitle1\">Dose (interval)</td> </tr> <tr> <td>Levofloxacin</td> <td>500 to 750 mg every 24 hours</td> </tr> <tr> <td>Ciprofloxacin</td> <td>500 mg every 12 hours</td> </tr> <tr> <td>Ciprofloxacin XR</td> <td>1000 mg every 24 hours</td> </tr> <tr> <td>Trimethoprim-sulfamethoxazole</td> <td>1 double strength tablet* every 12 hours</td> </tr> <tr> <td>Trimethoprim</td> <td>100 mg every 12 hours</td> </tr> <tr> <td>Cefpodoxime</td> <td>200 mg every 12 hours</td> </tr> <tr> <td>Cefixime</td> <td>200 mg every 12 hours</td> </tr> <tr> <td>Amoxicillin<sup>&#182;</sup></td> <td>1000 mg every&nbsp;8 hours</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For completion of antibiotic course following abscess drainage and initial clinical improvement on parenteral therapy. For Staphylococcus aureus infections in the setting of bacteremia, parenteral antibiotics are typically used for the duration of treatment. Choice of antibiotic should be informed by culture and susceptibility testing results. The doses recommended above are intended for patients with normal renal function; the doses of some of these agents must be adjusted in patients with renal insufficiency.</div><div class=\"graphic_footnotes\">* 160 mg trimethoprim with 800 mg sulfamethoxazole per tablet.<br />&para; For treatment of ampicillin-susceptible enterococcus.</div><div id=\"graphicVersion\">Graphic 58686 Version 7.0</div></div></div>"},"58687":{"type":"graphic_figure","displayName":"Acute respiratory disorders","title":"Compensations to acute respiratory acidosis and alkalosis","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Compensations to acute respiratory acidosis and alkalosis</div><div class=\"cntnt\"><img style=\"width:453px; height:491px;\" src=\"images/NEPH/58687_Acute_respiratory_disorders.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Combined significance bands for plasma pH and concentrations of H+ and HCO3- in acute respiratory acidosis and alkalosis in humans. In uncomplicated acute respiratory acid-base disorders, values for the H+ and HCO3- concentrations will, with an estimated 95 percent probability, fall within the band. Values lying outside the band indicate the presence of a complicating metabolic acid-base disturbance.</div><div class=\"graphic_reference\">Arbus GS, Herbert LA, Levesque PR, et al. N Engl J Med 1969; 280:117. By permission from the New England Journal of Medicine.</div><div id=\"graphicVersion\">Graphic 58687 Version 5.0</div></div></div>"},"58689":{"type":"graphic_figure","displayName":"Electrical activity in AF","title":"Electrical activity in atrial fibrillation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electrical activity in atrial fibrillation</div><div class=\"cntnt\"><img style=\"width:357px; height:280px;\" src=\"images/CARD/58689_Electrical_activity_in_AF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During atrial fibrillation there are multiple reentrant circuits within the right and left atrium, resulting in nonuniform activitation of the atrial myocardium. These circuits, which produce multiple wavelets, often occur around the normal structures of the atrial including the orifices of the superior (SVC) and inferior (IVC) vena cavae, the orifice of the pulmonary veins (PVs), and the right (RAA) and left (LAA) atrial appendages.</div><div id=\"graphicVersion\">Graphic 58689 Version 1.0</div></div></div>"},"58691":{"type":"graphic_figure","displayName":"Viruses and host factors","title":"Viruses and host factors","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Viruses and host factors</div><div class=\"cntnt\"><img style=\"width:580px; height:226px;\" src=\"images/ALLRG/58691_Viruses_and_host_factors.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Viruses interact with host susceptibility factors to promote recurrent wheeze and asthma development. The nature of these interactions are both virus and age specific. Interactions between lung and immune factors play a role in determining the severity of viral infections and long-term outcomes.</div><div class=\"graphic_footnotes\">AHR: airway hyperresponsiveness; LRI: lower respiratory tract infection.</div><div class=\"graphic_reference\">Reproduced from: Gern JE, Rosenthal LA, Sorkness RL, Lemanske RF. Effects of viral respiratory infections on lung development and childhood asthma. J Allergy Clin Immunol 2005; 115:668. Copyright © 2005. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 58691 Version 3.0</div></div></div>"},"58692":{"type":"graphic_figure","displayName":"Reciprocal translocations","title":"Mechanism of reciprocal translocations","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Mechanism of reciprocal translocations</div><div class=\"cntnt\"><img style=\"width:511px; height:765px;\" src=\"images/PC/58692_Reciprocal_translocat_PR.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nonhomologous chromosomes exchange parts without loss of genetic content. When meiotic division occurs, the normal and translocated chromosomes can only pair by forming a quadrivalent structure. The resulting segregation products include a normal chromosome complement, a balanced rearrangement, and four unbalanced products. The unbalanced products can be subdivided into two products with correct and two products with incorrect centromere segregation. The latter event is rare and associated with decreased viability.</div><div id=\"graphicVersion\">Graphic 58692 Version 9.0</div></div></div>"},"58693":{"type":"graphic_figure","displayName":"Frank-Starling curves in heart failure","title":"Frank-Starling curves in heart failure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Frank-Starling curves in heart failure</div><div class=\"cntnt\"><img style=\"width:330px; height:236px;\" src=\"images/PC/58693_FrankStarlingcurvesinHF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Idealized family of Frank-Starling curves produced by worsening ventricular function in heart failure. In ventricles with normal cardiac performance, there is a steep and positive relationship between increased cardiac filling pressures (as estimated from the&nbsp;LVEDP or pulmonary capillary wedge pressure) and increased stroke volume or cardiac output (top curve). By comparison, during progression from mild to severe myocardial dysfunction, this relationship is right shifted (ie, a higher filling pressure is required to achieve the same cardiac output) and flattened so that continued increases in left heart filling pressures lead to minimal increases in cardiac output at the possible expense of pulmonary edema. The onset of mild heart failure results in an initial reduction in cardiac function (from point A to point B), a change that can be normalized, at least at rest, by raising the LVEDP via fluid retention (point C). Diuretic therapy reduces left ventricular filling pressure at the expense of mildly decreased cardiac output (moving from point C to point B). By comparison, normalization of stroke volume is not attainable in severe heart failure (bottom curve).</div><div class=\"graphic_footnotes\">LVEDP: &nbsp;left ventricular end-diastolic pressure.</div><div id=\"graphicVersion\">Graphic 58693 Version 7.0</div></div></div>"},"58694":{"type":"graphic_figure","displayName":"Male obstruction","title":"Uroflowmetry obstruction","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Uroflowmetry obstruction</div><div class=\"cntnt\"><img style=\"width:540px; height:319px;\" src=\"images/PC/58694_Uroflowmetryobstruction.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This uroflow study demonstrates male obstruction, with an intermittency plateau pattern. The Qmax is 8 mL/s.</div><div id=\"graphicVersion\">Graphic 58694 Version 2.0</div></div></div>"},"58695":{"type":"graphic_picture","displayName":"Early lesion in PHX","title":"Pulmonary Langerhans cell histiocytosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary Langerhans cell histiocytosis</div><div class=\"cntnt\"><img style=\"width:357px; height:234px;\" src=\"images/PULM/58695_Early_lesion_in_PHX.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Early lesions of pulmonary Langerhans cell histiocytosis appear as cellular infiltrates along small airways.</div><div class=\"graphic_reference\">From Colby, TV, Koss, MN, Travis, WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.</div><div id=\"graphicVersion\">Graphic 58695 Version 1.0</div></div></div>"},"58697":{"type":"graphic_figure","displayName":"Protocol dobutamine stress Tc99m SPECT","title":"Protocol dobutamine stress Tc99m SPECT*<SUP>¶</SUP>","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Protocol dobutamine stress Tc99m SPECT*<SUP>¶</SUP></div><div class=\"cntnt\"><img style=\"width:485px; height:328px;\" src=\"images/CARD/58697_Protocoldobutaminestress.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Standard dobutamine infusion protocol for pharmacologic stress testing with myocardial perfusion imaging. The dobutamine dose is increased every three minutes until the patient achieves at least 85% of maximum predicted heart rate (MPHR). If the heart rate remains &lt;85% MPHR following infusion of dobutamine 40 mcg/kg/min, arm exercise can be performed and/or atropine may be infused in an effort to further increase the heart rate. The radiopharmaceutical may be injected at any point once the patient's heart rate exceeds 85% MPHR or the development of symptoms.</div><div class=\"graphic_footnotes\">SPECT: single photon emission computed tomography.<br />* Addition of atropine, arm exercise at 15 minutes if heart rate remains &lt;85% maximum predicted.<br />¶ Imaging should occur 15 to 45 minutes after protocol.<br />Δ​ Injection of the radiopharmaceutical should take place once the patient's heart rate has reached ≥85% of the MPHR. This may occur at any dose of the dobutamine infusion.</div><div id=\"graphicVersion\">Graphic 58697 Version 5.0</div></div></div>"},"58698":{"type":"graphic_figure","displayName":"Transanal endoscopic microsurgery","title":"Transanal endoscopic microsurgery","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Transanal endoscopic microsurgery</div><div class=\"cntnt\"><img style=\"width:523px; height:557px;\" src=\"images/SURG/58698_Transanalendoscopicmicrosurgery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the placement of the operating endoscope and cutting instrument used for the local excision of a rectal lesion.</div><div id=\"graphicVersion\">Graphic 58698 Version 1.0</div></div></div>"},"58699":{"type":"graphic_table","displayName":"Causes of CPP","title":"Conditions associated with chronic pelvic pain in women","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with chronic pelvic pain in women</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n \n   <tr>\n  \n   <td  class=\"subtitle1_single\">\n  \n   Gynecologic\n  \n   </td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Endometriosis*</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Chronic pelvic inflammatory disease*</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Pelvic adhesions</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Pelvic congestion (pelvic varicosities)</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Adenomyosis</td>\n  \n   </tr>\n  \n  \n   <tr>\n  \n   <td>Ovarian remnant syndrome</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Residual ovary syndrome</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Leiomyoma</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Endosalpingiosis</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Neoplasia</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Fallopian tubal prolapse (post-hysterectomy)</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Tuberculous salpingitis</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Benign cystic mesothelioma</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Postoperative peritoneal cysts</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td  class=\"subtitle1_single\">\n  \n   Mental health issues\n  \n   </td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Somatization</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Substance abuse</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Physical and sexual abuse</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Depression</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Sleep disorders</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td  class=\"subtitle1_single\">\n  \n   Urinary tract\n  \n   </td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Interstitial cystitis/painful bladder syndrome*</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Recurrent urinary tract infection</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Urethral diverticulum</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Chronic urethral syndrome</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Neoplasia</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Radiation cystitis</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td  class=\"subtitle1_single\">\n  \n   Gastrointestinal tract\n  \n   </td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Irritable bowel syndrome*</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Inflammatory bowel disease and other causes of colitis</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Diverticular colitis</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Chronic intermittent bowel obstruction</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Neoplasia</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Chronic constipation</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Celiac disease (Sprue)</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td  class=\"subtitle1_single\">\n  \n   Musculoskeletal\n  \n   </td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Pelvic floor myalgia*</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Myofascial pain (trigger points)*</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Coccygodynia</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Piriformis syndrome</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Hernia</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Abnormal posture</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Fibromyalgia</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Peripartum pelvic pain syndrome</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td  class=\"subtitle1_single\">\n  \n   Neurologic disorders\n  \n   </td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Neuralgia, especially of the iliohypogastric, ilioinguinal, genitofemoral, or pudendal nerves*</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Herniated nucleus pulposus</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Neoplasia</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Neuropathic pain</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Abdominal epilepsy</td>\n  \n   </tr>\n  \n   <tr>\n  \n   <td>Abdominal migraine</td>\n  \n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">19.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=42155&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Causes_of_CPP.htm</title></head></div><div class=\"graphic_footnotes\">* These diagnoses are the most common causes of&nbsp;chronic pelvic pain&nbsp;and backed by substantial evidence.</div><div id=\"graphicVersion\">Graphic 58699 Version 3.0</div></div></div>"},"58705":{"type":"graphic_figure","displayName":"Distal clavicle fracture type II B","title":"Distal clavicle fracture type II B","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Distal clavicle fracture type II B</div><div class=\"cntnt\"><img style=\"width:454px; height:246px;\" src=\"images/EM/58705_Clav_fx_dist_type2b.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture depicts a type II B fracture of the distal clavicle. The conoid ligament is ruptured, whereas the trapezoid ligament remains attached to the distal segment. The proximal fragment is displaced.</div><div class=\"graphic_reference\">Reproduced with permission from: Rockwood CA Jr, Green DP, Bucholz RW, Heckman JD (Eds). Rockwood and Green's Fractures in Adults, 4th ed, Lippincott-Raven, Philadelphia 1996. Copyright &copy; 1996 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58705 Version 4.0</div></div></div>"},"58706":{"type":"graphic_figure","displayName":"Sex hormone production males","title":"Sites of sex hormone production in males","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Sites of sex hormone production in males</div><div class=\"cntnt\"><img style=\"width:481px; height:240px;\" src=\"images/ENDO/58706_Sex_hormone_production_male.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sites of production and metabolism of sex steroid hormones in males.</div><div class=\"graphic_footnotes\">A: androstenedione; AR: androgen receptor; DHT: dihydrotestosterone; E1: estrone; E2: estradiol; ER: estrogen receptor; T: testosterone; SHBG: sex hormone-binding globulin.</div><div class=\"graphic_reference\">Adapted from Braunstein, GD. Pubertal gynecomastia. In: Pediatric Endocrinology, Lifshitz, F (Ed), Marcel Dekker, New York, 1996, p. 197.</div><div id=\"graphicVersion\">Graphic 58706 Version 2.0</div></div></div>"},"58707":{"type":"graphic_table","displayName":"Extrapancreatic manif AIP","title":"Extrapancreatic manifestations of autoimmune pancreatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Extrapancreatic manifestations of autoimmune pancreatitis</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td>Inflammatory bowel disease (primarily ulcerative colitis)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>IgG4-associated cholangitis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Lung nodules, adenopathy, infiltrates</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Sj&#246;gren's syndrome</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Retroperitoneal fibrosis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Bile duct strictures, especially long strictures without beading</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Tubulointerstitial nephritis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Autoimmune thyroiditis</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 58707 Version 2.0</div></div></div>"},"58708":{"type":"graphic_algorithm","displayName":"Pathophysiology Eisenmenger","title":"Pathophysiology of the Eisenmenger syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathophysiology of the Eisenmenger syndrome</div><div class=\"cntnt\"><img style=\"width:273px; height:303px;\" src=\"images/CARD/58708_Pathophysiology_Eisenmenger.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Redrawn from Vongpatanasin, W, Brickner, E, Hillis, LD, et al, Ann Intern Med 1998; 128:749.</div><div id=\"graphicVersion\">Graphic 58708 Version 2.0</div></div></div>"},"58709":{"type":"graphic_diagnosticimage","displayName":"DIP joints in psoriasis x ray","title":"DIP involvement in psoriatic arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">DIP involvement in psoriatic arthritis</div><div class=\"cntnt\"><img style=\"width:249px; height:342px;\" src=\"images/RHEUM/58709_DIP_joints_in_psoriasis_x_r.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Psoriatic arthritis associated with pencil-in-cup abnormality in the distal interphalangeal (DIP) joints of the first and second fingers (arrows), plus early changes in the DIP joint of the fourth finger. Other changes include ankylosis in the DIP joint in the fifth finger (arrowhead) and destruction of the wrist.</div><div class=\"graphic_reference\">Courtesy of Dafna D Gladman, MD.</div><div id=\"graphicVersion\">Graphic 58709 Version 3.0</div></div></div>"},"58710":{"type":"graphic_table","displayName":"Monitoring immunosuppressives","title":"Suggested monitoring for immunosuppressive drugs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested monitoring for immunosuppressive drugs</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug or class</td> <td class=\"subtitle1\">Toxicities</td> <td class=\"subtitle1\">Monitoring</td> </tr> <tr> <td>Glucocorticoids</td> <td>Hypertension, hyperglycemia, hyperlipidemia, cataracts, and osteoporosis</td> <td>Periodic blood pressure, serum glucose, lipid profile, eye exam, and bone densitometry</td> </tr> <tr> <td>Methotrexate</td> <td>Myelosuppression and hepatotoxicity, including cirrhosis</td> <td>Complete blood count (CBC), liver enzymes, albumin, creatinine every&nbsp;one to two&nbsp;months</td> </tr> <tr> <td>Hydroxychloroquine</td> <td>Macular damage</td> <td>Fundoscopic and visual field exams every 6 to 12 months</td> </tr> <tr> <td>Sulfasalazine</td> <td>Myelosuppression</td> <td>CBC monthly for&nbsp;three months, then every&nbsp;three months</td> </tr> <tr> <td>Azathioprine</td> <td>Myelosuppression, hepatotoxicity, and lymphoproliferative disorders</td> <td>CBC, liver enzymes every&nbsp;one to two&nbsp;months (CBC every&nbsp;one to two&nbsp;weeks with change in dose</td> </tr> <tr> <td>Cyclophosphamide</td> <td>Myelosuppression, myeloproliferative disorders, hemorrhagic cystitis, bladder cancer, and other neoplasms</td> <td>CBC, urinalysis every&nbsp;two weeks</td> </tr> <tr> <td>Chlorambucil</td> <td>Myelosuppression, myeloproliferative disorders, and other neoplasms</td> <td>CBC every&nbsp;two weeks</td> </tr> <tr> <td>Cyclosporine and FK 506</td> <td>Renal insufficiency, anemia, and hypertension</td> <td>Blood pressure and creatinine every month (every&nbsp;two weeks with change in dose), periodic CBC, potassium, and liver enzymes</td> </tr> <tr> <td>Leflunomide</td> <td>Diarrhea, alopecia, and asymptomatic liver transaminase elevations</td> <td>CBC, liver enzymes, and creatinine every&nbsp;one to two&nbsp;months</td> </tr> <tr> <td>Etanercept</td> <td>Infection, injection site reactions</td> <td>PPD prior to therapy; periodic CBC</td> </tr> <tr> <td>Infliximab</td> <td>Infection</td> <td>PPD prior to therapy; periodic CBC</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58710 Version 2.0</div></div></div>"},"58711":{"type":"graphic_figure","displayName":"Bilateral pectoralis flap","title":"Bilateral pectoralis flap to fill sternal defect","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Bilateral pectoralis flap to fill sternal defect</div><div class=\"cntnt\"><img style=\"width:550px; height:262px;\" src=\"images/SURG/58711_Bilateral_pectoralis_flap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Bilateral pectoralis major flap dissection. The dashed vertical black line indicates the extent of undermining and dissection of the pectoralis major muscle needed to extend it over the sternum.<br> (B) Bilateral medial advancement and placement over mediastinal defect.</div><div class=\"graphic_reference\">Reproduced with permission from: Orgill DP, Austen WG, Butler CE, et al. Guidelines for Treatment of Complex Chest Wounds with Negative Pressure Wound Therapy [review]. Wounds 2004; Suppl B: A compendium of clinical research and practice. Copyright &#169; 2004 HMP Communications, LLC.</div><div id=\"graphicVersion\">Graphic 58711 Version 1.0</div></div></div>"},"58712":{"type":"graphic_figure","displayName":"Scrotum anatomy","title":"Scrotum anatomy","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Scrotum anatomy</div><div class=\"cntnt\"><img style=\"width:512px; height:675px;\" src=\"images/EM/58712_Scrotumanatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The scrotal layers from external to internal include the skin, dartos, intercrural fascia, cremaster muscle, infundibulum, parietal tunica vaginalis, and visceral tunica vaginalis. Superficial lacerations of the scrotum (A) should undergo local wound care and closure with absorbable sutures. Penetrating scrotal trauma to or through the dartos layer (B) has a high rate of associated testicular injury and warrants prompt referral to a urologist for surgical exploration in the operating room. </div><div id=\"graphicVersion\">Graphic 58712 Version 3.0</div></div></div>"},"58713":{"type":"graphic_table","displayName":"Gem plus doc for advanced sarcoma","title":"Gemcitabine plus docetaxel for advanced sarcoma<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gemcitabine plus docetaxel for advanced sarcoma<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Gemcitabine</td> <td>900 mg/m<sup>2</sup> IV (for soft tissue sarcoma if no prior pelvic radiation therapy [RT]*)</td> <td>Dilute with 250 mL normal saline (NS) (final concentration &#60;40 mg/mL) and administer over 90 minutes (ie, 10 mg/m<sup>2</sup> per min).</td> <td>Days 1 and 8</td> </tr> <tr class=\"divider_bottom\"> <td>Docetaxel</td> <td>75 or 100 mg/m<sup>2</sup> IV (if no prior pelvic RT)<sup>&#182;</sup></td> <td>Dilute with 250 mL NS (final concentration of 0.3 to 0.74 mg/mL) and administer over 60 minutes.</td> <td>Day 8</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE (30 to 90% frequency of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Premedicate with dexamethasone prior to docetaxel administration.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Docetaxel is an irritant but can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>This regimen was designed to include primary prophylaxis with granulocyte colony stimulating factors (starting on day 9).<sup>[1]</sup> </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Docetaxel should not be administered if serum bilirubin is above the ULN or if the AST and/or ALT are &#62;1.5 times ULN concomitant with alkaline phosphatase &#62;2.5 times ULN.<sup>[2]</sup> A lower starting dose of gemcitabine may be needed in patients with impaired liver function. </li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for known drug interactions</strong></td> <td colspan=\"3\"> <ul> <li>Caution is needed when administering docetaxel with strong CYP3A4 inhibitors. Although specific dose recommendations are not available, the United States Prescribing Information suggests close monitoring for toxicity and consideration of docetaxel dose reduction if coadministration with a strong CYP3A4 inhibitor cannot be avoided.<sup>[2]</sup> </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor CBC with differential and platelet count weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess basic metabolic panel (including serum creatinine) and liver function tests prior to each treatment cycle. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess for neuropathy, pulmonary toxicity, and fluid retention (weight gain, shortness of breath, peripheral edema, ascites) during treatment. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>The original protocol used the following dose adjustment parameters.<sup>[1]</sup> For febrile neutropenia or a platelet count &#60;25,000/microL lasting more than five days, reduce dose of both gemcitabine and docetaxel by 25% for all subsequent cycles. Delay treatment by one week if the day 1 ANC is &#60;1000 cells/microL or platelet count &#60;100,000/microL; discontinue treatment if not recovered to these levels after two weeks. If day 8 ANC is 500 to 999 cells/microL or platelet count 50,000 to 99,000/microL, reduce gemcitabine and docetaxel by 25%. If ANC &#60;500 cells/microL or platelets &#60;50,000/microL on day 8, eliminate day 8 doses of both drugs for that cycle. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>For grade 3 or 4 neurotoxicity, delay treatment one week; if neurotoxicity resolves to &#8804;grade 2, resume treatment with docetaxel dose reduced by 25% of the previous dose for all subsequent cycles. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Thrombotic microangiopathy</strong></td> <td colspan=\"3\"> <ul> <li>Thrombotic microangiopathy (TMA, also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine, in individuals who have received a large or small cumulative dose.<sup>[3]</sup> Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP. </li> <li>Refer to UpToDate topic on \"Drug-induced thrombotic microangiopathy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>A variety of manifestations of pulmonary toxicity have been reported in patients treated with gemcitabine. Discontinue treatment immediately and permanently. </li> <li>Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Hepatotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>For bilirubin level &#62;1.5 mg/dL, hold docetaxel for that cycle. If bilirubin returns to &#60;1.5 mg/dL, resume docetaxel treatment in subsequent cycles.<sup>[1]</sup> Gemcitabine is commonly associated with a transient rise in serum transaminases, but these are seldom of clinical significance. There is insufficient information from clinical studies to allow clear dose recommendations in these patients. </li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other toxicities</strong></td> <td colspan=\"3\"> <ul> <li>For all other grade 3 or 4 nonhemalogic toxicities (except alopecia), hold treatment for up to two weeks; resume treatment when toxicity has resolved to &#60;grade 2. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; ULN: upper limit of normal; AST: aspartate aminotransferase; ALT: alanine transaminase; CBC: complete blood count; ANC: absolute neutrophil count.<br />* In the original protocol, patients with prior pelvic RT received 25% lower doses of gemcitabine (675 mg/m<SUP>2</SUP> on days 1 and 8). This lower gemcitabine dose was also used when this protocol was administered to patients with refractory, advanced osteosarcoma.<SUP>[4]</SUP><br />¶ In the original protocol, patients without prior pelvic RT received 100 mg/m<SUP>2</SUP> docetaxel, and the dose was reduced to 75 mg/m<SUP>2</SUP> for patients with prior pelvic RT. However, given the toxicity seen with this combination in a randomized trial of gemcitabine plus docetaxel,<SUP>[5]</SUP> many clinicians consider the 100 mg/m<SUP>2</SUP> docetaxel dose to be too high for off-protocol use, even in patients without prior pelvic RT. Off protocol, we give docetaxel 75 mg/m<SUP>2</SUP> on day 8 of each 21 day cycle, with a reduction for prior pelvic irradiation.<SUP>[6]</SUP> Another alternative is a lower dose weekly docetaxel schedule of 30 mg/m<SUP>2</SUP> on days 1, 8, and 15 of each 28 day cycle (with gemcitabine 800 mg/m<SUP>2</SUP> on days 1, 8, and 15).<SUP>[7]</SUP> This schedule has not been prospectively examined in sarcomas.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Hensley ML, et al. J Clin Oncol 2002; 20:2824.</LI>&#xD;&#xA;<LI>Docetaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on January 3, 2012).</LI>&#xD;&#xA;<LI>Gemcitabine hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on January 3, 2012).</LI>&#xD;&#xA;<LI>Navid F, et al. Cancer 2008; 113:419.</LI>&#xD;&#xA;<LI>Maki RG, et al. J Clin Oncol 2007; 25:2755.</LI>&#xD;&#xA;<LI>Hensley ML, et al. Gynecol Oncol 2009; 112:563.</LI>&#xD;&#xA;<LI>O'Shaughnessy JA, et al. Clin Breast Cancer 2006; 6:505.</LI></OL></div><div id=\"graphicVersion\">Graphic 58713 Version 15.0</div></div></div>"},"58714":{"type":"graphic_table","displayName":"Differential diagnosis of foodborne disease by item consumed","title":"Differential diagnosis of foodborne disease by item consumed","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of foodborne disease by item consumed</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Item</td> <td class=\"subtitle1\">Commonly associated microbes*</td> </tr> <tr> <td>Raw seafood</td> <td>Norwalk-like virus, <em>Vibrio </em>spp, hepatitis A</td> </tr> <tr> <td>Raw eggs</td> <td><em>Salmonella </em>spp</td> </tr> <tr> <td>Undercooked meat or poultry</td> <td><em>Salmonella </em>spp, <em>Campylobacter </em>spp, STEC, <em>Clostridium perfringens</em></td> </tr> <tr> <td>Unpasteurized milk or juice</td> <td><em>Salmonella </em>spp, <em>Campylobacter </em>spp, STEC, <em>Yersinia enterocolitica</em></td> </tr> <tr> <td>Unpasteurized soft cheeses</td> <td><em>Salmonella </em>spp, <em>Campylobacter </em>spp, STEC, <em>Y. enterocolitica</em>, <em>Listeria monocytogenes</em></td> </tr> <tr> <td>Homemade canned goods</td> <td><em>Clostridium botulinum</em></td> </tr> <tr> <td>Raw hot dogs, deli meat</td> <td><em>L. monocytogenes</em></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">STEC: shiga toxin-producing <EM>Escherichia coli</EM>.<br />* This association lists the commonly associated organisms and is not fully comprehensive.</div><div id=\"graphicVersion\">Graphic 58714 Version 3.0</div></div></div>"},"58715":{"type":"graphic_table","displayName":"CF incidence and carrier frequency by ethnic origin","title":"Cystic fibrosis incidence and carrier frequency by ethnic origin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cystic fibrosis incidence and carrier frequency by ethnic origin</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Group </td> <td class=\"subtitle1\">Incidence of cystic fibrosis </td> <td class=\"subtitle1\">Carrier frequency of a CFTR gene mutation </td> <td class=\"subtitle1\">&#916;F508, percent </td> </tr> <tr> <td>Non-Hispanic whites</td> <td>1/3300</td> <td>1/25</td> <td>70</td> </tr> <tr> <td>Hispanics</td> <td>1/8000 to 9000</td> <td>1/46</td> <td>46</td> </tr> <tr> <td>Ashkenazi Jews</td> <td>1/3300</td> <td>1/24</td> <td>30</td> </tr> <tr> <td rowspan=\"2\">Native Americans</td> <td>1/3970 Pueblo</td> <td>1/31 Pueblo</td> <td rowspan=\"2\">0</td> </tr> <tr> <td>1/1500 Zuni</td> <td>1/20 Zuni</td> </tr> <tr> <td>African Americans</td> <td>1/15,300</td> <td>1/65</td> <td>48</td> </tr> <tr> <td>Asian Americans</td> <td>1/32,100</td> <td>1/94</td> <td>30</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CFTR: cystic fibrosis conductance transmembrane regulator.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>National Institutes of Health. Genetic testing for cystic fibrosis. NIH Consensus Statement 1997; 15:1.</LI>&#xD;&#xA;<LI>Committee on Genetics, American College of Obstetricians and Gynecologists. ACOG Committee Opinion. Number 325, December 2005. Update on carrier screening for cystic fibrosis. Obstet Gynecol 2005; 106:1465.</LI></OL></div><div id=\"graphicVersion\">Graphic 58715 Version 2.0</div></div></div>"},"58718":{"type":"graphic_table","displayName":"Class gastric ca precurs","title":"Classifications of gastric cancer and precursor lesions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classifications of gastric cancer and precursor lesions</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\" rowspan=\"2\">Padova classification</td>\n\t\t\t\t\t<td class=\"subtitle1\" colspan=\"2\">Japanese classification</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2\">Category</td>\n\t\t\t\t\t<td class=\"subtitle2\">Definition</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>1. Negative for dysplasia</td>\n\t\t\t\t\t<td rowspan=\"6\">Group I</td>\n\t\t\t\t\t<td rowspan=\"6\">Normal mucosa and benign lesions with no atypia</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">1.0 Normal</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">1.1 Reactive foveolar hyperplasia</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">1.2 Intestinal metaplasia (IM)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">1.2.1 IM Complete type</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">1.2.2 IM Incomplete type</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>2. Indefinite for dysplasia</td>\n\t\t\t\t\t<td rowspan=\"3\">Group II</td>\n\t\t\t\t\t<td rowspan=\"3\">Lesions showing atypia but diagnosed as benign (nonneoplastic)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">2.1 Foveolar hyperproliferation</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">2.2 Hyperproliferative IM</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>3. Non-invasive neoplasia (flat or elevated [synonym adenoma])</td>\n\t\t\t\t\t<td rowspan=\"5\">Group III</td>\n\t\t\t\t\t<td rowspan=\"5\">Borderline lesions between benign and malignant</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">3.1 Low-grade</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">3.2 High-grade</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">3.2.1 Including suspicious for carcinoma without invasion (intreglandular)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">3.2.2 Including carcinoma without invasion (intraglandular)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>4. Suspicious for invasive carcinoma</td>\n\t\t\t\t\t<td>Group IV</td>\n\t\t\t\t\t<td>Lesions strongly suspected of carcinoma</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>5. Invasive adenocarcinoma</td>\n\t\t\t\t\t<td>Group V</td>\n\t\t\t\t\t<td>Carcinoma</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 58718 Version 1.0</div></div></div>"},"58719":{"type":"graphic_figure","displayName":"Hip dislocation","title":"Pathologic changes in developmental dysplasia of the hip (DDH)","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Pathologic changes in developmental dysplasia of the hip (DDH)</div><div class=\"cntnt\"><img style=\"width:483px; height:155px;\" src=\"images/PEDS/58719_Hip_dislocation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pathologic changes of DDH occur along a spectrum in time and severity, as depicted in images A through C above. Changes begin with laxity of the hip joint capsule (A), which permits the femoral head to move out of the acetabulum. This movement results in eversion of the labrum and elongation of the ligamentum teres (B), eventually preventing relocation of the femoral head into the acetabulum (C).</div><div id=\"graphicVersion\">Graphic 58719 Version 2.0</div></div></div>"},"58721":{"type":"graphic_picture","displayName":"Prolymphocytic leukemia","title":"Peripheral blood smear in a patient with prolymphocytic leukemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peripheral blood smear in a patient with prolymphocytic leukemia</div><div class=\"cntnt\"><img style=\"width:355px; height:291px;\" src=\"images/HEME/58721_Prolymphocytic_leukemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear from a 71-year-old male patient with splenomegaly and a white blood cell count of 50,000/&#181;L, with a preponderance of prolymphocytes. The prolymphocytes shown here are large cells with a moderate amount of clear to lightly basophilic cytoplasm, coarse nuclear chromatin, and a prominent single nucleolus (arrows).</div><div class=\"graphic_reference\">From Brunning, RD, McKenna, RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 58721 Version 3.0</div></div></div>"},"58725":{"type":"graphic_diagnosticimage","displayName":"Metacarpal base fracture","title":"Fracture at the base of the second metacarpal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fracture at the base of the second metacarpal</div><div class=\"cntnt\"><img style=\"width:360px; height:324px;\" src=\"images/EM/58725_Metacarpal_base_fx_displace.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anteroposterior radiograph shows a displaced fracture of the base of the second metacarpal.</div><div class=\"graphic_reference\">Courtesy of Josh Bloom, MD, MPH.</div><div id=\"graphicVersion\">Graphic 58725 Version 3.0</div></div></div>"},"58727":{"type":"graphic_figure","displayName":"Rx post MI ischemia DANAMI","title":"Revascularization in patients with inducible ischemia after thrombolysis improves outcome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Revascularization in patients with inducible ischemia after thrombolysis improves outcome</div><div class=\"cntnt\"><img style=\"width:383px; height:433px;\" src=\"images/CARD/58727_Rx_post_MI_ischemia_DANAMI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The DANAMI study randomly assigned 1008 postinfarction patients with spontaneous or exercise induced ischemia after thrombolytic therapy for acute myocardial infarction (MI) to conservative therapy or invasive therapy with revascularization, if appropriate, based upon anatomy. The invasive strategy significantly reduced the incidence of reinfarction, death, or admission for unstable angina; 44 versus 32 percent at four years (upper panel) but did not affect total mortality (lower panel).</div><div class=\"graphic_reference\">Data from Madsen JK, Grande P, Saunamaki K, et al, on behalf of the DANAMI Study Group, Circulation 1997; 96:748.</div><div id=\"graphicVersion\">Graphic 58727 Version 2.0</div></div></div>"},"58729":{"type":"graphic_picture","displayName":"Stool ova and parasites","title":"Appearance and relative sizes of stool ova and parasites","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Appearance and relative sizes of stool ova and parasites</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/ID/58729_Stoolovaandparasites.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(1) Hookworm egg; (2) whipworm egg (<EM>Trichuris trichura</EM>); (3) <EM>Taenia</EM> egg; (4) <EM>Entamoeba histolytica </EM>cyst; (5) <EM>Giardia lamblia </EM>cyst; (6) infertile <EM>Ascaris lumbricoides </EM>egg; (7) red blood cells;&nbsp;(8)<EM> Schistosoma mansoni</EM> egg.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 58729 Version 2.0</div></div></div>"},"58730":{"type":"graphic_movie","displayName":"Left atrial myxoma five chamber echocardiogram 1","title":"Left atrial myxoma","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left atrial myxoma</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/58730_5chlamy1conv.mp4\" style=\"width:328px;height:248px\"></div><img style=\"width:244px; height:442px;\" src=\"images/CARD/58730_5chlamy1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The five-chamber view from a 2-D echocardiogram shows a very large left atrial myxoma, which has a broad stalk and is adherent to the interatrial septum. During diastole, the tumor extends into the left ventricle. The presence of left atrial enlargement suggests that there is mitral regurgitation.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 58730 Version 3.0</div></div></div>"},"58732":{"type":"graphic_diagnosticimage","displayName":"Computer calculation of LV mass","title":"Computer calculation of an estimate of left ventricular mass","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Computer calculation of an estimate of left ventricular mass</div><div class=\"cntnt\"><img style=\"width:456px; height:144px;\" src=\"images/CARD/58732_Computer_measure_LV_mass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Only four simple measurements on the 2D echocardiogram&nbsp;are required&nbsp;for&nbsp;computer&nbsp;calculation of&nbsp;an estimate of left ventricular (LV) mass. The first two measurements are of the areas subtended by the epicardium and endocardium (A1 and A2), the third of the semimajor axis a, and the fourth, the truncated semimajor axis d.</div><div id=\"graphicVersion\">Graphic 58732 Version 4.0</div></div></div>"},"58733":{"type":"graphic_figure","displayName":"Cho stitch","title":"Cho stitch","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Cho stitch</div><div class=\"cntnt\"><img style=\"width:514px; height:382px;\" src=\"images/OBGYN/58733_Cho_stitch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cho described a technique in which a straight number 7 or 8 needle with #1 chromic catgut is  used to place sutures in a small rectangular array to compress the anterior and posterior uterine walls  against one another at sites of heavy bleeding. The through and through sutures extend from the serosa of the anterior wall to the serosa of the posterior wall. After creating a square, the ends are tied down as tight as possible to compress the myometrium. Two to five squares/rectangles are made, as needed.</div><div class=\"graphic_reference\">Cho, JH, Jun, HS, Lee, CN. Hemostatic suturing technique for uterine bleeding during cesarean delivery. Obstet Gynecol 2000; 96:129.</div><div id=\"graphicVersion\">Graphic 58733 Version 2.0</div></div></div>"},"58734":{"type":"graphic_figure","displayName":"Colonoscopy versus sigmoidoscopy PI","title":"Colonoscopy versus sigmoidoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Colonoscopy versus sigmoidoscopy</div><div class=\"cntnt\"><img style=\"width:386px; height:568px;\" src=\"images/PI/58734_Colonosc_vs_sigmoid_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During a colonoscopy or a sigmoidoscopy, you lie on your side, and the doctor or nurse puts a thin tube with a camera into your anus (from behind). Then the doctor or nurse advances the tube into the rectum and colon. The camera sends pictures from inside your colon to a television screen.<br />A colonoscopy allows the doctor to see the whole colon (shown in pink and green). A sigmoidoscopy allows the doctor to see only the last part of the colon (shown in green).</div><div id=\"graphicVersion\">Graphic 58734 Version 5.0</div></div></div>"},"58736":{"type":"graphic_figure","displayName":"Retinopathy onset in NIDDM","title":"Onset of retinopathy precedes diagnosis of type 2 diabetes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Onset of retinopathy precedes diagnosis of type 2 diabetes</div><div class=\"cntnt\"><img style=\"width:429px; height:214px;\" src=\"images/ENDO/58736_Retinopathy_onset_in_NIDDM.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prevalence of retinopathy in relation to years after onset of diabetes among patients in southern Wisconsin (blue circles) and rural western Australia (red squares). At diagnosis (year 0), retinopathy was already present in 10 to 20 percent of patients. The lines extrapolate back to an estimated onset of retinopathy four to seven years before the clinical diagnosis was made.</div><div class=\"graphic_reference\">Data from: Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992; 15:815.</div><div id=\"graphicVersion\">Graphic 58736 Version 3.0</div></div></div>"},"58737":{"type":"graphic_diagnosticimage","displayName":"EUS celiac ganglion inject","title":"Endoscopic ultrasound celiac ganglion inject","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic ultrasound&nbsp;celiac ganglion inject</div><div class=\"cntnt\"><img style=\"width:304px; height:442px;\" src=\"images/GAST/58737_EUS_celiac_ganglion_inject.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Initial pre-injection appearance (A) of a celiac ganglion as compared to that following injection (B).</div><div class=\"graphic_reference\">Copyrighted and used with permission of Mayo Foundation for Medical Education and Research.</div><div id=\"graphicVersion\">Graphic 58737 Version 11.0</div></div></div>"},"58738":{"type":"graphic_table","displayName":"Doxorubicin cardiac monitoring","title":"Guidelines for monitoring cardiac function in patients receiving doxorubicin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for monitoring cardiac function in patients receiving doxorubicin</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Perform baseline radionuclide angiocardiography at rest for calculation of left ventricular ejection fraction (LVEF) prior to administration of 100 mg/m<sup>2</sup> doxorubicin.</td> </tr> <tr> <td>Subsequent studies are performed at least three weeks after the indicated total cumulative doses have been given, before consideration of the next dose.</td> </tr> <tr> <td class=\"subtitle1_single\">Patients with normal baseline LVEF (&#8805;50 percent)</td> </tr> <tr> <td>Perform a second study after 250 to 300 mg/m<sup>2</sup>. Repeat study after 400 mg/m<sup>2</sup> in patients with known heart disease, radiation exposure, abnormal electrocardiographic results, or cyclophosphamide therapy; or after 450 mg/m<sup>2</sup> in the absence of any these risk factors.</td> </tr> <tr> <td>Perform sequential studies thereafter prior to each dose.&nbsp;</td> </tr> <tr> <td>Discontinue doxorubicin therapy once functional criteria for cardiotoxicity develop, eg, absolute decrease in LVEF &#8805;10 percent (EF Units) associated with a decline to a level of &#8804;50 percent (EF Units).</td> </tr> <tr> <td class=\"subtitle1_single\">Patients with abnormal baseline LVEF (&#8804;50 percent)</td> </tr> <tr> <td>Doxorubicin therapy should <strong>not</strong> be initiated with baseline LVEF &#8804;30 percent.</td> </tr> <tr> <td>In patients with LVEF &#62;30 percent and &#60;50 percent, sequential studies should be obtained prior to each dose.</td> </tr> <tr> <td>Discontinue doxorubicin with cardiotoxicity: absolute decrease in LVEF &#8805;10 percent (EF units) and/or final LVEF &#8804;30 percent.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LVEF: left ventricular ejection fraction.</div><div class=\"graphic_reference\">Adapted from: Schwartz RG, McKenzie WB, Alexander J, et al. Am J Med 1987; 82:1109.</div><div id=\"graphicVersion\">Graphic 58738 Version 3.0</div></div></div>"},"58741":{"type":"graphic_table","displayName":"Euthanasia PAS Europe","title":"Euthanasia and PAS practices in Europe","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Euthanasia and PAS practices in Europe</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\"> <p>Belgium, 2013</p> <p><sup>[1,2]</sup></p> <p>Legal</p> </td> <td class=\"subtitle1\"> <p>Denmark<sup>[3]</sup></p> Not legal</td> <td class=\"subtitle1\"> <p>Italy<sup>[3]</sup></p> <p>Legal</p> </td> <td class=\"subtitle1\"> <p>Sweden<sup>[3]</sup></p> <p>Not legal</p> </td> <td class=\"subtitle1\"> <p>Switzerland<sup>[3]</sup></p> <p>Legal</p> </td> <td class=\"subtitle1\"> <p>Netherlands, 2015<sup>[4]</sup></p> <p>Legal</p> </td> </tr> <tr> <td>Percent of deaths from any type of doctor-assisted dying</td> <td>6.3</td> <td>0.79</td> <td>0.10</td> <td>0.23</td> <td>1.04</td> <td>4.9</td> </tr> <tr> <td>Percent of deaths from VAE</td> <td>4.6</td> <td>0.06</td> <td>0.04</td> <td>0</td> <td>0.27</td> <td>4.5</td> </tr> <tr> <td>Percent of deaths from PAD</td> <td>0.05</td> <td>0.06</td> <td>0.00</td> <td>0</td> <td>0.36</td> <td>0.1</td> </tr> <tr> <td>Percent of deaths from lethal medication without patient's consent (LAWER)</td> <td>1.7</td> <td>0.67</td> <td>0.06</td> <td>0.23</td> <td>0.42</td> <td>0.3</td> </tr> <tr> <td>Percent of doctor-assisted deaths involving cancer patients</td> <td>69</td> <td>58</td> <td>100</td> <td>37</td> <td>31&#916;</td> <td>84</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PAS: physician-assisted suicide; VAE: voluntary active euthanasia; PAD: physician-assisted dying.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Chambaere K, Vander Stichele R, Mortier F, et al. Recent trends in euthanasia and other end-of-life practices in Belgium. N Engl J Med 2015; 372:1179.</LI>&#xD;&#xA;<LI>Dierickx S, Deliens L, Cohen J, Chambaere K. Euthanasia in Belgium: trends in reported cases between 2003 and 2013. CMAJ 2016; 188:E407.</LI>&#xD;&#xA;<LI>van der Heide A, Deliens L, Faisst K, et al. End-of-life decision-making in six European countries: descriptive study. Lancet 2003; 362:345.</LI>&#xD;&#xA;<LI>Onwuteaka-Philipsen BD, Brinkman-Stoppelenburg A, Penning C, et al. Trends in end-of-life practices before and after the enactment of the euthanasia law in the Netherlands from 1990 to 2010: a repeated cross-sectional survey. Lancet 2012; 380:908.</LI></OL></div><div id=\"graphicVersion\">Graphic 58741 Version 11.0</div></div></div>"},"58742":{"type":"graphic_picture","displayName":"Urothelial papilloma","title":"Urothelial papilloma","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Urothelial papilloma</div><div class=\"cntnt\"><img style=\"width:598px; height:434px;\" src=\"images/ONC/58742_Urothelial_papilloma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A-D: Most papillomas have a simple non-branching arrangement, slender fibrovascular stalks, with a predominantly exophytic pattern. Papillary fronds are lined by normal appearing urothelium (20x).</div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 58742 Version 1.0</div></div></div>"},"58746":{"type":"graphic_movie","displayName":"Ebstein anomaly echocardiogram four-chamber view","title":"Ebstein anomaly echocardiogram four-chamber view","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ebstein anomaly echocardiogram four-chamber view</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/58746_4chebsanconv.mp4\" style=\"width:383px;height:276px\"></div><img style=\"width:445px; height:241px;\" src=\"images/CARD/58746_4chebsan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The four-chamber view of a transthoracic echocardiogram shows a large right atrium (RA), due to atrialization of the right ventricle (RV) and a large sail-like tricuspid valve (TV). A vestigal septal leaflet can be seen (red arrow).</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 58746 Version 3.0</div></div></div>"},"58747":{"type":"graphic_diagnosticimage","displayName":"Apical 4 chamber contrast echo normal LV","title":"Apical 4-chamber view of an echocardiogram showing contrast-enhanced images","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apical 4-chamber view of an echocardiogram showing contrast-enhanced images</div><div class=\"cntnt\"><img style=\"width:396px; height:246px;\" src=\"images/CARD/58747_Contrast_echo_normal_LV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Successive frames from the apical 4-chamber view of a contrast-enhanced echocardiogram of a normal left ventricle (LV) shows homogenous LV intracavitary contrast flow (pattern A).</div><div class=\"graphic_reference\">Reproduced from Thanigaraj S, Chugh R, Schectman KB, et al. Am J Cardiol 2000; 85:65, with permission from Excerpta Medica, Inc.</div><div class=\"contractual\"><br/><a href=\"http://www.elsevier.com/locate/jacc\">http://www.elsevier.com/locate/jacc</a><br/><a href=\"http://www.sciencedirect.com/\"> http://www.sciencedirect.com</a></div><div id=\"graphicVersion\">Graphic 58747 Version 4.0</div></div></div>"},"58749":{"type":"graphic_diagnosticimage","displayName":"US appendicitis in pregnancy2","title":"Sonogram of appendicitis in pregnancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sonogram of appendicitis in pregnancy</div><div class=\"cntnt\"><img style=\"width:432px; height:210px;\" src=\"images/OBGYN/58749_US_appendicitis_pregnancy2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sonogram of the right lower quadrant in a woman with appendicitis at 21 weeks of gestation. Note the fluid-filled appendix with appendicoliths (arrow).</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 58749 Version 2.0</div></div></div>"},"58751":{"type":"graphic_picture","displayName":"Naegleria fowleri trophozoite","title":"<EM>Naegleria fowleri </EM>trophozoite","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\"><EM>Naegleria fowleri </EM>trophozoite</div><div class=\"cntnt\"><img style=\"width:504px; height:366px;\" src=\"images/ID/58751_Naegleria_fowleri_tropho_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Naegleria fowleri </EM>trophozoites (arrows) with neutrophilic exudate; Wright's Giemsa-stained cytospin preparation of cerebrospinal fluid, day of presentation, x50.</div><div class=\"graphic_reference\">From: Mackowiak PA. Ten-Year-Old With Fever, Headache, and Neck Stiffness. Clin Infect Dis 2012; 55:1677. By permission of the Infectious Diseases Society of America. Copyright © 2013 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 58751 Version 5.0</div></div></div>"},"58752":{"type":"graphic_table","displayName":"Indications bone density","title":"The National Osteoporosis Foundation indications for bone density testing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The National Osteoporosis Foundation indications for bone density testing</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Women age 65 years and older and men age 70 years and older, regardless of clinical risk factors.</td> </tr> <tr> <td>Younger postmenopausal women, women in the menopausal transition,&nbsp;and men age 50 to 69 years with clinical risk factors for fracture.</td> </tr> <tr> <td>Adults who have a fracture after age 50 years.</td> </tr> <tr> <td>Adults with a condition (eg, rheumatoid arthritis) or taking a medication (eg, glucocorticoids in a daily dose &#8805;5 mg prednisone or equivalent for &#8805;3 months) associated with low bone mass or bone loss.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2013. <A spellcheck=true href=\"https://my.nof.org/file/bonesource/Clinicians-Guide.pdf\">https://my.nof.org/file/bonesource/Clinicians-Guide.pdf</A></div><div id=\"graphicVersion\">Graphic 58752 Version 5.0</div></div></div>"},"58753":{"type":"graphic_table","displayName":"Screening adrenal incidentaloma","title":"Evaluation of the patient with an incidentally-discovered adrenal mass","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of the patient with an incidentally-discovered adrenal mass</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Diagnosis</td> <td class=\"subtitle1\">Suggestive clinical features</td> <td class=\"subtitle1\">Laboratory tests</td> </tr> <tr> <td rowspan=\"5\">Pheochromocytoma</td> <td rowspan=\"5\">Hypertension, paroxysmal symptoms (eg, palpitation, diaphoresis, headache, pallor, tremor)</td> <td class=\"sublist1_start\">24-hour urine:</td> </tr> <tr> <td class=\"sublist1\">Fractionated metanephrines</td> </tr> <tr> <td class=\"sublist1\">Fractionated catecholamines</td> </tr> <tr> <td class=\"sublist1_start\">Blood:</td> </tr> <tr> <td class=\"sublist1\">Fractionated metanephrines</td> </tr> <tr> <td rowspan=\"4\">Cushing's syndrome</td> <td rowspan=\"4\">Central obesity, proximal muscle weakness, thin skin, supraclavicular fat pad, facial plethora</td> <td class=\"sublist1_start\">For patients with symptoms of Cushing's syndrome:</td> </tr> <tr> <td class=\"sublist1\">24-hour urinary free cortisol</td> </tr> <tr> <td class=\"sublist1_start\">For patients lacking symptoms of Cushing's syndrome:</td> </tr> <tr> <td class=\"sublist1\">1 mg overnight dexamethasone suppression test</td> </tr> <tr> <td rowspan=\"2\">Primary aldosteronism</td> <td rowspan=\"2\">Hypertension, hypokalemia</td> </tr> <tr> <td>Plasma aldosterone concentration, plasma renin activity</td> </tr> <tr> <td rowspan=\"2\">Adrenocortical carcinoma</td> <td rowspan=\"2\">Mass effect symptoms; symptoms related to excess glucocorticoid, mineralocorticoid, androgen, or estrogen secretion</td> <td>Serum DHEAS</td> </tr> <tr> <td>Measures of clinically-indicated steroid</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DHEAS: dehydroepiandrosterone sulfate.</div><div id=\"graphicVersion\">Graphic 58753 Version 4.0</div></div></div>"},"58756":{"type":"graphic_table","displayName":"Emetogenicity chemo drugs","title":"Emetogenicity of parenteral chemotherapeutic drugs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Emetogenicity of parenteral chemotherapeutic drugs</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Level</td> <td class=\"subtitle1\">Frequency of emesis (%)</td> <td class=\"subtitle1\">Chemotherapeutic drug and dose</td> </tr> <tr class=\"divider_bottom\"> <td>High</td> <td>&#62;90</td> <td> <p>Anthracycline/cyclophosphamide for breast cancer</p> <p>Carmustine</p> <p>Cisplatin</p> <p>Cyclophosphamide &#8805;1500 mg/m<sup>2</sup></p> <p>Dacarbazine</p> <p>Mechlorethamine</p> <p>Streptozocin</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Moderate</td> <td>30 to 90</td> <td> <p>Alemtuzumab</p> <p>Azacytidine</p> <p>Bendamustine</p> <p>Carboplatin</p> <p>Clofarabine</p> <p>Cyclophosphamide &#60;1500 mg/m<sup>2</sup></p> <p>Cytarabine &#62;1000 mg/m<sup>2</sup></p> <p>Daunorubicin*</p> <p>Doxorubicin*</p> <p>Epirubicin*</p> <p>Idarubicin*</p> <p>Ifosfamide</p> <p>Irinotecan, liposomal irinotecan</p> <p>Oxaliplatin</p> <p>Romidepsin</p> <p>Temozolomide</p> <p>Thiotepa</p> <p>Trabectedin</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Low<sup>&#182;</sup></td> <td>10 to 30</td> <td> <p>Aflibercept</p> <p>Belinostat</p> <p>Blinatumomab</p> <p>Bortezomib</p> <p>Brentuximab</p> <p>Cabazitaxel</p> <p>Carfilzomib</p> <p>Catumaxumab</p> <p>Cetuximab</p> <p>Cytarabine &#8804;1000 mg/m<sup>2</sup></p> <p>Docetaxel</p> <p>Eribulin</p> <p>Etoposide</p> <p>Fluorouracil</p> <p>Gemcitabine</p> <p>Ipilimumab</p> <p>Ixabepilone</p> <p>Methotrexate<sup>&#916;</sup></p> <p>Mitomycin</p> <p>Mitoxantrone</p> <p>Paclitaxel and nab-paclitaxel</p> <p>Panitumumab</p> <p>Pegylated liposomal doxorubicin</p> <p>Pemetrexed</p> <p>Pertuzumab</p> <p>Temsirolimus</p> <p>Topotecan</p> <p>Ado-trastuzumab emtansine</p> <p>Vinflunine</p> </td> </tr> <tr> <td>Minimal<sup>&#9674;</sup></td> <td>&#60;10</td> <td> <p>Bevacizumab</p> <p>Bleomycin</p> <p>Busulfan</p> <p>2-Chlorodeoxyadenosine</p> <p>Cladribine</p> <p>Fludarabine</p> <p>Nivolumab</p> <p>Ofatumumab</p> <p>Pembrolizumab</p> <p>Pixantrone</p> <p>Pralatrexate</p> <p>Rituximab</p> <p>Trastuzumab</p> <p>Vinblastine</p> <p>Vincristine</p> <p>Vinorelbine</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* These anthracyclines, when combined with cyclophosphamide, are now designated as having high emetic risk.<br />¶ Another agent that is considered to be at low risk is daratumumab.<br />Δ&nbsp;At doses &gt;1 gram, methotrexate has at least moderate emetogenic potential.<br />◊ Other agents that are considered to be&nbsp;minimal risk include cetuximab, elotuzumab, necitumumab, obinutuzumab, and olaratumab.</div><div class=\"graphic_reference\">Reproduced with permission from: Aapro M, Gralla RJ, Herrstedt J, et al. MASCC/ESMO Antiemetic Guideline 2016. Copyright © 2016 Multinational Association of Supportive Care in Cancer. All rights reserved.</div><div id=\"graphicVersion\">Graphic 58756 Version 33.0</div></div></div>"},"58758":{"type":"graphic_table","displayName":"Physical causes anxiety Sxs","title":"Physical causes of anxiety-like symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physical causes of anxiety-like symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Cardiovascular</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Angina pectoris, arrhythmias, heart failure, hypertension, hypovolemia, myocardial infarction, syncope (multiple causes), valvular disease, vascular collapse (shock)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Dietary</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Caffeine, monosodium glutamate (Chinese restaurant syndrome), vitamin-deficiency diseases</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Drug-related</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Akathisia (secondary to antipsychotic drugs), anticholinergic toxicity, digitalis toxicity, hallucinogens, hypotensive agents, stimulants (amphetamines, cocaine, related drugs), withdrawal syndromes (alcohol, sedative-hypnotics), bronchodilators (theophylline, sympathomimetics)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Hematologic</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Anemias</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Immunologic</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Anaphylaxis, systemic lupus erythematosus</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Metabolic</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hyperadrenalism (Cushing's disease), hyperkalemia, hyperthermia, hyperthyroidism, hypocalcemia, hypoglycemia, hyponatremia, hypothyroidism, menopause, porphyria (acute intermittent)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Neurologic</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Encephalopathies (infectious, metabolic, toxic), essential tremor, intracranial mass lesions, postconcussive syndrome, seizure disorders (especially of the temporal lobe), vertigo</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Respiratory</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Asthma, chronic obstructive pulmonary disease, pneumonia, pneumothorax, pulmonary edema, pulmonary embolism</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Secreting tumors</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Carcinoid, insulinoma, pheochromocytoma</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: Rosenbaum, JF, N Engl J Med 1982; 306:401.</div><div id=\"graphicVersion\">Graphic 58758 Version 1.0</div></div></div>"},"58759":{"type":"graphic_table","displayName":"Conditions associated with ARDS","title":"Abbreviated list of conditions associated with acute respiratory distress syndrome (ARDS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Abbreviated list of conditions associated with acute respiratory distress syndrome (ARDS)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Sepsis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Aspiration</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Infectious pneumonia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Severe trauma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Surface burns</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Multiple blood transfusions</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Leukoagglutin reactions</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pancreatitis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Drug overdose</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Near drowning</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Smoke inhalation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cardiopulmonary bypass</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pulmonary contusion</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Multiple fractures</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Following upper airway obstruction</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Following bone marrow transplantation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Drug reaction</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Venous air embolism</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Amniotic fluid embolism</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Neurogenic pulmonary edema</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Acute eosinophilic pneumonia*</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Bronchiolitis obliterans organizing pneumonia (BOOP)*</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Miliary tuberculosis*</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* Specific treatment required.</div><div id=\"graphicVersion\">Graphic 58759 Version 2.0</div></div></div>"},"58760":{"type":"graphic_figure","displayName":"M-mode cardiomyopathy I","title":"M-mode echocardiogram in cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">M-mode echocardiogram in cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:435px; height:262px;\" src=\"images/CARD/58760_MmodecardiomyopathyI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The M-mode echocardiogram (left panel) and the left ventriculogram (right panel) are from a patient with a cardiomyopathy. The ventriculogram shows global hypokinesis, large end-diastolic (EDV) and end-systolic volumes (ESV), and an ejection fraction (EF) of 32 percent. The M-mode echocardiogram shows reduced septal (Sept) motion, a large left (LV) and right ventricle (RV), and an EPSS of 20 mm.</div><div class=\"graphic_footnotes\">Dia: diastole; Sys: systole.</div><div id=\"graphicVersion\">Graphic 58760 Version 2.0</div></div></div>"},"58761":{"type":"graphic_picture","displayName":"Blue toe syndrome","title":"Blue toe syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Blue toe syndrome</div><div class=\"cntnt\"><img style=\"width:432px; height:318px;\" src=\"images/CARD/58761_Blue_toe_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blue toes are a classic manifestation of peripheral embolization of atheromatous material from proximal arterial sources (eg, aorta); the pedal pulses are often normal. This patient, who has a 30-year history of type 1 diabetes and severe peripheral vascular disease, presented with foot pain and discoloration. Cholesterol microemboli from the aorta were suspected to be the cause.</div><div class=\"graphic_reference\">Reproduced with permission from Lawrence B Stack, MD. Copyright © Lawrence B Stack, MD.</div><div id=\"graphicVersion\">Graphic 58761 Version 2.0</div></div></div>"},"58762":{"type":"graphic_movie","displayName":"TEE prosthetic mitral valve vegetation","title":"Transophageal echocardiogram (TEE) showing a prosthetic mitral valve vegetation in patient with endocarditis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transophageal echocardiogram (TEE) showing a prosthetic mitral valve vegetation in patient with endocarditis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/58762_prmvend2conv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:261px; height:183px;\" src=\"images/CARD/58762_prmvend2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transesophageal echocardiogram shows large vegetations on a prosthetic mitral valve which has limited mobility.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 58762 Version 4.0</div></div></div>"},"58763":{"type":"graphic_waveform","displayName":"EPS tracing corrected sinus node recovery time","title":"Electrophysiology study (EPS) tracings used in the determination of the corrected sinus node recovery time (SNRT)","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Electrophysiology study (EPS) tracings used in the determination of the corrected sinus node recovery time (SNRT)</div><div class=\"cntnt\"><img style=\"width:514px; height:310px;\" src=\"images/CARD/58763_Corrected_SN_recovery_time.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This tracing is from a 76-year-old male with paroxysmal atrial fibrillation and recurrent near syncope associated with palpitations. Surface leads represented are I, II, III, V1, and V6. Intracardiac tracings shown are the high right atrium (HRA d), the proximal His bundle electrogram (HIS p), the mid His bundle electrogram (HIS m), the distal His bundle electrogram (HIS d), and the right ventricular apex (RVa d). High right atrial pacing at 400 milliseconds (150 beats per minute) is performed for 30 seconds. Upon termination of pacing, a sinus node recovery time of 2150 milliseconds is observed (arrow). The basal sinus cycle length was 1200 milliseconds, giving a corrected sinus node recovery time of 950 milliseconds, consistent with severe sinus node dysfunction. Note the significant secondary pause extending beyond the end of the tracing providing additional evidence of sinus node dysfunction.</div><div class=\"graphic_footnotes\">ms: milliseconds.</div><div class=\"graphic_reference\">Courtesy of Joseph J Germano, DO.</div><div id=\"graphicVersion\">Graphic 58763 Version 5.0</div></div></div>"},"58764":{"type":"graphic_figure","displayName":"VF sectoral defects","title":"Sectoral visual field defect","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sectoral visual field defect</div><div class=\"cntnt\"><img style=\"width:432px; height:207px;\" src=\"images/NEURO/58764_VF_sectoral_defects.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Central sector-sparing homonymous hemianopia caused by anterior choroidal artery occlusion and incomplete lateral geniculate body lesion</div><div class=\"graphic_reference\">Reproduced with permission from: Zhang X, Kedar S, Lynn MJ, et al. Homonymous hemianopias: clinical-anatomic correlations in 904 cases. Neurology 2006; 66:906. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58764 Version 6.0</div></div></div>"},"58766":{"type":"graphic_table","displayName":"Disorders with genital ambiguit","title":"Disorders with associated genital abnormalities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders with associated genital abnormalities</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Abnormality</td>\n\n      <td class=\"subtitle1\">Frequent in:</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"7\">Hypospadias/bifid scrotum</td>\n\n      <td>Aniridia-Wilms tumor association</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Deletion of 4p, 11q, 13q</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Bladder exstrophy sequence</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Fraser syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Fryn syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Smith-Lemli-Opitz syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Triploidy syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"7\">Micropenis</td>\n\n      <td>Anencephaly sequence</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Carpenter syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>CHARGE association</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Deletion of 9p, 18q</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>4p duplication syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Noonan syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Prader-Willi syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"18\">Cryptorchidism</td>\n\n      <td>Aarskog syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Carpenter syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Deletion of: 4p, 5p, 9p, 11q, 13q, 18q</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Duplication of 3q, 4p, 10q, 15q</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Distal arthrogryposis syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Cloacal exstrophy sequence</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Fraser syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Freeman-Sheldon syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Miller-Dieker syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Noonan syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Robinow syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Rubinstein-Taybi syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Smith-Lemli-Opitz syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Triploidy syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Trisomy 9 mosaic syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Trisomy 13</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Trisomy 18</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Weaver syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"4\">Hypoplasia of labia majora</td>\n\n      <td>Deletion of 9p, 18q</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Prader-Willi syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Robinow syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Trisomy 18 syndrome</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Jones, KL. Smith's recognizable patterns of human malformation, 4th ed, Saunders, Philadelphia 1998. p. 677.</div><div id=\"graphicVersion\">Graphic 58766 Version 1.0</div></div></div>"},"58767":{"type":"graphic_figure","displayName":"Mutations in heme pocket","title":"Mutations in heme pocket resulting in unstable hemoglobins","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Mutations in heme pocket resulting in unstable hemoglobins</div><div class=\"cntnt\"><img style=\"width:497px; height:388px;\" src=\"images/HEME/58767_Mutations_in_heme_pocket.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the heme pocket, showing the replacement site of several of the unstable hemoglobins. Valine E4 is at the corner of the pocket; its side chain does not make contact with the heme but does affect the placement of adjacent amino acid side chains.</div><div class=\"graphic_reference\">Reproduced with permission from: Williamson D, Brennan SO, Muir H, Carrell RW. Hemoglobin Collingwood beta 60 (E4) Val replaced by Ala. A new unstable hemoglobin.&nbsp;Hemoglobin 1983; 7:511. Copyright © 1983 Marcel Dekker.</div><div id=\"graphicVersion\">Graphic 58767 Version 3.0</div></div></div>"},"58768":{"type":"graphic_figure","displayName":"Kocher maneuver","title":"Kocher maneuver","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Kocher maneuver</div><div class=\"cntnt\"><img style=\"width:533px; height:659px;\" src=\"images/SURG/58768_Kocher_maneuver_edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dissection of the lateral peritoneal attachments of the duodenum (A) exposes the first, second, and third portion of the duodenum and the head and neck of the pancreas (B).</div><div id=\"graphicVersion\">Graphic 58768 Version 2.0</div></div></div>"},"58769":{"type":"graphic_picture","displayName":"Incontinentia pigmenti","title":"Incontinentia pigmenti","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Incontinentia pigmenti</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/58769_Incontinentiapigmenti.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous papules, vesicles, and crusts are present in linear streaks on the leg of this female infant.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 58769 Version 5.0</div></div></div>"},"58770":{"type":"graphic_figure","displayName":"Infection timeline SOT","title":"The timeline of infections following solid organ transplantation<sup>[1-3]</sup>","html":"<div class=\"graphic\"><div style=\"width: 640px\" class=\"figure\"><div class=\"ttl\">The timeline of infections following solid organ transplantation<sup>[1-3]</sup></div><div class=\"cntnt\"><img style=\"width:620px; height:512px;\" src=\"images/ID/58770_Infection_timeline_SOT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Common patterns of opportunistic infection are observed following solid organ transplantation based on epidemiologic exposures and the \"net state of immunosuppression.\" The timeline is altered based on the immunosuppressive regimen and prophylactic medications. The dynamic assessment of infectious risk represents assays that will measure an individual's risk for infection due to specific pathogens or in general.</div><div class=\"graphic_footnotes\">CMV: cytomegalovirus; EBV: Epstein-Barr virus; HSV: herpes simplex virus; MRSA: methicillin-resistant <em>Staphylococcus aureus</em>; PML: progressive multifocal leukoencephalopathy; PTLD: posttransplant lymphoproliferative disorder; SARS: severe acute respiratory syndrome; VRE: vancomycin-resistant enterococcus; VZV: varicella-zoster virus.</div><div class=\"graphic_reference\">Modified from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601.</li>&#xD;&#xA;    <li>Rubin RH, Wolfson JS, Cosimi AB, Tolkoff-Rubin NE. Infection in the renal transplant recipient. Am J Med 1981; 70:405.</li>&#xD;&#xA;    <li>Fishman JA, Rubin RH. Infection in organ-transplant recipients [see comments]. N Engl J Med 1998; 338:1741.</li>&#xD;&#xA;</ol>&#xD;&#xA;From: Fishman JA, and the AST Infectious Diseases Community of Practice. Introduction: Infection in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4):S3. Copyright &copy; 2009 American Society of Transplantation and the American Society of Transplant Surgeons. Reproduced with permission of John Wiley &amp; Sons, Inc.</div><div id=\"graphicVersion\">Graphic 58770 Version 5.0</div></div></div>"},"58771":{"type":"graphic_waveform","displayName":"TDE constriction v restriction","title":"Tissue Doppler echocardiography in constrictive pericarditis and restrictive cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Tissue Doppler echocardiography in constrictive pericarditis and restrictive cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:461px; height:328px;\" src=\"images/CARD/58771_TDEconstrictionvrestrict.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown are examples of echocardiograms from a normal subject, a patient with a restrictive cardiomyopathy, and a patient with constrictive pericarditis. Panel A shows the posterior left ventricular wall on an M-mode echocardiogram, panel B is the mitral inflow velocity obtained from Doppler echocardiogram, and panel C is from tissue Doppler echocardiogram. The Doppler echocardiogram from the mitral valve inflow records a deep narrow E wave and diminutive A wave in both constrictive pericarditis and restrictive cardiomyopathy. Tissue Doppler records a diminutive myocardial velocity (E') in restrictive cardiomyopathy (arrow), but E' is similar to E in constrictive pericarditis. Tissue Doppler is thus a powerful means to distinguish between these two disease entities.</div><div class=\"graphic_reference\">Courtesy of Ralph Shabeti, MD.</div><div id=\"graphicVersion\">Graphic 58771 Version 3.0</div></div></div>"},"58772":{"type":"graphic_table","displayName":"Therapies for allergic rhinitis in lactating women","title":"Therapies for allergic rhinitis in lactating women","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Therapies for allergic rhinitis in lactating women</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug category</td> <td class=\"subtitle1\">Amount passed to infant in breast milk</td> <td class=\"subtitle1\">Conclusions about maternal use during breastfeeding</td> </tr> <tr class=\"divider_bottom\"> <td>Intranasal glucocorticoid sprays<br /> (budesonide preferred)</td> <td>Minimal</td> <td>Compatible.</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Second-generation oral antihistamines</td> </tr> <tr> <td class=\"sublist1\">Cetirizine</td> <td>Minimal to small amounts</td> <td>Large doses or prolonged use may cause sedation in nursing infant. May decrease milk supply if combined with a sympathomimetic.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\">Loratadine</td> <td>Minimal to small amounts</td> <td>Compatible but might reduce milk supply if combined with a sympathomimetic such as pseudoephedrine.</td> </tr> <tr class=\"divider_bottom\"> <td>Antihistamine nasal sprays</td> <td>Minimal</td> <td>Probably compatible. Use intranasal glucocorticoid preferentially.</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Oral decongestants</td> </tr> <tr> <td class=\"sublist1\">Pseudoephedrine</td> <td>Passes into milk</td> <td>Use short-acting preparations only and take just after breastfeeding to minimize amount entering milk. Use intranasal glucocorticoid preferentially for persistent congestion; topical vasoconstrictor nasal spray for therapy of less than four days.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\">Phenylephrine</td> <td>Little information available</td> <td>Not recommended.</td> </tr> <tr class=\"divider_bottom\"> <td>Cromolyn nasal spray</td> <td>Insignificant</td> <td>Compatible.</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Leukotriene-receptor antagonists</td> </tr> <tr> <td class=\"sublist1\">Montelukast</td> <td>Unknown</td> <td>Use only if other compatible agents not sufficient and symptoms are significant. Avoid in newborn or preterm infant.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\">Zafirlukast</td> <td>About 20%</td> <td>Use only if other compatible agents are not sufficient and symptoms are significant. Avoid in newborn or preterm infant.</td> </tr> <tr> <td>Ipratropium nasal spray</td> <td>Unknown; maternal serum levels are negligible and milk levels will be very low, if at all; any drug in milk would not be absorbed by the infant</td> <td>Probably compatible.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Incaudo AF, Takach P. The diagnosis and treatment of allergic rhinitis during pregnancy and lactation. Immunol Allergy Clin N Am 2006; 26:137. </LI>&#xD;&#xA;<LI>Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation, 10th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2015. </LI>&#xD;&#xA;<LI>LactMed: United States National Library of Medicine. <A href=\"http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT\" target=_blank>http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT</A>. </LI></OL></div><div id=\"graphicVersion\">Graphic 58772 Version 5.0</div></div></div>"},"58773":{"type":"graphic_figure","displayName":"Hepatic adenoma symptoms","title":"Relative frequency of presentation of hepatic adenoma in female patients with a history of contraceptive steroid use from 4 clinical studies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Relative frequency of presentation of hepatic adenoma in female patients with a history of contraceptive steroid use from 4 clinical studies</div><div class=\"cntnt\"><img style=\"width:438px; height:252px;\" src=\"images/GAST/58773_Hepatic_adenoma_symptoms.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The mean frequency and range are shown. In many patients, there was more than one presenting symptom.</div><div class=\"graphic_reference\">Adapted from: Zimmerman H. Hormonal derivatives and related drugs. In: Hepatoxicity: The Adverse effects of drugs and other chemicals on the liver, 2nd edition, Zimmerman H (Ed), Lippincott Williams and Wilkins, Philadelphia 1999. p.555.</div><div id=\"graphicVersion\">Graphic 58773 Version 3.0</div></div></div>"},"58774":{"type":"graphic_figure","displayName":"Solitary enchondroma sites","title":"Skeletal distribution of solitary enchondroma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skeletal distribution of solitary enchondroma</div><div class=\"cntnt\"><img style=\"width:247px; height:605px;\" src=\"images/PEDS/58774_Solitary_enchondroma_sites.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58774 Version 2.0</div></div></div>"},"58775":{"type":"graphic_picture","displayName":"Asbestosis histology C","title":"Asbestos-related small airway disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Asbestos-related small airway disease</div><div class=\"cntnt\"><img style=\"width:360px; height:283px;\" src=\"images/PULM/58775_Asbestosis_histology_C.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph demonstrates a thickened membranous bronchiole. There is also fibrosis around the airway, and a mild chronic inflammatory cell infiltrate in its wall.</div><div class=\"graphic_reference\">Am J Respir Crit Care Med vol 170 pp 692, 2004; www.atsjournals.org</div><div id=\"graphicVersion\">Graphic 58775 Version 2.0</div></div></div>"},"58777":{"type":"graphic_table","displayName":"Pleural effusions in HIV I","title":"Pleural effusions in HIV: Differential diagnosis and diagnostic testing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pleural effusions in HIV: Differential diagnosis and diagnostic testing</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Etiology </td> <td class=\"subtitle1\">History/physical exam/lab findings </td> <td class=\"subtitle1\">Pleural fluid characteristics </td> <td class=\"subtitle1\">Additional tests of pleural fluid </td> <td class=\"subtitle1\">Other helpful tests </td> </tr> <tr> <td>Parapneumonic effusion</td> <td>Short duration of symptoms suggesting infection; parenchymal opacities on chest radiograph</td> <td> <p>Low pH</p> <p>Increased neutrophils</p> </td> <td>&nbsp;</td> <td>Blood culture</td> </tr> <tr> <td>Septic embolism</td> <td>Intravenous drug abuse</td> <td>Exudative</td> <td>&nbsp;</td> <td> <p>Blood culture</p> <p>Echocardiogram</p> <p>Chest CT may show multiple nodules</p> </td> </tr> <tr> <td>Pneumocystis jirovecii</td> <td> <p>Fever</p> <p>Dyspnea</p> <p>Inhaled pentamidine prophylaxis</p> <p>Low CD4</p> </td> <td> <p>Small to moderate effusion</p> <p>Serous or sanguinous</p> <p>Lymphocytic</p> <p>Eosinophilic aggregates</p> <p>LDH increased</p> </td> <td>Grocott silver for P. jiroveci cysts or Diff-Quik for trophozoites</td> <td>Induced sputum or bronchoalveolar lavage for P. jiroveci</td> </tr> <tr> <td>Mycobacterial disease</td> <td> <p>History of exposure</p> <p>Residence in an endemic area</p> <p>Low CD4</p> </td> <td> <p>Lymphocytic effusion</p> <p>Adenosine deaminase &#62;50 U/L</p> </td> <td>Mycobacterial smear and culture</td> <td> <p>PPD</p> <p>Induced sputum</p> <p>Pleural biopsy for histology, culture, and molecular testing&nbsp;</p> </td> </tr> <tr> <td>Nocardia</td> <td> <p>Acute or subacute onset of fever, night sweats, fatigue, anorexia, cough, dyspnea</p> <p>Low CD4</p> </td> <td>&nbsp;</td> <td> <p>Modified Kinyoun acid fast stain</p> <p>PCR for Nocardia</p> <p>Maintain aerobic culture for 5 to 21 days</p> </td> <td>Blood culture</td> </tr> <tr> <td>Cryptococcus</td> <td> <p>Fever, cough, dyspnea</p> <p>CD4 &#60;100/microL</p> </td> <td>Serous exudate</td> <td> <p>Cryptococcal antigen</p> <p>Cryptococcal culture (positive in 42 percent)</p> </td> <td> <p>Serum cryptococcal antigen</p> <p>Pleural biopsy</p> </td> </tr> <tr> <td>Histoplasma</td> <td> <p>History of residing in endemic area</p> <p>Subacute febrile illness</p> </td> <td>Serous or serosanguinous effusion</td> <td>Wright-Giemsa stain for intracellular Histoplasma yeast forms</td> <td>&nbsp;</td> </tr> <tr> <td>Toxoplasma</td> <td> <p>Usually evidence of disseminated toxoplasmosis</p> <p>CD4 &#60;100 cells/microL</p> </td> <td>Unilateral or bilateral</td> <td>Giemsa stain for tachyzoites within neutrophils</td> <td>&nbsp;</td> </tr> <tr> <td>Leishmaniasis</td> <td> <p>Fever</p> <p>Leukopenia</p> <p>Lymphopenia</p> <p>Thrombocytopenia</p> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p>Serologic studies positive in 50 percent</p> <p>Peripheral smear</p> <p>Bone marrow smear positive 67 percent</p> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58777 Version 3.0</div></div></div>"},"58778":{"type":"graphic_diagnosticimage","displayName":"Heel spur","title":"Heel spur","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Heel spur</div><div class=\"cntnt\"><img style=\"width:265px; height:286px;\" src=\"images/RHEUM/58778_Heel_spur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain film of the calcaneus bone demonstrates enlargement with inflammation around a spur at the insertion of the plantar aponeurosis inferior to the calcaneus bone (arrow).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 58778 Version 2.0</div></div></div>"},"58779":{"type":"graphic_table","displayName":"IWG response criteria for Hodgkin lymphoma","title":"The International Working Group response criteria for Hodgkin lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The International Working Group response criteria for Hodgkin lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Response category</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td rowspan=\"4\">Complete remission</td> <td>No clinical evidence of disease or disease-related symptoms.</td> </tr> <tr> <td>A post-treatment residual mass of any size is permitted as long as it is PET negative.</td> </tr> <tr> <td>Spleen and liver must be non-palpable and without nodules.</td> </tr> <tr> <td>If a pre-treatment bone marrow biopsy was positive, an adequate bone marrow biopsy (with a core size of at least 20 mm) from the same site must be cleared of infiltrate; if this is indeterminate by morphology, immunohistochemistry should be negative.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Partial remission</td> <td>A decrease by at least 50 percent in the sum of the products of the largest perpendicular diameters (SPD) of up to six of the largest measurable lesions.</td> </tr> <tr> <td>The post-treatment PET should be positive in at least one previously involved site.</td> </tr> <tr> <td>There should be no increase in the size of other nodes, liver, or spleen and no new areas of disease.</td> </tr> <tr> <td>Splenic or hepatic nodules must decrease by at least 50 percent in the SPD (or in the greatest transverse diameter for single nodules).</td> </tr> <tr> <td>Bone marrow biopsy results are not useful in determining PR. However, if the patient otherwise fits the CR criteria but has a positive bone marrow biopsy, the patient is labeled as having a PR.</td> </tr> <tr class=\"divider_top\"> <td>Stable disease</td> <td>Failure to attain a CR or PR with no evidence of progressive disease. The post-treatment PET should be positive at prior sites of disease and no new sites should be present on PET or CT.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Progressive disease or relapse after CR</td> <td>Any new lesion or an increase from nadir by at least 50 percent of previously involved sites.</td> </tr> <tr> <td>Development of a new lesion is defined by the appearance of any new lesion more than 1.5 cm in long axis. If the long axis diameter is from 1.1 to 1.5 cm, the lesion should only be considered abnormal if its short axis is more than 1.0 cm.</td> </tr> <tr> <td>Progressive disease is also defined as an increase of at least 50 percent in the longest diameter of a previously identified node more than 1 cm in short axis or in the SPD of more than one node.</td> </tr> <tr> <td>Lesions should be PET positive unless they are below a detectable size (ie, &#60;1.5 cm in long axis by CT).</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The International Working Group response criteria for Hodgkin lymphoma define complete remission, partial remission, stable disease, and progressive disease based upon findings on history, physical examination, computed tomography (CT), positron emission tomography (PET) scan, and bone marrow biopsy (in appropriate cases).</div><div class=\"graphic_footnotes\">PET: positron emission tomography; SPD: sum of the product of the diameters; PR: partial remission; CR: complete remission; CT: computed tomography.</div><div class=\"graphic_reference\">Modified from: Cheson, BD, Pfistner, B, Juweid, ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579.</div><div id=\"graphicVersion\">Graphic 58779 Version 2.0</div></div></div>"},"58781":{"type":"graphic_movie","displayName":"Shigella protrusion from the cell","title":"Shigella protrusion from the cell","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Shigella protrusion from the cell</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/58781_shgprotrconv.mp4\" style=\"width:250px;height:266px\"></div><img style=\"width:313px; height:313px;\" src=\"images/CARD/58781_shgprotr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shigella within a membrane-bound protrusion (arrow) from the host cell surface, viewed looking down on the apical cell surface. The bacterium containing protrusions can extend several bacterial lengths away from the cell surface with the bacterium at the tip; they enable the bacterium to pass into adjacent cells.</div><div class=\"graphic_reference\">Courtesy of Marcia B Goldberg, MD.</div><div id=\"graphicVersion\">Graphic 58781 Version 3.0</div></div></div>"},"58784":{"type":"graphic_diagnosticimage","displayName":"Spondylolysis and spondylolisthesis imaging","title":"Classic radiographic signs of spondylolysis and spondylolisthesis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Classic radiographic signs of spondylolysis and spondylolisthesis</div><div class=\"cntnt\"><img style=\"width:414px; height:512px;\" src=\"images/PEDS/58784_Spondylolisthesis_imaging.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Lateral lumbar spine. Note the pars defects (arrow) and anterior displacement of the L5 vertebra. B) Oblique lumbar spine. Observe the clearly visible lucent collar (arrow). C) Stepladder sign. On an oblique film, the alignment of the facet joints changes abruptly at the level of slippage. D) Axial CT L5. Note that the pars defects are readily identified (arrows). Observe the asymmetry of the defects, which is usually present in spondylolysis and may explain why some pars defects are hard to demonstrate on symmetrically positioned 45° oblique lumbar radiographs.</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum And Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright ©2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58784 Version 4.0</div></div></div>"},"58785":{"type":"graphic_table","displayName":"Karnofsky Performance Status scale","title":"Karnofsky Performance Status scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Karnofsky Performance Status scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Value</td> <td class=\"subtitle1\">Level of functional capacity</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td>100</td> <td>Normal, no complaints, no evidence of disease</td> <td rowspan=\"3\">Able to carry on normal activity and to work; no special care needed</td> </tr> <tr> <td>90</td> <td>Able to carry on normal activity, minor signs or symptoms of disease</td> </tr> <tr> <td>80</td> <td>Normal activity with effort, some signs or symptoms of disease</td> </tr> <tr class=\"divider_top\"> <td>70</td> <td>Cares for self, unable to carry on normal activity or to do active work</td> <td rowspan=\"3\">Unable to work; able to live at home and care for most personal needs; various degrees of assistance needed</td> </tr> <tr> <td>60</td> <td>Requires occasional assistance but is able to care for most needs</td> </tr> <tr> <td>50</td> <td>Requires considerable assistance and frequent medical care</td> </tr> <tr class=\"divider_top\"> <td>40</td> <td>Disabled, requires special care and assistance</td> <td rowspan=\"5\">Unable to care for self; requires equivalent of institutional or hospital care; disease may be progressing rapidly</td> </tr> <tr> <td>30</td> <td>Severely disabled, hospitalization is indicated although death is not imminent</td> </tr> <tr> <td>20</td> <td>Hospitalization is necessary, very sick, active supportive treatment necessary</td> </tr> <tr> <td>10</td> <td>Moribund, fatal processes progressing rapidly</td> </tr> <tr> <td>0</td> <td>Dead</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58785 Version 6.0</div></div></div>"},"58787":{"type":"graphic_table","displayName":"HCV transmission counseling","title":"Counseling to avoid transmission of hepatitis C virus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Counseling to avoid transmission of hepatitis C virus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td>HCV-infected individuals should be counseled to: <ul class=\"decimal_heading\"> <li>Avoid sharing toothbrushes and dental or shaving equipment </li> <li>Cover any bleeding wound to prevent others from coming into contact with their blood </li> <li>Not donate blood </li> <li>Discuss their HCV status prior to donation of body organs, other tissues, or semen </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>In general, HCV-infected individuals should be counseled that the risk of sexual transmission is low and that HCV infection itself is not a reason for barrier protection.<br /> However, HCV-infected individuals with HIV co-infection, multiple sexual partners, or sexually transmitted infections should be encouraged to use barrier precautions to prevent sexual transmission.</td> </tr> <tr class=\"divider_bottom\"> <td>HCV-infected individuals who use illicit drugs should be counseled to: <ul class=\"decimal_heading\"> <li>Stop using illicit drugs and enter substance abuse treatment </li> </ul> Those who continue to inject drugs should be counseled to: <ul class=\"decimal_heading\"> <li>Avoid reusing or sharing syringes, needles, water, cotton, and other drug preparation equipment </li> <li>Use new sterile syringes and filters and disinfected cookers </li> <li>Clean the injection site with a new alcohol swab </li> <li>Dispose safely of syringes and needles after one use in a safe, puncture-proof container </li> </ul> </td> </tr> <tr> <td>Household surfaces or items visibly contaminated with blood from an HCV-infected individual should be cleaned using diluted household bleach (1 part bleach in 9 parts water). Gloves should be worn when cleaning blood spills.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HCV: hepatitis C virus.</div><div class=\"graphic_reference\">Adapted from: AASLD-IDSA. HCV testing and linkage to care. Recommendations for testing, managing, and treating hepatitis C. Available at: <a href=\"http://www.hcvguidelines.org/full-report/hcv-testing-and-linkage-care\" target=\"_blank\">http://www.hcvguidelines.org/full-report/hcv-testing-and-linkage-care</a> (Accessed July 8, 2016).</div><div id=\"graphicVersion\">Graphic 58787 Version 4.0</div></div></div>"},"58788":{"type":"graphic_table","displayName":"GnRH add back regimens","title":"GnRH agonists combined with steroid \"add-back\"","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">GnRH agonists combined with steroid &quot;add-back&quot;</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Low dose steroid hormone regimen</td> <td class=\"subtitle1\">Comment</td> <td class=\"subtitle1\">Investigator</td> </tr> <tr> <td>Transdermal estradiol patch 25 mcg/day, plus medroxyprogesterone acetate 2.5 mg daily</td> <td>This regimen did not completely prevent bone loss. The estradiol concentration achieved is in the range of 30 pg/ml.</td> <td>Howell, 1995</td> </tr> <tr> <td>Norethindrone acetate 5 mg daily</td> <td>This is a very high dose of progestin, which is associated with a decrease in HDL cholesterol.</td> <td>Hornstein, 1997</td> </tr> <tr> <td>Conjugated equine estrogen 0.625 mg plus norethindrone acetate 5 mg daily</td> <td>This regimen prevented bone loss and markedly reduces the vasomotor symptoms reported. Pain relief was excellent.</td> <td>Hornstein, 1997</td> </tr> <tr> <td>Conjugated equine estrogen 0.625 mg plus medroxyprogesterone acetate 5 mg daily</td> <td>This regimen did not completely prevent bone loss.</td> <td>Moghissi, 1998</td> </tr> <tr> <td>Conjugated equine estrogen 0.3 mg plus medroxyprogesterone acetate 2.5 mg daily</td> <td>This regimen did not completely prevent bone loss.</td> <td>Moghissi, 1998</td> </tr> <tr> <td>Transdermal estradiol 25 mcg/day, plus norethindrone acetate 5 mg daily</td> <td>This regimen did not completely prevent bone loss.</td> <td>Zupi, 2004</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">GnRH agonist treatment combined with low dose steroid \"add-back\" causes atrophy in endometriosis, improves pelvic pain, and minimizes vasomotor symptoms and bone loss. The low-dose steroid hormone regimens that have been documented to be effective in randomized clinical trials when used in combination with a GnRH agonist are listed above.</div><div class=\"graphic_footnotes\">GnRH: gonadotropin-releasing hormone; HDL: high-density lipoprotein.</div><div class=\"graphic_reference\">Courtesy of Robert L. Barbieri, MD.</div><div id=\"graphicVersion\">Graphic 58788 Version 4.0</div></div></div>"},"58789":{"type":"graphic_picture","displayName":"DIP histology","title":"Desquamative interstitial pneumonia pattern","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Desquamative interstitial pneumonia pattern</div><div class=\"cntnt\"><img style=\"width:519px; height:225px;\" src=\"images/PULM/58789_DIP_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The alveolar spaces are diffusely involved by marked alveolar macrophage accumulation and there is mild interstitial thickening. (B) The alveolar walls are mildly thickened by fibrous connective tissue and a few chronic inflammatory cells. The alveolar spaces are filled with macrophages.</div><div id=\"graphicVersion\">Graphic 58789 Version 2.0</div></div></div>"},"58790":{"type":"graphic_picture","displayName":"Endomyocardial biopsy specimen with microvascular changes","title":"Endomyocardial biopsy specimen with microvascular changes","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Endomyocardial biopsy specimen with microvascular changes</div><div class=\"cntnt\"><img style=\"width:500px; height:371px;\" src=\"images/CARD/58790_Endo_biopsy_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Micrograph from routine endomyocardial biopsy after heart transplantation showing stenotic microvasculopathy as evidenced by prominent endothelial cells, thickening of the basal membranes, and neointima resulting in luminal narrowing.</div><div class=\"graphic_reference\">Courtesy of Dr. C. B. Andersen, Rigshospitalet, Denmark.</div><div id=\"graphicVersion\">Graphic 58790 Version 2.0</div></div></div>"},"58791":{"type":"graphic_diagnosticimage","displayName":"Sacroiliitis grade 4 example 1","title":"Sacroiliitis grade 4 example 1","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Sacroiliitis grade 4 example 1</div><div class=\"cntnt\"><img style=\"width:504px; height:403px;\" src=\"images/RHEUM/58791_Sacroiliitis_grade_4_ex_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral grade 4 sacroiliitis with complete fusion of sacroiliac joints.</div><div class=\"graphic_reference\">Courtesy of Xenofon Baraliakos, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität, Herne, Germany.</div><div id=\"graphicVersion\">Graphic 58791 Version 4.0</div></div></div>"},"58792":{"type":"graphic_table","displayName":"Modified RECIST for hepatocellular carcinoma","title":"Modified RECIST for hepatocellular carcinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified RECIST for hepatocellular carcinoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Response assessment</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Target lesions</td> </tr> <tr> <td class=\"indent1\">CR</td> <td>Disappearance of all target lesions or disappearance of any intratumoral arterial enhancement in all target lesions.</td> </tr> <tr> <td class=\"indent1\">PR</td> <td>At least 30% decrease in the sum of the diameters of viable (enhancing) target lesions, taking as a reference the baseline sum of the diameters of target lesions.*</td> </tr> <tr> <td class=\"indent1\">PD</td> <td>Any increase of at least 20% in the sum of the diameters of viable target lesions, taking as a reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since treatment started.*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">SD</td> <td>Any cases that do not qualify for either&nbsp;PR or PD.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Non-target lesions</td> </tr> <tr> <td class=\"indent1\">Malignant portal vein thrombosis</td> <td>Should be considered a nonmeasurable lesion.</td> </tr> <tr> <td class=\"indent1\">Lymph nodes</td> <td>If detected at the porta hepatis, should be considered malignant if the short axis dimension is &#8805;2.0 cm.</td> </tr> <tr> <td class=\"indent1\">Pleural effusions and ascites</td> <td>Emergence of, or increase in, ascites is common during the course of treatment of a cirrhotic patient, and may reflect worsening of the underlying chronic liver disease and be unrelated to cancer progression. The same is true of pleural effusions. Cytopathologic confirmation of the neoplastic nature of any effusion that appears during treatment is required when the measurable tumor has met criteria for response or SD.</td> </tr> <tr> <td class=\"indent1\">New lesions</td> <td>A newly detected hepatic nodule is classified as hepatocellular carcinoma (and declared evidence of progression) when its longest diameter is at least 1 cm and the nodule has a typical vascular pattern on dynamic imaging (hypervascular in arterial phase with washout in the portal venous or late venous phase). Liver lesions &#62;1 cm that do not show a typical vascular pattern can be diagnosed as hepatocellular carcinoma if there is at least 1 cm internal growth on subsequent scans.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RECIST: Response Evaluation Criteria In Solid Tumors; CR: complete response; PR: partial response; PD: progressive disease: SD: stable disease.<br> * Enhancement in the arterial phase reflects viable tumor tissue.</div><div class=\"graphic_reference\">Adapted from: Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30:52.</div><div id=\"graphicVersion\">Graphic 58792 Version 2.0</div></div></div>"},"58793":{"type":"graphic_table","displayName":"Isopropyl alcohol intoxication - Rapid overview","title":"Isopropyl alcohol intoxication: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Isopropyl alcohol intoxication: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">Clinical and laboratory features</td> </tr> <tr> <td>Patients with isopropanol toxicity generally present with an alteration in mental status similar to that seen in ethanol intoxication</td> </tr> <tr> <td>Rarely, massive overdose may present with hemodynamic instability</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic evaluation</td> </tr> <tr> <td>Fingerstick glucose, salicylate and acetaminophen levels, and an ECG should be obtained</td> </tr> <tr> <td>Basic electrolytes (with calculation of anion gap), BUN and creatinine, serum and urine ketones, serum osmolality, and an arterial or venous blood gas should be obtained</td> </tr> <tr> <td>Serum isopropyl alcohol level should be obtained if possible</td> </tr> <tr> <td>Laboratory hallmarks of isopropanol poisoning include an elevated osmolal gap <strong>without</strong> an anion gap acidosis, and a severe ketonemia</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td>Most patients recover uneventfully with supportive care alone; gastrointestinal decontamination with activated charcoal is unnecessary</td> </tr> <tr> <td>Profoundly intoxicated patients may require endotracheal intubation</td> </tr> <tr> <td>Hypotension should be treated with intravenous crystalloid, followed by vasopressors if needed. Refractory hypotension (which is very rare) is an indication for hemodialysis.</td> </tr> <tr> <td>Isopropanol does NOT cause a metabolic acidosis and is NOT associated with the significant toxicity that may be seen in methanol or ethylene glycol ingestions. Aggressive alkalinization and/or antidotal therapy with fomepizole or ethanol are NOT INDICATED in isolated isopropyl alcohol ingestions.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58793 Version 7.0</div></div></div>"},"58798":{"type":"graphic_picture","displayName":"Lyme disease rash PI","title":"Lyme disease rash","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lyme disease rash</div><div class=\"cntnt\"><img style=\"width:241px; height:360px;\" src=\"images/PI/58798_Erythema_migrans_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lyme disease can cause a circular rash that might look like a \"bull's eye.\"</div><div class=\"graphic_reference\">Courtesy of Dori F Zaleznik, MD.</div><div id=\"graphicVersion\">Graphic 58798 Version 4.0</div></div></div>"},"58800":{"type":"graphic_table","displayName":"Suggestion therapy for tic cough","title":"Major elements of a 15-minute suggestion-therapy session for tic cough syndrome*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major elements of a 15-minute suggestion-therapy session for tic cough syndrome*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>&#8226;&nbsp;Open the session expressing confidence that&nbsp;the coughing will be stopped. </td> </tr> <tr> <td>&#8226; <span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Explain&nbsp;the cough as a vicious cycle&nbsp;that started with an&nbsp;initial irritant that is now gone,&nbsp;and that the cough itself is causing more irritation more cough.</span></td> </tr> <tr> <td>&#8226; <span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Instruct the patient to concentrate solely on holding back the urge to cough, for an initially brief timed period (eg, 1 minute). Progressively increase this time period and utilize an alternative behavior, such as sipping lukewarm water or inhaling a soothing cool mist from a vaporizer, to &ldquo;ease the irritation.&rdquo;</span></td> </tr> <tr> <td>&#8226; <span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Tell the patient that each second the cough is delayed makes it easier to suppress further coughing. </span></td> </tr> <tr> <td>&#8226; <span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Repeat expressions of confidence that the patient is developing the ability to resist the urge to cough; &ldquo;it&rsquo;s becoming easier to hold back the cough, isn&rsquo;t it&rdquo; (nodding affirmatively generally results in a similar affirmation movement by the patient).</span></td> </tr> <tr> <td>&#8226; <span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">When the patient shows that he or she is able&nbsp;to suppress the cough (usually&nbsp;for about 10 minutes), ask in a rhetorical manner, &ldquo;you&rsquo;re beginning to feel that you can resist the urge to cough, aren&rsquo;t you?&rdquo; (said with an affirmative head nod).&nbsp; </span></td> </tr> <tr> <td>&#8226; <span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Close the session when the patient can repeatedly respond positively to the question, &ldquo;do you feel that you can now resist the urge to cough on your own?&rdquo; This question is only asked after the patient has gone 5 minutes without coughing.</span></td> </tr> <tr> <td>&#8226; Express confidence that if the urge to cough recurs, the patient can do the same thing at home (autosuggestion)<sup>&#182;</sup>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Tic cough was previously referred to as \"habit\" cough.<br />¶ The autosuggestion is for&nbsp;15-minute sessions at home, in which the patient&nbsp;concentrates on holding back the cough using sips of lukewarm water to “ease the irritation causing cough”.</div><div class=\"graphic_reference\">Reproduced with permission from the ©ERS 2017. Breathe Mar 2017, 13 (1) 22-30; DOI: 10.1183/20734735.015216.</div><div id=\"graphicVersion\">Graphic 58800 Version 4.0</div></div></div>"},"58801":{"type":"graphic_table","displayName":"Marrow asp bx complications","title":"Complications of bone marrow aspiration/biopsy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications of bone marrow aspiration/biopsy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Complication</td>\n<td class=\"subtitle1\">Comments</td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"2\">Bleeding&nbsp;</td>\n<td>Local hematoma (more common in thrombocytopenic patients)</td>\n</tr>\n<tr>\n\n<td>Retroperitoneal hemorrhage (rare)</td>\n</tr>\n<tr>\n<td>Local infection</td>\n<td>Usually minor and superficial</td>\n</tr>\n<tr>\n<td>Other</td>\n<td>Neuropathy, osteomyelitis, needle breakage</td>\n</tr>\n<tr>\n<td>Complications from sternal aspiration</td>\n<td>Cardiac tamponade, pulmonary emboli, pulmonary infection, bone erosion/thinning</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 58801 Version 1.0</div></div></div>"},"58804":{"type":"graphic_diagnosticimage","displayName":"2D TTE Subcostal view normal IVC","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from the subcostal view showing a normal inferior vena cava (IVC) during respiration","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from the subcostal view showing a normal inferior vena cava (IVC) during respiration</div><div class=\"cntnt\"><img style=\"width:491px; height:198px;\" src=\"images/CARD/58804_SubcostalviewnormalIVC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The subcostal view in a normal subject shows the inferior vena cava (IVC). Left panel: Prior to inspiration, the normal diastolic IVC diameter (arrows) is less than 20 mm. Right panel: During inspiration, the IVC collapses to less than 50 percent of its original diameter.</div><div class=\"graphic_footnotes\">L: liver.</div><div id=\"graphicVersion\">Graphic 58804 Version 4.0</div></div></div>"},"58805":{"type":"graphic_picture","displayName":"Scarlet fever rash - desquamation","title":"Scarlet fever rash - desquamation","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Scarlet fever rash - desquamation</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ID/58805_Desquamating_rash.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The rash of scarlet fever usually starts on the head and neck; subsequently, it expands rapidly to cover the trunk followed by the extremities and ultimately desquamates.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 58805 Version 6.0</div></div></div>"},"58808":{"type":"graphic_diagnosticimage","displayName":"MRI osteonecrosis glucocorticoids POI","title":"MRI of osteonecrosis in POI patient after glucocorticoids","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI of osteonecrosis in POI patient after glucocorticoids</div><div class=\"cntnt\"><img style=\"width:338px; height:308px;\" src=\"images/ENDO/58808_MRI_osteonec_glucocorts_pof.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MRI of osteonecrosis of the right knee (arrow) in a patient who had received glucocorticoids for treatment of POI.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; POI: primary ovarian insufficiency.</div><div class=\"graphic_reference\">Reproduced with permission from: Kalantaridou SN, Braddock DT, Patronas NJ, Nelson LM. Treatment of autoimmune premature ovarian failure. Hum Reprod 1999; 14:1777. Copyright &copy; 1999 Oxford University Press/Human Reproduction.</div><div id=\"graphicVersion\">Graphic 58808 Version 6.0</div></div></div>"},"58814":{"type":"graphic_table","displayName":"Etiology of diarrhea in children by age","title":"Etiology of diarrhea in children by age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of diarrhea in children by age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cause</td> <td class=\"subtitle1\">Infants and young children</td> <td class=\"subtitle1\">Older children and adolescents</td> </tr> <tr class=\"divider_bottom\"> <td>Gastrointestinal infections</td> <td> <p>Viruses*</p> <p>Bacteria*</p> Parasites</td> <td> <p>Viruses*</p> <p>Bacteria*</p> Parasites</td> </tr> <tr class=\"divider_bottom\"> <td>Nongastrointestinal infections (parenteral diarrhea)</td> <td> <p>Otitis media*</p> <p>Urinary tract infections*</p> Other systemic infections</td> <td> <p>Systemic infections</p> <p>Staphylococcal toxic shock syndrome<sup>&#182;</sup></p> </td> </tr> <tr class=\"divider_bottom\"> <td>Dietary disturbances</td> <td> <p>Functional diarrhea (eg, excess fructose and/or sorbitol intake [fruit juices])/overfeeding*</p> <p>Food allergy*</p> Starvation stools*</td> <td> <p>Starvation stools*</p> <p>&nbsp;</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Anatomic abnormalities</td> <td> <p>Intussusception<sup>&#182;</sup></p> <p>Hirschsprung-associated enterocolitis (&#177; toxic megacolon<sup>&#182;</sup>)</p> <p>Partial bowel obstruction<sup>&#182;</sup></p> <p>Blind loop syndrome (also in patients with dysmotility)</p> <p>Intestinal lymphangiectasis</p> Short gut syndrome</td> <td> <p>Appendicitis<sup>&#182;</sup></p> <p>Partial obstruction<sup>&#182;</sup></p> Blind loop syndrome</td> </tr> <tr class=\"divider_bottom\"> <td>Inflammatory bowel disease</td> <td>Early onset inflammatory bowel disease (rare, monogenic)</td> <td> <p>Ulcerative colitis (&#177; toxic megacolon<sup>&#182;</sup>)</p> Crohn disease (&#177; toxic megacolon<sup>&#182;</sup>)</td> </tr> <tr class=\"divider_bottom\"> <td>Malabsorption or increased secretion</td> <td> <p>Cystic fibrosis</p> <p>Celiac disease</p> <p>Disaccharidase deficiency (eg, lactase deficiency due to infectious diarrhea)*</p> <p>Acrodermatitis enteropathica</p> <p>Congenital secretory diarrhea</p> </td> <td> <p>Celiac disease</p> <p>Disaccharidase deficiency (primary or secondary)*</p> <p>Acrodermatitis enteropathica</p> Neuroendocrine secretory tumors</td> </tr> <tr class=\"divider_bottom\"> <td>Immunodeficiency</td> <td> <p>Severe combined immunodeficiencies and other genetic disorders</p> HIV infection</td> <td>HIV infection</td> </tr> <tr class=\"divider_bottom\"> <td>Endocrinopathy</td> <td>Congenital adrenal hyperplasia</td> <td> <p>Hyperthyroidism</p> Hypoparathyroidism</td> </tr> <tr> <td>Miscellaneous</td> <td> <p>Antibiotic-associated diarrhea*</p> <p><em>Clostridium difficile</em> colitis&nbsp;(&#177; pseudomembranous colitis<sup>&#182;</sup>)</p> <p>Toxins<sup>&#916;</sup></p> <p>Hemolytic uremic syndrome<sup>&#182;</sup></p> Neonatal drug withdrawal</td> <td> <p>Antibiotic-associated diarrhea* </p> <p><em>C. difficile</em> colitis (&#177; pseudomembranous colitis<sup>&#182;</sup>)</p> <p>Toxins<sup>&#916;</sup></p> <p>Irritable bowel syndrome*</p> Psychogenic disturbances*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.<br />* Common cause.<br />¶ Life-threatening cause.<br />Δ Potential toxins include foodborne toxin disease, poisonous plants or mushrooms, and organophosphates or carbamates.</div><div class=\"graphic_reference\">Courtesy of Gary R Fleisher, MD.</div><div id=\"graphicVersion\">Graphic 58814 Version 9.0</div></div></div>"},"58815":{"type":"graphic_picture","displayName":"Lichen sclerosus papules and plaques on wrist","title":"Extragenital lichen sclerosus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Extragenital lichen sclerosus</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/58815_Lich_slcer_pap_plaq_wrist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small, white papules, some coalescing into a larger plaque, are present on the wrist.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 58815 Version 5.0</div></div></div>"},"58817":{"type":"graphic_picture","displayName":"Postinflammatory hyperpigmentation in acne","title":"Postinflammatory hyperpigmentation and scarring in acne vulgaris","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Postinflammatory hyperpigmentation and scarring in acne vulgaris</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/58817_Postinflam_hyperpig_acne.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple hyperpigmented macules and scars are present in this woman with acne vulgaris.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 58817 Version 3.0</div></div></div>"},"58818":{"type":"graphic_picture","displayName":"Examination of finger DIP joint extension","title":"Examination of finger DIP joint extension","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Examination of finger DIP joint extension</div><div class=\"cntnt\"><img style=\"width:396px; height:309px;\" src=\"images/EM/58818_Finger_dip_exten.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distal interphalangeal (DIP) joint extension should be evaluated independently of other finger movements, as depicted in the photograph.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 58818 Version 2.0</div></div></div>"},"58820":{"type":"graphic_picture","displayName":"Megaloblastic smear","title":"Megaloblastic blood picture","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Megaloblastic blood picture</div><div class=\"cntnt\"><img style=\"width:389px; height:252px;\" src=\"images/HEME/58820_Megaloblastic_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear showing a hypersegmented neutrophil (seven lobes) and macro-ovalocytes, a pattern that can be seen with cobalamin or folate deficiency.</div><div class=\"graphic_reference\">Courtesy of Stanley L Schrier, MD.</div><div id=\"graphicVersion\">Graphic 58820 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"58821":{"type":"graphic_figure","displayName":"Rotavirus activity in US before and after rotavirus vaccine ","title":"Rotavirus season duration and peak activity by reporting years*, National Respiratory and Enteric Virus Surveillance System (NREVSS), United States, 2000-2014","html":"<div class=\"graphic\"><div style=\"width: 876px\" class=\"figure\"><div class=\"ttl\">Rotavirus season duration and peak activity by reporting years*, National Respiratory and Enteric Virus Surveillance System (NREVSS), United States, 2000-2014</div><div class=\"cntnt\"><img style=\"width:856px; height:539px;\" src=\"images/PEDS/58821_Rtvrs_effctvnss.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Prevaccine: 2000 to 2006; postvaccine: 2007 to 2014.<br />¶ 10% is the threshold proportion of positive test results that is used to determine the onset and offset of a rotavirus season.</div><div class=\"graphic_reference\">Reproduced from: Aliabadi N, Tate JE, Haynes AK, Parashar UD. Sustained decrease in laboratory detection of rotavirus after implementation of routine vaccination&nbsp;– United States, 2000-2014. MMWR Morb Mortal Wkly Rep 2015; 64:337.</div><div id=\"graphicVersion\">Graphic 58821 Version 8.0</div></div></div>"},"58822":{"type":"graphic_table","displayName":"Drug and toxin related anion gap changes","title":"Drug- and toxin-induced alterations in the anion gap","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drug- and toxin-induced alterations in the anion gap</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Increased anion gap with metabolic acidosis<br /> (&#62;13 meq/L)*</td> </tr> <tr> <td>Methanol</td> </tr> <tr> <td>Ethylene glycol</td> </tr> <tr> <td>Ethanol (alcoholic ketoacidosis)</td> </tr> <tr> <td>Salicylates</td> </tr> <tr> <td>Isoniazid</td> </tr> <tr> <td>Iron</td> </tr> <tr> <td>Glycol ethers</td> </tr> <tr> <td class=\"sublist1_start\">NSAID</td> </tr> <tr> <td class=\"sublist1\">Ketoprofen</td> </tr> <tr> <td class=\"sublist1\">Naproxen</td> </tr> <tr> <td class=\"sublist1\">Phenylbutazone</td> </tr> <tr> <td class=\"sublist1_start\">Sympathomimetics</td> </tr> <tr> <td class=\"sublist1\">Cocaine</td> </tr> <tr> <td class=\"sublist1\">Theophylline</td> </tr> <tr> <td class=\"sublist1\">Caffeine</td> </tr> <tr> <td class=\"sublist1\">Cathinones</td> </tr> <tr> <td class=\"sublist1\">Albuterol</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Increased anion gap with metabolic acidosis<br /> (&#62;13 meq/L) (cont)</td> </tr> <tr> <td>Salicylates</td> </tr> <tr> <td>Dinitrophenol</td> </tr> <tr> <td>Inorganic acid</td> </tr> <tr> <td>Metformin</td> </tr> <tr> <td>Phenformin</td> </tr> <tr> <td>Paraldehyde</td> </tr> <tr> <td>Formaldehyde</td> </tr> <tr> <td>Toluene</td> </tr> <tr> <td>Sulfur (elemental)</td> </tr> <tr> <td>Colchicine</td> </tr> <tr> <td>Fluroacetate</td> </tr> <tr> <td class=\"sublist1_start\">Cellular asphyxiants</td> </tr> <tr> <td class=\"sublist1\">Carbon monoxide</td> </tr> <tr> <td class=\"sublist1\">Cyanide</td> </tr> <tr> <td class=\"sublist1\">Hydrogen sulfide</td> </tr> <tr> <td class=\"sublist1\">Methemoglobinemia</td> </tr> <tr> <td>Propylene glycol</td> </tr> <tr> <td>Benzyl alcohol</td> </tr> <tr> <td>Phenol</td> </tr> <tr> <td>Strychnine</td> </tr> <tr> <td>Vacor</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Decreased anion gap<br /> (&#60;6 meq/L)</td> </tr> <tr> <td>Hypermagnesemia</td> </tr> <tr> <td>Hypercalcemia</td> </tr> <tr> <td>Bromide</td> </tr> <tr> <td>Nitrates</td> </tr> <tr> <td>Lithium</td> </tr> <tr> <td>Iodide</td> </tr> <tr> <td>Spironolactone</td> </tr> <tr> <td>Ammonium chloride</td> </tr> <tr> <td>Acetazolamide</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Any poison causing seizure, hypoxemia, shock (hypotension), cellular anoxia, or rhabdomyolysis will result in a high anion gap metabolic acidosis from increased serum lactic acid concentrations.</div><div id=\"graphicVersion\">Graphic 58822 Version 8.0</div></div></div>"},"58825":{"type":"graphic_picture","displayName":"Verruca vulgaris - finger","title":"Verruca vulgaris","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Verruca vulgaris</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/58825_Verruca_vulgaris_hand_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A well-defined, keratotic papule is present on the dorsal finger in this patient with verruca vulgaris (common wart).</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 58825 Version 4.0</div></div></div>"},"58826":{"type":"graphic_picture","displayName":"Cutaneous lichen planus interface dermatitis","title":"Cutaneous lichen planus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutaneous lichen planus</div><div class=\"cntnt\"><img style=\"width:402px; height:504px;\" src=\"images/DERM/58826_Cut_lichen_planus_dermat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A marked interface dermatitis resulting in vacuolization of the basal layer is present in this pathologic specimen from a lesion of lichen planus. Hypergranulosis is also present.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58826 Version 1.0</div></div></div>"},"58827":{"type":"graphic_diagnosticimage","displayName":"Coarctation aorta Echo","title":"Transthoracic echocardiographic (TTE) images with Doppler assessment in a patient with coarctation of the aorta","html":"<div class=\"graphic\"><div style=\"width: 704px\" class=\"figure\"><div class=\"ttl\">Transthoracic echocardiographic (TTE) images with Doppler assessment in a patient with coarctation of the aorta</div><div class=\"cntnt\"><img style=\"width:684px; height:458px;\" src=\"images/CARD/58827_Crct_art_ech.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Two-dimensional suprasternal TTE image demonstrating severe narrowing in the descending thoracic aorta (arrow).<br />(B) Color-flow Doppler demonstrating marked flow acceleration at the narrowed site.<br />(C) Parasternal short axis TTE image showing a bicuspid aortic valve (double asterisk), which frequently is seen in patients with coarctation.<br />(D) Pulsed-wave Doppler of the abdominal aorta demonstrating a low antegrade systolic velocity with persistent flow in diastole (arrow).<br />(E) Continuous-wave Doppler demonstrating severe obstruction at the site of coarctation with a peak systolic gradient of 65 mmHg and a mean gradient of 33 mmHg. Note persistent forward flow during diastole, consistent with persistent pressure gradient across the obstruction.</div><div class=\"graphic_footnotes\">AAO: ascending aorta; DAO: descending aorta; TTE: transthoracic echocardiographic.</div><div id=\"graphicVersion\">Graphic 58827 Version 3.0</div></div></div>"},"58829":{"type":"graphic_table","displayName":"Histol grading post preop chemo","title":"Histologic grading of the effect of preoperative chemotherapy on primary osteosarcoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histologic grading of the effect of preoperative chemotherapy on primary osteosarcoma</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Grade</td>\n\n      <td class=\"subtitle1\">Effect</td>\n\n    </tr>\n\n    <tr>\n\n      <td>I</td>\n\n      <td>Little or no effect identified</td>\n\n    </tr>\n\n    <tr>\n\n      <td>II</td>\n\n      <td>Areas of acellular tumor osteoid, necrotic, or fibrotic material attributable to the effect of chemotherapy, with other areas of histologically viable tumor</td>\n\n    </tr>\n\n\n\n    <tr>\n\n      <td>III</td>\n\n      <td>Predominant areas of acellular tumor osteoid, necrotic, or fibrotic material attributable to the effect of chemotherapy, with only scattered foci of histologically viable tumor cells identified</td>\n\n    </tr>\n\n\n\n\n    <tr>\n\n      <td>IV</td>\n\n      <td>No histologic evidence of viable tumor identified within the entire specimen</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Rosen G, et al. Primary osteogenic sarcoma: eight year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol 1983; 106 (suppl):55. Copyright &#169; 1983 Springer-Verlag.</div><div id=\"graphicVersion\">Graphic 58829 Version 2.0</div></div></div>"},"58831":{"type":"graphic_picture","displayName":"Adult with SWS and port wine stain","title":"Port wine stain affecting an adult with Sturge-Weber syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Port wine stain affecting an adult with Sturge-Weber syndrome</div><div class=\"cntnt\"><img style=\"width:248px; height:342px;\" src=\"images/PEDS/58831_Sturge-Weber_syndrome_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The appearance of the facial port wine stain changes with age. In the newborn, the lesion is flat and usually light pink in color. It typically darkens with age to a deep red, port wine appearance, and vascular ectasias develop as depicted above.</div><div class=\"graphic_reference\">Courtesy of John Bodensteiner, MD.</div><div id=\"graphicVersion\">Graphic 58831 Version 4.0</div></div></div>"},"58833":{"type":"graphic_figure","displayName":"Modified Ripstein rectopexy","title":"Modified Ripstein rectopexy","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Modified Ripstein rectopexy</div><div class=\"cntnt\"><img style=\"width:470px; height:514px;\" src=\"images/SURG/58833_Modified-Ripstein-rectopexy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts placement of nonabsorbable suture between the mesh sling and the presacral fascia as a component of the&#160;modified Ripstein rectopexy.</div><div id=\"graphicVersion\">Graphic 58833 Version 1.0</div></div></div>"},"58834":{"type":"graphic_table","displayName":"Major causes of mast cell-mediated angioedema","title":"Major causes of mast cell-mediated angioedema","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of mast cell-mediated angioedema</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">IgE-dependent allergic reactions </td> </tr> <tr> <td>Foods</td> </tr> <tr> <td>Drugs (antibiotics, local anesthetics, hormones)</td> </tr> <tr> <td>Stinging insects</td> </tr> <tr> <td>Latex</td> </tr> <tr> <td>Contact (fresh fruits and vegetables, animal saliva)</td> </tr> <tr> <td class=\"subtitle1_single\">Direct mast cell-mediator release </td> </tr> <tr> <td>Opiates</td> </tr> <tr> <td>Muscle relaxants (succinylcholine, curare)</td> </tr> <tr> <td>Radiocontrast agents</td> </tr> <tr> <td class=\"subtitle1_single\">Perturbations in arachidonic acid metabolism within mast cells </td> </tr> <tr> <td>Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E.</div><div id=\"graphicVersion\">Graphic 58834 Version 5.0</div></div></div>"},"58836":{"type":"graphic_table","displayName":"Anaphylaxis signs and symptoms","title":"Anaphylaxis signs and symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anaphylaxis signs and symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Signs and symptoms of anaphylaxis</td> </tr> <tr> <td>Dermatologic - Pruritus, flushing, urticaria, angioedema</td> </tr> <tr> <td>Eyes -&nbsp;Conjunctival injection, lacrimation, pruritus, periorbital edema</td> </tr> <tr> <td>Nose - Sneezing, rhinorrhea, nasal congestion</td> </tr> <tr> <td>Upper airway -&nbsp;Glossal/pharyngeal edema, metallic taste, hoarseness, stridor, sense of choking</td> </tr> <tr> <td>Lower airway - Dyspnea, tachypnea, wheezing, dry and repetitive cough, cyanosis</td> </tr> <tr> <td>Gastrointestinal/abdominal - Nausea, vomiting, crampy pain, diarrhea, uterine contractions (women)</td> </tr> <tr> <td>Cardiovascular - Hypotension, tachycardia (or sometimes bradycardia), palpitations, lightheadedness, syncope</td> </tr> <tr> <td>Neurologic - Sense of impending doom</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58836 Version 5.0</div></div></div>"},"58837":{"type":"graphic_table","displayName":"Causes of vitamin D deficiency","title":"Causes of vitamin D deficiency or resistance","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of vitamin D deficiency or resistance</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Deficient intake or absorption</td> </tr> <tr> <td class=\"indent1\">Dietary</td> </tr> <tr> <td class=\"indent1\">Malabsorption</td> </tr> <tr> <td class=\"indent1\">Gastric bypass (bariatric surgery, gastrectomy)</td> </tr> <tr> <td class=\"indent1\">Small bowel disease</td> </tr> <tr> <td class=\"indent1\">Pancreatic insufficiency</td> </tr> <tr> <td class=\"subtitle1_single\">Decreased skin synthesis</td> </tr> <tr> <td class=\"indent1\">Inadequate sunlight exposure</td> </tr> <tr> <td class=\"indent1\">Full sunscreen use&nbsp;</td> </tr> <tr> <td class=\"indent1\">Darkly pigmented skin</td> </tr> <tr> <td class=\"subtitle1_single\">Defective 25-hydroxylation</td> </tr> <tr> <td class=\"indent1\">Cirrhosis</td> </tr> <tr> <td class=\"subtitle1_single\">Increased catabolism of vitamin D to inactive metabolites</td> </tr> <tr> <td class=\"indent1\">Anticonvulsants</td> </tr> <tr> <td class=\"subtitle1_single\">Loss of vitamin D binding protein</td> </tr> <tr> <td class=\"indent1\">Nephrotic syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Defective 1-alpha 25-hydroxylation</td> </tr> <tr> <td class=\"indent1\">Hypoparathyroidism</td> </tr> <tr> <td class=\"indent1\">Renal failure</td> </tr> <tr> <td class=\"indent1\">1-alpha hydroxylase deficiency (vitamin D-dependent rickets, type 1)</td> </tr> <tr> <td class=\"subtitle1_single\">Defective target organ response to calcitriol</td> </tr> <tr> <td class=\"indent1\">Hereditary vitamin D-resistant rickets (vitamin D-dependent rickets, type 2)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58837 Version 6.0</div></div></div>"},"58841":{"type":"graphic_picture","displayName":"Lichen sclerosus - histopathology","title":"Lichen sclerosus - H&E","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen sclerosus - H&E</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/58841_Lichen_sclerosus_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Epidermal atrophy, hyperkeratosis, hyalinization of the upper dermis, and a dermal lymphocytic infiltrate are present in this histopathologic specimen from a lesion of lichen sclerosus.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 58841 Version 5.0</div></div></div>"},"58842":{"type":"graphic_figure","displayName":"Rib anatomy and external landmarks","title":"Rib anatomy and external landmarks","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Rib anatomy and external landmarks</div><div class=\"cntnt\"><img style=\"width:612px; height:455px;\" src=\"images/EM/58842_Rib_anat_ext_landmarks.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Clay JH, Pounds DM. Basic Clinical Massage Therapy: Integrating Anatomy and Treatment. Baltimore: Lippincott Williams &amp; Wilkins, 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58842 Version 3.0</div></div></div>"},"58843":{"type":"graphic_diagnosticimage","displayName":"Normal postoperative UGI series after gastric plication","title":"Normal postoperative upper gastrointestinal (UGI) series after gastric plication","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal postoperative upper gastrointestinal (UGI) series after gastric plication</div><div class=\"cntnt\"><img style=\"width:408px; height:304px;\" src=\"images/SURG/58843_Norm_postop_UGI_plication.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an upper gastrointestinal image after greater curve plication, which looks similar to a sleeve gastrectomy on x-ray.</div><div id=\"graphicVersion\">Graphic 58843 Version 5.0</div></div></div>"},"58844":{"type":"graphic_diagnosticimage","displayName":"Gallstone in gallbladder US","title":"Cholelithiasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cholelithiasis</div><div class=\"cntnt\"><img style=\"width:333px; height:288px;\" src=\"images/GAST/58844_Gallstone_in_gallbladder_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound of the gallbladder shows posterior acoustic shadowing (arrowhead) produced by a stone in the lumen of the gallbladder (arrow). There is no gallbladder wall thickening, a finding that may be seen with cholecystitis.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 58844 Version 2.0</div></div></div>"},"58845":{"type":"graphic_diagnosticimage","displayName":"Echinococcal liver cyst CT","title":"Echinococcal cyst of the liver","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Echinococcal cyst of the liver</div><div class=\"cntnt\"><img style=\"width:540px; height:346px;\" src=\"images/ID/58845_Echinococ_liver_cyst_CT_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A computed tomogram shows a multilocular cyst in the liver of a patient with hydatid disease.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Parasitic Disorders: Pathology, Diagnosis, and Management, 2nd edition. Baltimore: Lippincott Williams &amp; Wilkins, 1999. Copyright © 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58845 Version 4.0</div></div></div>"},"58846":{"type":"graphic_table","displayName":"Causes of acute arterial occlusion","title":"Causes of acute arterial occlusion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of acute arterial occlusion</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tr>\n\t\t<td class=\"container\">\n\t\t\t<table cellspacing=\"0\">\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Embolus</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\t\n\t\t\t\t\t<td class=\"sublist1_start\">Cardiac source</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">Atrial fibrillation</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">Myocardial infarction</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">Endocarditis </td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">Valvular disease</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">Atrial myxoma</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">Prosthetic valves</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1_start\">Arterial source</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">Aneurysm</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">Atherosclerotic plaque</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Paradoxical embolus</td>\n\t\t\t\t</tr>\n\t\t\t</table>\n\t\t</td>\n\t\t<td class=\"container\">\n\t\t\t<table cellspacing=\"0\">\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Thrombosis</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Vascular grafts</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Atherosclerosis</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Thrombosis of aneurysm</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Entrapment syndrome</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Hypercoagulable state</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Low flow state</td>\n\t\t\t\t</tr>\n\t\t\t</table>\n\t\t</td>\n\t\t<td class=\"container\">\n\t\t\t<table cellspacing=\"0\">\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Trauma</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Blunt</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Penetrating</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Iatrogenic</td>\n\t\t\t\t</tr>\n\t\t\t</table>\n\t\t</td>\n    </tr>\n</table></div><div id=\"graphicVersion\">Graphic 58846 Version 2.0</div></div></div>"},"58848":{"type":"graphic_waveform","displayName":"Incremental response with high-frequency RNS in LEMS","title":"Incremental response with high-frequency repetitive nerve stimulation (RNS) in a patient with Lambert-Eaton myasthenic syndrome (LEMS)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Incremental response with high-frequency repetitive nerve stimulation (RNS)&nbsp;in a patient with Lambert-Eaton myasthenic syndrome (LEMS)</div><div class=\"cntnt\"><img style=\"width:436px; height:257px;\" src=\"images/NEURO/58848_CMAPpostactivationfacilit.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Responses to a train of 50 stimulations at 50 Hz in a patient with Lambert-Eaton myasthenic syndrome. Note the low initial CMAP amplitude (0.3 mV) and the marked facilitation to 1.5 mV (400 percent).</div><div class=\"graphic_reference\">Reproduced with permission from: Howard JF, Sanders DB, Massey JM. The electrodiagnosis of myasthenia gravis and the Lambert-Eaton myasthenic syndrome. Neurol Clin 1994; 12:305. Copyright © 1994 Elsevier.</div><div id=\"graphicVersion\">Graphic 58848 Version 5.0</div></div></div>"},"58849":{"type":"graphic_figure","displayName":"Positions of gaze","title":"Diagnostic positions of gaze","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagnostic positions of gaze</div><div class=\"cntnt\"><img style=\"width:439px; height:534px;\" src=\"images/NEURO/58849_Positions_of_gaze.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The nine diagnostic positions of gaze, used for testing versions (saccades and pursuit). Pure elevation (supraduction) and depression (infraduction) of the eyes are predominantly functions of the superior and inferior rectus muscles, respectively, with some help from the oblique muscles. The eyes are rotated directly upward primarily by the superior rectus with some help from the inferior oblique; the eyes are rotated directly downward primarily by the inferior rectus with some help from the superior oblique.</div><div class=\"graphic_reference\">Reproduced with permission from: Lavin, PJM. Eye movement disorders and diplopia. In: Neurology in Clinical Practice: Principles of Diagnosis and Management, 2nd ed, Bradley, WG (Ed), Butterworth-Heinemann, Boston 1996. p. 185. Copyright &#169; 1996 Elsevier.</div><div id=\"graphicVersion\">Graphic 58849 Version 1.0</div></div></div>"},"58850":{"type":"graphic_figure","displayName":"Fewer ulcers with celecoxib","title":"Fewer gastroduodenal ulcers with celecoxib","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fewer gastroduodenal ulcers with celecoxib</div><div class=\"cntnt\"><img style=\"width:320px; height:251px;\" src=\"images/GAST/58850_Fewer_ulcers_with_celecoxib.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Results of two trials in which the cumulative incidence of gastroduodenal ulcers as detected by four serial endoscopies over&nbsp;12 weeks in patients treated with the COX-2 inhibitor celecoxib and either naproxen (study 3) or diclofenac or ibuprofen (study 4). Celecoxib was associated with significantly fewer gastroduodenal ulcers than naproxen or ibuprofen (p&lt;0.001).</div><div class=\"graphic_footnotes\">C: Celecoxib 200 mg twice daily; N: Naproxen 500 mg twice daily; D: Diclofenac 75 mg twice daily; I: Ibuprofen 800 mg three times daily; COX: cyclooxygenase.</div><div class=\"graphic_reference\">Data from the US Food and Drug Administration (FDA).</div><div id=\"graphicVersion\">Graphic 58850 Version 3.0</div></div></div>"},"58851":{"type":"graphic_table","displayName":"Probability of pregnancy after unprotected intercourse ","title":"Probability of pregnancy after unprotected intercourse by timing of coitus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Probability of pregnancy after unprotected intercourse by timing of coitus</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_left\">\n   3 days before ovulation\n   </td>\n   <td>15 percent</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_left\">\n   1 or 2 days before ovulation\n   </td>\n   <td>30 percent</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_left\">\n   day of ovulation\n   </td>\n   <td>12 percent</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_left\">\n   1 or 2 days after ovulation\n   </td>\n   <td>near zero</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">19.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=21885&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Chance_of_pregnancy.htm</title></head></div><div class=\"graphic_reference\">Adapted from: Trussell J, Rodríguez G, Ellertson C. New estimates of the effectiveness of the Yuzpe regimen of emergency contraception. Contraception 1998; 57:363.</div><div id=\"graphicVersion\">Graphic 58851 Version 3.0</div></div></div>"},"58853":{"type":"graphic_picture","displayName":"Hairy cell leukemia spleen","title":"Hairy cell leukemia in the spleen","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hairy cell leukemia in the spleen</div><div class=\"cntnt\"><img style=\"width:383px; height:296px;\" src=\"images/HEME/58853_Hairy_cell_leukemia_spleen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This splenic section from a patient with hairy cell leukemia shows infiltration with a monotonous population of medium-sized cells with clear cytoplasm and interlocking cell borders, giving a halo or &quot;fried egg&quot; appearance.</div><div class=\"graphic_reference\">From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14,1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 58853 Version 2.0</div></div></div>"},"58854":{"type":"graphic_figure","displayName":"Pollen-food cross reactivity PI","title":"Cross-reactivity patterns in pollen-food allergy syndrome","html":"<div class=\"graphic\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Cross-reactivity patterns in pollen-food allergy syndrome</div><div class=\"cntnt\"><img style=\"width:608px; height:786px;\" src=\"images/PI/58854_Cross_reactivity_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical patterns of cross-reactivity between pollens and fruits and vegetables. Individual foods are grouped by their taxonomical families.</div><div class=\"graphic_reference\">Adapted and extended from: Sicherer SH. Clinical implications of cross-reactive food allergens. J Allergy Clin Immunol 2001; 108:881.</div><div id=\"graphicVersion\">Graphic 58854 Version 2.0</div></div></div>"},"58856":{"type":"graphic_figure","displayName":"Oxygen exchange in IPVDs","title":"Proposed mechanism for partial response to oxygen in the hepatopulmonary syndrome","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Proposed mechanism for partial response to oxygen in the hepatopulmonary syndrome</div><div class=\"cntnt\"><img style=\"width:485px; height:192px;\" src=\"images/PULM/58856_Oxygen_exchange_IPVD_edit.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffusion-perfusion impairment (also called alveolar-capillary oxygen disequlibrium) occurs in the setting of vasodilation of alveolar capillaries; the partial pressure (or driving pressure) of oxygen in the alveolus is insufficient to achieve equilibration with blood moving near the center of the vessel. When alveolar oxygen is increased, the gradient for diffusion increases and oxygenation improves.</div><div class=\"graphic_footnotes\">P<sub>A</sub>O<sub>2</sub>: partial pressure of alveolar oxygen; P<sub>a</sub>O<sub>2</sub>: partial pressure of arterial oxygen; %: percent.</div><div id=\"graphicVersion\">Graphic 58856 Version 6.0</div></div></div>"},"58857":{"type":"graphic_picture","displayName":"Piebaldism","title":"Piebaldism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Piebaldism</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/58857_Piebaldism.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patchy areas of depigmentation in a child with piebaldism.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 58857 Version 3.0</div></div></div>"},"58858":{"type":"graphic_algorithm","displayName":"Pediatric headache and focal neurologic examination","title":"Headache in child with focal neurologic examination or papilledema","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Headache in child with focal neurologic examination or papilledema</div><div class=\"cntnt\"><img style=\"width:516px; height:530px;\" src=\"images/EM/58858_Hdch_focalexam_child_edit1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography; CSF: cerebrospinal fluid; RBCs: red blood cells; WBCs: white blood cells.<br />* Distinguish idiopathic intracranial hypertension from cerebral venous thrombosis by obtaining magnetic resonance imaging or magnetic resonance venogram.</div><div id=\"graphicVersion\">Graphic 58858 Version 3.0</div></div></div>"},"58861":{"type":"graphic_table","displayName":"Leishmaniasis species","title":"Classification of leishmaniasis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of leishmaniasis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Subgenus</td> <td class=\"subtitle1\">Complex</td> <td class=\"subtitle1\">Species</td> <td class=\"subtitle1\">Main geographic locations</td> <td class=\"subtitle1\">Main clinical manifestation</td> <td class=\"subtitle1\">Other</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Old World</td> </tr> <tr> <td class=\"indent1\" rowspan=\"5\"><em>Leishmania</em></td> <td rowspan=\"2\"><em>L. donovani</em></td> <td><em>L. donovani</em></td> <td>India, sub-Saharan Africa, China, Pakistan</td> <td>Visceral leishmaniasis</td> <td>Post kala-azar dermal leismaniasis (PKDL)</td> </tr> <tr> <td><em>L. infantum</em>*</td> <td>Mediterranean, Middle East, north and sub-Saharan Africa, Balkans, China</td> <td>Visceral leishmaniasis</td> <td>&nbsp;</td> </tr> <tr> <td><em>L. major</em></td> <td><em>L. major</em></td> <td>Middle East, Africa, India, China</td> <td>Cutaneous leishmaniasis (\"wet ulcer\")</td> <td>&nbsp;</td> </tr> <tr> <td><em>L. tropica</em></td> <td><em>L. tropica</em></td> <td>Middle East, India, southern Europe, western Asia</td> <td>Cutaneous leishmaniasis (\"dry ulcer\")</td> <td>Leishmaniasis recidivans (LR) and viscerotropic leishmaniasis</td> </tr> <tr> <td><em>L. aethiopica</em></td> <td><em>L. aethiopica</em></td> <td>Ethiopia, Kenya, Yemen</td> <td>Cutaneous leishmaniasis</td> <td>Diffuse cutaneous leishmaniasis (DCL)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">New World</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\"><em>Leishmania</em></td> <td><em>L. donovani</em></td> <td><em>L. chagasi</em>*</td> <td>Latin America</td> <td>Visceral leishmaniasis</td> <td>&nbsp;</td> </tr> <tr> <td rowspan=\"3\"><em>L. mexicana</em></td> <td><em>L. venezuelensis</em></td> <td>Venezuela</td> <td>Cutaneous leishmaniasis</td> <td>&nbsp;</td> </tr> <tr> <td><em>L. mexicana</em></td> <td>Mexico, Central America, Texas, Oklahoma</td> <td>Cutaneous leishmaniasis</td> <td>Diffuse cutaneous leishmaniasis </td> </tr> <tr> <td><em>L. amazonensis</em></td> <td>Amazon basin, Brazil</td> <td>Cutaneous leishmaniasis</td> <td>Diffuse cutaneous leishmaniasis; has also been associated with viceral leishmaniasis.</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\"><em>Viannia</em></td> <td rowspan=\"2\"><em>L. braziliensis</em></td> <td><em>L. braziliensis</em></td> <td>Latin America </td> <td>Cutaneous and mucocutaneous leishmaniasis</td> <td>&nbsp;</td> </tr> <tr> <td><em>L. peruviana</em></td> <td>Peru and Argentina (highlands)</td> <td>Cutaneous leishmaniasis</td> <td>&nbsp;</td> </tr> <tr> <td rowspan=\"2\"><em>L. guyanensis</em></td> <td><em>L. guyanensis</em></td> <td>Northern Amazon basin, Guyanas</td> <td>Cutaneous leishmaniasis</td> <td>&nbsp;</td> </tr> <tr> <td><em>L. panamensis</em></td> <td>Panama, Costa Rica, Columbia</td> <td>Cutaneous leishmaniasis</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Organisms belonging to the subgenus <EM>Leishmania</EM> develop in the sandfly midgut, whereas organisms belonging to the subspecies <EM>Viannia</EM> develop in the hindgut.<br />* <EM>L. infantum</EM> and <EM>L. chagasi</EM> are now thought to be the same organism.</div><div id=\"graphicVersion\">Graphic 58861 Version 4.0</div></div></div>"},"58863":{"type":"graphic_figure","displayName":"Presternal PD catheter","title":"Presternal peritoneal dialysis catheter","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Presternal peritoneal dialysis catheter</div><div class=\"cntnt\"><img style=\"width:464px; height:624px;\" src=\"images/NEPH/58863_Presternal_PD_catheter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of&nbsp;three components of a&nbsp;presternal peritoneal dialysis catheter after implantation.</div><div class=\"graphic_reference\">Modified from: Crabtree JH. Selected best demonstrated practices in peritoneal dialysis access. Kidney Int Suppl 2006; 103:S27.</div><div id=\"graphicVersion\">Graphic 58863 Version 2.0</div></div></div>"},"58867":{"type":"graphic_figure","displayName":"Hysteroscopic viewing angles","title":"Hysteroscope with different viewing angles","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Hysteroscope with different viewing angles</div><div class=\"cntnt\"><img style=\"width:509px; height:342px;\" src=\"images/OBGYN/58867_Hysteroscopic_viewing_angle.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 58867 Version 1.0</div></div></div>"},"58869":{"type":"graphic_picture","displayName":"Contact stomatitis","title":"Contact stomatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Contact stomatitis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/58869_Contact_stomatitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 58869 Version 3.0</div></div></div>"},"58870":{"type":"graphic_table","displayName":"Basic measures to control exposure to indoor allergens","title":"Basic measures to control exposure to indoor allergens","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Basic measures to control exposure to indoor allergens</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Indoor allergen</td> <td class=\"subtitle1\">Recommendations for reducing exposure</td> </tr> <tr> <td rowspan=\"3\">Animal dander</td> <td>Remove animal from house, or at minimum, keep animal out of patient's bedroom. Keep pet in a room with a HEPA filter, and replace the filter as recommended by the manufacturer.</td> </tr> <tr> <td>Cover air ducts that lead to bedroom with filters. Replace filters as recommended by the manufacturer.</td> </tr> <tr> <td>Use air filters and vacuums with HEPA filters. Replace the filter as recommended by the manufacturer.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"7\">Dust mites</td> <td class=\"sublist1_start\">Less costly</td> </tr> <tr> <td class=\"sublist1\">Encase mattress, pillows, and box spring in allergen-impermeable covers. Finely woven covers for pillows and duvets are preferable.</td> </tr> <tr> <td class=\"sublist1\">Wash bedding weekly in warm water with detergent or use an electric dryer on the hot setting.</td> </tr> <tr> <td class=\"sublist1\">Reduce indoor humidity to &#60;50%.</td> </tr> <tr> <td class=\"sublist1_start\">More costly</td> </tr> <tr> <td class=\"sublist1\">Remove carpets from the bedroom.</td> </tr> <tr> <td class=\"sublist1\">Replace old upholstered furniture with leather, vinyl, or wood.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Cockroaches</td> <td>Use poison bait or traps to control. Consult professional exterminator for severe infestation.</td> </tr> <tr> <td>Periodically clean home thoroughly.</td> </tr> <tr> <td>Encase all food fully and do not store garbage or papers inside the home.</td> </tr> <tr> <td>Fix water leaks.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Indoor mold</td> <td>Clean moldy surfaces with dilute bleach solution.</td> </tr> <tr> <td>Fix water leaks.</td> </tr> <tr> <td>Reduce indoor humidity to &#60;50%. Avoid use of humidifiers.</td> </tr> <tr> <td>Evaporative (or swamp) coolers should be avoided or cleaned regularly.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Rodents</td> <td>Consult a professional exterminator.</td> </tr> <tr> <td>Periodically clean home thoroughly.</td> </tr> <tr> <td>All food should be stored in sealed containers. Do not store garbage inside.</td> </tr> <tr> <td>Repair holes in walls, doors, floors, and block other entry points.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The measures that can effectively reduce exposure are different for each indoor allergen. Those listed are suggested, but have not been verified to be effective in isolation. Studies showing greatest benefit from indoor allergen remediation were those that adapted the measures to each patient's individual sensitivities, and addressed all of a patient's allergies in parallel.</div><div class=\"graphic_footnotes\">HEPA: high-efficiency particulate air.</div><div class=\"graphic_reference\">Adapted from: The Allergy Report. American Academy of Allergy, Asthma, and Immunology (www.aaaai.org).</div><div id=\"graphicVersion\">Graphic 58870 Version 5.0</div></div></div>"},"58872":{"type":"graphic_picture","displayName":"Adherence of Helicobacter pylori","title":"Adherence of Helicobacter pylori","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Adherence of Helicobacter pylori</div><div class=\"cntnt\"><img style=\"width:320px; height:190px;\" src=\"images/GAST/58872_H_pylori_adherence_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph shows the attachment of <EM>Helicobacter pylori</EM> to gastric epithelial cells.</div><div class=\"graphic_reference\">Courtesy of the American Gastroenterological Association&#169;. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner-Fenwick, Inc. at 1-800-432-8433.</div><div id=\"graphicVersion\">Graphic 58872 Version 4.0</div></div></div>"},"58875":{"type":"graphic_picture","displayName":"Erythema nodosum leprosum","title":"Erythema nodosum leprosum (type 2 reaction)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema nodosum leprosum (type 2 reaction)</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/ID/58875_Erythema_nodosum_leprosum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical inflammatory&nbsp;erythema nodosum leprosum&nbsp;lesions, some of which are undergoing pustulation and ulceration.</div><div class=\"graphic_reference\">Courtesy of James L Krahenbuhl, PhD, and Robert R Jacobson, MD, PhD.</div><div id=\"graphicVersion\">Graphic 58875 Version 3.0</div></div></div>"},"58877":{"type":"graphic_table","displayName":"Treatment of osteomyelitis","title":"Antibiotic therapy for acute osteomyelitis in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antibiotic therapy for acute osteomyelitis in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Infectious agent</td> <td class=\"subtitle1\">Antibiotic</td> <td class=\"subtitle1\">Dosing</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">MSSA</td> <td>Nafcillin</td> <td>2 g IV every 4 hours</td> </tr> <tr> <td>Oxacillin</td> <td>2 g IV every 4 hours</td> </tr> <tr class=\"divider_bottom\"> <td>Cefazolin</td> <td>2 g IV every 8 hours</td> </tr> <tr class=\"divider_bottom\"> <td>MRSA*</td> <td>Vancomycin<sup>&#182;</sup></td> <td>30 to 40 mg/kg IV every 24 hours in two or three divided doses; not to exceed 2 g/dose</td> </tr> <tr class=\"divider_bottom\"> <td>Coagulase-negative staphylococci</td> <td>Vancomycin<sup>&#182;</sup></td> <td><span style=\"color: black;\">30 to 40 mg/kg IV every 24 hours in two or three divided doses; not to exceed 2 g/dose unless serum trough levels are inappropriately low</span></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Gram-negative organisms (including <em>Pseudomonas</em>)</td> <td>Ciprofloxacin</td> <td><span style=\"color: black;\">750 mg orally twice daily or 400 mg IV every 12 hours; if treating <em>Pseudomonas, </em>increase IV dose to 400 mg IV every 8 hours<sup>&#916;</sup></span></td> </tr> <tr> <td>Levofloxacin</td> <td>750 mg orally or IV once daily</td> </tr> <tr> <td>Ceftazidime</td> <td>2 g IV every 8 hours</td> </tr> <tr class=\"divider_bottom\"> <td>Cefepime</td> <td>2 g IV every 8 to 12 hours</td> </tr> <tr> <td>Empiric therapy</td> <td colspan=\"2\">Vancomycin PLUS an agent with activity against gram-negative organisms</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">In stable patients, antibiotics may be held pending establishment of microbiologic diagnosis or obtaining cultures from bone debridement or biopsy. Total duration of antibiotic therapy (IV and step-down oral) is four to eight weeks. The doses in this table are intended for patients with normal renal function. The doses of many of these agents must be adjusted in the setting of renal insufficiency; refer to the Lexicomp drug-specific monographs for renal dose adjustments.</div><div class=\"graphic_footnotes\">MSSA: methicillin-susceptible <EM>Staphylococcus aureus</EM>; MRSA: methicillin-resistant <EM>S. aureus</EM>; IV: intravenously.<br />* For alternative agents with activity against MRSA, refer to the topic on treatment of <SPAN style=\"COLOR: black\">invasive methicillin-resistant <EM>S. aureus</EM> infections in adults.<br />¶ In adults, vancomycin is dosed based on actual body weight. Vancomycin dose should be adjusted for target trough concentration of 15 to 20 mcg/mL. Refer to the UpToDate topic review on vancomycin parenteral dosing and serum concentration monitoring in adults.<br />Δ Oral ciprofloxacin at&nbsp;dose shown in table achieves therapeutic levels for treatment of <EM innerHtml>Pseudomonas</EM>.</SPAN></div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Calhoun JH, Manring MM. Adult osteomyelitis. Infect Dis Clin North Am 2005; 19:765.</li>&#xD;&#xA;    <li>Berbari EF, Kanj SS, Kowalski TJ, et al. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis 2015; 61:e26.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 58877 Version 6.0</div></div></div>"},"58878":{"type":"graphic_picture","displayName":"Candidiasis of cord","title":"Candidiasis of umbilical cord","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Candidiasis of umbilical cord</div><div class=\"cntnt\"><img style=\"width:392px; height:523px;\" src=\"images/OBGYN/58878_Candidiasis_of_cord.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Gross candidiasis of umbilical cord; (B) Microscopic view of umbilical cord candidiasis.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 58878 Version 2.0</div></div></div>"},"58884":{"type":"graphic_figure","displayName":"Low back flexion test","title":"Testing for low back flexion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Testing for low back flexion</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/RHEUM/58884_Low_back_flexion_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schober test to measure the forward flexion of the lumbar spine in a patient with suspected or proven ankylosing spondylitis. With the patient standing erect, make a mark over the spinous process of the&nbsp;fifth lumbar vertebra or on the imaginary line joining the posterior superior iliac spine. Make another mark 10 cm above it in the midline. When the patient bends maximally forward, the distance between the two points normally exceeds 15 cm.</div><div class=\"graphic_reference\">Courtesy of Craig W Wiesenhutter, MD.</div><div id=\"graphicVersion\">Graphic 58884 Version 3.0</div></div></div>"},"58885":{"type":"graphic_figure","displayName":"Purine nucleotide cycle","title":"Purine nucleotide cycle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Purine nucleotide cycle</div><div class=\"cntnt\"><img style=\"width:363px; height:176px;\" src=\"images/RHEUM/58885_Purine_nucleotide_cycle.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic showing the purine nucleotide cycle; this pathway catalyzes the conversion of two adenosine diphosphate (ADP) molecules into one molecule of adenosine triphosphate (ATP) and one molecule of adenosine monophosphate (AMP). The AMP may then be deaminated to inosine monophosphate (IMP) by myoadenylate deaminase, with concurrent production of ammonia. The enzymes involved are: 1, myodenylate deaminase (MADA); 2, adenylosuccinate synthetase; 3, adenylosuccinate lyase; 4, ATPase; 5, muscle adenylate kinase.</div><div class=\"graphic_footnotes\">GDP: guanosine 5'-diphosphate; GTP: guanosine 5' triphosphate.</div><div id=\"graphicVersion\">Graphic 58885 Version 1.0</div></div></div>"},"58886":{"type":"graphic_diagnosticimage","displayName":"DCRV","title":"Double chambered right ventricle ","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Double chambered right ventricle </div><div class=\"cntnt\"><img style=\"width:584px; height:277px;\" src=\"images/CARD/58886_DCRV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transesophageal echocardiographic views of double chambered right ventricle (DCRV) without (A) and with color (B) at the base of the heart showing an obstructive muscle bundle separating&nbsp;the proximal high pressure (PC) and distal low pressure (DC) chambers.</div><div class=\"graphic_reference\">Reprinted with permission: Ammash N. Ventricular Septal Defects. In: Adult Congenital Heart Disease, Warnes, CA (Ed). &copy; 2009 American Heart Association, Inc.</div><div id=\"graphicVersion\">Graphic 58886 Version 10.0</div></div></div>"},"58887":{"type":"graphic_picture","displayName":"Perforated hard palate","title":"Congenital syphilis: Perforated hard palate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital syphilis: Perforated hard palate</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PEDS/58887_Perforated_hard_palate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient with congenital syphilis has developed a perforation of hard palate due to gummatous destruction. These destructive tumors can also attack the skin, long bones, eyes, mucous membranes, throat, liver, or stomach lining.</div><div class=\"graphic_reference\">Reproduced from: the Public Health Image Library, Centers for Disease Control and Prevention. Photo by Susan Lindsley.</div><div id=\"graphicVersion\">Graphic 58887 Version 2.0</div></div></div>"},"58888":{"type":"graphic_figure","displayName":"Schematic CGH for microarray setup","title":"Schematic CGH for microarray setup","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">Schematic CGH for microarray setup</div><div class=\"cntnt\"><img style=\"width:578px; height:498px;\" src=\"images/PC/58888_Schematic_microarray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the array CGH technique for a focused analysis of copy number imbalances along a region of interest (eg, 8q21.1). A tiling path of genomic clones (eg, BACs, PACs, PIs, cosmids) is generated to cover the region. After extraction and purification, these genomic DNA targets are arrayed onto glass slides.<br> Array CGH is performed by hybridizing labeled normal (Cy3) and tumor (Cy5) genomic DNA into the microarray and detected using a microarray scanner.<br> Each array spot, realigned <em>in silico</em> as a single contiguous map to correspond with the tiling path, can be analyzed by fluorescence ratio to identify the regions of copy number changes. These results may be correlated with <em>in silico</em> techniques to identify candidate genes of interest.</div><div class=\"graphic_footnotes\">CGH: comparative genomic hybridization; BAC: bacterial artificial chromosome; PAC: P1 bacteriophage artificial chromosome; P1: P1 bacteriophage; Cy3: cyanine dye with green fluorescence; Cy5: cyanine dye with red fluorescence.</div><div class=\"graphic_reference\">Reproduced from: Beheshti B, Park PC, Braude I, Squire JA. Micorarray CGH. In: Molecular Cytogenetics: Protocols and Applications. Humana Press, 2002, with kind permission from Springer Science + Business Media B.V. Copyright © 2002.</div><div id=\"graphicVersion\">Graphic 58888 Version 10.0</div></div></div>"},"58890":{"type":"graphic_table","displayName":"Thyrotoxicosis child","title":"Causes of thyrotoxicosis in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of thyrotoxicosis in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Name</td> <td class=\"subtitle1\">Synonyms</td> <td class=\"subtitle1\">Mechanism</td> <td class=\"subtitle1\">Antibody tests</td> <td class=\"subtitle1\">RAI</td> <td class=\"subtitle1\">Thyroid exam</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Thyroid gland hyperfunction (increased synthesis of thyroid hormones)</td> </tr> <tr> <td class=\"indent1\">Graves' disease</td> <td> <p>Hyperthyroid goiter</p> von Basedow's disease</td> <td>Thyrotropin receptor-stimulating antibodies (TSHR-Ab)</td> <td> <p>TSHR-Ab* positive (TSI positive <em>and</em> TBII positive in typical cases)</p> TPO-Ab positive or negative</td> <td>High, diffuse</td> <td>Symmetric nontender goiter</td> </tr> <tr> <td class=\"indent1\">Multinodular hyperthyroid goiter</td> <td>Toxic multinodular goiter</td> <td>Autonomous overproduction of thyroid hormone by nodules</td> <td>All negative</td> <td>Normal or high, multifocal</td> <td>Nodular</td> </tr> <tr> <td class=\"indent1\">Autonomous nodule</td> <td> <p>Plummer's disease</p> Toxic nodule</td> <td>Same</td> <td>All negative</td> <td>High, single focus; rest of gland suppressed</td> <td>Single nodule</td> </tr> <tr> <td class=\"indent1\">TSH-producing pituitary adenoma</td> <td>&nbsp;</td> <td>Autonomous overproduction of TSH</td> <td>All negative</td> <td>High</td> <td>Normal or symmetric goiter</td> </tr> <tr> <td class=\"indent1\">Pituitary resistance to thyroid hormone</td> <td>&nbsp;</td> <td>Overproduction of TSH</td> <td>All negative</td> <td>High, diffuse</td> <td>Symmetric goiter</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Thyrotoxic phase of thyroiditis (excess secretion of preformed thyroid hormones)</td> </tr> <tr> <td class=\"indent1\">Thyrotoxic phase of chronic lymphocytic (Hashimoto's) thyroiditis</td> <td> <p>Hashitoxicosis</p> Lymphadenoid goiter</td> <td>Autoimmune; release of preformed hormone. Predominantly women.</td> <td> <p>TPO-Ab positive</p> <p>Anti-thyroglobulin antibody positive</p> TSHR-Ab* usually negative (TSI is usually negative; TBII may be positive)</td> <td>Low in majority, but can be elevated if TSHR-Ab positive; inhomogeneous pattern</td> <td>Firm goiter, sometimes tender</td> </tr> <tr> <td class=\"indent1\">Subacute lymphocytic thyroiditis</td> <td> <p>Painless sporadic thyroiditis</p> Silent thyroiditis</td> <td>Autoimmune; release of preformed hormone. May also be associated with drugs (IFN-alpha, IL-2, lithium).</td> <td>TPO-Ab positive</td> <td>Low (during thyrotoxic phase)</td> <td>Firm nontender, mildly enlarged thyroid</td> </tr> <tr> <td class=\"indent1\">Subacute granulomatous thyroiditis</td> <td> <p>Subacute thyroiditis</p> <p>Painful subacute thyroiditis</p> <p>de Quervain's thyroiditis</p> Granulomatous giant cell thyroiditis</td> <td>Viral; release of preformed hormone</td> <td> <p>TPO-Ab negative</p> Elevated ESR</td> <td>Low (during thyrotoxic phase)</td> <td>Painful goiter</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Drug-induced thyrotoxicosis</td> </tr> <tr> <td class=\"indent1\">Factitous thyroiditis</td> <td>Thyrotoxicosis factitia</td> <td>&nbsp;</td> <td>Low TSH</td> <td>Low or absent</td> <td>No goiter</td> </tr> <tr> <td class=\"indent1\">Iodine-induced hyperthyroidism</td> <td>&nbsp;</td> <td>Underlying multinodular goiter; thyroid hormone release triggered by exposure to iodine (eg, contrast agents, amiodarone)</td> <td>&nbsp;</td> <td>Increased</td> <td>Often multinodular</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TSHR-Ab: thyrotropin (TSH)-receptor stimulating antibodies; TPO-Ab: thyroid peroxidase antibodies; TBII: thyrotropin binding inhibitor immunoglobulin; RAI: radioactive iodine uptake.<br />* TSHR-Ab can be measured by either a thyroid stimulating immunoglobulin (TSI) or thyrotropin binding inhibitor immunoglobulin (TBII). TSI is a more accurate test for Graves' disease because it confirms the presence of a stimulating antibody. TBII confirms that there is an antibody that competes with TSH binding to its receptor, but does not provide information about whether it is a stimulating or blocking antibody.</div><div id=\"graphicVersion\">Graphic 58890 Version 8.0</div></div></div>"},"58891":{"type":"graphic_picture","displayName":"Ankle anterior drawer test","title":"Anterior drawer test","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Anterior drawer test</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/EM/58891_Ankle_anterior_drawer_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The test is performed with patient's foot in neutral position. The lower leg is stabilized by the examiner with one hand. With the other hand, the examiner grasps the heel while the patient's foot rests on the anterior aspect of the examiner's arm. An anterior force (direction of the arrow) is applied to the heel while holding the distal anterior leg fixed. Excessive anterior displacement suggests ligamentous injury.</div><div class=\"graphic_reference\">Courtesy of Karen Maughan, MD.</div><div id=\"graphicVersion\">Graphic 58891 Version 2.0</div></div></div>"},"58894":{"type":"graphic_picture","displayName":"Inspection and palpation of the olecranon bursa","title":"Inspection and palpation of the olecranon bursa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inspection and palpation of the olecranon bursa</div><div class=\"cntnt\"><img style=\"width:421px; height:294px;\" src=\"images/EM/58894_Olecranon_bursa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the elbow flexed at 90 degrees, the bursa is palpated for ballotable cystic swelling, the degree of associated soft tissue reaction (redness, heat, induration), and in the case of chronic bursitis, the degree of bursal wall thickening.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 58894 Version 4.0</div></div></div>"},"58895":{"type":"graphic_waveform","displayName":"ECG AVNRT via Mahaim pathway","title":"12-lead electrocardiogram (ECG) showing atrioventricular nodal reentrant tachycardia (AVNRT) via Mahaim pathway","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) showing atrioventricular nodal reentrant tachycardia (AVNRT) via Mahaim pathway</div><div class=\"cntnt\"><img style=\"width:541px; height:304px;\" src=\"images/CARD/58895_AVNRT_via_Mahaim_pathway.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The QRS complexes in this extremely rapid (approximately 450 beats/min) and regular tachycardia are widened or aberrant. The mechanisms for the arrhythmia include an atrioventricular nodal reentrant tachycardia with aberration or an antidromic atrioventricular reentrant tachycardia (AVRT) in a patient with the Wolff-Parkinson-White syndrome and antegrade conduction to the ventricle via a Kent pathway. At electrophysiologic testing, the etiology was determined to be an AVNRT with antegrade conduction to ventricle via an atriofascicular (Mahaim) accessory pathway.</div><div class=\"graphic_reference\">Courtesy of Morton Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 58895 Version 3.0</div></div></div>"},"58896":{"type":"graphic_table","displayName":"Healthy vulval hygiene PI","title":"Healthy vulval hygiene practices","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Healthy vulval hygiene practices</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Do not use&nbsp;</td> <td class=\"subtitle1\">Instead use</td> </tr> <tr> <td rowspan=\"2\">Pantyhose </td> <td>Stockings with a garter belt</td> </tr> <tr> <td>Thigh high or knee high stockings</td> </tr> <tr> <td>Synthetic underwear</td> <td>Cotton underwear or no underwear</td> </tr> <tr> <td>Jeans and other tight pants</td> <td>Loose pants, skirts, dresses</td> </tr> <tr> <td>Swimsuits, leotards, thongs, or lycra clothes</td> <td>Loose-fitting cotton clothes</td> </tr> <tr> <td>Pantyliners</td> <td>Tampons or cotton pads</td> </tr> <tr> <td>Scented soaps or shampoos</td> <td>Fragrance free pH neutral soap (such as Basis, Neutrogena, Dove soap)</td> </tr> <tr> <td>Bubble bath</td> <td>Tub baths in the morning and at night with nothing added to the water&nbsp;and at a comfortable temperature</td> </tr> <tr> <td>Scented detergents</td> <td>Unscented detergents</td> </tr> <tr> <td>Washcloths</td> <td>Use fingertips for washing</td> </tr> <tr> <td>Feminine sprays, douches, powders</td> <td>These are not necessary. Do not&nbsp;use them. &nbsp;</td> </tr> <tr> <td>Dyed toilet paper and other products</td> <td>Toilet&nbsp;paper and other products&nbsp;without dyes</td> </tr> <tr> <td>Hair dryers to dry vulva skin without contact</td> <td>Dry vulva by gentle patting with a clean towel. Do not rub dry.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58896 Version 3.0</div></div></div>"},"58897":{"type":"graphic_picture","displayName":"Foramen cecum cystic lesion","title":"Cystic lesion at the foramen cecum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cystic lesion at the foramen cecum</div><div class=\"cntnt\"><img style=\"width:368px; height:282px;\" src=\"images/PEDS/58897_Foramen_cecum_mucocele.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cystic lesion, possible thyroglossal duct cyst (TGDC), at the junction of the anterior two-thirds and posterior one-third of the tongue.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 58897 Version 5.0</div></div></div>"},"58898":{"type":"graphic_figure","displayName":"Irritant diaper dermatitis","title":"Pattern for irritant diaper dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pattern for irritant diaper dermatitis</div><div class=\"cntnt\"><img style=\"width:450px; height:264px;\" src=\"images/PEDS/58898_Irritant_diaper_dermatitis.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 58898 Version 4.0</div></div></div>"},"58899":{"type":"graphic_figure","displayName":"Vaccine effectiveness","title":"Effectiveness of routine childhood immunizations","html":"<div class=\"graphic\"><div style=\"width: 638px\" class=\"figure\"><div class=\"ttl\">Effectiveness of routine childhood immunizations</div><div class=\"cntnt\"><img style=\"width:618px; height:1082px;\" src=\"images/PEDS/58899_Vaccine_effectiveness_edt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cases of disease except as otherwise indicated for invasive Hib disease and invasive pneumococcal disease<SUP>¶</SUP>. Dashed blue lines indicate the approximate date of routine childhood immunization against the disease.</div><div class=\"graphic_footnotes\">Hib: <em>Haemophilus influenzae</em> type b; PCV7: 7-valent pneumococcal conjugate vaccine.<br />* The time period for this graph precedes the measles outbreaks that occurred across the United States during and after 2008.<br />&para; Incidence per 100,000 children under five years of age.</div><div class=\"graphic_reference\">Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases, 11<SUP>th</SUP> ed, Atkinson W, Wolfe S, Hamborsky J, McIntyre L (Eds), Public Health Foundation, Washington DC 2009.</div><div id=\"graphicVersion\">Graphic 58899 Version 8.0</div></div></div>"},"58901":{"type":"graphic_table","displayName":"Epistaxis management equipment list","title":"Epistaxis management equipment list","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Epistaxis management equipment list</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Equipment: </td> </tr> <tr> <td>Gloves, gown, mask, drapes</td> </tr> <tr> <td>Emesis basin</td> </tr> <tr> <td>Tongue depressors</td> </tr> <tr> <td>Cotton pledgets, cotton swabs, and sterile gauze</td> </tr> <tr> <td>Nasal speculum</td> </tr> <tr> <td>Bayonet forceps</td> </tr> <tr> <td>Frazier (or comparable) suction catheter</td> </tr> <tr> <td>Syringes (10 and 20 mL)</td> </tr> <tr> <td>Angiocatheter (22 gauge)</td> </tr> <tr> <td>Isotonic saline; sterile water</td> </tr> <tr> <td>Silver nitrate sticks</td> </tr> <tr> <td>Electrical cautery device</td> </tr> <tr> <td>Nasal tampons (eg, Merocel&#174;)</td> </tr> <tr> <td>Nasal balloon catheters (eg, RapidRhino&#174;)</td> </tr> <tr> <td>Foley catheter (12 French) and small c-clamp (eg, from nasogastric tube kit)</td> </tr> <tr> <td>Ribbon gauze</td> </tr> <tr> <td class=\"subtitle1_single\">Medications: </td> </tr> <tr> <td>Oxymetazoline</td> </tr> <tr> <td>Topical lidocaine (2 percent) or topical cocaine (4 percent)</td> </tr> <tr> <td>Topical antibiotic ointment</td> </tr> <tr> <td>Injectable lidocaine (1 or 2 percent) with epinephrine</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58901 Version 3.0</div></div></div>"},"58902":{"type":"graphic_diagnosticimage","displayName":"2D and M-mode parasternal short axis echo normal aortic root","title":"2D and M-mode echocardiographic images of the normal aortic root from the parasternal short axis position","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">2D and M-mode echocardiographic images of the normal aortic root from the parasternal short axis position</div><div class=\"cntnt\"><img style=\"width:472px; height:192px;\" src=\"images/CARD/58902_Mmodenormalaorticroot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The M-mode beam is directed through the two dimensional image of the aortic root at the base of the heart (panel A). The resulting M-mode echocardiogram (panel B) demonstrates normal systolic and diastolic motion patterns; the anterior excursion is over 14 mm and the diastolic posterior excursion mainly occurs early in diastole. The aortic (Ao) valve leaflets open as widely as the internal dimensions of the root permit and remain open throughout systole, creating a box-like configuration. The anterior motion of the root and the behavior of the valve are typical findings when the stroke volume is normal.</div><div class=\"graphic_footnotes\">PA: main pulmonary artery; LA: left atrium; RVOT: right ventricular outflow tract.</div><div id=\"graphicVersion\">Graphic 58902 Version 6.0</div></div></div>"},"58903":{"type":"graphic_figure","displayName":"Kaplan Meier curves in COPD","title":"Survival in COPD","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Survival in COPD</div><div class=\"cntnt\"><img style=\"width:355px; height:278px;\" src=\"images/PULM/58903_Kaplan_Meier_curves_in_COPD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier survival curves for nonhypercapnic patients (type 1), reversible hypercapnics (type 2.1), and chronic hypercapnic patients (type 2.2). Survival among type 2.2 patients was significantly worse (P&lt;0.05) by the Cox-Mantel test) than the other two groups. Percentages refer to proportion of patients who survived 5 years.</div><div class=\"graphic_reference\">Redrawn from Costello, R, Deegan, P, Fitzpatrick, M, McNicholas, WT, Am J Med 1997; 103:239.</div><div id=\"graphicVersion\">Graphic 58903 Version 1.0</div></div></div>"},"58904":{"type":"graphic_picture","displayName":"Birdshot choroidopathy","title":"Birdshot choroidopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Birdshot choroidopathy</div><div class=\"cntnt\"><img style=\"width:433px; height:322px;\" src=\"images/RHEUM/58904_Birdshot_choroidopathy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple round chorioretinal lesions characteristic of a rare form of uveitis known as birdshot choroidopathy.</div><div class=\"graphic_reference\">Courtesy of James T Rosenbaum.</div><div id=\"graphicVersion\">Graphic 58904 Version 1.0</div></div></div>"},"58905":{"type":"graphic_table","displayName":"Anthrax PEP","title":"Oral postexposure prophylaxis for anthrax*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral postexposure prophylaxis for anthrax*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Nonpregnant adults</td> <td class=\"subtitle1\">Pregnant, postpartum, and lactating&nbsp;women</td> <td class=\"subtitle1\">Children and adolescents<br /> (age &#8805;1 month through 17 years)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">For all strains, regardless of penicillin susceptibility or if susceptibility is unknown:</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Preferred:</td> </tr> <tr> <td class=\"indent2\">Ciprofloxacin 500 mg every 12 hours <strong>OR</strong></td> <td>Ciprofloxacin 500 mg every 12 hours</td> <td>Ciprofloxacin 30 mg/kg per day divided every 12 hours, not to exceed 500 mg per dose <strong>OR</strong></td> </tr> <tr> <td class=\"indent2\">Doxycycline 100 mg every 12 hours</td> <td>&nbsp;</td> <td>Doxycycline<sup>&#182; </sup> <ul class=\"decimal_heading\"> <li>&#60;45 kg: 4.4 mg/kg per day divided every 12 hours, not to exceed 100 mg per dose </li> <li>&#8805;45 kg: 100 mg every 12 hours </li> </ul> </td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Alternatives if preferred agent(s) are unavailable, in order of preference:</td> </tr> <tr> <td class=\"indent2\">Levofloxacin 750 mg every 24 hours <strong>OR</strong></td> <td>Clindamycin 600 mg every 8 hours <strong>OR</strong></td> <td>Clindamycin 30 mg/kg per day divided every 8 hours, not to exceed 600 mg per dose <strong>OR</strong></td> </tr> <tr> <td class=\"indent2\">Moxifloxacin 400 mg every 24 hours <strong>OR</strong></td> <td>Doxycycline 100 mg every 12 hours</td> <td>Levofloxacin<sup>&#916; </sup> <ul class=\"decimal_heading\"> <li>&#60;50 kg: 16 mg/kg per day divided every 12 hours, not to exceed 250 mg per dose </li> <li>&#8805;50 kg: 500 mg every 24 hours </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Clindamycin 600 mg every 8 hours</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Alternatives for penicillin-susceptible strains (MIC &#60;0.125 mcg/mL):</td> </tr> <tr> <td class=\"indent2\">Amoxicillin 1 g every 8 hours<sup>&#9674;</sup><strong> OR</strong></td> <td>Amoxicillin 1 g every 8 hours<sup>&#9674;</sup> <strong>OR</strong></td> <td>Amoxicillin 75 mg/kg per day divided every 8 hours, not to exceed 1 g/dose<sup>&#9674;</sup> <strong>OR</strong></td> </tr> <tr> <td class=\"indent2\">Penicillin V potassium 500 mg every 6 hours<sup>&#9674;</sup></td> <td>Penicillin V potassium 500 mg every 6 hours<sup>&#9674;</sup></td> <td>Penicillin V potassium 50 to 75 mg/kg per day divided every 6 to 8 hours not to exceed 500 mg per dose<sup>&#9674;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">PEP is started as soon as possible for suspected aerosolized exposure to <EM>Bacillus anthracis</EM>, pending risk assessment. All patients who meet criteria for receiving PEP should also receive three doses of anthrax vaccine adsorbed by subcutaneous administration at zero, two, and four weeks. Recommendations for PEP regimens are based on the susceptibilities of <EM>B. anthracis</EM> isolated during the 2001 bioterrorism event in the United States. In the setting of another bioterrorism event, susceptibilities must be rechecked and antimicrobial therapy modified accordingly. The duration of therapy for PEP is 60 days. Refer to the UpToDate topic on prevention of anthrax for additional details.</div><div class=\"graphic_footnotes\">MIC: minimum inhibitory concentration; PEP: postexposure prophylaxis.<br />* The doses recommended above are intended for patients with normal renal function; the doses of some of these agents must be adjusted in patients with renal insufficiency.<br />¶&nbsp;A single 14-day course of doxycycline is not routinely associated with tooth staining, but some degree of staining is likely with a prolonged treatment course of up to 60 days in children &lt;8 years of age.<br />Δ Safety data for levofloxacin are limited to 14 days for duration of therapy in children and 30 days in adults.<br />◊&nbsp;Be aware of the possibility of emergence of penicillin resistance during monotherapy with amoxicillin or penicillin.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Hendricks KA, Wright ME, Shadomy SV, et al. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis 2014; 20.</LI>&#xD;&#xA;<LI>Meaney-Delman D, Zotti ME, Creanga AA, et al. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. Emerg Infect Dis 2014; 20.</LI>&#xD;&#xA;<LI>Bradley JS, Peacock G, Krug SE, et al. Pediatric anthrax clinical management. Pediatrics 2014; 133:e1411.</LI></OL></div><div id=\"graphicVersion\">Graphic 58905 Version 5.0</div></div></div>"},"58907":{"type":"graphic_figure","displayName":"Homeostenosis","title":"Homeostenosis","html":"<div class=\"graphic\"><div style=\"width: 578px\" class=\"figure\"><div class=\"ttl\">Homeostenosis</div><div class=\"cntnt\"><img style=\"width:558px; height:272px;\" src=\"images/PC/58907_Homeostenosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Based on information from: Taffet GE. Physiology of aging. In: Cassel CK, Leipzig RM, Cohen HJ, et al [eds]. Geriatric Medicine: An Evidence-Based Approach, 4th ed. New York, Springer, 2003.</div><div id=\"graphicVersion\">Graphic 58907 Version 9.0</div></div></div>"},"58908":{"type":"graphic_table","displayName":"Causes of false-negative TST","title":"Potential causes of false-negative tuberculin tests","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential causes of false-negative tuberculin tests</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Technical (potentially correctable)</td> </tr> <tr> <td class=\"sublist2_start\">Tuberculin material:</td> </tr> <tr> <td class=\"sublist2\">Improper storage (exposure to light or heat)</td> </tr> <tr> <td class=\"sublist2\">Contamination, improper dilution, or chemical denaturation</td> </tr> <tr> <td class=\"sublist2_start\">Administration:</td> </tr> <tr> <td class=\"sublist2\">Injection of too little tuberculin or too deeply (should be intradermal)</td> </tr> <tr> <td class=\"sublist2\">Administration more than 20 minutes after drawing up into the syringe</td> </tr> <tr> <td class=\"sublist2_start\">Reading:</td> </tr> <tr> <td class=\"sublist2\">Inexperienced or biased reader</td> </tr> <tr> <td class=\"sublist2\">Error in recording</td> </tr> <tr> <td class=\"subtitle1_single\">Biologic (not correctable)</td> </tr> <tr> <td class=\"sublist2_start\">Infections:</td> </tr> <tr> <td class=\"sublist2\">Active tuberculosis (especially if advanced)</td> </tr> <tr> <td class=\"sublist2\">Other bacterial infection (typhoid fever, brucellosis, typhus, leprosy, pertussis)</td> </tr> <tr> <td class=\"sublist2\">HIV infection (especially if CD4 count &#60;200)</td> </tr> <tr> <td class=\"sublist2\">Other viral infection (measles, mumps, varicella)</td> </tr> <tr> <td class=\"sublist2\">Fungal infection (South American blastomycosis)</td> </tr> <tr> <td class=\"indent1\">Recent live-virus vaccination (measles, mumps, polio)</td> </tr> <tr> <td class=\"indent1\">Immunosuppressive drugs (corticosteroids, tumor necrosis factor inhibitors, and others)</td> </tr> <tr> <td class=\"indent1\">Metabolic disease (chronic renal failure, severe malnutrition, stress [surgery, burns])</td> </tr> <tr> <td class=\"indent1\">Diseases of lymphoid organs (lymphoma, chronic lymphocytic leukemia, sarcoidosis)</td> </tr> <tr> <td class=\"indent1\">Age (infants &#60;6 months, older adults)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58908 Version 9.0</div></div></div>"},"58910":{"type":"graphic_table","displayName":"Diagnosis cardiac sarcoidosis","title":"Guidelines for the diagnosis of cardiac sarcoidosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for the diagnosis of cardiac sarcoidosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Histologic diagnosis</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Endomyocardial biopsy demonstrating noncaseating epithelioid granulomas</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Clinical diagnosis</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Among patients with a histologic diagnosis of\nextracardiac sarcoidosis, cardiac sarcoidosis should be suspected when\ncriterion \"a\" and at least one of criteria \"b\" to \"e\" is present in\npatients in whom other causes such as hypertension and coronary heart\ndisease have been excluded:</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">a. Complete right bundle branch block, AV block, ventricular tachycardia,\nventricular premature beats or pathologic Q wave or ST-T changes on the\nelectrocardiogram</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">b. Abnormal wall motion, regional wall thickening, or left ventricular dilation</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">c. Perfusion defect on myocardial perfusion imaging or abnormal\naccumulation of 67-Gallium citrate or 99mTc-PYP myocardial scintigraphy</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">d. Abnormal intracardiac pressure, low cardiac, or abnormal wall motion or reduced ejection fraction of the left ventricle</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">e. On endomyocardial biopsy, interstitial fibrosis or more than moderate\ncellular infiltration, even if the findings are nonspecific</td>\n\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Hiraga H, Yuwai K, Hiroe M, et al. Guidelines for the diagnosis of cardiac sarcoidosis: Study Report of Diffuse Pulmonary Diseases. The Japanese Ministry of Health and Welfare 1993; p. 23.</div><div id=\"graphicVersion\">Graphic 58910 Version 2.0</div></div></div>"},"58911":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound bilateral renal agenesis","title":"Prenatal ultrasound bilateral renal agenesis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound bilateral renal agenesis</div><div class=\"cntnt\"><img style=\"width:432px; height:274px;\" src=\"images/OBGYN/58911_Bilateral_renal_genesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Neither kidney is visualized.</div><div class=\"graphic_footnotes\">RT: right; LT: left.</div><div class=\"graphic_reference\">Courtesy of Tulin Ozcan, MD.</div><div id=\"graphicVersion\">Graphic 58911 Version 3.0</div></div></div>"},"58913":{"type":"graphic_table","displayName":"Bacterial tracheitis treatment","title":"Suggested intravenous antimicrobial treatment regimens for bacterial tracheitis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested intravenous antimicrobial treatment regimens for bacterial tracheitis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">For patients without hypersensitivity to penicillin or cephalosporin</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\"> <p>Vancomycin*<sup>&#182;</sup></p> <strong>OR</strong></td> <td>40 to 60 mg/kg per day in three to four divided doses</td> </tr> <tr> <td>Maximum daily dose 4 g</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Clindamycin </td> <td>40 mg/kg per day in three divided doses</td> </tr> <tr> <td>Maximum daily dose 2.7 g</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong><span class=\"red\">PLUS</span></strong></td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\"> <p>Ceftriaxone<sup>&#916;</sup></p> <strong>OR</strong></td> <td>50 to 100 mg/kg per day once daily or in two divided doses</td> </tr> <tr> <td>Maximum daily dose 2 g</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\"> <p>Cefotaxime<sup>&#182;</sup><sup>&#916;</sup></p> <strong>OR</strong></td> <td>150 to 200 mg/kg per day in four divided doses</td> </tr> <tr> <td>Maximum daily dose 10 g</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Ampicillin-sulbactam<sup>&#182;</sup></td> <td>150 to 200 mg/kg (of ampicillin component) per day in four divided doses</td> </tr> <tr class=\"divider_bottom\"> <td>Maximum daily dose 8 g</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">For patients with potential severe hypersensitivity to beta-lactam antibiotics (eg, penicillin, cephalosporin) </td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\"> <p>Vancomycin*<sup>&#182;</sup></p> <p><strong>OR</strong></p> </td> <td>40 to 60 mg/kg per day in three to four divided doses</td> </tr> <tr> <td>Maximum daily dose 4 g</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Clindamycin </td> <td>40 mg/kg per day in three divided doses</td> </tr> <tr> <td>Maximum daily dose 2.7 g</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong><span class=\"red\">PLUS</span></strong> </td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\"> <p>Levofloxacin<sup>&#182;</sup></p> <strong>OR</strong></td> <td> <p>6 months to 5 years: 20 mg/kg per day in two divided doses</p> &#8805;5 years: 10 mg/kg once per day</td> </tr> <tr> <td>Maximum daily dose 500 mg</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Ciprofloxacin<sup>&#182;</sup></td> <td>20 to 30 mg/kg per day in two divided doses</td> </tr> <tr class=\"divider_bottom\"> <td>Maximum daily dose 800 mg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">For patients with nonanaphylactic hypersensitivity to penicillin and cephalosporin</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\"> <p>Vancomycin*<sup>&#182;</sup></p> <strong>OR</strong></td> <td>40 to 60 mg/kg per day in three to four divided doses</td> </tr> <tr> <td>Maximum daily dose 2 g</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Clindamycin </td> <td>40 mg/kg per day in three divided doses</td> </tr> <tr> <td>Maximum daily dose 2.7 g</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong><span class=\"red\">PLUS</span></strong></td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\"> <p>Aztreonam<sup>&#182;</sup></p> <strong>OR</strong></td> <td>90 to 120 mg/kg per day in three to four divided doses</td> </tr> <tr> <td>Maximum daily dose 8 g</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Meropenem<sup>&#182;</sup></td> <td>60 to 120 mg/kg per day in three divided doses</td> </tr> <tr> <td>Maximum daily dose 6 g</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Vancomycin is indicated in patients with moderate to severe sepsis, patients who may have concomitant meningitis, and patients from areas with an increased prevalence of clindamycin-resistant and/or methicillin-resistant Staphylococcus aureus isolates. Trough levels of 15-20 mcg/mL are suggested for severe infections.<br />¶ Dosage modification for renal insufficiency is necessary. See drug information topic.<br />Δ A third-generation cephalosporin (ceftriaxone or cefotaxime) is preferred to ampicillin sulbactam.</div><div id=\"graphicVersion\">Graphic 58913 Version 3.0</div></div></div>"},"58915":{"type":"graphic_figure","displayName":"Electrocautery eso rings","title":"Electrocautery incision of a lower esophageal ring","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electrocautery incision of a lower esophageal ring</div><div class=\"cntnt\"><img style=\"width:286px; height:347px;\" src=\"images/GAST/58915_Electrocautery_eso_rings.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocautery incision of lower esophageal ring using a needle knife papillotome. The ring is splayed by incising in four quadrants starting from the luminal edge of the ring toward the esophageal wall for seven-eighths of the ring thickness.</div><div class=\"graphic_reference\">Adapted from Burdick, JS, Venu, RP, Hogan, WJ. Gastrointest Endosc 1993; 39:616.</div><div id=\"graphicVersion\">Graphic 58915 Version 2.0</div></div></div>"},"58920":{"type":"graphic_table","displayName":"Nonorganic low back pain signs (Waddell)","title":"Nonorganic signs in low back pain (originally described by Waddell)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nonorganic&nbsp;signs in low back pain (originally described by Waddell)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Overreaction during physical examination</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Superficial or widespread tenderness</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Inconsistent supine and seated (distracted) straight leg raise test</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Unexplainable neurologic deficits</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Pain on simulated axial load (top of head pressure)</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=60028&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Non-organic_signs_Waddell.htm</title></head></div><div id=\"graphicVersion\">Graphic 58920 Version 2.0</div></div></div>"},"58921":{"type":"graphic_picture","displayName":"Isometric jaw forward thrust","title":"Isometric jaw forward thrust","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Isometric jaw forward thrust</div><div class=\"cntnt\"><img style=\"width:241px; height:361px;\" src=\"images/RHEUM/58921_Isometric_jaw_forward_thrus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The isometric jaw forward thrust exercise is performed by pushing the jaw forward against the hand, holding and then relaxing. This is repeated five times per session.</div><div class=\"graphic_reference\">Reproduced with permission from Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.</div><div id=\"graphicVersion\">Graphic 58921 Version 1.0</div></div></div>"},"58922":{"type":"graphic_table","displayName":"Approach to the treatment of vulvovaginal warts","title":"Approach to the treatment of vulvovaginal warts","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approach to the treatment of vulvovaginal warts</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Self-administered therapies (vulva)</td> </tr> <tr> <td class=\"indent1\">Podofilox 0.5 percent solution</td> </tr> <tr> <td class=\"indent1\">Imiquimod 5 percent cream</td> </tr> <tr> <td class=\"indent1\">Sinecatechins 15 percent ointment</td> </tr> <tr> <td class=\"subtitle1_single\">Provider-admininstered therapies (vulva)</td> </tr> <tr> <td class=\"subtitle2_single\">Without anesthesia</td> </tr> <tr> <td class=\"indent1\">Cryotherapy with liquid nitrogen or cryoprobe</td> </tr> <tr> <td class=\"indent1\">Podophyllin resin 10 to 25 percent in a compound tincture of benzoin</td> </tr> <tr> <td class=\"indent1\">Trichloroacetic acid or bichloroacetic acid 80 to 90 percent</td> </tr> <tr> <td class=\"subtitle2_single\">With anesthesia</td> </tr> <tr> <td class=\"indent1\">Surgical removal (sharp, electrocautery, curettage, laser)</td> </tr> <tr> <td class=\"subtitle1_single\">Therapies preferred for pregnant women (vulva)</td> </tr> <tr> <td class=\"subtitle2_single\">Without anesthesia</td> </tr> <tr> <td class=\"indent1\">Trichloroacetic acid or bichloroacetic acid 80 to 90 percent</td> </tr> <tr> <td class=\"indent1\">Cryotherapy with liquid nitrogen or cryoprobe</td> </tr> <tr> <td class=\"subtitle2_single\">With anesthesia</td> </tr> <tr> <td class=\"indent1\">Surgical removal (sharp, electrocautery, curettage, laser)</td> </tr> <tr> <td class=\"subtitle1_single\">Therapies preferred for treatment of vaginal warts</td> </tr> <tr> <td class=\"subtitle2_single\">Without anesthesia</td> </tr> <tr> <td class=\"indent1\">Cryotherapy with liquid nitrogen</td> </tr> <tr> <td class=\"indent1\">Trichloroacetic acid or bichloroacetic acid 80 to 90 percent</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58922 Version 3.0</div></div></div>"},"58923":{"type":"graphic_picture","displayName":"Seborrheic keratosis 3","title":"Seborrheic keratoses","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Seborrheic keratoses</div><div class=\"cntnt\"><img style=\"width:405px; height:332px;\" src=\"images/DERM/58923_Seborrheic_keratosis_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These &quot;stuck-on&quot; appearing lesions are most often confused with malignant melanoma.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58923 Version 3.0</div></div></div>"},"58924":{"type":"graphic_table","displayName":"Causes of fatty liver","title":"Causes of fatty liver according to size of fat deposits","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of fatty liver according to size of fat deposits</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Microvesicular fat</td>\n\n</tr>\n<tr>\n<td>Alcoholic foamy degeneration</td>\n\n</tr>\n<tr>\n<td>Acute fatty liver of pregnancy</td>\n\n</tr>\n<tr>\n<td>Reye's syndrome</td>\n\n</tr>\n<tr>\n<td>Valproic acid</td>\n\n</tr>\n<tr>\n<td>Tetracycline</td>\n\n</tr>\n<tr>\n<td>Jamaican vomiting sickness</td>\n\n</tr><tr><td class=\"subtitle1\">Macrovesicular fat</td></tr><tr><td>Alcohol</td></tr><tr><td>Malnutrition</td></tr><tr><td>Obesity</td></tr><tr><td>Diabetes mellitus</td></tr><tr><td>Corticosteroids</td></tr><tr><td>Total parenteral nutrition</td></tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 58924 Version 1.0</div></div></div>"},"58925":{"type":"graphic_picture","displayName":"Donovanosis","title":"Donovanosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Donovanosis</div><div class=\"cntnt\"><img style=\"width:250px; height:367px;\" src=\"images/ID/58925_Donovanosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous ulcerogranulomatous, friable lesions are visible in the inguinal area and on the scrotum in a patient with donovanosis.</div><div class=\"graphic_reference\">Courtesy of Lee T Nesbitt, Jr.; The Skin and Infection: A Color Atlas and Text, Sanders, CV, Nesbitt, LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 58925 Version 3.0</div></div></div>"},"58927":{"type":"graphic_figure","displayName":"Mechanism Bowtie atrophy","title":"Mechanism of Bowtie atrophy","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Mechanism of Bowtie atrophy</div><div class=\"cntnt\"><img style=\"width:525px; height:393px;\" src=\"images/NEURO/58927_Mechanism_Bowtie_atrophy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mechanism of &quot;bow-tie&quot; atrophy due to an optic tract lesion. Top: Following a chronic lesion (&quot;X&quot;) in the left optic tract, three groups of retinal ganglion cell fibers atrophy: A: those from the nasal half of the macula in the right eye; B, those from the nasal retina in the right eye; and C, those from the temporal retina of the left eye. A and B result in a bow-tie or band pattern of optic atrophy (white areas) in the right disc, and C result in temporal atrophy of the left disc (white area). Bottom: This pattern of optic atrophy is similar to that seen in homonymous hemianopic atrophy due to a congenital lesion of the geniculocalcarine pathway.</div><div class=\"graphic_reference\">Reprinted with permission from: Liu, GT, Volpe, NJ, Galetta, SL. Retrochiasm disorders. In: Neuro-ophthalmology. Diagnosis and Management, Liu, GT, Volpe, NJ, Galetta, SL (Eds), WB Saunders, Philadelphia, 2001. p. 300. Copyright &#169;2001 Elsevier.</div><div id=\"graphicVersion\">Graphic 58927 Version 1.0</div></div></div>"},"58931":{"type":"graphic_figure","displayName":"Unicornuate uterus","title":"Unicornuate uterus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Unicornuate uterus</div><div class=\"cntnt\"><img style=\"width:250px; height:296px;\" src=\"images/OBGYN/58931_Unicornuateuterus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 58931 Version 13.0</div></div></div>"},"58932":{"type":"graphic_diagnosticimage","displayName":"Retroperitoneal nodes CT","title":"Retroperitoneal lymphadenopathy in follicular non-Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retroperitoneal lymphadenopathy in follicular non-Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:380px; height:269px;\" src=\"images/HEME/58932_Retroperitoneal_nodes_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography of the abdomen at the level of the renal pelvis in a patient with extensive follicular non-Hodgkin lymphoma. There is massive enlargement of the retroperitoneal nodes (arrow), along with matted mesenteric nodes (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Arnold S Freedman, MD, Jonathan W Friedberg, MD, and Pam DePiro, MD.</div><div id=\"graphicVersion\">Graphic 58932 Version 4.0</div></div></div>"},"58934":{"type":"graphic_diagnosticimage","displayName":"Cryptogenic organizing pneumonia CXR II","title":"Cryptogenic organizing pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cryptogenic organizing pneumonia</div><div class=\"cntnt\"><img style=\"width:332px; height:282px;\" src=\"images/PULM/58934_BOOP_PA_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thirty-seven year old woman with a two week history of cough, dyspnea with exertion, fatigue, and fever. She developed respiratory failure and was hospitalized. Posteroanterior roentgenogram reveals bilateral patchy opacities and volume loss. An open lung biopsy confirmed an extensive&nbsp;COP pattern. There was complete resolution following&nbsp;glucocorticoid therapy without recurrence after&nbsp;glucocorticoids were discontinued.</div><div class=\"graphic_footnotes\">COP: cryptogenic organizing pneumonia.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King Jr, MD.</div><div id=\"graphicVersion\">Graphic 58934 Version 4.0</div></div></div>"},"58936":{"type":"graphic_diagnosticimage","displayName":"Tricuspid regurgitation CW Doppler","title":"Tricuspid regurgitation CW Doppler","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Tricuspid regurgitation CW Doppler</div><div class=\"cntnt\"><img style=\"width:572px; height:431px;\" src=\"images/CARD/58936_Tricus_regurg_CW_Doppler_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This echocardiographic still frame demonstrates Doppler interrogation of tricuspid insufficiency to estimate the gradient between the right ventricle and the right atrium. The continuous wave Doppler beam, represented by the dotted cursor line, is directed into the tricuspid insufficiency jet in this parasternal long axis inflow window. Using the modified Bernoulli equation (pressure = 4 [velocity]<sup>2</sup>), the Doppler velocity of 3.3 m/sec translates into a gradient between the right atrium and right ventricle of 44 mmHg; adding the estimated right atrial pressure of 10 mmHg, the estimated right ventricular pressure in this patient is 54 mmHg.</div><div id=\"graphicVersion\">Graphic 58936 Version 2.0</div></div></div>"},"58939":{"type":"graphic_movie","displayName":"Optical forceps extraction","title":"Optical forceps","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Optical forceps</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/58939_opticalforcepsfbeconv.mp4\" style=\"width:352px;height:256px\"></div><img style=\"width:323px; height:225px;\" src=\"images/CARD/58939_opticalforcepsfbe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Removal of a peanut.</div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 58939 Version 2.0</div></div></div>"},"58941":{"type":"graphic_table","displayName":"Disorders that can mimic PD","title":"Disorders that can mimic Parkinson disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders that can mimic Parkinson disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Neurodegenerative causes </td> </tr> <tr> <td>Alzheimer disease</td> </tr> <tr> <td>Corticobasal degeneration</td> </tr> <tr> <td>Dementia with Lewy bodies</td> </tr> <tr> <td>Frontotemporal dementia</td> </tr> <tr> <td>Huntington disease</td> </tr> <tr> <td>Multiple system atrophy</td> </tr> <tr> <td>Parkinsonism-dementia-ALS complex of Guam</td> </tr> <tr> <td>Progressive supranuclear palsy</td> </tr> <tr> <td>Spinocerebellar ataxias</td> </tr> <tr> <td class=\"subtitle1_single\">Symptomatic </td> </tr> <tr> <td>Drug-induced (neuroleptics, other dopamine receptor antagonists)</td> </tr> <tr> <td>Infectious (post-encephalitic, Creutzfeldt-Jakob disease)</td> </tr> <tr> <td>Metabolic (Wilson disease, neurodegeneration with brain iron accumulation, hepatocerebral degeneration, parathyroid disorders)</td> </tr> <tr> <td>Neoplastic</td> </tr> <tr> <td>Post-traumatic</td> </tr> <tr> <td>Toxic (carbon monoxide, manganese, MPTP)</td> </tr> <tr> <td>Vascular</td> </tr> <tr> <td class=\"subtitle1_single\">Other </td> </tr> <tr> <td>Essential tremor</td> </tr> <tr> <td>Normal pressure hydrocephalus</td> </tr> <tr> <td>SWEDD (Scans Without Evidence of Dopaminergic Deficit): patients with relatively isolated upper extremity tremor resembling early Parkinson&nbsp;disease who <span style=\"font-family: 'verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: 'times new roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'times new roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: en-us; mso-fareast-language: en-us; mso-bidi-language: ar-sa;\">lack evidence of nigrostriatal dopamine deficiency on dopamine transporter imaging</span></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58941 Version 2.0</div></div></div>"},"58942":{"type":"graphic_figure","displayName":"Doppler echo for LV pressure","title":"Left ventricular filling pressures in hypertrophic cardiomyopathy measured by tissue Doppler echocardiography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left ventricular filling pressures in hypertrophic cardiomyopathy measured by tissue Doppler echocardiography</div><div class=\"cntnt\"><img style=\"width:432px; height:415px;\" src=\"images/CARD/58942_DopplerechoforLVpressur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left ventricular filling pressures can be estimated using transmitral velocity (panel A), mitral annular velocity (panel B), and the flow propagation velocity (panel C), which is the slope of the linear component of the color border produced by the propagation of early filling peak velocity (E) into the left ventricle, past the mitral valve. In this patient, the early diastolic peak filling velocity across the mitral valve (E) is about 100 cm/sec and lower than late diastolic peak filling velocity (panel A). The early diastolic peak filling velocity across the mitral annulus (Ea) is 6 cm/sec and is also lower than the late peak filling velocity (Aa). The ratio of E/Ea (16.7) correlates with the left ventricular filling pressure (Pre A) of 24 mmHg obtained at the time of cardiac catheterization (panel D). EDP indicates LVEDP; Pre-A, left ventricular filling pressure prior to atrial contraction.</div><div class=\"graphic_footnotes\">EDP: LVEDP; LVEDP: left ventricular end-diastolic pressure;&nbsp;Pre-A: left ventricular filling pressure prior to atrial contraction.</div><div class=\"graphic_reference\">Reproduced with permission from Nagueh MD, Lakkis NM, Middleton KJ, et al. Circulation 1999; 99:254.</div><div id=\"graphicVersion\">Graphic 58942 Version 2.0</div></div></div>"},"58943":{"type":"graphic_picture","displayName":"Bladder exstrophy","title":"Exstrophy in a male newborn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Exstrophy in a male newborn</div><div class=\"cntnt\"><img style=\"width:288px; height:346px;\" src=\"images/PEDS/58943_Bladder_exstrophy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Laurence Baskin, MD.</div><div id=\"graphicVersion\">Graphic 58943 Version 3.0</div></div></div>"},"58944":{"type":"graphic_picture","displayName":"HSV gingivostomatitis","title":"Primary herpes simplex virus gingivostomatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary herpes simplex virus gingivostomatitis</div><div class=\"cntnt\"><img style=\"width:350px; height:220px;\" src=\"images/PEDS/58944_HSV_gingivostomatitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Martha Ann Keels, DDS, PhD.</div><div id=\"graphicVersion\">Graphic 58944 Version 1.0</div></div></div>"},"58945":{"type":"graphic_figure","displayName":"ACL graft sites PI","title":"Grafts used to replace torn anterior cruciate ligament","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Grafts used to replace torn anterior cruciate ligament</div><div class=\"cntnt\"><img style=\"width:501px; height:429px;\" src=\"images/PI/58945_ACL_graft_sites_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 58945 Version 4.0</div></div></div>"},"58947":{"type":"graphic_figure","displayName":"Myomectomy with hysteroscope","title":"Myomectomy with hysteroscope","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Myomectomy with hysteroscope</div><div class=\"cntnt\"><img style=\"width:507px; height:232px;\" src=\"images/OBGYN/58947_Myomectomy_with_hysteroscop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Resection of uterine leiomyoma.</div><div id=\"graphicVersion\">Graphic 58947 Version 2.0</div></div></div>"},"58949":{"type":"graphic_figure","displayName":"Global reported measles cases and vaccine coverage 1980-2009","title":"Measles global annual reported cases and measles-containing vaccine coverage, 1980-2009","html":"<div class=\"graphic\"><div style=\"width: 644px\" class=\"figure\"><div class=\"ttl\">Measles global annual reported cases and measles-containing vaccine coverage, 1980-2009</div><div class=\"cntnt\"><img style=\"width:624px; height:405px;\" src=\"images/ID/58949_Glob_report_measles_cases.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: World Health Organization. WHO/IVB Database, 2010. Available at: http://www.who.int/immunization_monitoring/diseases/measles/en/index.html.</div><div id=\"graphicVersion\">Graphic 58949 Version 1.0</div></div></div>"},"58951":{"type":"graphic_table","displayName":"Dry powder inhaler technique in children","title":"Techniques for use of various dry powder inhalers in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Techniques for use of various dry powder inhalers in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Diskhaler</td> </tr> <tr> <td class=\"indent1\">Remove mouthpiece cover and pull tray out from device.</td> </tr> <tr> <td class=\"indent1\">Place disk on wheel with numbers facing up.</td> </tr> <tr> <td class=\"indent1\">Rotate disk by sliding tray out and in.</td> </tr> <tr> <td class=\"indent1\">Lift back of lid until fully upright so that needle pierces both sides of blister.</td> </tr> <tr> <td class=\"indent1\">Keep device level while inhaling dose with a rapid and steady flow.</td> </tr> <tr> <td class=\"indent1\">Breathe in rapidly and steadily, as deeply as possible; hold breath for 5 to 10 seconds.</td> </tr> <tr> <td class=\"indent1\">Remove device from mouth and exhale outside device.</td> </tr> <tr> <td class=\"indent1\">Brush off any powder remaining within device once every week; store device in cool, dry place.</td> </tr> <tr> <td class=\"subtitle1_single\">Diskus</td> </tr> <tr> <td class=\"indent1\">Open the device and slide the lever until it clicks.</td> </tr> <tr> <td class=\"indent1\">Keep device level while inhaling dose.</td> </tr> <tr> <td class=\"indent1\">Breathe in rapidly and steadily, as deeply as possible; hold breath for 5 to 10 seconds.</td> </tr> <tr> <td class=\"indent1\">Remove device from mouth and exhale outside device; store device in cool, dry place.</td> </tr> <tr> <td class=\"subtitle1_single\">Flexhaler</td> </tr> <tr> <td class=\"indent1\">Prime the inhaler: This is done only with the initial dose. Holding the inhaler in the upright position, twist the brown grip as far as it will go in one direction, then twist it all the way back in the other direction. A click will be heard during one of the turns. This step should be repeated to complete the priming of the device.</td> </tr> <tr> <td class=\"indent1\">Load a dose: Holding the inhaler in an upright position, twist the brown grip as far as it will go in one direction, then twist it all the way back in the other direction.</td> </tr> <tr> <td class=\"indent1\">Inhale the dose: Turn away from the inhaler and breathe out. Then place the mouthpiece in your mouth, close your lips, and inhale deeply.</td> </tr> <tr> <td class=\"subtitle1_single\">Twisthaler</td> </tr> <tr> <td class=\"indent1\">Hold the inhaler straight up with the pink portion (the base) on the bottom.</td> </tr> <tr> <td class=\"indent1\">Remove the cap while it is in the upright position to make sure you get the right amount of medicine with each dose.</td> </tr> <tr> <td class=\"indent1\">Hold the pink base and twist the cap in a counter-clockwise direction to remove it.</td> </tr> <tr> <td class=\"indent1\">As you lift off the cap, the dose counter on the base will count down by one. This action loads the medicine that you are now ready to inhale.</td> </tr> <tr> <td class=\"indent1\">Make sure the indented arrow located on the white portion (directly above the pink base) is pointing to the dose counter.</td> </tr> <tr> <td class=\"indent1\">Breathe out normally - do not exhale into the device.</td> </tr> <tr> <td class=\"indent1\">Place the mouthpiece into your mouth, with the mouthpiece facing towards you, and close your lips tightly around it.</td> </tr> <tr> <td class=\"indent1\">Inhale dose with a rapid and steady flow while holding the Twisthaler horizontal.</td> </tr> <tr> <td class=\"indent1\">Remove the mouthpiece from your mouth and hold your breath for 5 to 10 seconds (or as long as you comfortably can).</td> </tr> <tr> <td class=\"indent1\">When you exhale, be sure that you are not exhaling into the device.</td> </tr> <tr> <td class=\"indent1\">Immediately replace the cap and turn in a clockwise direction as you gently press down until you hear a click.</td> </tr> <tr> <td class=\"indent1\">Firmly close the Twisthaler to assure that your next dose is properly loaded.</td> </tr> <tr> <td class=\"indent1\">Be sure that the arrow is in line with the dose-counter window.</td> </tr> <tr> <td class=\"indent1\">Store device in cool dry place.</td> </tr> <tr> <td class=\"indent1\">The dose counter displays the number of doses remaining. When the unit reads 01, this indicates the last remaining dose. When the counter reads 00, the unit must then be discarded.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58951 Version 6.0</div></div></div>"},"58952":{"type":"graphic_figure","displayName":"Model for rapid response systems","title":"Model for rapid response systems","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Model for rapid response systems</div><div class=\"cntnt\"><img style=\"width:532px; height:534px;\" src=\"images/PC/58952_Mod_ration_rapid_resp_syst.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rapid response systems seek to identify warning signs of clinical decompensation and prevent cardiac arrest.</div><div class=\"graphic_reference\">References:<br> <ol> <li>Sprung CL, et al. Evaluation of triage decisions for intensive care admission. Critical Care Medicine 1999; 27:1073. </li> <li>Hodgetts TJ, et al. Incidence, location and reasons for avoidable in-hospital cardiac arrest in a district general hospital. Resuscitation 2002; 54:115. </li> </ol></div><div id=\"graphicVersion\">Graphic 58952 Version 1.0</div></div></div>"},"58954":{"type":"graphic_figure","displayName":"Elbow joint PI","title":"Elbow joint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Elbow joint</div><div class=\"cntnt\"><img style=\"width:420px; height:540px;\" src=\"images/PI/58954_Elbow_joint_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The elbow is made up of 3 bones (the radius, ulna, and humerus).</div><div id=\"graphicVersion\">Graphic 58954 Version 1.0</div></div></div>"},"58955":{"type":"graphic_diagnosticimage","displayName":"Septic emboli MRSA osteo","title":"Pulmonary septic emboli in community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) osteomyelitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary septic emboli in community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) osteomyelitis</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/PEDS/58955_Septic_emboli_MRSA_osteo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography of the chest in a 9-year-old with CA-MRSA osteomyelitis of the tibia demonstrating multiple nodules consistent with pulmonary emboli.</div><div class=\"graphic_reference\">Courtesy of Sheldon L Kaplan, MD. Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 58955 Version 2.0</div></div></div>"},"58956":{"type":"graphic_table","displayName":"Desquamative interstitial pneum","title":"Causes of desquamative interstitial pneumonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of desquamative interstitial pneumonia</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Idiopathic DIP</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">DIP-like reaction (often associated with other specific histologic findings)</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Respiratory bronchiolitis</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\"> Connective tissue diseases</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Eosinophilic granuloma</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Asbestosis</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Hard-metal pneumoconiosis (cobalt)</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\"> Gaucher's disease </td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Neimann-Pick disease</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Hermansky-Pudlak syndrome</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\"> Drugs</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist2\">Nitrofurantoin</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Amiodarone</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 58956 Version 1.0</div></div></div>"},"58957":{"type":"graphic_picture","displayName":"MDI spacers","title":"Spacers used with metered dose inhalers","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spacers used with metered dose inhalers</div><div class=\"cntnt\"><img style=\"width:220px; height:490px;\" src=\"images/PULM/58957_MDI_spacers_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) AeroChamber, (B) AeroChamber with mask, and (C) InspirEase. These devices can make it easier to use a metered dose inhaler and decrease the amount of drug that lands in the mouth and throat.</div><div id=\"graphicVersion\">Graphic 58957 Version 4.0</div></div></div>"},"58958":{"type":"graphic_figure","displayName":"Tracheostomy button","title":"Tracheostomy button","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tracheostomy button</div><div class=\"cntnt\"><img style=\"width:446px; height:300px;\" src=\"images/PULM/58958_Olympic_trach_button.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Figure A shows&nbsp;a tracheostomy button when properly inserted into the upper airway. Figure B shows that when the inner cannula is withdrawn an adapter may be attached to permit suctioning or assisted ventilation with an Ambu bag.</div><div id=\"graphicVersion\">Graphic 58958 Version 2.0</div></div></div>"},"58961":{"type":"graphic_figure","displayName":"Internal podalic version","title":"Internal podalic version","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Internal podalic version</div><div class=\"cntnt\"><img style=\"width:483px; height:500px;\" src=\"images/OBGYN/58961_Internal_podalic_version.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified&nbsp;from: Pritchard JA, MacDonald PC. Williams Obstetrics, 16th Edition, Appleton-Century-Crofts, New York 1980.</div><div id=\"graphicVersion\">Graphic 58961 Version 2.0</div></div></div>"},"58962":{"type":"graphic_figure","displayName":"Stage 1 prolapse","title":"Stage I posterior vaginal wall prolapse","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stage I posterior vaginal wall prolapse</div><div class=\"cntnt\"><img style=\"width:447px; height:308px;\" src=\"images/OBGYN/58962_Stage_1_prolapse.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When the levator ani no longer holds the vagina closed, the anterior wall pressure no longer balances the posterior wall pressure. Stress is placed on the connective tissue support structures, as the pressure on the rectum is not counterbalanced. A rectocele may subsequently develop (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright ©2007 Elsevier.</div><div id=\"graphicVersion\">Graphic 58962 Version 2.0</div></div></div>"},"58963":{"type":"graphic_figure","displayName":"EMIAT beta blocker amiodarone","title":"Possible interaction between beta blockers and amiodarone after acute MI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Possible interaction between beta blockers and amiodarone after acute MI</div><div class=\"cntnt\"><img style=\"width:434px; height:224px;\" src=\"images/CARD/58963_EMIAT_beta_blocker_amiodaro.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An intention to treat analysis of the two-year total cardiac mortality in 1486 patients with a recent acute myocardial infarction (MI) and a left ventricular ejection fraction below 40 percent in the EMIAT trial. Those receiving a beta blocker with amiodarone had a trend toward a better outcome compared to patients receiving amiodarone alone (P = 0.06). No effect of concomitant therapy with digoxin or ACE inhibitors was noted.</div><div class=\"graphic_reference\">Data from Kennedy HL. Am J Cardiol 1997; 80:1208.</div><div id=\"graphicVersion\">Graphic 58963 Version 3.0</div></div></div>"},"58964":{"type":"graphic_diagnosticimage","displayName":"MRI cavernous vascular malformation","title":"Brain MRI of cavernous vascular malformation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brain MRI of cavernous vascular malformation</div><div class=\"cntnt\"><img style=\"width:282px; height:361px;\" src=\"images/PEDS/58964_Cavernous_vasc_malformation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T2 MRI (axial view) of a focal right temporal cavernous malformation with characteristic findings of acute and chronic hemorrhage (arrow) in a five-year-old boy with seizures.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 58964 Version 4.0</div></div></div>"},"58965":{"type":"graphic_picture","displayName":"Tinea versicolor potassium hydroxide","title":"Microscopic tinea versicolor","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Microscopic tinea versicolor</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/PC/58965_TnvrsclrKOH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Potassium hydroxide preparation of tinea versicolor demonstrating short hyphae and yeast cells.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 58965 Version 4.0</div></div></div>"},"58967":{"type":"graphic_movie","displayName":"Membranous VSD subcostal coronal 2D","title":"Membranous VSD subcostal coronal 2D","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Membranous VSD subcostal coronal 2D</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/58967_MembrVSDsubcostmovie.mp4\" style=\"width:496px;height:384px\"></div><img style=\"width:504px; height:396px;\" src=\"images/CARD/58967_MembrVSDsubcostposter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subcostal coronal movie clip showing the membranous ventricular septal defect (VSD) and adjacent structures. The atrioventricular valves can be seen in motion in their respective ventricles.</div><div class=\"graphic_footnotes\">AO: aorta; LV: left ventricle; RV: right ventricle; LA: left atrium; RA: right atrium; IVS: intact trabecular portion of the intraventricular septum; arrow: VSD.</div><div id=\"graphicVersion\">Graphic 58967 Version 2.0</div></div></div>"},"58969":{"type":"graphic_picture","displayName":"Erythema multiforme tongue","title":"Erythema multiforme","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema multiforme</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/58969_Erythema_multiforme_tongue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hemorrhagic crusting and mucosal erosions involving the lips and tongue in a patient with erythema multiforme.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 58969 Version 5.0</div></div></div>"},"58970":{"type":"graphic_figure","displayName":"Testosterone level in obesity","title":"Serum testosterone concentrations in obesity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Serum testosterone concentrations in obesity</div><div class=\"cntnt\"><img style=\"width:450px; height:320px;\" src=\"images/ENDO/58970_Testosterone_level_in_obesi.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Obesity is characterized by a reduction in serum total testosterone concentration (left panel) but a normal serum free testosterone concentration (right panel) due to decreased SHBG.</div><div class=\"graphic_footnotes\">SHBG: sex hormone-binding globulin.</div><div class=\"graphic_reference\">Data from Glass AR, Swerdloff RS, Bray GA, et al. Low serum testosterone and sex-hormone-binding-globulin in massively obese men.&nbsp;J Clin Endocrinol Metab 1977; 45:1211.</div><div id=\"graphicVersion\">Graphic 58970 Version 4.0</div></div></div>"},"58973":{"type":"graphic_picture","displayName":"Hood silicone stent","title":"Hood silicone stent","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hood silicone stent</div><div class=\"cntnt\"><img style=\"width:364px; height:252px;\" src=\"images/PULM/58973_Hood_silicone_stent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Smooth-walled silicone Hood tracheobronchial stent with Y configuration.</div><div id=\"graphicVersion\">Graphic 58973 Version 2.0</div></div></div>"},"58974":{"type":"graphic_table","displayName":"Complement receptors: Ligands and functions","title":"Complement receptors: Ligands and functions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complement receptors: Ligands and functions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Receptor</td> <td class=\"subtitle1\">Major ligands</td> <td class=\"subtitle1\">Functions</td> </tr> <tr> <td>CR1</td> <td>C3b/C4b, C1q, MBL, ficolins</td> <td>Immune adherence; immune complex clearance; regulation of C3b/C4b</td> </tr> <tr> <td>CR2</td> <td>C3dg/iC3b</td> <td>B cell coreceptor; immune complex localization; EBV receptor</td> </tr> <tr> <td>CR3</td> <td>iC3b</td> <td>Phagocytosis</td> </tr> <tr> <td>CR4</td> <td>iC3b</td> <td>Phagocytosis</td> </tr> <tr> <td>C3aR</td> <td>C3a</td> <td>Cell activation; histamine release</td> </tr> <tr> <td>C5aR</td> <td>C5a</td> <td>Cell activation; histamine release; chemotaxis</td> </tr> <tr> <td>C1qR</td> <td>C1q</td> <td>Phagocytosis</td> </tr> <tr> <td>CRIg</td> <td>C3b/iC3b</td> <td>Phagocytosis; alternative pathway inhibitor</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CR: complement receptor; MBL: mannose-binding lectin; EBV: Epstein-Barr virus; CRIg: complement receptor of the immunoglobulin superfamily.</div><div id=\"graphicVersion\">Graphic 58974 Version 8.0</div></div></div>"},"58975":{"type":"graphic_diagnosticimage","displayName":"Patellar tendon tear","title":"Patellar tendon tear and avulsion fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patellar tendon tear and avulsion fracture</div><div class=\"cntnt\"><img style=\"width:303px; height:432px;\" src=\"images/RHEUM/58975_Patellar_tendon_tear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lateral radiograph of the knee demonstrates a high position of the patella (arrow) secondary to a torn patellar tendon. A small fragment of the inferior aspect of the patella (patellar avulsion fracture) is also noted (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.</div><div id=\"graphicVersion\">Graphic 58975 Version 2.0</div></div></div>"},"58977":{"type":"graphic_figure","displayName":"Hypercoagulability","title":"Hypercoagulability","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Hypercoagulability</div><div class=\"cntnt\"><img style=\"width:593px; height:273px;\" src=\"images/SURG/58977_Hypercoagulability.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Citrated rapid-TEG reflecting hypercoagulability. The red tracing indicates a normal study.<br> This study shows a shortened to normal ACT, R time, and K time, reflecting enzymatic hypercoagulability; high alpha angle, MA, and G, reflecting platelet hypercoagulability and/or excessive fibrin deposition; normal LY30. To distinguish the relative contribution of platelet hypercoagulability and excessive fibrin deposition, one would need to perform TEG platelet mapping or RoTEM&#174; fibrin function testing.</div><div class=\"graphic_footnotes\">R (reaction time): time from sample placement or activation until the tracing amplitude reaches 2 mm; K (clot formation time): time elapsed between the R-time and the point where the tracing amplitude reaches 20 mm; alpha angle: angle between the middle line of the tracing and a tangential line to the developing &quot;body&quot; of the tracing; MA (maximal amplitude): the maximal amplitude reached after clot initiation; G: a calculated measure of total clot strength based on amplitude; LY30: the amount of clot lysis detected 30 minutes after the maximal amplitute (MA) is reached; SP (split point): time from sample placement (or activation with an exogenous procoagulant) until the earliest detectable resistance.</div><div id=\"graphicVersion\">Graphic 58977 Version 3.0</div></div></div>"},"58978":{"type":"graphic_picture","displayName":"Moraxella catarrhalis in sputum ","title":"<em>Moraxella catarrhalis</em> in sputum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Moraxella catarrhalis</em> in sputum</div><div class=\"cntnt\"><img style=\"width:353px; height:240px;\" src=\"images/ID/58978_Moraxellasputum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of sputum (x1000) shows inflammatory cells and gram-negative diplococci. <EM>Moraxella</EM> (formerly <EM>Branhamella</EM>) <EM>catarrhalis </EM>grew from this patient's sputum. Although encountered less frequently, either <EM>Neisseria</EM> or <EM>Acinetobacter </EM>could have this appearance.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 58978 Version 3.0</div></div></div>"},"58981":{"type":"graphic_diagnosticimage","displayName":"Cervical disc herniation","title":"Flexion distraction injury","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Flexion distraction injury</div><div class=\"cntnt\"><img style=\"width:514px; height:565px;\" src=\"images/PEDS/58981_Cervical_disc_herniation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Lateral radiograph of a patient with flexion distraction injury resulting in acute disc herniation at C5-C6. Note the narrowed disc space and the distruption of the cervical spine alignment.<br />(B) MRI of the same patient demonstrating the cervical disc herniation.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Charles A Reitman, MD.</div><div id=\"graphicVersion\">Graphic 58981 Version 3.0</div></div></div>"},"58982":{"type":"graphic_table","displayName":"Ligaments of the elbow","title":"Ligaments of the elbow","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ligaments of the elbow</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Ligament</td> <td class=\"subtitle1\">Origin</td> <td class=\"subtitle1\">Insertion</td> <td class=\"subtitle1\">Function</td> </tr> <tr> <td>Ulnar collateral </td> <td>Medial epicondyle</td> <td>Sublime tubercle</td> <td>Medial stability</td> </tr> <tr> <td>Annular</td> <td>Ulnar notch</td> <td>Ulnar notch</td> <td>Maintains contact between proximal radius and ulna</td> </tr> <tr> <td>Radial collateral</td> <td>Lateral epicondyle</td> <td>Annular ligament</td> <td>Maintains radio-capitellar alignment</td> </tr> <tr> <td>Lateral ulnar collateral</td> <td>Lateral epicondyle (distal to radial collateral)</td> <td>Supinator tubercle of ulna </td> <td>Maintains lateral elbow stability</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 58982 Version 4.0</div></div></div>"},"58983":{"type":"graphic_diagnosticimage","displayName":"Infant humeral fracture","title":"9 week old with mid left humerus fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">9 week old with mid left humerus fracture</div><div class=\"cntnt\"><img style=\"width:318px; height:216px;\" src=\"images/PEDS/58983_Infant_humeral_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Rajvee Shah, MD.</div><div id=\"graphicVersion\">Graphic 58983 Version 2.0</div></div></div>"},"58984":{"type":"graphic_diagnosticimage","displayName":"Hysteroscopic microinsert HSG2","title":"Hysteroscopic sterilization microinsert: Hysterosalpingography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hysteroscopic sterilization microinsert: Hysterosalpingography</div><div class=\"cntnt\"><img style=\"width:357px; height:578px;\" src=\"images/OBGYN/58984_Hysterosc_microinsert.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Hysterosalpingogram scout film shows microinsert in expected location.<br> (B) During filling phase, contrast fills the uterus but does not extend out to the fallopian tubes.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 58984 Version 3.0</div></div></div>"},"58985":{"type":"graphic_figure","displayName":"MAZE III procedure","title":"MAZE III procedure","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">MAZE III procedure</div><div class=\"cntnt\"><img style=\"width:574px; height:454px;\" src=\"images/CARD/58985_MAZE_III_procedure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Modification of the posterior incisions to the vena cava and placement of the septal incision posterior to the orifice of the superior vena cava (SVC) are noted.</div><div class=\"graphic_footnotes\">CS: coronary sinus; FO: foramen ovale; IVC: inferior vena cava; LAA: left atrial appendage; MV: mitral valve; RAA: right atrial appendage; SAN: sinoatrial node; TV: tricuspid valve.</div><div class=\"graphic_reference\">Reproduced from: Cheng A, Shah A, Hogue CW. Cardiac electrophysiology: Diagnosis and treatment. In: Kaplan's Cardiac Anesthesia, 6th ed, Kaplan JA, Reich DL, Lake CL, Konstadt SN (Eds), Saunders, Philadelphia 2011. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 58985 Version 2.0</div></div></div>"},"58986":{"type":"graphic_diagnosticimage","displayName":"Distal type I endoleak","title":"Distal type I endoleak","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distal type I endoleak</div><div class=\"cntnt\"><img style=\"width:449px; height:603px;\" src=\"images/SURG/58986_Distal_type_I_endoleak.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distal type Ib endoleak noted (arrows) with poor apposition of the iliac limb to the vessel wall at the iliac bifurcation despite balloon angioplasty. Note a widely patent internal iliac artery.</div><div id=\"graphicVersion\">Graphic 58986 Version 3.0</div></div></div>"},"58987":{"type":"graphic_figure","displayName":"GH peaks adult stim tests","title":"Peak serum GH concentrations with arginine/GHRH","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Peak serum GH concentrations with arginine/GHRH</div><div class=\"cntnt\"><img style=\"width:545px; height:402px;\" src=\"images/ENDO/58987_GH_peaks_adult_stim_tests.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">GH&nbsp;concentrations in patients with&nbsp;MPHD and in age and gender-matched control subjects following the administration of a combination of arginine and GHRH. The median peak GH level in each group is denoted with a horizontal bar. The dashed lines and superscripts indicate diagnostic cut-points as follows: using (a)&nbsp;a maximum response of 4.1 ng/mL, the combination of specificity (91 percent) and sensitivity (95 percent) is maximized, whereas using (b) a maximum response of 4.6 ng/mL or (c) a minimum response of 1.5 ng/mL, sensitivity and specificity are 95 percent, respectively. The inset illustrates the time course of the mean serum&nbsp;GH concentration in response to the stimuli in the two groups of subjects.</div><div class=\"graphic_footnotes\">GH: growth hormone; GHRH: growth hormone-releasing hormone;&nbsp;MPHD: multiple pituitary hormone deficiencies.</div><div class=\"graphic_reference\">Data from: Biller BM, Samuels MH, Zagar A, et al. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab 2002; 87:2067.</div><div id=\"graphicVersion\">Graphic 58987 Version 4.0</div></div></div>"},"58989":{"type":"graphic_table","displayName":"Classification hepatic cysts","title":"Classification of hepatic cysts","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of hepatic cysts</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Simple (solitary) cyst*</td> </tr> <tr> <td>Polycystic disease*</td> </tr> <tr> <td class=\"sublist1_start\">Parasitic</td> </tr> <tr> <td class=\"sublist1\">Hydatid (echinococcal)<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist1_start\">Neoplastic</td> </tr> <tr> <td class=\"sublist1\">Primary</td> </tr> <tr> <td class=\"sublist2\">Cystadenoma<sup>&#182;</sup>, cystadenocarcinoma<sup>&#916;</sup>, squamous cell carcinoma<sup>&#916;</sup></td> </tr> <tr> <td class=\"sublist1\">Secondary</td> </tr> <tr> <td class=\"sublist2\">Carcinoma of ovary<sup>&#916;</sup>, pancreas<sup>&#916;</sup>, colon<sup>&#916;</sup>, kidney<sup>&#916;</sup>, neuroendocrine<sup>&#916;</sup></td> </tr> <tr> <td class=\"sublist1_start\">Duct related</td> </tr> <tr> <td class=\"sublist1\">Caroli's disease<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist1\">Bile duct duplication<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist1_start\">False cysts</td> </tr> <tr> <td class=\"sublist1\">Traumatic intrahepatic hemorrhage<sup>&#916;</sup></td> </tr> <tr> <td class=\"sublist1\">Intrahepatic infarction<sup>&#916;</sup></td> </tr> <tr> <td class=\"sublist1\">Intrahepatic biloma<sup>&#916;</sup></td> </tr> <tr> <td>Ciliated foregut cyst<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Common.<br />¶ Uncommon.<br />Δ Rare.</div><div id=\"graphicVersion\">Graphic 58989 Version 2.0</div></div></div>"},"58994":{"type":"graphic_figure","displayName":"Richters hernia","title":"Richter's hernia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Richter's hernia</div><div class=\"cntnt\"><img style=\"width:381px; height:226px;\" src=\"images/SURG/58994_Richters_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic diagram showing a Richter's hernia, in which the antimesenteric border, but not the whole wall, of the bowel is incarcerated.</div><div class=\"graphic_reference\">Reproduced with permission from: Mulholland MW, Lillemoe KD. Greenfield's Surgery: Scientific Principles And Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 58994 Version 2.0</div></div></div>"}};